INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120001, 'Isoprenaline', 'Insulin human (zinc)', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120139/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120002, 'Isoprenaline', 'Insulin human (zinc extended)', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120140/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120003, 'Isoetharine', 'Isoprenaline', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine, Mometasone furoate, Umeclidinium, Aclidinium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120141/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120004, 'Ivabradine', 'Isoprenaline', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Adenosine, Regadenoson, Felodipine, Acetylsalicylic acid, Amlodipine, Nifedipine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120142/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120005, 'Isoprenaline', 'Ivosidenib', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120143/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120006, 'Isoprenaline', 'Ketoconazole', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120144/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120007, 'Isoprenaline', 'Labetalol', 'Moderate', 'Some beta-blockers may antagonize the bronchodilatory, hypotensive, and tachycardic effects of isoproterenol. The mechanism is blockade of beta-adrenergic receptors, which leads to bronchoconstriction, vasodilation, and increased heart rate. Beta-blockers have been used successfully to treat catecholamine or isoproterenol-induced tachyarrhythmias.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Patients who are receiving isoproterenol for cardiac conditions should be closely monitored for adequate therapeutic effect if a beta blocker is added. If no alternative exists, small doses of a B-1 selective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, or metoprolol) may be preferable; however, respiratory status should be closely monitored in patients with obstructive pulmonary disease.', 'Antagonism', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine, Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120145/', '[1] Ziegler MG, Chernow B, Woodson LC, Coyle J, Cruess D, Lake CR "The effect of propranolol on catecholamine clearance." Clin Pharmacol Ther 40 (1986): 116-9[2] Pickles H, Perucca E, Fish A, Richens A "Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor." Clin Pharmacol Ther 30 (1981): 303-10[3] Johnsson G, Svedmyr N, Thiringer G "Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics." Eur J Clin Pharmacol 8 (1975): 175-80[4] Thiringer G, Svedmyr N "Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics." Eur J Clin Pharmacol 10 (1976): 163-70[5] Vlay SC "Isoproterenol-induced bradyarrhythmias." Am Heart J 122 (1991): 1169[6] Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986): 251-60[7] Vlay SC "Catecholamine-sensitive ventricular tachycardia." Am Heart J 114 (1987): 455-61[8] Messerli FH, Kuchel O, Tolis G, Hamet P, Fraysse J, Genest J "Effects of beta-adrenergic blockade on plasma cyclic AMP and blood sugar responses to glucagon and isoproterenol in man." Int J Clin Pharmacol Biopharm 14 (1976): 189-94[9] Mann DE, Marmont P, Shultz J, Reiter MJ "Atrioventricular nodal reentrant tachycardia initiated by catecholamine-induced ventricular tachycardia. A case report." J Electrocardiol 24 (1991): 191-5', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120008, 'Isoprenaline', 'Lapatinib', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120146/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120009, 'Isoprenaline', 'Lefamulin', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Vancomycin, Metronidazole, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120147/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120010, 'Isoprenaline', 'Lenvatinib', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120148/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120011, 'Isoprenaline', 'Levosalbutamol', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Cromoglicic acid, Ipratropium, Tiotropium', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120149/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120012, 'Isoprenaline', 'Levmetamfetamine (nasal)', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120150/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120013, 'Isoprenaline', 'Levobetaxolol (ophthalmic)', 'Moderate', 'Some beta-blockers may antagonize the bronchodilatory, hypotensive, and tachycardic effects of isoproterenol. The mechanism is blockade of beta-adrenergic receptors, which leads to bronchoconstriction, vasodilation, and increased heart rate. Beta-blockers have been used successfully to treat catecholamine or isoproterenol-induced tachyarrhythmias.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Patients who are receiving isoproterenol for cardiac conditions should be closely monitored for adequate therapeutic effect if a beta blocker is added. If no alternative exists, small doses of a B-1 selective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, or metoprolol) may be preferable; however, respiratory status should be closely monitored in patients with obstructive pulmonary disease.', 'Antagonism', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Metaraminol, Methoxamine, Mephentermine, Formoterol, Cromoglicic acid, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120151/', '[1] Ziegler MG, Chernow B, Woodson LC, Coyle J, Cruess D, Lake CR "The effect of propranolol on catecholamine clearance." Clin Pharmacol Ther 40 (1986): 116-9[2] Pickles H, Perucca E, Fish A, Richens A "Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor." Clin Pharmacol Ther 30 (1981): 303-10[3] Johnsson G, Svedmyr N, Thiringer G "Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics." Eur J Clin Pharmacol 8 (1975): 175-80[4] Thiringer G, Svedmyr N "Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics." Eur J Clin Pharmacol 10 (1976): 163-70[5] Vlay SC "Isoproterenol-induced bradyarrhythmias." Am Heart J 122 (1991): 1169[6] Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986): 251-60[7] Vlay SC "Catecholamine-sensitive ventricular tachycardia." Am Heart J 114 (1987): 455-61[8] Messerli FH, Kuchel O, Tolis G, Hamet P, Fraysse J, Genest J "Effects of beta-adrenergic blockade on plasma cyclic AMP and blood sugar responses to glucagon and isoproterenol in man." Int J Clin Pharmacol Biopharm 14 (1976): 189-94[9] Mann DE, Marmont P, Shultz J, Reiter MJ "Atrioventricular nodal reentrant tachycardia initiated by catecholamine-induced ventricular tachycardia. A case report." J Electrocardiol 24 (1991): 191-5', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120014, 'Isoprenaline', 'Levobunolol (ophthalmic)', 'Moderate', 'Some beta-blockers may antagonize the bronchodilatory, hypotensive, and tachycardic effects of isoproterenol. The mechanism is blockade of beta-adrenergic receptors, which leads to bronchoconstriction, vasodilation, and increased heart rate. Beta-blockers have been used successfully to treat catecholamine or isoproterenol-induced tachyarrhythmias.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Patients who are receiving isoproterenol for cardiac conditions should be closely monitored for adequate therapeutic effect if a beta blocker is added. If no alternative exists, small doses of a B-1 selective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, or metoprolol) may be preferable; however, respiratory status should be closely monitored in patients with obstructive pulmonary disease.', 'Antagonism', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, More', 'Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120152/', '[1] Ziegler MG, Chernow B, Woodson LC, Coyle J, Cruess D, Lake CR "The effect of propranolol on catecholamine clearance." Clin Pharmacol Ther 40 (1986): 116-9[2] Pickles H, Perucca E, Fish A, Richens A "Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor." Clin Pharmacol Ther 30 (1981): 303-10[3] Johnsson G, Svedmyr N, Thiringer G "Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics." Eur J Clin Pharmacol 8 (1975): 175-80[4] Thiringer G, Svedmyr N "Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics." Eur J Clin Pharmacol 10 (1976): 163-70[5] Vlay SC "Isoproterenol-induced bradyarrhythmias." Am Heart J 122 (1991): 1169[6] Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986): 251-60[7] Vlay SC "Catecholamine-sensitive ventricular tachycardia." Am Heart J 114 (1987): 455-61[8] Messerli FH, Kuchel O, Tolis G, Hamet P, Fraysse J, Genest J "Effects of beta-adrenergic blockade on plasma cyclic AMP and blood sugar responses to glucagon and isoproterenol in man." Int J Clin Pharmacol Biopharm 14 (1976): 189-94[9] Mann DE, Marmont P, Shultz J, Reiter MJ "Atrioventricular nodal reentrant tachycardia initiated by catecholamine-induced ventricular tachycardia. A case report." J Electrocardiol 24 (1991): 191-5', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120015, 'Isoprenaline', 'Levofloxacin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin, Tinidazole, Pantoprazole, Tetracycline, Dexlansoprazole, Rabeprazole, Sucralfate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120153/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120016, 'Isoprenaline', 'Levacetylmethadol', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More', 'Diamorphine, Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120154/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120017, 'Isoprenaline', 'Levomilnacipran', 'Moderate', 'Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors. The use of SNRIs alone has been associated with sustained increases in blood pressure and heart rate, and cases of elevated blood pressure requiring immediate treatment have been reported in postmarketing experience.', NULL, 'Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.', NULL, 'Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate. Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter. Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate.', 'Synergism', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, More', 'Paroxetine, St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120155/', '[1] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[4] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[6] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[12] Maish WA, Hampton EM, Whitsett TL, Shepard JD, Lovallo WR "Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics." Pharmacotherapy 16 (1996): 1046-52', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120018, 'Isoprenaline', 'Linezolid', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.', NULL, 'Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.', NULL, 'Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.', 'Synergism', 'Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Vancomycin, Metronidazole, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, More', 'Arbutamine, Angiotensin II, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120156/', '[1] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5[3] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[4] "Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals, East Hanover, NJ.[5] Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981): 402-4[6] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[7] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim, Ridgefield, CT.[12] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[13] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[14] "Product Information. Isuprel (isoproterenol)." Sanofi Winthrop Pharmaceuticals, New York, NY.[15] "Product Information. S2 Inhalant (racepinephrine)." Nephron Pharmaceuticals, Orlando, FL.[16] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[17] "Product Information. Tornalate Metered Dose (bitolterol)." Dura Pharmaceuticals, San Diego, CA.[18] "Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985): 443-9[19] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[20] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[21] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[22] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[23] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[24] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[25] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[26] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[27] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[28] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[29] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[30] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[31] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[32] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[33] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[34] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[35] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[36] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[37] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120019, 'Isoprenaline', 'Liraglutide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, More', 'Simvastatin, Guar gum, Rosuvastatin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120157/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120020, 'Isoprenaline', 'Lisdexamfetamine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, More', 'Pemoline, Citicoline, Caffeine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120158/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120021, 'Isoprenaline', 'Lithium carbonate', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Dopamine, Mephentermine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120159/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120022, 'Isoprenaline', 'Lofexidine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More', 'Diamorphine, Acamprosate, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120160/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120023, 'Isoprenaline', 'Lomefloxacin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120161/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120024, 'Isoprenaline', 'Macimorelin', 'Major', 'Macimorelin can cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of macimorelin with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of macimorelin with other drugs that can prolong the QT interval should generally be avoided. A sufficient washout period following discontinuation of these drugs is recommended prior to macimorelin administration. Patients treated with any medication that can cause QT prolongation should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, Galactose, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, Edrophonium, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120162/', '[1] "Product Information. Macrilen (macimorelin)." Aeterna Zentaris, Charleston, SC.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] "Product Information. Macrilen (macimorelin)." Aeterna Zentaris, Charleston, SC.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120025, 'Isoprenaline', 'Maprotiline', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Paroxetine, St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Epinephrine, Methoxamine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120163/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120026, 'Isoprenaline', 'Mazindol', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', NULL, 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', NULL, 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Dexfenfluramine, Lorcaserin, Orlistat, Naltrexone', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine, Mometasone furoate, Umeclidinium, Budesonide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120164/', '[1] "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company, Indianapolis, IN.[2] "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.[3] Cavanaugh JH, Griffith JD, Oates JA "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther 11 (1970): 656[4] "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.[5] "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.[6] "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.[7] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res 1 (1979): 45-52[8] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[9] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[10] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120027, 'Isoprenaline', 'Mefloquine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120165/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120028, 'Isoprenaline', 'Mephentermine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Dobutamine, Norepinephrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More', 'Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Isoprenaline', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120166/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120029, 'Isoprenaline', 'Mesoridazine', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Metaraminol, Methoxamine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120167/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120030, 'Isoprenaline', 'Orciprenaline', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Isoprenaline', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Cromoglicic acid, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120168/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120031, 'Isoprenaline', 'Metaraminol', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Isoprenaline', 'Dobutamine, Norepinephrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120169/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120032, 'Isoprenaline', 'Metamfetamine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', NULL, 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', NULL, 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, More', 'Pemoline, Citicoline, Caffeine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120170/', '[1] "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company, Indianapolis, IN.[2] "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.[3] Cavanaugh JH, Griffith JD, Oates JA "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther 11 (1970): 656[4] "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.[5] "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.[6] "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.[7] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res 1 (1979): 45-52[8] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[9] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[10] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120033, 'Isoprenaline', 'Methotrimeprazine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Metaraminol, Methoxamine, More', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120171/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120034, 'Isoprenaline', 'Methoxamine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Isoprenaline', 'Dobutamine, Norepinephrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120172/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120035, 'Isoprenaline', 'Methylprednisolone', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', NULL, '-', NULL, '-', 'Synergism', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Dapsone, Azelaic acid, Adapalene, Deflazacort, More', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120173/', '[1] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120036, 'Isoprenaline', 'Metipranolol (ophthalmic)', 'Moderate', 'Some beta-blockers may antagonize the bronchodilatory, hypotensive, and tachycardic effects of isoproterenol. The mechanism is blockade of beta-adrenergic receptors, which leads to bronchoconstriction, vasodilation, and increased heart rate. Beta-blockers have been used successfully to treat catecholamine or isoproterenol-induced tachyarrhythmias.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Patients who are receiving isoproterenol for cardiac conditions should be closely monitored for adequate therapeutic effect if a beta blocker is added. If no alternative exists, small doses of a B-1 selective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, or metoprolol) may be preferable; however, respiratory status should be closely monitored in patients with obstructive pulmonary disease.', 'Antagonism', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, More', 'Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120174/', '[1] Ziegler MG, Chernow B, Woodson LC, Coyle J, Cruess D, Lake CR "The effect of propranolol on catecholamine clearance." Clin Pharmacol Ther 40 (1986): 116-9[2] Pickles H, Perucca E, Fish A, Richens A "Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor." Clin Pharmacol Ther 30 (1981): 303-10[3] Johnsson G, Svedmyr N, Thiringer G "Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics." Eur J Clin Pharmacol 8 (1975): 175-80[4] Thiringer G, Svedmyr N "Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics." Eur J Clin Pharmacol 10 (1976): 163-70[5] Vlay SC "Isoproterenol-induced bradyarrhythmias." Am Heart J 122 (1991): 1169[6] Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986): 251-60[7] Vlay SC "Catecholamine-sensitive ventricular tachycardia." Am Heart J 114 (1987): 455-61[8] Messerli FH, Kuchel O, Tolis G, Hamet P, Fraysse J, Genest J "Effects of beta-adrenergic blockade on plasma cyclic AMP and blood sugar responses to glucagon and isoproterenol in man." Int J Clin Pharmacol Biopharm 14 (1976): 189-94[9] Mann DE, Marmont P, Shultz J, Reiter MJ "Atrioventricular nodal reentrant tachycardia initiated by catecholamine-induced ventricular tachycardia. A case report." J Electrocardiol 24 (1991): 191-5', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120037, 'Isoprenaline', 'Metoprolol', 'Moderate', 'Some beta-blockers may antagonize the bronchodilatory, hypotensive, and tachycardic effects of isoproterenol. The mechanism is blockade of beta-adrenergic receptors, which leads to bronchoconstriction, vasodilation, and increased heart rate. Beta-blockers have been used successfully to treat catecholamine or isoproterenol-induced tachyarrhythmias.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Patients who are receiving isoproterenol for cardiac conditions should be closely monitored for adequate therapeutic effect if a beta blocker is added. If no alternative exists, small doses of a B-1 selective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, or metoprolol) may be preferable; however, respiratory status should be closely monitored in patients with obstructive pulmonary disease.', 'Antagonism', 'Felodipine, Acetylsalicylic acid, Amlodipine, Nifedipine', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine, Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Ipratropium, Beclomethasone dipropionate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120175/', '[1] Ziegler MG, Chernow B, Woodson LC, Coyle J, Cruess D, Lake CR "The effect of propranolol on catecholamine clearance." Clin Pharmacol Ther 40 (1986): 116-9[2] Pickles H, Perucca E, Fish A, Richens A "Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor." Clin Pharmacol Ther 30 (1981): 303-10[3] Johnsson G, Svedmyr N, Thiringer G "Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics." Eur J Clin Pharmacol 8 (1975): 175-80[4] Thiringer G, Svedmyr N "Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics." Eur J Clin Pharmacol 10 (1976): 163-70[5] Vlay SC "Isoproterenol-induced bradyarrhythmias." Am Heart J 122 (1991): 1169[6] Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986): 251-60[7] Vlay SC "Catecholamine-sensitive ventricular tachycardia." Am Heart J 114 (1987): 455-61[8] Messerli FH, Kuchel O, Tolis G, Hamet P, Fraysse J, Genest J "Effects of beta-adrenergic blockade on plasma cyclic AMP and blood sugar responses to glucagon and isoproterenol in man." Int J Clin Pharmacol Biopharm 14 (1976): 189-94[9] Mann DE, Marmont P, Shultz J, Reiter MJ "Atrioventricular nodal reentrant tachycardia initiated by catecholamine-induced ventricular tachycardia. A case report." J Electrocardiol 24 (1991): 191-5', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120038, 'Isoprenaline', 'Midostaurin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120176/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120039, 'Isoprenaline', 'Mifepristone', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Ulipristal, Danazol, Ospemifene, Raloxifene, Bazedoxifene, Prasterone', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120177/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120040, 'Isoprenaline', 'Miglitol', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Simvastatin, Guar gum, Rosuvastatin', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120178/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120041, 'Isoprenaline', 'Milnacipran', 'Moderate', 'Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors. The use of SNRIs alone has been associated with sustained increases in blood pressure and heart rate, and cases of elevated blood pressure requiring immediate treatment have been reported in postmarketing experience.', NULL, 'Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.', NULL, 'Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate. Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter. Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate.', 'Synergism', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, More', 'Paroxetine, St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120179/', '[1] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[4] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[6] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[12] Maish WA, Hampton EM, Whitsett TL, Shepard JD, Lovallo WR "Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics." Pharmacotherapy 16 (1996): 1046-52', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120042, 'Isoprenaline', 'Mirtazapine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Paroxetine, St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120180/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120043, 'Isoprenaline', 'Modafinil', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Pemoline, Citicoline, Caffeine', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120181/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120044, 'Isoprenaline', 'Moxifloxacin', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Rifamycin, Kanamycin, Ampicillin, Acyclovir, Netilmicin, Polymyxin B, Famciclovir, Cefuroxime, Trifluridine, Tobramycin, Benzylpenicillin, More', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120182/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120045, 'Isoprenaline', 'Nadolol', 'Moderate', 'Some beta-blockers may antagonize the bronchodilatory, hypotensive, and tachycardic effects of isoproterenol. The mechanism is blockade of beta-adrenergic receptors, which leads to bronchoconstriction, vasodilation, and increased heart rate. Beta-blockers have been used successfully to treat catecholamine or isoproterenol-induced tachyarrhythmias.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Patients who are receiving isoproterenol for cardiac conditions should be closely monitored for adequate therapeutic effect if a beta blocker is added. If no alternative exists, small doses of a B-1 selective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, or metoprolol) may be preferable; however, respiratory status should be closely monitored in patients with obstructive pulmonary disease.', 'Antagonism', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine, Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120183/', '[1] Ziegler MG, Chernow B, Woodson LC, Coyle J, Cruess D, Lake CR "The effect of propranolol on catecholamine clearance." Clin Pharmacol Ther 40 (1986): 116-9[2] Pickles H, Perucca E, Fish A, Richens A "Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor." Clin Pharmacol Ther 30 (1981): 303-10[3] Johnsson G, Svedmyr N, Thiringer G "Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics." Eur J Clin Pharmacol 8 (1975): 175-80[4] Thiringer G, Svedmyr N "Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics." Eur J Clin Pharmacol 10 (1976): 163-70[5] Vlay SC "Isoproterenol-induced bradyarrhythmias." Am Heart J 122 (1991): 1169[6] Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986): 251-60[7] Vlay SC "Catecholamine-sensitive ventricular tachycardia." Am Heart J 114 (1987): 455-61[8] Messerli FH, Kuchel O, Tolis G, Hamet P, Fraysse J, Genest J "Effects of beta-adrenergic blockade on plasma cyclic AMP and blood sugar responses to glucagon and isoproterenol in man." Int J Clin Pharmacol Biopharm 14 (1976): 189-94[9] Mann DE, Marmont P, Shultz J, Reiter MJ "Atrioventricular nodal reentrant tachycardia initiated by catecholamine-induced ventricular tachycardia. A case report." J Electrocardiol 24 (1991): 191-5', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120046, 'Isoprenaline', 'Naphazoline (nasal)', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120184/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120047, 'Isoprenaline', 'Naphazoline (ophthalmic)', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120185/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120048, 'Isoprenaline', 'Nateglinide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Simvastatin, Guar gum, Rosuvastatin', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120186/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120049, 'Isoprenaline', 'Nilotinib', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120187/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120050, 'Isoprenaline', 'Nilutamide', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120188/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120051, 'Isoprenaline', 'Norepinephrine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Isoprenaline', 'Dobutamine, Norepinephrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120189/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120052, 'Isoprenaline', 'Norfloxacin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Amikacin, Rifamycin, Kanamycin, Ampicillin, More', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120190/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120053, 'Isoprenaline', 'Nortriptyline', 'Moderate', 'The concomitant use of isoproterenol and tricyclic antidepressants may increase the risk of arrhythmias, especially at high doses. The mechanism has not been delineated. Tachycardia has been reported in clinical studies.', NULL, 'Some authorities suggest that the initial rate and dose of isoproterenol should be reduced in patients taking tricyclic antidepressants, and then titrated, as is usual according to clinical response to avoid the risk of developing hypertension or arrhythmias.', NULL, 'Some authorities suggest that the initial rate and dose of isoproterenol should be reduced in patients taking tricyclic antidepressants, and then titrated, as is usual according to clinical response to avoid the risk of developing hypertension or arrhythmias. Patients receiving this combination should be monitored and advised to notify their physician if they experience a fast or irregular pulse.', 'Synergism', 'Paroxetine, St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Mephentermine, Mometasone, Mometasone furoate, Beclomethasone dipropionate, Cromoglicic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120191/', '[1] Kadar D "Letter: Amitriptyline and isoproterenol: fatal drug combination." Can Med Assoc J 112 (1975): 556-7[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120054, 'Isoprenaline', 'Ofloxacin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin, Tinidazole, Tetracycline, Cefepime, Metronidazole, Cefuroxime, Secnidazole, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120192/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120055, 'Isoprenaline', 'Olanzapine', 'Moderate', 'It is uncertain whether olanzapine causes clinically significant prolongation of the QT interval.', NULL, 'Some authorities recommend caution when olanzapine is used with drugs that are known to cause QT prolongation.', NULL, 'Some authorities recommend caution when olanzapine is used with drugs that are known to cause QT prolongation.', 'Synergism', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120193/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[4] "Product Information. Qbrexza (glycopyrrolate topical)." Dermira, Inc., Menlo Park, CA.[5] "Product Information. Anoro Ellipta (umeclidinium-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[6] "Product Information. Combivent (albuterol-ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[7] "Product Information. Atrovent (ipratropium)." Boehringer-Ingelheim, Ridgefield, CT.[8] "Product Information. Yupelri (revefenacin)." Mylan Specialty, Morgantown, WV.[9] "Product Information. Tudorza Pressair (aclidinium)." Forest Pharmaceuticals, St. Louis, MO.[10] "Product Information. Spiriva (tiotropium)." Boehringer Ingelheim, Ridgefield, CT.[11] Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21[12] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[16] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[17] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[18] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[19] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120056, 'Isoprenaline', 'Oliceridine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More', 'Naltrexone, Oxymorphone, Oxycodone, Pentazocine, Morphine, Butorphanol, Fentanyl, Ibuprofen, Codeine, Nalbuphine, Acetaminophen, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120194/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120057, 'Isoprenaline', 'Ondansetron', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Nabilone, Scopolamine, Rolapitant, Aprepitant, Dronabinol', 'Droxidopa, Norepinephrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Dopamine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120195/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120058, 'Isoprenaline', 'Opicapone', 'Moderate', 'COMT inhibitors affect the elimination of drugs metabolized by catechol-O-methyltransferase (COMT) and may potentiate their effects. Arrhythmias, increased heart rate, and blood pressure changes may occur. Entacapone has increased heart rates up to 80% when coadministered with isoproterenol and epinephrine. Ventricular tachycardia has also been reported.', NULL, 'The manufacturer recommends that caution be exercised when these drugs are given together.', NULL, 'The manufacturer recommends that caution be exercised when these drugs are given together. Monitoring for changes in hemodynamic status and ECG is recommended.', 'Metabolism', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Methoxamine, More', 'Ropinirole, Cabergoline, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Amantadine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120196/', '[1] "Product Information. Comtan (entacapone)" Novartis Pharmaceuticals, East Hanover, NJ.[2] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[3] Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A "The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine." Clin Pharmacol Ther 58 (1995): 221-7[4] "Product Information. Ongentys (opicapone)." Neurocrine Biosciences, Inc., San Diego, CA.[5] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120059, 'Isoprenaline', 'Osilodrostat', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120197/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120060, 'Isoprenaline', 'Osimertinib', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120198/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120061, 'Isoprenaline', 'Oxaliplatin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120199/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120062, 'Isoprenaline', 'Oxtriphylline', 'Moderate', 'Concomitant use of beta-2 adrenergic agonists with theophylline may increase the risk and/or severity of hypokalemia and adverse cardiovascular effects such as palpitation, tachycardia, and blood pressure elevation. Adverse events, especially hypokalemia, may be more likely with systemic or nebulized formulations of beta-2 agonists or high dosages of theophylline. Beta-2 agonists can cause clinically significant but usually transient decreases in serum potassium concentrations, while hypokalemia associated with theophylline often occurs in toxicity. Pharmacokinetically, some beta-2 agonists given systemically may decrease the plasma concentrations of theophylline.', NULL, 'Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer.', NULL, 'Although theophylline and beta-2 agonists are commonly used together to produce bronchodilation, it may be appropriate to monitor patient response as well as serum potassium level, blood pressure and heart rate during coadministration, especially if the beta-2 agonist is administered systemically or by nebulizer. Close monitoring is particularly important in patients with severe asthma, since the potential increases in blood pressure and heart rate may have more serious consequences in the presence of hypoxemia or hypercapnia due to increased myocardial oxygen consumption. Patients should be advised to notify their physician if they experience worsening of their respiratory condition or potential signs and symptoms of hypokalemia such as fatigue, weakness, myalgia, muscle cramps, numbness, tingling, abdominal pain, constipation, palpitation, and irregular heartbeat.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', 'Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Mepolizumab, Roflumilast, Pentoxifylline, Zafirlukast, Bromotheophylline', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120200/', '[1] Garty M, Paul-Keslin L, Ilfeld DN, et al "Increased theophylline clearance in asthmatic patients due to terbutaline." Eur J Clin Pharmacol 36 (1989): 25-8[2] Amirav I, Amitai Y, Avital A, Godfrey S "Enhancement of theophylline clearance by intravenous albuterol." Chest 94 (1988): 444-5[3] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[4] Cusack BJ, Nielson CP, Morgan ME, Vestal RE "Additive effect of theophylline on the cardiac response to isoproterenol." Clin Pharmacol Ther 41 (1987): 289-96[5] Griffith JA, Kozloski GD "Isoproterenol-theophylline interaction: possible potentiation by other drugs." Clin Pharm 9 (1990): 54-7[6] Conrad KA, Woodworth JR "Orciprenaline does not alter theophylline elimination." Br J Clin Pharmacol 12 (1981): 756-7[7] Flatt A, Burgess C, Windom H, Beasley R, Purdie G, Crane J "The cardiovascular effects of inhaled fenoterol alone and during treatment with oral theophylline." Chest 96 (1989): 1317-20[8] Smith SR, Kendall MJ "Potentiation of the adverse effects of intravenous terbutaline by oral theophylline." Br J Clin Pharmacol 21 (1986): 451-3[9] Danzinger Y, Garty M, Volwitz B, Ilfeld D, Varsano I, Rosenfeld JB "Reduction of serum theophylline levels by terbutaline in children with asthma." Clin Pharmacol Ther 37 (1985): 469-71[10] O''Rourke PP, Crone RK "Effect of isoproterenol on measured theophylline levels." Crit Care Med 12 (1984): 373-5[11] Whyte KF, Reid C, Addis GJ, Whitesmith R, Reid JL "Salbutamol induced hypokalaemia: the effect of theophylline alone and in combination with adrenaline." Br J Clin Pharmacol 25 (1988): 571-8[12] Coleman JJ, Vollmer WM, Barker AF, et al "Cardiac arrhythmias during the combined use of beta-adrenergic agonist drugs and theophylline." Chest 90 (1986): 45-51[13] Kelly HW "Controversies in asthma therapy with theophylline and the beta2-adrenergic agonists." Clin Pharm 3 (1984): 386-95[14] Amitai Y, Glustein J, Godfrey S "Enhancement of theophylline clearance by oral albuterol." Chest 102 (1992): 786-9[15] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[16] "Interactions between methyl xanthines and beta adrenergic agonists." FDA Drug Bull 11 (1981): 19-20[17] Chow OK, Fung KP "Slow-release terbutaline and theophylline for the long-term therapy of children with asthma: a Latin square and factorial study of drug effects and interactions." Pediatrics 84 (1989): 119-25[18] Hemstreet MP, Miles MV, Rutland RO "Effect of intravenous isoproterenol on theophylline kinetics." J Allergy Clin Immunol 69 (1982): 360-4[19] Upton RA "Pharmacokinetic interactions between theophylline and other medication (Part I)." Clin Pharmacokinet 20 (1991): 66-80[20] Rachelefsky GS, Katz RM, Mickey MR Jr, Siegel SC "Metaproterenol and theophylline in asthmatic children." Ann Allergy 45 (1980): 207-12[21] Josephson GW, Kennedy HL, MacKenzie EJ, Gibson G "Cardiac dysrhythmias during the treatment of acute asthma. A comparison of two treatment regimens by a double blind protocol." Chest 78 (1980): 429-35[22] Dawson KP, Fergusson DM "Effects of oral theophylline and oral salbutamol in the treatment of asthma." Arch Dis Child 57 (1982): 674-6[23] Jonkman JH, Borgstrom L, van der Boon WJ, de Noord OE "Theophylline-terbutaline, a steady state study on possible pharmacokinetic interactions with special reference to chronopharmacokinetic aspects." Br J Clin Pharmacol 26 (1988): 285-93[24] Deenstra M, Haalboom JR, Struyvenberg A "Decrease of plasma potassium due to inhalation of beta-2 agonists: absence of an additional effect of intravenous theophylline." Eur J Clin Invest 18 (1988): 162-5[25] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[26] Lombardi TP, Bertino JS, Goldberg A, Middleton E, Slaughter RL "The effects of a beta-2 selective adrenergic agonist and a beta- nonselective antagonist on theophylline clearance." J Clin Pharmacol 27 (1987): 523-9', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120063, 'Isoprenaline', 'Oxymetazoline (nasal)', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120201/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120064, 'Isoprenaline', 'Oxymetazoline (ophthalmic)', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120202/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120065, 'Isoprenaline', 'Oxymetazoline (topical)', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120203/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120066, 'Isoprenaline', 'Oxytocin', 'Moderate', 'Concomitant use of oxytocic agents with sympathomimetic amines may increase the risk of hypertension due to additive vasoconstrictive effects. Severe hypertension and headache have been reported when oxytocin was given 3 to 4 hours following prophylactic administration of a vasoconstrictor in conjunction with caudal block anesthesia.', NULL, 'Close monitoring of blood pressure is recommended during coadministration.', NULL, 'Close monitoring of blood pressure is recommended during coadministration.', 'Synergism', 'Methylergometrine, Misoprostol, Ergometrine, Dinoprostone, Terlipressin', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120204/', '[1] "Product Information. Syntocinon (oxytocin)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[4] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[5] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120067, 'Isoprenaline', 'Ozanimod', 'Major', 'Due to the risk of bradycardia and atrioventricular (AV) block, the risk of QT prolongation and torsade de pointes arrhythmia may be increased during initiation of ozanimod treatment in patients receiving drugs that prolong the QT interval.', NULL, 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval.', NULL, 'Ozanimod has not been studied in patients receiving drugs that can prolong the QT interval. Because bradycardia and AV block are recognized risk factors for QT prolongation and torsade de pointes arrhythmia, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.', 'Synergism', 'Arbutamine, Angiotensin II, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120205/', '[1] "Product Information. Zeposia (ozanimod)." Celgene Corporation, Summit, NJ.[2] "Product Information. Zeposia (ozanimod)." Celgene Corporation, Summit, NJ.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120068, 'Isoprenaline', 'Panobinostat', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120206/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120069, 'Isoprenaline', 'Pasireotide', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120207/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120070, 'Isoprenaline', 'Pazopanib', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120208/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120071, 'Isoprenaline', 'Penbutolol', 'Moderate', 'Some beta-blockers may antagonize the bronchodilatory, hypotensive, and tachycardic effects of isoproterenol. The mechanism is blockade of beta-adrenergic receptors, which leads to bronchoconstriction, vasodilation, and increased heart rate. Beta-blockers have been used successfully to treat catecholamine or isoproterenol-induced tachyarrhythmias.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Patients who are receiving isoproterenol for cardiac conditions should be closely monitored for adequate therapeutic effect if a beta blocker is added. If no alternative exists, small doses of a B-1 selective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, or metoprolol) may be preferable; however, respiratory status should be closely monitored in patients with obstructive pulmonary disease.', 'Antagonism', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine, Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120209/', '[1] Ziegler MG, Chernow B, Woodson LC, Coyle J, Cruess D, Lake CR "The effect of propranolol on catecholamine clearance." Clin Pharmacol Ther 40 (1986): 116-9[2] Pickles H, Perucca E, Fish A, Richens A "Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor." Clin Pharmacol Ther 30 (1981): 303-10[3] Johnsson G, Svedmyr N, Thiringer G "Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics." Eur J Clin Pharmacol 8 (1975): 175-80[4] Thiringer G, Svedmyr N "Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics." Eur J Clin Pharmacol 10 (1976): 163-70[5] Vlay SC "Isoproterenol-induced bradyarrhythmias." Am Heart J 122 (1991): 1169[6] Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986): 251-60[7] Vlay SC "Catecholamine-sensitive ventricular tachycardia." Am Heart J 114 (1987): 455-61[8] Messerli FH, Kuchel O, Tolis G, Hamet P, Fraysse J, Genest J "Effects of beta-adrenergic blockade on plasma cyclic AMP and blood sugar responses to glucagon and isoproterenol in man." Int J Clin Pharmacol Biopharm 14 (1976): 189-94[9] Mann DE, Marmont P, Shultz J, Reiter MJ "Atrioventricular nodal reentrant tachycardia initiated by catecholamine-induced ventricular tachycardia. A case report." J Electrocardiol 24 (1991): 191-5', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120072, 'Isoprenaline', 'Perflutren', 'Moderate', 'Perflutren lipid microsphere suspension (Definity) has been reported to cause prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is recommended if perflutren lipid microsphere suspension is used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if perflutren lipid microsphere suspension is used in combination with other drugs that can prolong the QT interval. Please refer to the prescribing information for these drugs for more information. No data are available regarding the effect of perflutren protein-type A microsphere suspension (Optison) on the QT interval of the electrocardiogram.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120210/', '[1] "Product Information. Definity (perflutren)." Lantheus Medical Imaging Inc, North Billerica, MA.[2] "Product Information. Optison (perflutren)." Mallinckrodt Medical Inc, St. Louis, MO.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120073, 'Isoprenaline', 'Perphenazine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Metaraminol, Methoxamine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120211/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120074, 'Isoprenaline', 'Phendimetrazine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', NULL, 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', NULL, 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120212/', '[1] "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company, Indianapolis, IN.[2] "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.[3] Cavanaugh JH, Griffith JD, Oates JA "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther 11 (1970): 656[4] "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.[5] "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.[6] "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.[7] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res 1 (1979): 45-52[8] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[9] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[10] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120075, 'Isoprenaline', 'Phenelzine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.', NULL, 'Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.', NULL, 'Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.', 'Synergism', 'Paroxetine, St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Arbutamine, Angiotensin II, Mometasone furoate, Umeclidinium, Budesonide, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120213/', '[1] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5[3] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[4] "Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals, East Hanover, NJ.[5] Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981): 402-4[6] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[7] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim, Ridgefield, CT.[12] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[13] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[14] "Product Information. Isuprel (isoproterenol)." Sanofi Winthrop Pharmaceuticals, New York, NY.[15] "Product Information. S2 Inhalant (racepinephrine)." Nephron Pharmaceuticals, Orlando, FL.[16] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[17] "Product Information. Tornalate Metered Dose (bitolterol)." Dura Pharmaceuticals, San Diego, CA.[18] "Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985): 443-9[19] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[20] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[21] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[22] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[23] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[24] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[25] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[26] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[27] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[28] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[29] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[30] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[31] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[32] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[33] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[34] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[35] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[36] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[37] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120076, 'Isoprenaline', 'Phenylephrine (nasal)', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Dobutamine, Norepinephrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120214/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120077, 'Isoprenaline', 'Phenylephrine (topical)', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Dobutamine, Norepinephrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120215/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120078, 'Isoprenaline', 'Phenylpropanolamine', 'Moderate', 'Central nervous system (CNS) stimulants, particularly the amphetamines, can potentiate the adrenergic response to vasopressors and other sympathomimetic agents. Additive increases in blood pressure and heart rate may occur due to enhanced peripheral sympathetic activity.', NULL, 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents.', NULL, 'Caution is advised if CNS stimulants are used with vasopressors or other sympathomimetic agents. Pulse and blood pressure should be closely monitored.', 'Synergism', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120216/', '[1] "Product Information. Strattera (atomoxetine)." Lilly, Eli and Company, Indianapolis, IN.[2] "Product Information. Focalin (dexmethylphenidate)." Mikart Inc, Atlanta, GA.[3] Cavanaugh JH, Griffith JD, Oates JA "Effect of amphetamine on the pressor response to tyramine: formation of p-hydroxynorephedrine from amphetamine in man." Clin Pharmacol Ther 11 (1970): 656[4] "Product Information. Tenuate (diethylpropion)" Aventis Pharmaceuticals, Swiftwater, PA.[5] "Product Information. Adderall (amphetamine-dextroamphetamine)" Shire Richwood Pharmaceutical Company, Florence, KY.[6] "Product Information. Sanorex (mazindol)" Novartis Pharmaceuticals, East Hanover, NJ.[7] Rosenblatt JE, Lake CR, van Kammen DP, Ziegler MG, Bunney WE Jr "Interactions of amphetamine, pimozide, and lithium on plasma norepineophrine and dopamine-beta-hydroxylase in schizophrenic patients." Psychiatry Res 1 (1979): 45-52[8] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[9] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[10] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120079, 'Isoprenaline', 'Pimavanserin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120217/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120080, 'Isoprenaline', 'Pimozide', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120218/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120081, 'Isoprenaline', 'Pindolol', 'Moderate', 'Some beta-blockers may antagonize the bronchodilatory, hypotensive, and tachycardic effects of isoproterenol. The mechanism is blockade of beta-adrenergic receptors, which leads to bronchoconstriction, vasodilation, and increased heart rate. Beta-blockers have been used successfully to treat catecholamine or isoproterenol-induced tachyarrhythmias.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Patients who are receiving isoproterenol for cardiac conditions should be closely monitored for adequate therapeutic effect if a beta blocker is added. If no alternative exists, small doses of a B-1 selective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, or metoprolol) may be preferable; however, respiratory status should be closely monitored in patients with obstructive pulmonary disease.', 'Antagonism', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine, Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120219/', '[1] Ziegler MG, Chernow B, Woodson LC, Coyle J, Cruess D, Lake CR "The effect of propranolol on catecholamine clearance." Clin Pharmacol Ther 40 (1986): 116-9[2] Pickles H, Perucca E, Fish A, Richens A "Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor." Clin Pharmacol Ther 30 (1981): 303-10[3] Johnsson G, Svedmyr N, Thiringer G "Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics." Eur J Clin Pharmacol 8 (1975): 175-80[4] Thiringer G, Svedmyr N "Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics." Eur J Clin Pharmacol 10 (1976): 163-70[5] Vlay SC "Isoproterenol-induced bradyarrhythmias." Am Heart J 122 (1991): 1169[6] Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986): 251-60[7] Vlay SC "Catecholamine-sensitive ventricular tachycardia." Am Heart J 114 (1987): 455-61[8] Messerli FH, Kuchel O, Tolis G, Hamet P, Fraysse J, Genest J "Effects of beta-adrenergic blockade on plasma cyclic AMP and blood sugar responses to glucagon and isoproterenol in man." Int J Clin Pharmacol Biopharm 14 (1976): 189-94[9] Mann DE, Marmont P, Shultz J, Reiter MJ "Atrioventricular nodal reentrant tachycardia initiated by catecholamine-induced ventricular tachycardia. A case report." J Electrocardiol 24 (1991): 191-5', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120082, 'Isoprenaline', 'Pioglitazone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, More', 'Simvastatin, Guar gum, Rosuvastatin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120220/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120083, 'Isoprenaline', 'Pitolisant', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120221/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120084, 'Isoprenaline', 'Posaconazole', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Caspofungin, Micafungin, Amphotericin B, Itraconazole, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120222/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120085, 'Isoprenaline', 'Pramlintide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Budesonide, Aclidinium, Mometasone, More', 'Simvastatin, Guar gum, Rosuvastatin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120223/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120086, 'Isoprenaline', 'Prednisolone', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', NULL, '-', NULL, '-', 'Synergism', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Clobetasol, Fluorometholone, Indomethacin, Fluocinolone acetonide, Diclofenac, More', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120224/', '[1] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120087, 'Isoprenaline', 'Prednisone', 'Minor', 'Although they are often combined in clinical practice, the concomitant use of beta-2 adrenergic agonists and corticosteroids may result in additive hypokalemic effects. Since beta-2 agonists can sometimes cause QT interval prolongation, the development of hypokalemia may potentiate the risk of ventricular arrhythmias including torsade de pointes. However, clinical data are limited, and the potential significance is unknown. Patients who are receiving systemic or nebulized formulations of beta-2 agonists, high dosages of inhaled beta-2 agonists, or systemic corticosteroid therapy may be at a greater risk of developing hypokalemia.', NULL, '-', NULL, '-', 'Synergism', 'Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Mesalazine, Deflazacort', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120225/', '[1] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120088, 'Isoprenaline', 'Primaquine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120226/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120089, 'Isoprenaline', 'Probucol', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Cholestyramine, Rosuvastatin, Fenofibrate, Mipomersen, Evinacumab, Dextrothyroxine, Simvastatin, Cerivastatin, Lomitapide, Ezetimibe, Niacin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120227/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120090, 'Isoprenaline', 'Procainamide', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120228/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120091, 'Isoprenaline', 'Procarbazine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.', NULL, 'Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.', NULL, 'Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.', 'Synergism', 'Arbutamine, Angiotensin II, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, Ipratropium, More', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120229/', '[1] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5[3] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[4] "Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals, East Hanover, NJ.[5] Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981): 402-4[6] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[7] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim, Ridgefield, CT.[12] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[13] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[14] "Product Information. Isuprel (isoproterenol)." Sanofi Winthrop Pharmaceuticals, New York, NY.[15] "Product Information. S2 Inhalant (racepinephrine)." Nephron Pharmaceuticals, Orlando, FL.[16] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[17] "Product Information. Tornalate Metered Dose (bitolterol)." Dura Pharmaceuticals, San Diego, CA.[18] "Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985): 443-9[19] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[20] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[21] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[22] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[23] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[24] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[25] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[26] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[27] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[28] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[29] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[30] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[31] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[32] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[33] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[34] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[35] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[36] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[37] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120092, 'Isoprenaline', 'Promazine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Metaraminol, Methoxamine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120230/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120093, 'Isoprenaline', 'Promethazine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Metaraminol, Methoxamine, Mephentermine, More', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120231/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120094, 'Isoprenaline', 'Propafenone', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Phenylephrine, Fenoldopam, Metaraminol, More', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120232/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120095, 'Isoprenaline', 'Propranolol', 'Moderate', 'Some beta-blockers may antagonize the bronchodilatory, hypotensive, and tachycardic effects of isoproterenol. The mechanism is blockade of beta-adrenergic receptors, which leads to bronchoconstriction, vasodilation, and increased heart rate. Beta-blockers have been used successfully to treat catecholamine or isoproterenol-induced tachyarrhythmias.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Patients who are receiving isoproterenol for cardiac conditions should be closely monitored for adequate therapeutic effect if a beta blocker is added. If no alternative exists, small doses of a B-1 selective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, or metoprolol) may be preferable; however, respiratory status should be closely monitored in patients with obstructive pulmonary disease.', 'Antagonism', 'Felodipine, Acetylsalicylic acid, Amlodipine, Nifedipine', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine, Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120233/', '[1] Ziegler MG, Chernow B, Woodson LC, Coyle J, Cruess D, Lake CR "The effect of propranolol on catecholamine clearance." Clin Pharmacol Ther 40 (1986): 116-9[2] Pickles H, Perucca E, Fish A, Richens A "Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor." Clin Pharmacol Ther 30 (1981): 303-10[3] Johnsson G, Svedmyr N, Thiringer G "Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics." Eur J Clin Pharmacol 8 (1975): 175-80[4] Thiringer G, Svedmyr N "Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics." Eur J Clin Pharmacol 10 (1976): 163-70[5] Vlay SC "Isoproterenol-induced bradyarrhythmias." Am Heart J 122 (1991): 1169[6] Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986): 251-60[7] Vlay SC "Catecholamine-sensitive ventricular tachycardia." Am Heart J 114 (1987): 455-61[8] Messerli FH, Kuchel O, Tolis G, Hamet P, Fraysse J, Genest J "Effects of beta-adrenergic blockade on plasma cyclic AMP and blood sugar responses to glucagon and isoproterenol in man." Int J Clin Pharmacol Biopharm 14 (1976): 189-94[9] Mann DE, Marmont P, Shultz J, Reiter MJ "Atrioventricular nodal reentrant tachycardia initiated by catecholamine-induced ventricular tachycardia. A case report." J Electrocardiol 24 (1991): 191-5', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120096, 'Isoprenaline', 'Protriptyline', 'Moderate', 'The concomitant use of isoproterenol and tricyclic antidepressants may increase the risk of arrhythmias, especially at high doses. The mechanism has not been delineated. Tachycardia has been reported in clinical studies.', NULL, 'Some authorities suggest that the initial rate and dose of isoproterenol should be reduced in patients taking tricyclic antidepressants, and then titrated, as is usual according to clinical response to avoid the risk of developing hypertension or arrhythmias.', NULL, 'Some authorities suggest that the initial rate and dose of isoproterenol should be reduced in patients taking tricyclic antidepressants, and then titrated, as is usual according to clinical response to avoid the risk of developing hypertension or arrhythmias. Patients receiving this combination should be monitored and advised to notify their physician if they experience a fast or irregular pulse.', 'Synergism', 'Paroxetine, St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Mephentermine, Mometasone furoate, Budesonide, Mometasone, Fluticasone, Cromoglicic acid, Beclomethasone dipropionate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120234/', '[1] Kadar D "Letter: Amitriptyline and isoproterenol: fatal drug combination." Can Med Assoc J 112 (1975): 556-7[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120097, 'Isoprenaline', 'Quetiapine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120235/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120098, 'Isoprenaline', 'Quinidine', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Lidocaine, Tocainide, Mexiletine, Bretylium, Moricizine', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Phenylephrine, Fenoldopam, Metaraminol, Epinephrine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120236/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120099, 'Isoprenaline', 'Quinine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Proguanil, Sulfadoxine', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120237/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120100, 'Isoprenaline', 'Racepinephrine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Cromoglicic acid, Ipratropium, Tiotropium', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120238/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120101, 'Isoprenaline', 'Ranolazine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Adenosine, Regadenoson', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120239/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120102, 'Isoprenaline', 'Rasagiline', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.', NULL, 'Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.', NULL, 'Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.', 'Synergism', 'Droxidopa, Arbutamine, Angiotensin II, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Fluticasone, Cromoglicic acid, More', 'Ropinirole, Cabergoline, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Amantadine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120240/', '[1] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5[3] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[4] "Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals, East Hanover, NJ.[5] Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981): 402-4[6] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[7] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim, Ridgefield, CT.[12] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[13] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[14] "Product Information. Isuprel (isoproterenol)." Sanofi Winthrop Pharmaceuticals, New York, NY.[15] "Product Information. S2 Inhalant (racepinephrine)." Nephron Pharmaceuticals, Orlando, FL.[16] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[17] "Product Information. Tornalate Metered Dose (bitolterol)." Dura Pharmaceuticals, San Diego, CA.[18] "Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985): 443-9[19] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[20] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[21] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[22] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[23] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[24] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[25] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[26] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[27] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[28] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[29] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[30] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[31] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[32] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[33] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[34] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[35] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[36] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[37] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120103, 'Isoprenaline', 'Relugolix', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Norethisterone, Nafarelin, Octreotide, Elagolix, Cetrorelix, Estradiol, Ganirelix, Lanreotide, Gonadorelin, Darolutamide, Anastrozole, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120241/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120104, 'Isoprenaline', 'Repaglinide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Simvastatin, Guar gum, Rosuvastatin', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120242/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120105, 'Isoprenaline', 'Reserpine', 'Moderate', 'Postganglionic adrenergic blocking agents may potentiate the pharmacologic effects of direct-acting sympathomimetic amines, while the hypotensive effect of the former may be diminished. Postganglionic adrenergic blocking agents such as guanadrel, guanethidine, and rauwolfia alkaloids work by depleting catecholamine stores from adrenergic nerve endings, thus they may sensitize adrenergic receptors to direct-acting sympathomimetics.', NULL, 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension.', NULL, 'Due to their pressor effect, sympathomimetic amines should be used cautiously in patients with hypertension. Conversely, alternatives to postganglionic adrenergic blocking agents should be considered in patients treated with sympathomimetic amines. If the combination is used, blood pressure and heart rate should be closely monitored.', 'Synergism', 'Prazosin, Clonidine, Hydralazine, Guanfacine, Clonidine, Methyldopa', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Formoterol, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate, Terbutaline, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120243/', '[1] Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):[2] Muelheims GH, Entrup RW, Paiewonsky D, Mierzwiak DS "Increased sensitivity of the heart to catecholamine-induced arrhythmias following guanethidine." Clin Pharmacol Ther 6 (1965): 757-62[3] Spiers AS, Calne DB "Action of dopamine on the human iris." Br Med J 4 (1969): 333-5', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120106, 'Isoprenaline', 'Ribociclib', 'Major', 'Ribociclib can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Coadministration of ribociclib with other drugs that can prolong the QT interval should generally be avoided.', NULL, 'Coadministration of ribociclib with other drugs that can prolong the QT interval should generally be avoided. However, if concomitant use is required, caution and clinical and laboratory monitoring are recommended. ECGs should be assessed prior to initiation of treatment, during treatment when clinically necessary, and more frequently if QTcF prolongation occurs at any time during treatment. Ribociclib should be permanently discontinued if the QTcF interval prolongation is either greater than 500 msec or there is a greater than 60 msec change from baseline and associated with any of the following: Torsades de Pointes, polymorphic ventricular tachycardia, unexplained syncope, or signs/symptoms of serious arrhythmia. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120244/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):[2] Witchel HJ, Hancox JC, Nutt DJ "Psychotropic drugs, cardiac arrhythmia, and sudden death." J Clin Psychopharmacol 23 (2003): 58-77[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[8] "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.[9] Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] Collins GB, Brosnihan KB, Zuti RA, Messina M, Gupta MK "Neuroendocrine, fluid balance, and thirst responses to alcohol in alcoholics." Alcohol Clin Exp Res 16 (1992): 228-32[12] Hirschl MM, Derfler K, Bieglmayer C, et.al "Hormonal derangements in patients with severe alcohol intoxication." Alcohol Clin Exp Res 18 (1994): 761-6[13] "Product Information. Vasostrict (vasopressin)." Par Pharmaceutical Inc, Chestnut Ridge, NY.[14] Taivainen H, Laitinen K, Tahtela R, Kilanmaa K, Valimaki MJ "Role of plasma vasopressin in changes of water balance accompanying acute alcohol intoxication." Alcohol Clin Exp Res 19 (1995): 759-62[15] Cerner Multum, Inc. "Australian Product Information." O 0[16] "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120107, 'Isoprenaline', 'Ritodrine', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Bremelanotide, Flibanserin, Cabergoline, Black cohosh, Bromocriptine, Naproxen, Ibuprofen', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Cromoglicic acid, Ipratropium, Tiotropium', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120245/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120108, 'Isoprenaline', 'Romidepsin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120246/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120109, 'Isoprenaline', 'Rosiglitazone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Simvastatin, Guar gum, Rosuvastatin', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120247/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120110, 'Isoprenaline', 'Rucaparib', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Pertuzumab, Olaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120248/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120111, 'Isoprenaline', 'Safinamide', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.', NULL, 'Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.', NULL, 'Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Droxidopa, Angiotensin II, Arbutamine, Epinephrine, Methoxamine, Mometasone furoate, Umeclidinium, Budesonide, More', 'Ropinirole, Cabergoline, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Amantadine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120249/', '[1] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5[3] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[4] "Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals, East Hanover, NJ.[5] Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981): 402-4[6] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[7] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim, Ridgefield, CT.[12] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[13] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[14] "Product Information. Isuprel (isoproterenol)." Sanofi Winthrop Pharmaceuticals, New York, NY.[15] "Product Information. S2 Inhalant (racepinephrine)." Nephron Pharmaceuticals, Orlando, FL.[16] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[17] "Product Information. Tornalate Metered Dose (bitolterol)." Dura Pharmaceuticals, San Diego, CA.[18] "Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985): 443-9[19] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[20] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[21] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[22] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[23] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[24] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[25] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[26] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[27] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[28] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[29] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[30] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[31] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[32] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[33] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[34] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[35] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[36] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[37] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120112, 'Isoprenaline', 'Salmeterol', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Salmeterol', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120250/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120113, 'Isoprenaline', 'Saxagliptin', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, More', 'Simvastatin, Guar gum, Rosuvastatin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120251/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120114, 'Isoprenaline', 'Selegiline', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.', NULL, 'Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.', NULL, 'Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.', 'Synergism', 'Ropinirole, Cabergoline, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Amantadine', 'Droxidopa, Arbutamine, Angiotensin II, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120252/', '[1] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5[3] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[4] "Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals, East Hanover, NJ.[5] Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981): 402-4[6] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[7] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim, Ridgefield, CT.[12] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[13] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[14] "Product Information. Isuprel (isoproterenol)." Sanofi Winthrop Pharmaceuticals, New York, NY.[15] "Product Information. S2 Inhalant (racepinephrine)." Nephron Pharmaceuticals, Orlando, FL.[16] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[17] "Product Information. Tornalate Metered Dose (bitolterol)." Dura Pharmaceuticals, San Diego, CA.[18] "Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985): 443-9[19] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[20] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[21] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[22] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[23] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[24] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[25] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[26] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[27] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[28] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[29] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[30] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[31] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[32] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[33] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[34] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[35] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[36] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[37] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120115, 'Isoprenaline', 'Selpercatinib', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120253/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120116, 'Isoprenaline', 'Sertraline', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', 'Paroxetine, St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120254/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120117, 'Isoprenaline', 'Sevoflurane', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', 'Thiopental, Alfentanil, Remifentanil, Isoflurane, Sodium oxybate, Methohexital, Fentanyl, Desflurane, Nitrous oxide, Sufentanil, Enflurane, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120255/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120118, 'Isoprenaline', 'Sibutramine', 'Moderate', 'Additive or synergistic effects on blood pressure and heart rate may occur when sibutramine is combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors. Sibutramine is a potent inhibitor of norepinephrine and serotonin reuptake, and a less potent inhibitor of dopamine reuptake.', NULL, 'Caution is advised if sibutramine is coadministered with other drugs that can increase blood pressure and/or heart rate.', NULL, 'Caution is advised if sibutramine is coadministered with other drugs that can increase blood pressure and/or heart rate. Blood pressure and pulse should be measured prior to initiating therapy with sibutramine and monitored at regular intervals thereafter. Dose reduction or discontinuation of sibutramine should be considered in patients who experience a sustained increase in blood pressure or pulse rate.', 'Synergism', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, More', 'Dexfenfluramine, Lorcaserin, Orlistat, Naltrexone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120256/', '[1] "Product Information. Meridia (sibutramine)." Knoll Pharmaceutical Company, Whippany, NJ.[2] Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68[3] "Product Information. Didrex (benzphetamine)" Pharmacia and Upjohn, Kalamazoo, MI.[4] "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals, Cranford, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120119, 'Isoprenaline', 'Siponimod', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120257/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120120, 'Isoprenaline', 'Solifenacin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Phenylephrine, Fenoldopam, Metaraminol, More', 'Darifenacin, Tadalafil, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120258/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120121, 'Isoprenaline', 'Solriamfetol', 'Moderate', 'Additive or synergistic effects on blood pressure and/or heart rate may occur when solriamfetol is combined with other drugs that increase blood pressure and/or heart rate. The use of solriamfetol alone has been associated with dose-dependent increases in blood pressure and heart rate.', NULL, 'Caution is advised if solriamfetol is used with other drugs that increase blood pressure and/or heart rate.', NULL, 'Caution is advised if solriamfetol is used with other drugs that increase blood pressure and/or heart rate. Blood pressure should be monitored prior to initiating solriamfetol therapy and regularly during treatment. In addition, hypertension should be controlled prior to treatment, and any new-onset hypertension or exacerbations of pre-existing hypertension that occur during solriamfetol therapy should be treated. Discontinuation of solriamfetol should be considered in patients who experience an increase in blood pressure or heart rate that cannot be managed with dose reduction of solriamfetol or other appropriate medical intervention.', 'Synergism', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, Mometasone, More', 'Pemoline, Citicoline, Caffeine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120259/', '[1] "Product Information. Sunosi (solriamfetol)." Jazz Pharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120122, 'Isoprenaline', 'Sorafenib', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120260/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120123, 'Isoprenaline', 'Sotalol', 'Moderate', 'Some beta-blockers may antagonize the bronchodilatory, hypotensive, and tachycardic effects of isoproterenol. The mechanism is blockade of beta-adrenergic receptors, which leads to bronchoconstriction, vasodilation, and increased heart rate. Beta-blockers have been used successfully to treat catecholamine or isoproterenol-induced tachyarrhythmias.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Patients who are receiving isoproterenol for cardiac conditions should be closely monitored for adequate therapeutic effect if a beta blocker is added. If no alternative exists, small doses of a B-1 selective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, or metoprolol) may be preferable; however, respiratory status should be closely monitored in patients with obstructive pulmonary disease.', 'Antagonism', 'Felodipine, Acetylsalicylic acid, Amlodipine, Nifedipine', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine, Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120261/', '[1] Ziegler MG, Chernow B, Woodson LC, Coyle J, Cruess D, Lake CR "The effect of propranolol on catecholamine clearance." Clin Pharmacol Ther 40 (1986): 116-9[2] Pickles H, Perucca E, Fish A, Richens A "Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor." Clin Pharmacol Ther 30 (1981): 303-10[3] Johnsson G, Svedmyr N, Thiringer G "Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics." Eur J Clin Pharmacol 8 (1975): 175-80[4] Thiringer G, Svedmyr N "Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics." Eur J Clin Pharmacol 10 (1976): 163-70[5] Vlay SC "Isoproterenol-induced bradyarrhythmias." Am Heart J 122 (1991): 1169[6] Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986): 251-60[7] Vlay SC "Catecholamine-sensitive ventricular tachycardia." Am Heart J 114 (1987): 455-61[8] Messerli FH, Kuchel O, Tolis G, Hamet P, Fraysse J, Genest J "Effects of beta-adrenergic blockade on plasma cyclic AMP and blood sugar responses to glucagon and isoproterenol in man." Int J Clin Pharmacol Biopharm 14 (1976): 189-94[9] Mann DE, Marmont P, Shultz J, Reiter MJ "Atrioventricular nodal reentrant tachycardia initiated by catecholamine-induced ventricular tachycardia. A case report." J Electrocardiol 24 (1991): 191-5', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120124, 'Isoprenaline', 'Sparfloxacin', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Enoxacin, Nalidixic acid, Cinoxacin, Trovafloxacin, Delafloxacin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120262/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120125, 'Isoprenaline', 'Sunitinib', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120263/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120126, 'Isoprenaline', 'Tacrolimus', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Diclofenac, More', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120264/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120127, 'Isoprenaline', 'Tapentadol', 'Moderate', 'Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors. The use of SNRIs alone has been associated with sustained increases in blood pressure and heart rate, and cases of elevated blood pressure requiring immediate treatment have been reported in postmarketing experience.', NULL, 'Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.', NULL, 'Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate. Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter. Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate.', 'Synergism', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Budesonide, Aclidinium, Mometasone, More', 'Naltrexone, Oxymorphone, Oxycodone, Pentazocine, Morphine, Butorphanol, Fentanyl, Ibuprofen, Codeine, Nalbuphine, Acetaminophen, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120265/', '[1] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[4] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[6] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[12] Maish WA, Hampton EM, Whitsett TL, Shepard JD, Lovallo WR "Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics." Pharmacotherapy 16 (1996): 1046-52', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120128, 'Isoprenaline', 'Telavancin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Vancomycin, Metronidazole, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120266/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120129, 'Isoprenaline', 'Telithromycin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dirithromycin, Lincomycin, Troleandomycin, Clindamycin', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120267/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120130, 'Isoprenaline', 'Terbutaline', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Isoprenaline, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium', 'Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Terbutaline, Umeclidinium, Aclidinium, Glycopyrronium, Cromoglicic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120268/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120131, 'Isoprenaline', 'Terfenadine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120269/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120132, 'Isoprenaline', 'Tetrabenazine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120270/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120133, 'Isoprenaline', 'Tetryzoline (nasal)', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120271/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120134, 'Isoprenaline', 'Tetryzoline (ophthalmic)', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120272/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120135, 'Isoprenaline', 'Thallous Chloride', 'Moderate', 'Coadministration of certain drugs may alter the myocardial uptake of thallous chloride Tl-201 and interfere with results of myocardial imaging studies. Drugs that increase or decrease coronary blood flow or potassium uptake may alter the biodistribution of thallous chloride Tl-201.', NULL, 'Clinicians should be aware of possible diagnostic interference by these drugs.', NULL, 'Clinicians should be aware of possible diagnostic interference by these drugs.', 'Others', 'Droxidopa, Norepinephrine, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120273/', '[1] "Product Information. Thallous Chloride Tl 201 (thallous chloride Tl-201)." GE Healthcare, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Nuclear Pharmacy Website. University of Arkansas for Medical Sciences. College of Pharmacy "Drug - Radiopharmaceutical Interactions. Available from: URL: http://nuclearpharmacy.uams.edu/nicki.html#tl." ([cited Feb2015]):', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120136, 'Isoprenaline', 'Thioridazine', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Metaraminol, Methoxamine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120274/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120137, 'Isoprenaline', 'Timolol', 'Moderate', 'Some beta-blockers may antagonize the bronchodilatory, hypotensive, and tachycardic effects of isoproterenol. The mechanism is blockade of beta-adrenergic receptors, which leads to bronchoconstriction, vasodilation, and increased heart rate. Beta-blockers have been used successfully to treat catecholamine or isoproterenol-induced tachyarrhythmias.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Patients who are receiving isoproterenol for cardiac conditions should be closely monitored for adequate therapeutic effect if a beta blocker is added. If no alternative exists, small doses of a B-1 selective beta-blocker (e.g., acebutolol, atenolol, betaxolol, bisoprolol, or metoprolol) may be preferable; however, respiratory status should be closely monitored in patients with obstructive pulmonary disease.', 'Antagonism', 'Latanoprost, Apraclonidine, Methazolamide, Neostigmine, Pilocarpine, Clonidine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, More', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Methoxamine, Mometasone furoate, Umeclidinium, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, Beclomethasone dipropionate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120275/', '[1] Ziegler MG, Chernow B, Woodson LC, Coyle J, Cruess D, Lake CR "The effect of propranolol on catecholamine clearance." Clin Pharmacol Ther 40 (1986): 116-9[2] Pickles H, Perucca E, Fish A, Richens A "Propranolol and sotalol as antagonists of isoproterenol-enhanced physiologic tremor." Clin Pharmacol Ther 30 (1981): 303-10[3] Johnsson G, Svedmyr N, Thiringer G "Effects of intravenous propranolol and metoprolol and their interaction with isoprenaline on pulmonary function, heart rate and blood pressure in asthmatics." Eur J Clin Pharmacol 8 (1975): 175-80[4] Thiringer G, Svedmyr N "Interaction of orally administered metoprolol, practolol and propranolol with isoprenaline in asthmatics." Eur J Clin Pharmacol 10 (1976): 163-70[5] Vlay SC "Isoproterenol-induced bradyarrhythmias." Am Heart J 122 (1991): 1169[6] Falliers CJ, Vincent ME, Medakovic M "Effect of single doses of labetalol, metoprolol, and placebo on ventilatory function in patients with bronchial asthma: interaction with isoproterenol." J Asthma 23 (1986): 251-60[7] Vlay SC "Catecholamine-sensitive ventricular tachycardia." Am Heart J 114 (1987): 455-61[8] Messerli FH, Kuchel O, Tolis G, Hamet P, Fraysse J, Genest J "Effects of beta-adrenergic blockade on plasma cyclic AMP and blood sugar responses to glucagon and isoproterenol in man." Int J Clin Pharmacol Biopharm 14 (1976): 189-94[9] Mann DE, Marmont P, Shultz J, Reiter MJ "Atrioventricular nodal reentrant tachycardia initiated by catecholamine-induced ventricular tachycardia. A case report." J Electrocardiol 24 (1991): 191-5', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120138, 'Isoprenaline', 'Tizanidine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Carisoprodol, Orphenadrine, Chlorzoxazone, Baclofen, Cyclobenzaprine, Methocarbamol, Chlormezanone', 'Dobutamine, Norepinephrine, Midodrine, Droxidopa, Angiotensin II, Ephedrine, Arbutamine, Phenylephrine, Metaraminol, Dopamine, Methoxamine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120276/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120139, 'Isoprenaline', 'Tolazamide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Simvastatin, Guar gum, Rosuvastatin', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120277/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120140, 'Isoprenaline', 'Tolbutamide', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Umeclidinium, Budesonide, Glycopyrronium, Aclidinium, More', 'Methacholine, Hexaminolevulinate, Secretin human, Sermorelin, Sorbitol, Galactose, Magnesium sulfate, Vitamin A, Caffeine, Metyrapone, Edrophonium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120278/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120141, 'Isoprenaline', 'Tolcapone', 'Moderate', 'COMT inhibitors affect the elimination of drugs metabolized by catechol-O-methyltransferase (COMT) and may potentiate their effects. Arrhythmias, increased heart rate, and blood pressure changes may occur. Entacapone has increased heart rates up to 80% when coadministered with isoproterenol and epinephrine. Ventricular tachycardia has also been reported.', NULL, 'The manufacturer recommends that caution be exercised when these drugs are given together.', NULL, 'The manufacturer recommends that caution be exercised when these drugs are given together. Monitoring for changes in hemodynamic status and ECG is recommended.', 'Metabolism', 'Ropinirole, Cabergoline, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Amantadine', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Methoxamine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120279/', '[1] "Product Information. Comtan (entacapone)" Novartis Pharmaceuticals, East Hanover, NJ.[2] "Product Information. Tasmar (tolcapone)." Valeant Pharmaceuticals, Costa Mesa, CA.[3] Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A "The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine." Clin Pharmacol Ther 58 (1995): 221-7[4] "Product Information. Ongentys (opicapone)." Neurocrine Biosciences, Inc., San Diego, CA.[5] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120142, 'Isoprenaline', 'Toremifene', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Darolutamide, Anastrozole, Fulvestrant, Letrozole, Aminoglutethimide, Exemestane', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120280/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120143, 'Isoprenaline', 'Tranylcypromine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) can potentiate the cardiovascular adverse effects of beta-2 adrenergic agonists such as hypertension, palpitation, tachycardia, and chest pain.', NULL, 'Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.', NULL, 'Cardiovascular status should be closely monitored when beta-2 agonists are coadministered with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). Preferably, at least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with beta-2 agonists.', 'Synergism', 'Paroxetine, St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Arbutamine, Angiotensin II, Mometasone furoate, Umeclidinium, Budesonide, Aclidinium, Mometasone, Cromoglicic acid, Ipratropium, Tiotropium, Beclomethasone dipropionate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120281/', '[1] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5[3] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[4] "Product Information. Brethaire (terbutaline)." Novartis Pharmaceuticals, East Hanover, NJ.[5] Finch JS "Cardiovascular toxicity: clinical evaluation of albuterol, isoproterenol and placebo in rising dose tolerance trial." Ann Allergy 47 (1981): 402-4[6] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[7] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Alupent (metaproterenol)." Boehringer-Ingelheim, Ridgefield, CT.[12] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[13] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[14] "Product Information. Isuprel (isoproterenol)." Sanofi Winthrop Pharmaceuticals, New York, NY.[15] "Product Information. S2 Inhalant (racepinephrine)." Nephron Pharmaceuticals, Orlando, FL.[16] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[17] "Product Information. Tornalate Metered Dose (bitolterol)." Dura Pharmaceuticals, San Diego, CA.[18] "Adverse effects and complications of treatment with beta-adrenergic agonist drugs. Committee on drugs, the American Academy of Allergy and Immunology." J Allergy Clin Immunol 75 (1985): 443-9[19] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[20] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[21] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[22] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[23] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[24] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[25] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[26] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[27] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[28] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[29] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[30] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[31] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[32] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[33] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[34] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[35] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[36] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[37] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120144, 'Isoprenaline', 'Triclabendazole', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Praziquantel, Oxamniquine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120282/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120145, 'Isoprenaline', 'Trifluoperazine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Metaraminol, Methoxamine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120283/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120146, 'Isoprenaline', 'Triflupromazine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Metaraminol, Methoxamine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120284/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120147, 'Isoprenaline', 'Alimemazine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Milrinone, Arbutamine, Phenylephrine, Metaraminol, Methoxamine, More', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120285/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120148, 'Isoprenaline', 'Trimipramine', 'Moderate', 'The concomitant use of isoproterenol and tricyclic antidepressants may increase the risk of arrhythmias, especially at high doses. The mechanism has not been delineated. Tachycardia has been reported in clinical studies.', NULL, 'Some authorities suggest that the initial rate and dose of isoproterenol should be reduced in patients taking tricyclic antidepressants, and then titrated, as is usual according to clinical response to avoid the risk of developing hypertension or arrhythmias.', NULL, 'Some authorities suggest that the initial rate and dose of isoproterenol should be reduced in patients taking tricyclic antidepressants, and then titrated, as is usual according to clinical response to avoid the risk of developing hypertension or arrhythmias. Patients receiving this combination should be monitored and advised to notify their physician if they experience a fast or irregular pulse.', 'Synergism', 'Paroxetine, St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Mephentermine, Mometasone furoate, Budesonide, Mometasone, Cromoglicic acid, Beclomethasone dipropionate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120286/', '[1] Kadar D "Letter: Amitriptyline and isoproterenol: fatal drug combination." Can Med Assoc J 112 (1975): 556-7[2] Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120149, 'Isoprenaline', 'Troglitazone', 'Moderate', 'The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary.', NULL, 'Close clinical monitoring of glycemic control is recommended following initiation or discontinuation of these drugs, and the dosages of concomitant antidiabetic agents adjusted as necessary. Patients should be advised to notify their physician if their blood glucose is consistently high or if they experience symptoms of severe hyperglycemia such as excessive thirst and increases in the volume or frequency of urination.', 'Antagonism', 'Simvastatin, Guar gum, Rosuvastatin', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Metaraminol, Methoxamine, Mephentermine, Umeclidinium, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120287/', '[1] Jori A, Carrara MC "On the mechanism of the hyperglycaemic effect of chlorpromazine." J Pharm Pharmacol 18 (1966): 623-4[2] "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Thorazine (chlorpromazine)." SmithKline Beecham, Philadelphia, PA.[4] Blayac JP, Ribes G, Buys D, Puech R, Loubatieres-Mariani MM "Effects of a new benzothiadiazine derivative, LN 5330, on insulin secretion." Arch Int Pharmacodyn Ther 253 (1981): 154-63[5] "Product Information. Elzonris (tagraxofusp)." Stemline Therapeutics, New York, NY.[6] "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.[7] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[8] Jones IG, Pickens PT "Diabetes mellitus following oral diuretics." Practitioner 199 (1967): 209-10[9] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.[10] "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.[11] Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3[12] Virutamasen P, Wongsrichanalai C, Tangkeo P, Nitichai Y, Rienprayoon D "Metabolic effects of depot-medroxyprogesterone acetate in long-term users: a cross-sectional study." Int J Gynaecol Obstet 24 (1986): 291-6[13] Wehring H, Alexander B, Perry PJ "Diabetes mellitus associated with clozapine therapy." Pharmacotherapy 20 (2000): 844-7[14] Spellacy WN, Ellingson AB, Tsibris JC "The effects of two triphasic oral contraceptives on carbohydrate metabolism in women during 1 year of use." Fertil Steril 51 (1989): 71-4[15] Andersen OO, Persson I "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J 2 (1968): 798-801[16] Berlin I "Prazosin, diuretics, and glucose intolerance." Ann Intern Med 119 (1993): 860[17] Malherbe C, Burrill KC, Levin SR, Karam JH, Forsham PH "Effect of diphenylhydantoin on insulin secretion in man." N Engl J Med 286 (1972): 339-42[18] Carter BL, Small RE, Mandel MD, Starkman MT "Phenytoin-induced hyperglycemia." Am J Hosp Pharm 38 (1981): 1508-12[19] Al-Rubeaan K, Ryan EA "Phenytoin-induced insulin insensitivity." Diabet Med 8 (1991): 968-70[20] "Product Information. Zolinza (vorinostat)." Merck & Company Inc, West Point, PA.[21] Goldman JA, Neri A, Ovadia J, Eckerling B, Vries A, de "Effect of chlorothiazide on intravenous glucose tolerance in pregnancy." Am J Obstet Gynecol 105 (1969): 556-60[22] Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM "A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM." Diabetologia 38 (1995): 853-9[23] Seltzer HS, Allen EW "Hyperglycemia and inhibition of insulin secretion during administration of diazoxide and trichlormethiazide in man." Diabetes 18 (1969): 19-28[24] Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4[25] Leary WP, Reyes AJ "Drug interactions with diuretics." S Afr Med J 65 (1984): 455-61[26] "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb, Princeton, NJ.[27] Pollare T, Lithell H, Berne C "A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension." N Engl J Med 321 (1989): 868-73[28] Gunnarsson R, Lundgren G, Magnusson G, Ost L, Groth CG "Steroid diabetes--a sign of overtreatment with steroids in the renal graft recipient?" Scand J Urol Nephrol Suppl 54 (1980): 135-8[29] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[30] "Product Information. Synthroid (levothyroxine)." Abbott Pharmaceutical, Abbott Park, IL.[31] Murphy MB, Kohner E, Lewis PJ, Schumer B, Dollery CT "Glucose intolerance in hypertensive patients treated with diuretics: a fourteen-year follow-up." Lancet 2 (1982): 1293-5[32] "Product Information. Fortovase (saquinavir)" Roche Laboratories, Nutley, NJ.[33] Coni NK, Gordon PW, Mukherjee AP, Read PR "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing 3 (1974): 85-90[34] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[35] Domenet JG "Diabetogenic effect of oral diuretics." Br Med J 3 (1968): 188[36] Rowe P, Mather H "Hyperosmolar non-ketotic diabetes mellitus associated with metolazone." Br Med J 291 (1985): 25-6[37] Winchester JF, Kellett RJ, Boddy K, Boyle P, Dargie HJ, Mahaffey ME, Ward DM, Kennedy AC "Metolazone and bendroflumethiazide in hypertension: physiologic and metabolic observations." Clin Pharmacol Ther 28 (1980): 611-8[38] "Product Information. Carafate (sucralfate)." Hoechst Marion-Roussel Inc, Kansas City, MO.[39] Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6[40] "Product Information. Apidra (insulin glulisine)." Aventis Pharmaceuticals, Bridgewater, NJ.[41] "Product Information. Prezista (darunavir)." Ortho Biotech Inc, Bridgewater, NJ.[42] Haiba NA, el-Habashy MA, Said SA, Darwish EA, Abdel-Sayed WS, Nayel SE "Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters." Contraception 39 (1989): 619-32[43] Erle G, Basso M, Federspil G, Sicolo N, Scandellari C "Effect of chlorpromazine on blood glucose and plasma insulin in man." Eur J Clin Pharmacol 11 (1977): 15-8[44] Pickkers P, Schachter M, Hughes AD, Feher MD, Sever PS "Thiazide-induced hyperglycaemia: a role for calcium-activated potassium channels?" Diabetologia 39 (1996): 861-4[45] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[46] Curtis J, Horrigan F, Ahearn D, Varney R, Sandler SG "Chlorthalidone-induced hyperosmolar hyperglycemic nonketotic coma." JAMA 220 (1972): 1592-3[47] "Product Information. Hyperstat I.V. (diazoxide)." Schering Corp, Kenilworth, NJ.[48] "Product Information. Piqray (alpelisib)." Novartis Pharmaceuticals, East Hanover, NJ.[49] Bell DS "Insulin resistance. An often unrecognized problem accompanying chronic medical disorders." Postgrad Med 93 (1993): 99-103,[50] Stambaugh JE, Tucker DC "Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia." Diabetes 23 (1974): 679-83[51] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[52] Miller NR, Moses H "Transient oculomotor nerve palsy. Association with thiazide-induced glucose intolerance." JAMA 240 (1978): 1887-8[53] Javier Z, Gershberg H, Hulse M "Ovulatory suppressants, estrogens, and carbohydrate metabolism." Metabolism 17 (1968): 443-56[54] Goldman JA, Ovadia JL "The effect of estrogen on intravenous glucose tolerance in woman." Am J Obstet Gynecol 103 (1969): 172-8[55] Charan VD, Desai N, Singh AP, Choudhry VP "Diabetes mellitus and pancreatitis as a complication of L- asparaginase therapy." Indian Pediatr 30 (1993): 809-10[56] Seifer DB, Freedman LN, Cavender JR, Baker RA "Insulin-dependent diabetes mellitus associated with danazol." Am J Obstet Gynecol 162 (1990): 474-5[57] "Product Information. Orinase (tolbutamide)" Pharmacia and Upjohn, Kalamazoo, MI.[58] Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8[59] Hannaford PC, Kay CR "Oral contraceptives and diabetes mellitus." BMJ 299 (1989): 1315-6[60] Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51[61] Chowdhury FR, Bleicher SJ "Chlorthalidone--induced hypokalemia and abnormal carbohydrate metabolism." Horm Metab Res 2 (1970): 13-6[62] Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7[63] Greenstone MA, Shaw AB "Alternate day corticosteroid causes alternate day hyperglycaemia." Postgrad Med J 63 (1987): 761-4[64] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[65] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[66] Elmfeldt D, Berglund G, Wedel H, Wilhelmsen L "Incidence and importance of metabolic side-effects during antihypertensive therapy." Acta Med Scand Suppl 672 (1983): 79-83[67] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[68] Diamond MT "Hyperglycemic hyperosmolar coma associated with hydrochlorothiazide and pancreatitis." N Y State J Med 72 (1972): 1741-2[69] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[70] "Product Information. Precose (acarbose)." Bayer, West Haven, CT.[71] "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.[72] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[73] Sotaniemi E, Kontturi M, Larmi T "Effect of diethylstilbestrol on blood glucose of prostatic cancer patients." Invest Urol 10 (1973): 438-41[74] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[75] Petri M, Cumber P, Grimes L, Treby D, Bryant R, Rawlins D, Ising H "The metabolic effects of thiazide therapy in the elderly: a population study." Age Ageing 15 (1986): 151-5[76] Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R "Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans." Diabetologia 36 (1993): 84-7[77] "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.[78] Chaudhuri ML, Catania J "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract 42 (1988): 427-9[79] Black DM, Filak AT "Hyperglycemia with non-insulin-dependent diabetes following intraarticular steroid injection." J Fam Pract 28 (1989): 462-3[80] "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.[81] "Product Information. Torisel (temsirolimus)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[82] Schmitz O, Hermansen K, Nielsen OH, Christensen CK, Arnfred J, Hansen HE, Mogensen CE, Orskov H, Beck-Nielsen H "Insulin action in insulin-dependent diabetics after short-term thiazide therapy." Diabetes Care 9 (1986): 631-6[83] Kansal PC, Buse J, Buse MG "Thiazide diuretics and control of diabetes mellitus." South Med J 62 (1969): 1372-9[84] Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res 25 (1993): 557-9[85] "Product Information. NovoLog Mix 70/30 (insulin aspart-insulin aspart protamine)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[86] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[87] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[88] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[89] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[90] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[91] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[92] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[93] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[94] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[95] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120150, 'Isoprenaline', 'Valbenazine', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Inotersen, Amifampridine, Tafamidis', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120288/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120151, 'Isoprenaline', 'Vandetanib', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Imatinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Tepotinib, Fedratinib, Avapritinib, Larotrectinib, Selumetinib, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120289/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120152, 'Isoprenaline', 'Vasopressin', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Droxidopa, Midodrine, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, Methoxamine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120290/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120153, 'Isoprenaline', 'Vemurafenib', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120291/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120154, 'Isoprenaline', 'Venlafaxine', 'Moderate', 'Additive or synergistic effects on blood pressure and heart rate may occur when serotonin-norepinephrine reuptake inhibitors (SNRIs) are combined with sympathomimetic agents such as nasal decongestants, adrenergic bronchodilators, ophthalmic vasoconstrictors, and systemic vasopressors. The use of SNRIs alone has been associated with sustained increases in blood pressure and heart rate, and cases of elevated blood pressure requiring immediate treatment have been reported in postmarketing experience.', NULL, 'Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate.', NULL, 'Caution is advised if SNRIs are used with other drugs that can increase blood pressure and/or heart rate. Blood pressure and pulse should be measured prior to initiating SNRI therapy and monitored at regular intervals thereafter. Dose reduction or discontinuation of the SNRI should be considered in patients who experience a sustained increase in blood pressure or pulse rate.', 'Synergism', 'Paroxetine, St. John''s Wort, Nefazodone, Oxitriptan, Viloxazine, Vortioxetine, Tryptophan, Vilazodone, Esketamine, Fluvoxamine', 'Droxidopa, Amrinone, Angiotensin II, Milrinone, Arbutamine, Fenoldopam, Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Mometasone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120292/', '[1] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] "Product Information. Cymbalta (duloxetine)." Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Nucynta (tapentadol)." PriCara Pharmaceuticals, Raritan, NJ.[4] "Product Information. Effexor (venlafaxine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] "Product Information. Pristiq (desvenlafaxine)." Wyeth Laboratories, Philadelphia, PA.[6] "Product Information. Savella (milnacipran)." Forest Pharmaceuticals, St. Louis, MO.[7] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[9] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[10] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[11] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[12] Maish WA, Hampton EM, Whitsett TL, Shepard JD, Lovallo WR "Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics." Pharmacotherapy 16 (1996): 1046-52', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120155, 'Isoprenaline', 'Voriconazole', 'Moderate', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death. Clinically significant prolongation of QT interval and hypokalemia occur infrequently when beta-2 agonists are inhaled at normally recommended dosages. However, these effects may be more common when the drugs are administered systemically or when recommended dosages are exceeded.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval.', NULL, 'Caution is recommended if beta-2 agonists are used in combination with other drugs that can prolong the QT interval. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Synergism', 'Caspofungin, Micafungin, Amphotericin B, Itraconazole, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120293/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[3] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[4] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[5] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[6] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[7] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24[8] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[9] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[10] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[11] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[12] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[13] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[14] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[15] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[16] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[17] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[18] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[19] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[20] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[21] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[22] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[23] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[24] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[25] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[26] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[27] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[28] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[29] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[30] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120156, 'Isoprenaline', 'Xylometazoline (nasal)', 'Moderate', 'Coadministration of beta-2 adrenergic agonists with other adrenergic agents may potentiate the risk of cardiovascular side effects. Beta-2 adrenergic agonists can produce clinically significant cardiovascular effects including increases in pulse rate and systolic or diastolic blood pressure as well as ECG changes such as flattening of the T wave, prolongation of the QTc interval, and ST segment depression. The risk is lower when beta-2 adrenergic agonists are inhaled at normally recommended dosages.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used concomitantly with other adrenergic agents, particularly in patients with cardiovascular disorders such as coronary insufficiency, cardiac arrhythmias, hypertrophic obstructive cardiomyopathy, or hypertension. Blood pressure and heart rate should be closely monitored.', 'Synergism', 'Dobutamine, Norepinephrine, Droxidopa, Amrinone, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Fenoldopam, Metaraminol, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120294/', '[1] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[2] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[3] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[4] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[5] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.[6] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[7] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[8] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[9] "Product Information. Striverdi Respimat (olodaterol)." Boehringer Ingelheim, Ridgefield, CT.[10] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[11] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120157, 'Isoprenaline', 'Ziprasidone', 'Major', 'Beta-2 adrenergic agonists can cause dose-related prolongation of the QT interval and potassium loss. Theoretically, coadministration with other agents that can prolong the QT interval may result in additive effects and increased risk of ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride.', NULL, 'Caution is advised if beta-2 adrenergic agonists are used in combination with other drugs that prolong the QT interval, including class IA and III antiarrhythmic agents, certain neuroleptic agents, phenothiazines, tricyclic antidepressants, quinolones, ketolide and macrolide antibiotics, and cisapride. It may be appropriate to monitor ECG and serum electrolytes during chronic systemic use or high-dose therapy. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Synergism', 'Thiothixene, Lumateperone, Loxapine, Molindone, Cariprazine, Brexpiprazole, Lurasidone', 'Dobutamine, Norepinephrine, Midodrine, Amrinone, Droxidopa, Angiotensin II, Ephedrine, Milrinone, Arbutamine, Phenylephrine, Metaraminol, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120295/', '[1] Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R "A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol." N Z Med J 103 (1990): 259-61[2] Rakhmanina NY, Kearns GL, Farrar HC "Hypokalemia in an asthmatic child from abuse of albuterol metered dose inhaler." Pediatr Emerg Care 14 (1998): 145-7[3] Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32[4] Braden GL, vonOeyen PT, Germain MJ, Watson DJ, Haag BL "Ritodrine- and terbutaline-induced hypokalemia in preterm labor: Mechanisms and consequences." Kidney Int 51 (1997): 1867-75[5] Kantola I, Tarssanen L "Hypokalemia from usual salbutamol dosage ." Chest 89 (1986): 619-20[6] Dickens GR, Mccoy RA, West R, Stapczynski JS, Clifton GD "Effect of nebulized albuterol on serum potassium and cardiac rhythm in patients with asthma or chronic obstructive pulmonary disease." Pharmacotherapy 14 (1994): 729-33[7] Larsson S, Svedmyr N "Bronchodilating effect and side effects of beta2- adrenoceptor stimulants by different modes of administration (tablets, metered aerosol, and combinations thereof). A study with salbutamol inasthmatics." Am Rev Respir Dis 116 (1977): 861-9[8] Hurlbert BJ, Edelman JD, David K "Serum potassium levels during and after terbutaline." Anesth Analg 60 (1981): 723-5[9] Tveskov C, Djurhuus MS, Klitgaard NAH, Egstrup K "Potassium and magnesium distribution, ECG changes, and ventricular ectopic beats during beta(2)-adrenergic stimulation with terbutaline in healthy subjects." Chest 106 (1994): 1654-9[10] "Product Information. Proventil (albuterol)." Schering Laboratories, Kenilworth, NJ.[11] "Product Information. Foradil (formoterol)" Novartis Pharmaceuticals, East Hanover, NJ.[12] Gross TL, Sokol RJ "Severe hypokalemia and acidosis: a potential complication of beta- adrenergic treatment." Am J Obstet Gynecol 138 (1980): 1225-6[13] Lowe MD, Rowland E, Brown MJ, Grace AA "Beta(2) adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium." Heart 86 (2001): 45-51[14] Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6[15] Sun ZH, Swan H, Vitasalo M, Toivonen L "Effects of epinephrine and phenylephrine on QT interval dispersion in congenital long QT syndrome." J Am Coll Cardiol 31 (1998): 1400-5[16] "Product Information. Brovana (arformoterol)." Sepracor Inc, Marlborough, MA.[17] Whyte KF, Addis GJ, Whitesmith R, Reid JL "The mechanism of salbutamol-induced hypokalaemia." Br J Clin Pharmacol 23 (1987): 65-71[18] "Product Information. Xopenex (levalbuterol)." Sepracor, Marlborough, MA.[19] "Product Information. Maxair (pirbuterol)." 3M Pharmaceuticals, St. Paul, MN.[20] Hastwell G, Lambert BE "The effect of oral salbutamol on serum potassium and blood sugar." Br J Obstet Gynaecol 85 (1978): 767-9[21] "Product Information. Severent (salmeterol)." Glaxo Wellcome, Research Triangle Park, NC.[22] Milic M, Bao X, Rizos D, Liu F, Ziegler MG "Literature review and pilot studies of the effect of qt correction formulas on reported beta(2)-agonist-induced QTc prolongation." Clin Ther 28 (2006): 582-90[23] Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE "Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma." Lancet 336 (1990): 1396-9[24] Sanders JP, Potter DE, Ellis S, Bee DE, Grant JA "Metabolic and cardiovascular effects of carbuterol and metaproterenol." J Allergy Clin Immunol 60 (1977): 174-9[25] Clifton GD, Hunt BA, Patel RC, Burki NK "Effects of sequential doses of parenteral terbutaline on plasma levels of potassium and related cardiopulmonary responses." Am Rev Respir Dis 141 (1990): 575-9[26] "Hypokalaemia due to salbutamol overdosage." Br Med J (Clin Res Ed) 283 (1981): 500-1[27] Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C "Cardiovascular Safety of Salmeterol in COPD." Chest 123 (2003): 1817-24', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120158, 'Isosorbide dinitrate', 'Amoxapine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120296/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120159, 'Isosorbide dinitrate', 'Oxybuprocaine (ophthalmic)', 'Moderate', 'Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.', 'Synergism', 'Nesiritide, Vericiguat, Zinc sulfate, Diltiazem, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Prednisolone, Betamethasone, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120297/', '[1] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009): 837-45[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Hurricaine (benzocaine topical)." Beutlich, Waukegan, IL.[4] "Product Information. Chloraseptic (benzocaine-menthol topical)." Prestige Brands (formerly MedTech), Tarrytown, NY.[5] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011): 757-61[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Karim A, Ahmed S, Siddiqui R, Mattana J "Methemoglobinemia complicating topical lidocaine used during endoscopic procedures." Am J Med 111 (2001): 150-3', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120160, 'Isosorbide dinitrate', 'Butabarbital', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120298/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120161, 'Isosorbide dinitrate', 'Chloral hydrate', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120299/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120162, 'Isosorbide dinitrate', 'Chlorpromazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120300/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120163, 'Isosorbide dinitrate', 'Dapsone', 'Moderate', 'Coadministration of oral or topical dapsone with other agents associated with methemoglobinemia may have additive effects and theoretically increase the risk of drug-induced methemoglobinemia. Oral and topical dapsone have been associated with methemoglobinemia, and the risk is increased in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital or idiopathic methemoglobinemia.', NULL, 'Concurrent use of oral or topical dapsone with other methemoglobinemia-inducing medications should be followed with monitoring for signs and symptoms of methemoglobinemia (e.', NULL, 'Concurrent use of oral or topical dapsone with other methemoglobinemia-inducing medications should be followed with monitoring for signs and symptoms of methemoglobinemia (e.g., cyanosis, hypoxia).', 'Synergism', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Clofazimine', 'Nesiritide, Vericiguat, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Prednisolone, Betamethasone, Fluorometholone, Zinc gluconate, Dexamethasone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120301/', '[1] "Product Information. Aczone (dapsone topical)." QLT USA, Inc, Fort Collins, CO.[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120164, 'Isosorbide dinitrate', 'Cinchocaine (topical)', 'Moderate', 'Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.', 'Synergism', 'Nesiritide, Vericiguat, Zinc sulfate, Diltiazem, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Prednisolone, Betamethasone, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120302/', '[1] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009): 837-45[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Hurricaine (benzocaine topical)." Beutlich, Waukegan, IL.[4] "Product Information. Chloraseptic (benzocaine-menthol topical)." Prestige Brands (formerly MedTech), Tarrytown, NY.[5] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011): 757-61[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Karim A, Ahmed S, Siddiqui R, Mattana J "Methemoglobinemia complicating topical lidocaine used during endoscopic procedures." Am J Med 111 (2001): 150-3', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120165, 'Isosorbide dinitrate', 'Dimenhydrinate', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120303/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120166, 'Isosorbide dinitrate', 'Epoprostenol', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Triamcinolone, Zinc gluconate', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120304/', '[1] "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC.[2] "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Buchdahl RM, Taylor P, Warner JD "Nebulised ribavirin for adenovirus pneumonia." Lancet 2 (1985): 1070-1[5] "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120167, 'Isosorbide dinitrate', 'Ergometrine', 'Moderate', 'Ergot alkaloids, by causing vasoconstriction, may theoretically antagonize the effects of nitrates. In addition, nitrates may increase splanchnic blood flow, resulting in decreased first-pass metabolism of dihydroergotamine and increased bioavailability.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Ergot alkaloids are considered contraindicated in patients with ischemic heart disease.', 'Antagonism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Misoprostol, Dinoprostone, Oxytocin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120305/', '[1] Bobik A, Jennings G, Skews H, Esler M, McLean A "Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension." Clin Pharmacol Ther 30 (1981): 673-9[2] Raberger G, Schutz W, Zimpfer M, Kraupp O "The influence of dihydroergotamine on adenosine-induced and reactive coronary vasodilation. Interaction of dihydroergotamine and coronary vasodilation." Basic Res Cardiol 71 (1976): 645-51[3] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[7] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120168, 'Isosorbide dinitrate', 'Ergotamine', 'Moderate', 'Ergot alkaloids, by causing vasoconstriction, may theoretically antagonize the effects of nitrates. In addition, nitrates may increase splanchnic blood flow, resulting in decreased first-pass metabolism of dihydroergotamine and increased bioavailability.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Ergot alkaloids are considered contraindicated in patients with ischemic heart disease.', 'Antagonism', 'Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Naratriptan, Galcanezumab, Zolmitriptan, More', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120306/', '[1] Bobik A, Jennings G, Skews H, Esler M, McLean A "Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension." Clin Pharmacol Ther 30 (1981): 673-9[2] Raberger G, Schutz W, Zimpfer M, Kraupp O "The influence of dihydroergotamine on adenosine-induced and reactive coronary vasodilation. Interaction of dihydroergotamine and coronary vasodilation." Basic Res Cardiol 71 (1976): 645-51[3] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[7] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120169, 'Isosorbide dinitrate', 'Ertugliflozin', 'Moderate', 'Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.', NULL, 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.', NULL, 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.', 'Synergism', 'Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate', 'Exenatide, Lixisenatide, Albiglutide, Acetohexamide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120307/', '[1] "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb, Princeton, NJ.[5] "Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals, Titusville, NJ.[6] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[9] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[10] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120170, 'Isosorbide dinitrate', 'Fluphenazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120308/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120171, 'Isosorbide dinitrate', 'Flurazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 'Nesiritide, Vericiguat, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Prednisolone, Betamethasone, Fluorometholone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120309/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120172, 'Isosorbide dinitrate', 'Fosinopril', 'Moderate', 'Angiotensin converting enzyme (ACE) inhibitors may enhance the vasodilatory and hypotensive effects of nitroglycerin. Data have also shown that captopril can prevent nitrate tolerance. ACE inhibitors can decrease systemic vascular resistance and cardiac work, further enhancing the effectiveness of nitroglycerin.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose. Blood pressure monitoring is advisable.', 'Synergism', 'Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120310/', '[1] Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7[2] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[3] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[4] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120173, 'Isosorbide dinitrate', 'Garlic', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', 'Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120311/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120174, 'Isosorbide dinitrate', 'Haloperidol', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120312/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120175, 'Isosorbide dinitrate', 'Diamorphine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Acamprosate, Naltrexone, Disulfiram, Levacetylmethadol, Nalmefene', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120313/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120176, 'Isosorbide dinitrate', 'Hydromorphone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120314/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120177, 'Isosorbide dinitrate', 'Hydroxyzine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Halazepam', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120315/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120178, 'Isosorbide dinitrate', 'Iloperidone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Droperidol, Pimozide, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120316/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120179, 'Isosorbide dinitrate', 'Iloprost', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate, Dexamethasone', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120317/', '[1] "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC.[2] "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Buchdahl RM, Taylor P, Warner JD "Nebulised ribavirin for adenovirus pneumonia." Lancet 2 (1985): 1070-1[5] "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120180, 'Isosorbide dinitrate', 'Imipramine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120318/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120181, 'Isosorbide dinitrate', 'Licorice', 'Moderate', 'Licorice use has been associated with hypertension and may antagonize the effects of antihypertensive agents. Glycyrrhizic acid, a component of licorice, is hydrolyzed in the intestine to a metabolite (glycyrrhetinic acid) that causes mineralocorticoid and renin-suppressing effects.', NULL, 'Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products.', NULL, 'Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products. Even relatively moderate doses of licorice may be problematic in susceptible patients when ingested regularly for prolonged periods.', 'Antagonism', 'Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120319/', '[1] Cumming AM "Metabolic effects of licorice." Br Med J 1 (1977): 906[2] Epstein MT, Espiner EA, Donald RA, Hughes H "Effect of eating liquorice on the renin-angiotensin aldosterone axis in normal subjects." Br Med J 1 (1977): 488-90[3] Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR "Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age." Lancet 2 (1987): 821-4[4] Elinav E, Chajek-Shaul T "Licorice consumption causing severe hypokalemic paralysis." Mayo Clin Proc 78 (2003): 767-8[5] Rosseel M, Schoors D "Chewing gum and hypokalaemia." Lancet 341 (1993): 175[6] Clyburn EB, DiPette DJ "Hypertension induced by drugs and other substances." Semin Nephrol 15 (1995): 72-86[7] Lin SH, Yang SS, Chau T, Halperin ML "An unusual cause of hypokalemic paralysis: chronic licorice ingestion." Am J Med Sci 325 (2003): 153-6[8] de Klerk GJ, Nieuwenhuis MG, Beutler JJ "Lesson of the week: hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum." BMJ 314 (1997): 731[9] Nielsen I, Pedersen RS "Life-threatening hypokalaemia caused by liquorice ingestion." Lancet 1 (1984): 1305[10] Cumming AM, Boddy K, Brown JJ, et al "Severe hypokalaemia with paralysis induced by small doses of liquorice." Postgrad Med J 56 (1980): 526-9[11] Cumming A "Severe reduction of serum potassium induced by licorice." Nurs Times 72 (1976): 367-70[12] Epstein MT, Espiner EA, Donald RA, Hughes H "Liquorice toxicity and the renin-angiotensin-aldosterone axis in man." Br Med J 1 (1977): 209-10[13] Sigurjonsdottir HA, Franzson L, Manhem K, Ragnarsson J, Sigurdsson G, Wallerstedt S "Liquorice-induced rise in blood pressure: a linear dose-response relationship." J Hum Hypertens 15 (2001): 549-52[14] Edwards CR "Lessons from licorice." N Engl J Med 325 (1991): 1242-3[15] Ishikawa S, Kato M, Tokuda T, Momoi H, Sekijima Y, Higuchi M, Yanagisawa N "Licorice-induced hypokalemic myopathy and hypokalemic renal tubular damage in anorexia nervosa." Int J Eating Disorder 26 (1999): 111-4[16] Holmes AM, Young J, Marrott PK, Prentice E "Pseudohyperaldosteronism induced by habitual ingestion of liquorice." Postgrad Med J 46 (1970): 625-9[17] Bannister B, Ginsburg R, Shneerson J "Cardiac arrest due to liquorice-induced hypokalaemia." Br Med J 2 (1977): 738-9[18] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20[19] Farese RV, Biglieri EG, Shackleton CH, Irony I, Gomez-Fontes R "Licorice-induced hypermineralocorticoidism." N Engl J Med 325 (1991): 1223-7[20] Dellow EL, Unwin RJ, Honour JW "Pontefract cakes can be bad for you: refractory hypertension and liquorice excess." Nephrol Dial Transplant 14 (1999): 218-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120182, 'Isosorbide dinitrate', 'Linezolid', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, More', 'Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120320/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120183, 'Isosorbide dinitrate', 'Lisinopril', 'Moderate', 'Angiotensin converting enzyme (ACE) inhibitors may enhance the vasodilatory and hypotensive effects of nitroglycerin. Data have also shown that captopril can prevent nitrate tolerance. ACE inhibitors can decrease systemic vascular resistance and cardiac work, further enhancing the effectiveness of nitroglycerin.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose. Blood pressure monitoring is advisable.', 'Synergism', 'Bempedoic acid', 'Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120321/', '[1] Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7[2] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[3] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[4] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120184, 'Isosorbide dinitrate', 'Lofexidine', 'Moderate', 'The hypotensive effects of lofexidine and antihypertensive agents may be additive. Postural hypotension may occur.', NULL, 'Hemodynamic responses should be monitored during coadministration of lofexidine with antihypertensive agents, especially during the first few weeks of therapy.', NULL, 'Hemodynamic responses should be monitored during coadministration of lofexidine with antihypertensive agents, especially during the first few weeks of therapy.', 'Synergism', 'Nesiritide, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', 'Acamprosate, Naltrexone, Disulfiram, Levacetylmethadol, Nalmefene', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120322/', '[1] "Product Information. Lucemyra (lofexidine)." US WorldMeds LLC, Louisville , KY.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120185, 'Isosorbide dinitrate', 'Lorazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Halazepam', 'Nesiritide, Vericiguat, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Zinc chloride, Betamethasone, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120323/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120186, 'Isosorbide dinitrate', 'Loxapine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120324/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120187, 'Isosorbide dinitrate', 'Lumateperone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Droperidol, Pimozide, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120325/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120188, 'Isosorbide dinitrate', 'Lurasidone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Droperidol, Pimozide, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120326/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120189, 'Isosorbide dinitrate', 'Maprotiline', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Desipramine, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120327/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120190, 'Isosorbide dinitrate', 'Maraviroc', 'Moderate', 'Maraviroc may potentiate the hypotensive effect of some medications.', NULL, 'Caution is advised when maraviroc is prescribed to patients on concomitant medications known to lower blood pressure.', NULL, 'Caution is advised when maraviroc is prescribed to patients on concomitant medications known to lower blood pressure. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', 'Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, Rilpivirine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120328/', '[1] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120191, 'Isosorbide dinitrate', 'Meperidine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Prednisolone, Betamethasone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120329/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120192, 'Isosorbide dinitrate', 'Meprobamate', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Halazepam, Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, More', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120330/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120193, 'Isosorbide dinitrate', 'Mesoridazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Droperidol, Pimozide, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120331/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120194, 'Isosorbide dinitrate', 'Methdilazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120332/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120195, 'Isosorbide dinitrate', 'Methocarbamol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Chlormezanone', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120333/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120196, 'Isosorbide dinitrate', 'Methotrimeprazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Droperidol, Pimozide, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120334/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120197, 'Isosorbide dinitrate', 'Methylergometrine', 'Moderate', 'Ergot alkaloids, by causing vasoconstriction, may theoretically antagonize the effects of nitrates. In addition, nitrates may increase splanchnic blood flow, resulting in decreased first-pass metabolism of dihydroergotamine and increased bioavailability.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Ergot alkaloids are considered contraindicated in patients with ischemic heart disease.', 'Antagonism', 'Misoprostol, Dinoprostone, Oxytocin', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120335/', '[1] Bobik A, Jennings G, Skews H, Esler M, McLean A "Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension." Clin Pharmacol Ther 30 (1981): 673-9[2] Raberger G, Schutz W, Zimpfer M, Kraupp O "The influence of dihydroergotamine on adenosine-induced and reactive coronary vasodilation. Interaction of dihydroergotamine and coronary vasodilation." Basic Res Cardiol 71 (1976): 645-51[3] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[7] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120198, 'Isosorbide dinitrate', 'Methysergide', 'Moderate', 'Ergot alkaloids, by causing vasoconstriction, may theoretically antagonize the effects of nitrates. In addition, nitrates may increase splanchnic blood flow, resulting in decreased first-pass metabolism of dihydroergotamine and increased bioavailability.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Ergot alkaloids are considered contraindicated in patients with ischemic heart disease.', 'Antagonism', 'Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Naratriptan, Galcanezumab, Zolmitriptan, More', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120336/', '[1] Bobik A, Jennings G, Skews H, Esler M, McLean A "Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension." Clin Pharmacol Ther 30 (1981): 673-9[2] Raberger G, Schutz W, Zimpfer M, Kraupp O "The influence of dihydroergotamine on adenosine-induced and reactive coronary vasodilation. Interaction of dihydroergotamine and coronary vasodilation." Basic Res Cardiol 71 (1976): 645-51[3] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[7] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120199, 'Isosorbide dinitrate', 'Midazolam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 'Nesiritide, Vericiguat, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Fluorometholone, Triamcinolone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120337/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120200, 'Isosorbide dinitrate', 'Minoxidil (topical)', 'Moderate', 'Theoretically, topical administration of minoxidil may potentiate the hypotensive effects of systemic minoxidil and other vasodilators. Increased systemic absorption may occur when topical minoxidil is used in excess of normally recommended dosages or applied to compromised skin.', NULL, 'Patients prescribed topical minoxidil in combination with systemic vasodilators or peripherally-acting antiadrenergic agents should be monitored for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.', NULL, 'Patients prescribed topical minoxidil in combination with systemic vasodilators or peripherally-acting antiadrenergic agents should be monitored for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.', 'Synergism', 'Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Abrocitinib, More', 'Vericiguat, Lidocaine, Zinc sulfate, Diltiazem, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120338/', '[1] Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988): 481-5[2] "Product Information. Rogaine (minoxidil topical)." Johnson and Johnson/McNeil Consumer, Fort Washington, PA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120201, 'Isosorbide dinitrate', 'Mirtazapine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120339/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120202, 'Isosorbide dinitrate', 'Moexipril', 'Moderate', 'Angiotensin converting enzyme (ACE) inhibitors may enhance the vasodilatory and hypotensive effects of nitroglycerin. Data have also shown that captopril can prevent nitrate tolerance. ACE inhibitors can decrease systemic vascular resistance and cardiac work, further enhancing the effectiveness of nitroglycerin.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose. Blood pressure monitoring is advisable.', 'Synergism', 'Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120340/', '[1] Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7[2] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[3] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[4] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120203, 'Isosorbide dinitrate', 'Molindone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Droperidol, Pimozide, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120341/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120204, 'Isosorbide dinitrate', 'Nabilone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Granisetron, Scopolamine, Rolapitant, Aprepitant, Dolasetron, Palonosetron', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120342/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120205, 'Isosorbide dinitrate', 'Nalbuphine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120343/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120206, 'Isosorbide dinitrate', 'Nefazodone', 'Moderate', 'Nefazodone may potentiate the hypotensive effect of many drugs including vasodilators and antihypertensive agents. Orthostatic hypotension may occur.', NULL, 'Caution and close monitoring for altered efficacy and safety are recommended if patients receive nefazodone with agents that can produce significant hypotension such as antihypertensive agents or vasodilators.', NULL, 'Caution and close monitoring for altered efficacy and safety are recommended if patients receive nefazodone with agents that can produce significant hypotension such as antihypertensive agents or vasodilators. Patients should be made aware of the possible side effects (e.g., dizziness, lightheadedness, orthostasis) and be cautioned about driving, operating machinery, or performing other hazardous tasks.', 'Synergism', 'Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate', 'Desipramine, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120344/', '[1] "Product Information. Serzone (nefazodone)." Bristol-Myers Squibb, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120207, 'Isosorbide dinitrate', 'Nesiritide', 'Moderate', 'The coadministration of nesiritide with intravenous vasodilators such as nitroglycerin, nitroprusside, and milrinone has not been evaluated. Theoretically, an increase in symptomatic hypotension may occur due to possible additive pharmacodynamic effects in the vasculature. A similar risk may exist during coadministration with oral vasodilators such as hydralazine and minoxidil and other agents with vasodilating effects.', NULL, 'Whether used alone or with other agents, nesiritide should be administered only in settings where blood pressure can be closely monitored.', NULL, 'Whether used alone or with other agents, nesiritide should be administered only in settings where blood pressure can be closely monitored. The dosage should be reduced or the drug discontinued in patients who develop hypotension.', 'Synergism', 'Nesiritide, Lidocaine, Zinc sulfate, Diltiazem, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Isosorbide dinitrate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120345/', '[1] "Product Information. Natrecore (nesiritide)" Scios Inc, Sunnyvale, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120208, 'Isosorbide dinitrate', 'Nortriptyline', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120346/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120209, 'Isosorbide dinitrate', 'Olanzapine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120347/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120210, 'Isosorbide dinitrate', 'Oliceridine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120348/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120211, 'Isosorbide dinitrate', 'Olopatadine (nasal)', 'Moderate', 'Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance. Somnolence has been reported in some patients using olopatadine nasal spray in clinical trials.', NULL, 'Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.', NULL, 'Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Nesiritide, Nitroglycerin, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120349/', '[1] "Product Information. Patanase (olopatadine nasal)." Alcon Laboratories Inc, Fort Worth, TX.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120212, 'Isosorbide dinitrate', 'Opium', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Eluxadoline, Diphenoxylate, Difenoxin, Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120350/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120213, 'Isosorbide dinitrate', 'Oxazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Halazepam', 'Nesiritide, Vericiguat, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Betamethasone, Fluorometholone, Triamcinolone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120351/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120214, 'Isosorbide dinitrate', 'Ozanimod', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate, Dexamethasone', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120352/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120215, 'Isosorbide dinitrate', 'Paraldehyde', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120353/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120216, 'Isosorbide dinitrate', 'Pentoxifylline', 'Moderate', 'Pentoxifylline may potentiate the action of hypotensive agents. Small decreases in blood pressure have been observed in some patients treated with pentoxifylline plus nifedipine or captopril. The mechanism of interaction has not been described.', NULL, 'Caution is advised if pentoxifylline is used in combination with hypotensive agents.', NULL, 'Caution is advised if pentoxifylline is used in combination with hypotensive agents. Periodic systemic blood pressure monitoring is recommended.', 'Synergism', 'Cyclandelate, Tolazoline, Phenoxybenzamine, Phentolamine, Isoxsuprine, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, More', 'Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120354/', '[1] "Product Information. Trental (pentoxifylline)." Hoechst Marion-Roussel Inc, Kansas City, MO.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120217, 'Isosorbide dinitrate', 'Perphenazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120355/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120218, 'Isosorbide dinitrate', 'Phenelzine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More', 'Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120356/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120219, 'Isosorbide dinitrate', 'Procarbazine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', 'Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120357/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120220, 'Isosorbide dinitrate', 'Promazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120358/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120221, 'Isosorbide dinitrate', 'Propiomazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120359/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120222, 'Isosorbide dinitrate', 'Quazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Betamethasone, Fluorometholone, Zinc gluconate', 'Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120360/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120223, 'Isosorbide dinitrate', 'Quetiapine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate', 'Droperidol, Pimozide, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120361/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120224, 'Isosorbide dinitrate', 'Ramipril', 'Moderate', 'Angiotensin converting enzyme (ACE) inhibitors may enhance the vasodilatory and hypotensive effects of nitroglycerin. Data have also shown that captopril can prevent nitrate tolerance. ACE inhibitors can decrease systemic vascular resistance and cardiac work, further enhancing the effectiveness of nitroglycerin.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose. Blood pressure monitoring is advisable.', 'Synergism', 'Bempedoic acid', 'Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120362/', '[1] Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7[2] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[3] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[4] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120225, 'Isosorbide dinitrate', 'Rasagiline', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', 'Opicapone, Rotigotine, Tolcapone, Entacapone, Pergolide, Levodopa', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120363/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120226, 'Isosorbide dinitrate', 'Remimazolam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Prednisolone, Betamethasone, Fluorometholone, More', 'Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120364/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120227, 'Isosorbide dinitrate', 'Riociguat', 'Major', 'Coadministration of riociguat with organic nitrates or nitric oxide donors may cause significant hypotension, syncope, and myocardial ischemia. Riociguat stimulates soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system that binds with nitric oxide (NO) to catalyze the synthesis of cyclic guanosine monophosphate (cGMP). The resultant accumulation of cGMP in vascular smooth muscle cells leads to peripheral vasodilation.', NULL, 'Concomitant use of riociguat with organic nitrates (e.', NULL, 'Concomitant use of riociguat with organic nitrates (e.g., nitroglycerin) or nitric oxide donors (e.g., amyl nitrite) in any form is considered contraindicated.', 'Synergism', 'Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, Betamethasone, More', 'Ambrisentan, Macitentan, Metyrosine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120365/', '[1] "Product Information. Adempas (riociguat)." Bayer Pharmaceutical Inc, West Haven, CT.[2] "Product Information. Adempas (riociguat)." Bayer Pharmaceutical Inc, West Haven, CT.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120228, 'Isosorbide dinitrate', 'Rosiglitazone', 'Moderate', 'The concomitant use of rosiglitazone with nitrates may increase the risk of myocardial ischemia. Results of clinical trials have suggested that rosiglitazone is associated with a higher risk of angina or myocardial infarction.', NULL, 'The concomitant use of rosiglitazone and nitrates should generally be avoided.', NULL, 'The concomitant use of rosiglitazone and nitrates should generally be avoided.', 'Synergism', 'Exenatide, Lixisenatide, Albiglutide, Acetohexamide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, More', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120366/', '[1] "Product Information. Avandia (rosiglitazone)" SmithKline Beecham, Philadelphia, PA.[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[6] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[7] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120229, 'Isosorbide dinitrate', 'Safinamide', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', 'Opicapone, Rotigotine, Tolcapone, Entacapone, Pergolide, Levodopa', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120367/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120230, 'Isosorbide dinitrate', 'Secobarbital', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120368/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120231, 'Isosorbide dinitrate', 'Selegiline', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', 'Opicapone, Rotigotine, Tolcapone, Entacapone, Pergolide, Levodopa', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120369/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120232, 'Isosorbide dinitrate', 'Selexipag', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120370/', '[1] "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC.[2] "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Buchdahl RM, Taylor P, Warner JD "Nebulised ribavirin for adenovirus pneumonia." Lancet 2 (1985): 1070-1[5] "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120233, 'Isosorbide dinitrate', 'Sildenafil', 'Major', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the hypotensive effect of organic nitrates. Severe hypotension, syncope, or myocardial ischemia may result from use of the combination. The mechanism involves peripheral vasodilation secondary to enhanced levels of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells, as PDE5 inhibitors prevent degradation of cGMP while nitrates promote its synthesis.', NULL, 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated.', NULL, 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated. A suitable time interval following sildenafil or vardenafil use for the safe administration of nitrates has not been determined. For patients treated with avanafil or tadalafil, at least 12 hours after the last dose of avanafil and 48 hours after the last dose of tadalafil are recommended before nitrate administration, should it be deemed medically necessary in a life-threatening situation. Even then, nitrates should only be administered under close medical supervision with appropriate hemodynamic monitoring. Patients should be advised to seek immediate medical attention if they experience anginal chest pain after taking a PDE5 inhibitor.', 'Synergism', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Clindamycin, Trichlormethiazide, More', 'Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120371/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[4] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[5] "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation, Silver Spring, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120234, 'Isosorbide dinitrate', 'Tadalafil', 'Major', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the hypotensive effect of organic nitrates. Severe hypotension, syncope, or myocardial ischemia may result from use of the combination. The mechanism involves peripheral vasodilation secondary to enhanced levels of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells, as PDE5 inhibitors prevent degradation of cGMP while nitrates promote its synthesis.', NULL, 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated.', NULL, 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated. A suitable time interval following sildenafil or vardenafil use for the safe administration of nitrates has not been determined. For patients treated with avanafil or tadalafil, at least 12 hours after the last dose of avanafil and 48 hours after the last dose of tadalafil are recommended before nitrate administration, should it be deemed medically necessary in a life-threatening situation. Even then, nitrates should only be administered under close medical supervision with appropriate hemodynamic monitoring. Patients should be advised to seek immediate medical attention if they experience anginal chest pain after taking a PDE5 inhibitor.', 'Synergism', 'Fesoterodine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Papaverine, More', 'Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120372/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[4] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[5] "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation, Silver Spring, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120235, 'Isosorbide dinitrate', 'Temazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 'Nesiritide, Vericiguat, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Betamethasone, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120373/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120236, 'Isosorbide dinitrate', 'Tetrabenazine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Dextromethorphan, Valbenazine, Dalfampridine, Riluzole, Inotersen, Pitolisant, Amifampridine, Deutetrabenazine, Tafamidis', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120374/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120237, 'Isosorbide dinitrate', 'Tetracaine (topical)', 'Moderate', 'Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.', 'Synergism', 'Nesiritide, Vericiguat, Zinc sulfate, Diltiazem, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Prednisolone, Betamethasone, More', 'Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Isosorbide dinitrate, Zinc chloride, Betamethasone, Fluorometholone, Zinc gluconate, Tripelennamine, Clemastine, Pheniramine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120375/', '[1] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009): 837-45[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Hurricaine (benzocaine topical)." Beutlich, Waukegan, IL.[4] "Product Information. Chloraseptic (benzocaine-menthol topical)." Prestige Brands (formerly MedTech), Tarrytown, NY.[5] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011): 757-61[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Karim A, Ahmed S, Siddiqui R, Mattana J "Methemoglobinemia complicating topical lidocaine used during endoscopic procedures." Am J Med 111 (2001): 150-3', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120238, 'Isosorbide dinitrate', 'Thallous Chloride', 'Moderate', 'Coadministration of certain drugs may alter the myocardial uptake of thallous chloride Tl-201 and interfere with results of myocardial imaging studies. Drugs that increase or decrease coronary blood flow or potassium uptake may alter the biodistribution of thallous chloride Tl-201.', NULL, 'Clinicians should be aware of possible diagnostic interference by these drugs.', NULL, 'Clinicians should be aware of possible diagnostic interference by these drugs.', 'Others', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Diltiazem, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120376/', '[1] "Product Information. Thallous Chloride Tl 201 (thallous chloride Tl-201)." GE Healthcare, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Nuclear Pharmacy Website. University of Arkansas for Medical Sciences. College of Pharmacy "Drug - Radiopharmaceutical Interactions. Available from: URL: http://nuclearpharmacy.uams.edu/nicki.html#tl." ([cited Feb2015]):', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120239, 'Isosorbide dinitrate', 'Thiethylperazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120377/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120240, 'Isosorbide dinitrate', 'Thioridazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120378/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120241, 'Isosorbide dinitrate', 'Thiothixene', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Droperidol, Pimozide, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120379/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120242, 'Isosorbide dinitrate', 'Tizanidine', 'Major', 'Tizanidine may potentiate the hypotensive effect of some medications secondary to its alpha-2 adrenergic activity. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.', NULL, 'A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications.', NULL, 'A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications. Although single doses of less than 8 mg of tizanidine have not been shown effective for spasticity in controlled clinical studies, it may be prudent to initiate treatment with 4 mg doses and gradually increase in 2 to 4 mg increments until optimum effect is achieved. The dose can be repeated at 6 to 8 hour intervals as needed, up to a maximum of three doses in 24 hours and a total daily dosage of 36 mg. However, experience with single doses exceeding 8 mg and daily doses exceeding 24 mg is limited. Close monitoring for development of hypotension is recommended.', 'Synergism', 'Chlormezanone', 'Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120380/', '[1] "Product Information. Zanaflex (tizanidine)." Acorda Therapeutics, Hawthorne, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120243, 'Isosorbide dinitrate', 'Tranylcypromine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More', 'Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120381/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120244, 'Isosorbide dinitrate', 'Treprostinil', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Caplacizumab, Argatroban, More', 'Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, Betamethasone, Fluorometholone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120382/', '[1] "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC.[2] "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Buchdahl RM, Taylor P, Warner JD "Nebulised ribavirin for adenovirus pneumonia." Lancet 2 (1985): 1070-1[5] "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120245, 'Isosorbide dinitrate', 'Trifluoperazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120383/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120246, 'Isosorbide dinitrate', 'Triflupromazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120384/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120247, 'Isosorbide dinitrate', 'Alimemazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Ketotifen, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120385/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120248, 'Isosorbide dinitrate', 'Trimipramine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Vilazodone, Esketamine, More', 'Nesiritide, Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120386/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120249, 'Isosorbide dinitrate', 'Verteporfin', 'Moderate', 'Drugs that decrease clotting, vasoconstriction, or platelet aggregation may interfere with the therapeutic effect of verteporfin. These agents may antagonize the physiologic responses to local damage of neovascular endothelium induced by activated verteporfin, which include the release of procoagulant and vasoactive factors that result in vessel occlusion. However, the clinical significance is unknown.', NULL, 'If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy.', NULL, 'If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy. Otherwise, the potential for diminished efficacy of verteporfin should be considered.', 'Antagonism', 'Aflibercept, Bevacizumab', 'Vericiguat, Lidocaine, Zinc sulfate, Tetracaine, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Prednisolone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120387/', '[1] "Product Information. Visudyne (verteporfin)" Valeant Pharmaceuticals, Costa Mesa, CA.[2] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120250, 'Isosorbide dinitrate', 'Zaleplon', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Hydrocortisone, Fluocinonide, Zinc chloride, Procaine, Betamethasone, More', 'Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120388/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120251, 'Isosorbide dinitrate', 'Ziprasidone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Procaine, Prednisolone, Betamethasone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120389/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120252, 'Isosorbide dinitrate', 'Zolpidem', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Thiopental, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Estazolam, Methylphenobarbital, More', 'Nesiritide, Vericiguat, Tetracaine, Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Zinc chloride, Procaine, Betamethasone, Fluorometholone, Zinc gluconate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120390/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120253, 'Hydralazine', 'Aurothioglucose', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Penicillamine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120391/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120254, 'Hydralazine', 'Benznidazole', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Miltefosine, Pentamidine, Nifurtimox, Fexinidazole', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120392/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120255, 'Hydralazine', 'Bismuth subsalicylate', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120393/', '[1] Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120256, 'Hydralazine', 'Butabarbital', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Quazepam, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More', 'Rauwolfia serpentina root, Reserpine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120394/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120257, 'Hydralazine', 'Cerivastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120395/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120258, 'Hydralazine', 'Chloral hydrate', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Rauwolfia serpentina root, Deserpidine', 'Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Quazepam, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120396/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120259, 'Hydralazine', 'Chlorpromazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120397/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120260, 'Hydralazine', 'Dapsone', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Erythromycin, Azelaic acid, Adapalene, Clofazimine', 'Minoxidil, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120398/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120261, 'Hydralazine', 'Diflunisal', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', 'Ziconotide, Methoxyflurane', 'Minoxidil, Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120399/', '[1] Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120262, 'Hydralazine', 'Elotuzumab', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120400/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120263, 'Hydralazine', 'Epoprostenol', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120401/', '[1] "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC.[2] "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Buchdahl RM, Taylor P, Warner JD "Nebulised ribavirin for adenovirus pneumonia." Lancet 2 (1985): 1070-1[5] "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120264, 'Hydralazine', 'Eribulin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120402/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120265, 'Hydralazine', 'Ertugliflozin', 'Moderate', 'Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.', NULL, 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.', NULL, 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.', 'Synergism', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120403/', '[1] "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb, Princeton, NJ.[5] "Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals, Titusville, NJ.[6] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[9] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[10] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120266, 'Hydralazine', 'Etanercept', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120404/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120267, 'Hydralazine', 'Ethambutol', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120405/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120268, 'Hydralazine', 'Ethionamide', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120406/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120269, 'Hydralazine', 'Etodolac', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', 'Rabeprazole, Phenylbutazone, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Valdecoxib', 'Minoxidil, Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120407/', '[1] Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120270, 'Hydralazine', 'Etoposide', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Topotecan, Irinotecan', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120408/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120271, 'Hydralazine', 'Etravirine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120409/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120272, 'Hydralazine', 'Fenoldopam', 'Moderate', 'The use of fenoldopam with other hypotensive agents has not been studied. However, these combinations would theoretically increase the risk of severe symptomatic hypotension.', NULL, 'Caution is strongly advised during concurrent use.', NULL, 'Caution is strongly advised during concurrent use. Inpatient monitoring of the heart rate and blood pressure is recommended. Sublingual nitroglycerin has been used safely with fenoldopam.', 'Synergism', 'Dobutamine, Norepinephrine, Midodrine, Droxidopa, Angiotensin II, Ephedrine, Arbutamine, Phenylephrine, Isoprenaline, Metaraminol, Epinephrine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120410/', '[1] "Product Information. Corlopam (fenoldopam)." Neurex, Menlo Park, CA.[2] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120273, 'Hydralazine', 'Fenoprofen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', 'Rabeprazole, Phenylbutazone, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Valdecoxib', 'Minoxidil, Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120411/', '[1] Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120274, 'Hydralazine', 'Fludarabine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Methotrexate, Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Pralatrexate, Cytarabine, More', 'Minoxidil, Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120412/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120275, 'Hydralazine', 'Fludrocortisone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Fluocinolone acetonide, Fluocinolone acetonide, Fluorometholone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120413/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120276, 'Hydralazine', 'Fluphenazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120414/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120277, 'Hydralazine', 'Flurazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Quazepam, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120415/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120278, 'Hydralazine', 'Flurbiprofen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', 'Rabeprazole, Dimethyl sulfoxide, Phenylbutazone, Rabeprazole, Phenylbutazone, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Valdecoxib, More', 'Minoxidil, Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120416/', '[1] Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120279, 'Hydralazine', 'Fluvastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120417/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120280, 'Hydralazine', 'Furosemide', 'Minor', 'Hydralazine causes a significant increase in the plasma clearance of furosemide. A decrease in the elimination half-life of furosemide results. The mechanism is believed to be a hydralazine-induced increase in renal blood flow, which increases the plasma clearance (and diuretic effect) of furosemide.', NULL, '-', NULL, '-', 'Excretion', 'Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Darunavir, More', 'Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120418/', '[1] Nomura A, Yasuda H, Katoh K, et al "Hydralazine and furosemide kinetics." Clin Pharmacol Ther 32 (1982): 303-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120281, 'Hydralazine', 'Sodium aurothiomalate', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Penicillamine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120419/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120282, 'Hydralazine', 'Golimumab', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120420/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120283, 'Hydralazine', 'Guanfacine', 'Moderate', 'Use of guanfacine in combination with antihypertensive agents may result in additive pharmacodynamic effects such as hypotension and syncope.', NULL, 'Caution is advised during coadministration of these agents.', NULL, 'Caution is advised during coadministration of these agents. Dosage adjustments may be required and hemodynamic responses should be monitored during concomitant therapy. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.', 'Synergism', 'Rauwolfia serpentina root, Reserpine, Deserpidine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120421/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Tenex (guanfacine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Intuniv (guanfacine)." Shire US Inc, Florence, KY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120284, 'Hydralazine', 'Haloperidol', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120422/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120285, 'Hydralazine', 'Hydromorphone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Tramadol, Naloxone', 'Rauwolfia serpentina root, Reserpine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120423/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120286, 'Hydroxychloroquine', 'Hydralazine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Artesunate, Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120424/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120287, 'Iloperidone', 'Hydralazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120425/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120288, 'Imipramine', 'Hydralazine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Duloxetine, Desipramine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John''s Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120426/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120289, 'Indomethacin', 'Hydralazine', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', 'Fluocinolone acetonide, Fluorometholone, Rabeprazole, Phenylbutazone, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Valdecoxib, Fluocinolone acetonide, More', 'Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120427/', '[1] Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120290, 'Infliximab', 'Hydralazine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120428/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120291, 'Interferon alfa-2a, Recombinant', 'Hydralazine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120429/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120292, 'Interferon alfa-n1', 'Hydralazine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Ropeginterferon alfa-2b, Peginterferon beta-1a, Interferon beta-1a, Sargramostim, Histamine, Pegademase, Pegfilgrastim, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120430/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120293, 'Interferon alfacon-1', 'Hydralazine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Ropeginterferon alfa-2b, Peginterferon beta-1a, Interferon beta-1a, Sargramostim, Histamine, Pegademase, Pegfilgrastim, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120431/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120294, 'Hydralazine', 'Diiodohydroxyquinoline', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Ascorbic acid, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Clindamycin, Ciclopirox, Vemurafenib, Darunavir, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120432/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120295, 'Isoniazid', 'Hydralazine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Streptomycin, Trimethoprim, Rifampicin, Cycloserine, Rifabutin, More', 'Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120433/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120296, 'Hydralazine', 'Ixabepilone', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Idarubicin, Valrubicin, Plicamycin, Mitoxantrone, Bleomycin, Doxorubicin, Mitomycin, Daunorubicin, Dactinomycin, Epirubicin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120434/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120297, 'Hydralazine', 'Ixazomib', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120435/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120298, 'Hydralazine', 'Ketoprofen', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', 'Rabeprazole, Phenylbutazone, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Valdecoxib, Rabeprazole, Dimethyl sulfoxide, Phenylbutazone', 'Minoxidil, Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120436/', '[1] Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120299, 'Hydralazine', 'Labetalol', 'Minor', 'Hydralazine may increase serum levels of some oral beta blockers. The proposed mechanism is reduced hepatic blood flow resulting in decreased biotransformation of beta blockers that undergo extensive first-pass metabolism. The interaction is less likely to occur with sustained-release preparations. Renally excreted beta-blockers such as atenolol, carteolol, nadolol, or sotalol are not expected to interact. This combination generally tends to have beneficial effects and is used commonly in the treatment of hypertension. The patient''s clinical response should be monitored. A dosage adjustment for the beta blocker may be required when given concomitantly with hydralazine.', NULL, '-', NULL, '-', 'Absorption', 'Nebivolol, Nebivolol', 'Nitroprusside, Diazoxide, Deserpidine', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120437/', '[1] Schneck DW, Vary JE "Mechanism by which hydralazine increases propranolol bioavailability." Clin Pharmacol Ther 35 (1984): 447-53[2] Janku I, Perlik F, Tkaczykova M, Brodanova M "Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects." Eur J Clin Pharmacol 42 (1992): 337-40[3] Le Coz F, Sauleman P, Poirier JM, Cuche JL, Midavaine M, Rames A, Lecocq B, Jaillon P "Oral pharmacokinetics of bisoprolol in resting and exercising healthy volunteers." J Cardiovasc Pharmacol 18 (1991): 28-34[4] Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):[5] Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y "Pharmacokinetics of carteolol in patients with impaired renal function." Eur J Clin Pharmacol 43 (1992): 417-21[6] Piquette-Miller M, Foster RT, Kappagoda CT, Jamali F "Effect of aging on the pharmacokinetics of acebutolol enantiomers." J Clin Pharmacol 32 (1992): 148-56[7] "Product Information. Levatol (penbutolol)." Reed and Carnrick, Jersey City, NJ.[8] Morgan T "Clinical pharmacokinetics and pharmacodynamics of carvedilol." Clin Pharmacokinet 26 (1994): 335-46[9] "Product Information. Betapace (sotalol)." Berlex, Richmond, CA.[10] McTavish D, Campoli-Richards D, Sorkin EM "Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy." Drugs 45 (1993): 232-58[11] "Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals, Wilmington, DE.[12] "Product Information. Blocadren (timolol)." Merck & Co, Inc, West Point, PA.[13] "Product Information. Cartrol (carteolol)." Abbott Pharmaceutical, Abbott Park, IL.[14] McLean AJ, Skews H, Bobik A, Dudley FJ "Interaction between oral propranolol and hydralazine." Clin Pharmacol Ther 27 (1980): 726-32[15] Stagni G, Davis PJ, Ludden TM "Human pharmacokinetics of betaxolol enantiomers." J Pharm Sci 80 (1991): 321-4[16] "Product Information. Corgard (nadolol)." Bristol-Myers Squibb, Princeton, NJ.[17] "Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[18] McGourty JC, Silas JH, Fleming JJ, McBurney A, Ward JW "Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin." Clin Pharmacol Ther 38 (1985): 409-13[19] "Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc, Cost Mesa, CA.[20] McLean AJ, Wilhelm D, Heinzow BG "Stable oral availability of atenolol coadministered with hydralazine. Comparison with propranolol, metoprolol and other B-Adrenoceptor antagonists." Drugs 25 (1983): 131-5[21] Lindeberg S, Holm B, Lundborg P, Regardh CG, Sandstrom B "The effect of hydralazine on steady-state plasma concentrations of metoprolol in pregnant hypertensive women." Eur J Clin Pharmacol 35 (1988): 131-5[22] Byrne AJ, McNeil JJ, Harrison PM, Louis W, Tonkin AM, McLean AJ "Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions." Br J Clin Pharmacol 17 Suppl (1984): s45-50[23] Seffart G ed. "Drug Dosage in Renal Insufficiency." Dordrecht, South Holland, : Kluwer Academic Publishers (1991):[24] Smith RL "Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance." Eur J Clin Pharmacol 28 (1985): 77-84[25] "Product Information. Normodyne (labetalol)." Schering Laboratories, Kenilworth, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120300, 'Hydralazine', 'Leflunomide', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120438/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120301, 'Hydralazine', 'Licorice', 'Moderate', 'Licorice use has been associated with hypertension and may antagonize the effects of antihypertensive agents. Glycyrrhizic acid, a component of licorice, is hydrolyzed in the intestine to a metabolite (glycyrrhetinic acid) that causes mineralocorticoid and renin-suppressing effects.', NULL, 'Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products.', NULL, 'Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products. Even relatively moderate doses of licorice may be problematic in susceptible patients when ingested regularly for prolonged periods.', 'Antagonism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120439/', '[1] Cumming AM "Metabolic effects of licorice." Br Med J 1 (1977): 906[2] Epstein MT, Espiner EA, Donald RA, Hughes H "Effect of eating liquorice on the renin-angiotensin aldosterone axis in normal subjects." Br Med J 1 (1977): 488-90[3] Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR "Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age." Lancet 2 (1987): 821-4[4] Elinav E, Chajek-Shaul T "Licorice consumption causing severe hypokalemic paralysis." Mayo Clin Proc 78 (2003): 767-8[5] Rosseel M, Schoors D "Chewing gum and hypokalaemia." Lancet 341 (1993): 175[6] Clyburn EB, DiPette DJ "Hypertension induced by drugs and other substances." Semin Nephrol 15 (1995): 72-86[7] Lin SH, Yang SS, Chau T, Halperin ML "An unusual cause of hypokalemic paralysis: chronic licorice ingestion." Am J Med Sci 325 (2003): 153-6[8] de Klerk GJ, Nieuwenhuis MG, Beutler JJ "Lesson of the week: hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum." BMJ 314 (1997): 731[9] Nielsen I, Pedersen RS "Life-threatening hypokalaemia caused by liquorice ingestion." Lancet 1 (1984): 1305[10] Cumming AM, Boddy K, Brown JJ, et al "Severe hypokalaemia with paralysis induced by small doses of liquorice." Postgrad Med J 56 (1980): 526-9[11] Cumming A "Severe reduction of serum potassium induced by licorice." Nurs Times 72 (1976): 367-70[12] Epstein MT, Espiner EA, Donald RA, Hughes H "Liquorice toxicity and the renin-angiotensin-aldosterone axis in man." Br Med J 1 (1977): 209-10[13] Sigurjonsdottir HA, Franzson L, Manhem K, Ragnarsson J, Sigurdsson G, Wallerstedt S "Liquorice-induced rise in blood pressure: a linear dose-response relationship." J Hum Hypertens 15 (2001): 549-52[14] Edwards CR "Lessons from licorice." N Engl J Med 325 (1991): 1242-3[15] Ishikawa S, Kato M, Tokuda T, Momoi H, Sekijima Y, Higuchi M, Yanagisawa N "Licorice-induced hypokalemic myopathy and hypokalemic renal tubular damage in anorexia nervosa." Int J Eating Disorder 26 (1999): 111-4[16] Holmes AM, Young J, Marrott PK, Prentice E "Pseudohyperaldosteronism induced by habitual ingestion of liquorice." Postgrad Med J 46 (1970): 625-9[17] Bannister B, Ginsburg R, Shneerson J "Cardiac arrest due to liquorice-induced hypokalaemia." Br Med J 2 (1977): 738-9[18] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20[19] Farese RV, Biglieri EG, Shackleton CH, Irony I, Gomez-Fontes R "Licorice-induced hypermineralocorticoidism." N Engl J Med 325 (1991): 1223-7[20] Dellow EL, Unwin RJ, Honour JW "Pontefract cakes can be bad for you: refractory hypertension and liquorice excess." Nephrol Dial Transplant 14 (1999): 218-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120302, 'Hydralazine', 'Linezolid', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120440/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120303, 'Hydralazine', 'Lithium carbonate', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Rauwolfia serpentina root, Deserpidine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120441/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120304, 'Hydralazine', 'Lofexidine', 'Moderate', 'The hypotensive effects of lofexidine and antihypertensive agents may be additive. Postural hypotension may occur.', NULL, 'Hemodynamic responses should be monitored during coadministration of lofexidine with antihypertensive agents, especially during the first few weeks of therapy.', NULL, 'Hemodynamic responses should be monitored during coadministration of lofexidine with antihypertensive agents, especially during the first few weeks of therapy.', 'Synergism', 'Acamprosate, Naltrexone, Varenicline, Levacetylmethadol, Nalmefene, Nicotine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120442/', '[1] "Product Information. Lucemyra (lofexidine)." US WorldMeds LLC, Louisville , KY.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120305, 'Hydralazine', 'Lorazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Halazepam', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120443/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120306, 'Hydralazine', 'Lovastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More', 'Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120444/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120307, 'Hydralazine', 'Lumateperone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120445/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120308, 'Hydralazine', 'Lurasidone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120446/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120309, 'Hydralazine', 'Maprotiline', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Duloxetine, Desipramine, Sertraline, Paroxetine, Desvenlafaxine, Fluoxetine, St. John''s Wort, Oxitriptan, Viloxazine, Milnacipran, Vortioxetine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120447/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120310, 'Hydralazine', 'Maraviroc', 'Moderate', 'Maraviroc may potentiate the hypotensive effect of some medications.', NULL, 'Caution is advised when maraviroc is prescribed to patients on concomitant medications known to lower blood pressure.', NULL, 'Caution is advised when maraviroc is prescribed to patients on concomitant medications known to lower blood pressure. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120448/', '[1] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120311, 'Hydralazine', 'Meclofenamic acid', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', 'Rabeprazole, Phenylbutazone, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Valdecoxib, Rabeprazole, Dimethyl sulfoxide, Phenylbutazone', 'Minoxidil, Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120449/', '[1] Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120312, 'Hydralazine', 'Mefenamic acid', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', 'Rabeprazole, Phenylbutazone, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Valdecoxib', 'Minoxidil, Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120450/', '[1] Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120313, 'Hydralazine', 'Meloxicam', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', 'Ropivacaine, Lidocaine, Chloroprocaine, Levobupivacaine, Bupivacaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, More', 'Minoxidil, Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120451/', '[1] Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120314, 'Hydralazine', 'Meperidine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Tramadol, Naloxone', 'Rauwolfia serpentina root, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120452/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120315, 'Hydralazine', 'Meprobamate', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Halazepam, Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Quazepam, Ramelteon, Lemborexant, Ethchlorvynol, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120453/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120316, 'Hydralazine', 'Mesoridazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120454/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120317, 'Hydralazine', 'Methdilazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More', 'Rauwolfia serpentina root, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120455/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120318, 'Hydralazine', 'Methocarbamol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Chlormezanone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120456/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120319, 'Hydralazine', 'Methylprednisolone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Minocycline, Clindamycin, Vitamin A, Isotretinoin, Fluorometholone, Tretinoin, Erythromycin, Azelaic acid, Adapalene, Fluocinolone acetonide, Fluocinonide, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120457/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120320, 'Hydralazine', 'Metoprolol', 'Minor', 'Hydralazine may increase serum levels of some oral beta blockers. The proposed mechanism is reduced hepatic blood flow resulting in decreased biotransformation of beta blockers that undergo extensive first-pass metabolism. The interaction is less likely to occur with sustained-release preparations. Renally excreted beta-blockers such as atenolol, carteolol, nadolol, or sotalol are not expected to interact. This combination generally tends to have beneficial effects and is used commonly in the treatment of hypertension. The patient''s clinical response should be monitored. A dosage adjustment for the beta blocker may be required when given concomitantly with hydralazine.', NULL, '-', NULL, '-', 'Absorption', 'Nebivolol, Ivabradine, Nebivolol, Nebivolol', 'Nitroprusside, Diazoxide, Deserpidine', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120458/', '[1] Schneck DW, Vary JE "Mechanism by which hydralazine increases propranolol bioavailability." Clin Pharmacol Ther 35 (1984): 447-53[2] Janku I, Perlik F, Tkaczykova M, Brodanova M "Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects." Eur J Clin Pharmacol 42 (1992): 337-40[3] Le Coz F, Sauleman P, Poirier JM, Cuche JL, Midavaine M, Rames A, Lecocq B, Jaillon P "Oral pharmacokinetics of bisoprolol in resting and exercising healthy volunteers." J Cardiovasc Pharmacol 18 (1991): 28-34[4] Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):[5] Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y "Pharmacokinetics of carteolol in patients with impaired renal function." Eur J Clin Pharmacol 43 (1992): 417-21[6] Piquette-Miller M, Foster RT, Kappagoda CT, Jamali F "Effect of aging on the pharmacokinetics of acebutolol enantiomers." J Clin Pharmacol 32 (1992): 148-56[7] "Product Information. Levatol (penbutolol)." Reed and Carnrick, Jersey City, NJ.[8] Morgan T "Clinical pharmacokinetics and pharmacodynamics of carvedilol." Clin Pharmacokinet 26 (1994): 335-46[9] "Product Information. Betapace (sotalol)." Berlex, Richmond, CA.[10] McTavish D, Campoli-Richards D, Sorkin EM "Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy." Drugs 45 (1993): 232-58[11] "Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals, Wilmington, DE.[12] "Product Information. Blocadren (timolol)." Merck & Co, Inc, West Point, PA.[13] "Product Information. Cartrol (carteolol)." Abbott Pharmaceutical, Abbott Park, IL.[14] McLean AJ, Skews H, Bobik A, Dudley FJ "Interaction between oral propranolol and hydralazine." Clin Pharmacol Ther 27 (1980): 726-32[15] Stagni G, Davis PJ, Ludden TM "Human pharmacokinetics of betaxolol enantiomers." J Pharm Sci 80 (1991): 321-4[16] "Product Information. Corgard (nadolol)." Bristol-Myers Squibb, Princeton, NJ.[17] "Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[18] McGourty JC, Silas JH, Fleming JJ, McBurney A, Ward JW "Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin." Clin Pharmacol Ther 38 (1985): 409-13[19] "Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc, Cost Mesa, CA.[20] McLean AJ, Wilhelm D, Heinzow BG "Stable oral availability of atenolol coadministered with hydralazine. Comparison with propranolol, metoprolol and other B-Adrenoceptor antagonists." Drugs 25 (1983): 131-5[21] Lindeberg S, Holm B, Lundborg P, Regardh CG, Sandstrom B "The effect of hydralazine on steady-state plasma concentrations of metoprolol in pregnant hypertensive women." Eur J Clin Pharmacol 35 (1988): 131-5[22] Byrne AJ, McNeil JJ, Harrison PM, Louis W, Tonkin AM, McLean AJ "Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions." Br J Clin Pharmacol 17 Suppl (1984): s45-50[23] Seffart G ed. "Drug Dosage in Renal Insufficiency." Dordrecht, South Holland, : Kluwer Academic Publishers (1991):[24] Smith RL "Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance." Eur J Clin Pharmacol 28 (1985): 77-84[25] "Product Information. Normodyne (labetalol)." Schering Laboratories, Kenilworth, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120321, 'Hydralazine', 'Midazolam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Quazepam, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More', 'Nitroprusside, Diazoxide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120459/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120322, 'Hydralazine', 'Minoxidil (topical)', 'Moderate', 'Theoretically, topical administration of minoxidil may potentiate the hypotensive effects of systemic minoxidil and other vasodilators. Increased systemic absorption may occur when topical minoxidil is used in excess of normally recommended dosages or applied to compromised skin.', NULL, 'Patients prescribed topical minoxidil in combination with systemic vasodilators or peripherally-acting antiadrenergic agents should be monitored for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.', NULL, 'Patients prescribed topical minoxidil in combination with systemic vasodilators or peripherally-acting antiadrenergic agents should be monitored for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.', 'Synergism', 'Tacrolimus, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, More', 'Nitroprusside, Diazoxide, Rauwolfia serpentina root, Clonidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120460/', '[1] Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988): 481-5[2] "Product Information. Rogaine (minoxidil topical)." Johnson and Johnson/McNeil Consumer, Fort Washington, PA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120323, 'Hydralazine', 'Nabumetone', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', 'Rabeprazole, Phenylbutazone, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Valdecoxib', 'Minoxidil, Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120461/', '[1] Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120324, 'Hydralazine', 'Nalbuphine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Tramadol, Naloxone', 'Rauwolfia serpentina root, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120462/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120325, 'Hydralazine', 'Naxitamab', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120463/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120326, 'Hydralazine', 'Nelarabine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Methotrexate, Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Clofarabine, Trifluridine, Floxuridine, Gemcitabine, Pralatrexate, Cytarabine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120464/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120327, 'Hydralazine', 'Nesiritide', 'Moderate', 'The coadministration of nesiritide with intravenous vasodilators such as nitroglycerin, nitroprusside, and milrinone has not been evaluated. Theoretically, an increase in symptomatic hypotension may occur due to possible additive pharmacodynamic effects in the vasculature. A similar risk may exist during coadministration with oral vasodilators such as hydralazine and minoxidil and other agents with vasodilating effects.', NULL, 'Whether used alone or with other agents, nesiritide should be administered only in settings where blood pressure can be closely monitored.', NULL, 'Whether used alone or with other agents, nesiritide should be administered only in settings where blood pressure can be closely monitored. The dosage should be reduced or the drug discontinued in patients who develop hypotension.', 'Synergism', 'Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120465/', '[1] "Product Information. Natrecore (nesiritide)" Scios Inc, Sunnyvale, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120328, 'Hydralazine', 'Nitrofurantoin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120466/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120329, 'Hydralazine', 'Oliceridine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Tramadol, Naloxone', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120467/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120330, 'Hydralazine', 'Olopatadine (nasal)', 'Moderate', 'Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance. Somnolence has been reported in some patients using olopatadine nasal spray in clinical trials.', NULL, 'Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.', NULL, 'Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Nitroprusside, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120468/', '[1] "Product Information. Patanase (olopatadine nasal)." Alcon Laboratories Inc, Fort Worth, TX.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120331, 'Hydralazine', 'Orphenadrine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Chlormezanone, Biperiden, Trihexyphenidyl, Benzatropine, Procyclidine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120469/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120332, 'Hydralazine', 'Oxaliplatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Sotorasib, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120470/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120333, 'Hydralazine', 'Oxazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Halazepam', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120471/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120334, 'Hydralazine', 'Ozanimod', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120472/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120335, 'Hydralazine', 'Paclitaxel (protein-bound)', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120473/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120336, 'Hydralazine', 'Peginterferon alfa-2a', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Ropeginterferon alfa-2b, Peginterferon beta-1a, Interferon beta-1a, Sargramostim, Histamine, Pegademase, Pegfilgrastim, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120474/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120337, 'Hydralazine', 'Peginterferon alfa-2b', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Oprelvekin, Sipuleucel-T, Elapegademase, Interferon beta-1b, Ropeginterferon alfa-2b, Peginterferon beta-1a, Interferon beta-1a, Sargramostim, Histamine, Pegademase, Pegfilgrastim, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120475/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120338, 'Hydralazine', 'Penbutolol', 'Minor', 'Hydralazine may increase serum levels of some oral beta blockers. The proposed mechanism is reduced hepatic blood flow resulting in decreased biotransformation of beta blockers that undergo extensive first-pass metabolism. The interaction is less likely to occur with sustained-release preparations. Renally excreted beta-blockers such as atenolol, carteolol, nadolol, or sotalol are not expected to interact. This combination generally tends to have beneficial effects and is used commonly in the treatment of hypertension. The patient''s clinical response should be monitored. A dosage adjustment for the beta blocker may be required when given concomitantly with hydralazine.', NULL, '-', NULL, '-', 'Absorption', 'Minoxidil, Nitroprusside, Diazoxide, Deserpidine', 'Nebivolol', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120476/', '[1] Schneck DW, Vary JE "Mechanism by which hydralazine increases propranolol bioavailability." Clin Pharmacol Ther 35 (1984): 447-53[2] Janku I, Perlik F, Tkaczykova M, Brodanova M "Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects." Eur J Clin Pharmacol 42 (1992): 337-40[3] Le Coz F, Sauleman P, Poirier JM, Cuche JL, Midavaine M, Rames A, Lecocq B, Jaillon P "Oral pharmacokinetics of bisoprolol in resting and exercising healthy volunteers." J Cardiovasc Pharmacol 18 (1991): 28-34[4] Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):[5] Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y "Pharmacokinetics of carteolol in patients with impaired renal function." Eur J Clin Pharmacol 43 (1992): 417-21[6] Piquette-Miller M, Foster RT, Kappagoda CT, Jamali F "Effect of aging on the pharmacokinetics of acebutolol enantiomers." J Clin Pharmacol 32 (1992): 148-56[7] "Product Information. Levatol (penbutolol)." Reed and Carnrick, Jersey City, NJ.[8] Morgan T "Clinical pharmacokinetics and pharmacodynamics of carvedilol." Clin Pharmacokinet 26 (1994): 335-46[9] "Product Information. Betapace (sotalol)." Berlex, Richmond, CA.[10] McTavish D, Campoli-Richards D, Sorkin EM "Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy." Drugs 45 (1993): 232-58[11] "Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals, Wilmington, DE.[12] "Product Information. Blocadren (timolol)." Merck & Co, Inc, West Point, PA.[13] "Product Information. Cartrol (carteolol)." Abbott Pharmaceutical, Abbott Park, IL.[14] McLean AJ, Skews H, Bobik A, Dudley FJ "Interaction between oral propranolol and hydralazine." Clin Pharmacol Ther 27 (1980): 726-32[15] Stagni G, Davis PJ, Ludden TM "Human pharmacokinetics of betaxolol enantiomers." J Pharm Sci 80 (1991): 321-4[16] "Product Information. Corgard (nadolol)." Bristol-Myers Squibb, Princeton, NJ.[17] "Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[18] McGourty JC, Silas JH, Fleming JJ, McBurney A, Ward JW "Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin." Clin Pharmacol Ther 38 (1985): 409-13[19] "Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc, Cost Mesa, CA.[20] McLean AJ, Wilhelm D, Heinzow BG "Stable oral availability of atenolol coadministered with hydralazine. Comparison with propranolol, metoprolol and other B-Adrenoceptor antagonists." Drugs 25 (1983): 131-5[21] Lindeberg S, Holm B, Lundborg P, Regardh CG, Sandstrom B "The effect of hydralazine on steady-state plasma concentrations of metoprolol in pregnant hypertensive women." Eur J Clin Pharmacol 35 (1988): 131-5[22] Byrne AJ, McNeil JJ, Harrison PM, Louis W, Tonkin AM, McLean AJ "Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions." Br J Clin Pharmacol 17 Suppl (1984): s45-50[23] Seffart G ed. "Drug Dosage in Renal Insufficiency." Dordrecht, South Holland, : Kluwer Academic Publishers (1991):[24] Smith RL "Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance." Eur J Clin Pharmacol 28 (1985): 77-84[25] "Product Information. Normodyne (labetalol)." Schering Laboratories, Kenilworth, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120339, 'Hydralazine', 'Pentoxifylline', 'Moderate', 'Pentoxifylline may potentiate the action of hypotensive agents. Small decreases in blood pressure have been observed in some patients treated with pentoxifylline plus nifedipine or captopril. The mechanism of interaction has not been described.', NULL, 'Caution is advised if pentoxifylline is used in combination with hypotensive agents.', NULL, 'Caution is advised if pentoxifylline is used in combination with hypotensive agents. Periodic systemic blood pressure monitoring is recommended.', 'Synergism', 'Niacin, Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, More', 'Diazoxide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120477/', '[1] "Product Information. Trental (pentoxifylline)." Hoechst Marion-Roussel Inc, Kansas City, MO.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120340, 'Hydralazine', 'Perphenazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120478/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120341, 'Hydralazine', 'Piroxicam', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', 'Rabeprazole, Phenylbutazone, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Valdecoxib, Rabeprazole, Dimethyl sulfoxide, Phenylbutazone, More', 'Minoxidil, Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120479/', '[1] Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120342, 'Hydralazine', 'Pitavastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120480/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120343, 'Hydralazine', 'Polatuzumab vedotin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120481/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120344, 'Hydralazine', 'Pomalidomide', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120482/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120345, 'Hydralazine', 'Ponatinib', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120483/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120346, 'Hydralazine', 'Pravastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, Cholestyramine, Ezetimibe, Clofibrate, Colestipol, More', 'Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120484/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120347, 'Hydralazine', 'Prednisolone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluocinolone acetonide, Fluorometholone, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120485/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120348, 'Hydralazine', 'Prednisone', 'Moderate', 'Corticosteroids may antagonize the effects of antihypertensive medications by inducing sodium and fluid retention. These effects may be more common with the natural corticosteroids (cortisone, hydrocortisone) because they have greater mineralocorticoid activity. Conversely, some calcium channel blockers such as diltiazem and verapamil may increase corticosteroid plasma levels and effects by inhibiting their clearance via CYP450 3A4 metabolism.', NULL, 'Patients on prolonged (i.', NULL, 'Patients on prolonged (i.e., longer than about a week) or high-dose corticosteroid therapy should have blood pressure, electrolyte levels, and body weight monitored regularly, and be observed for the development of edema and congestive heart failure. The dosages of antihypertensive medications may require adjustment.', 'Metabolism, Antagonism', 'Cromoglicic acid, Olsalazine, Sulfasalazine, Balsalazide, Beclomethasone dipropionate, Mesalazine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120486/', '[1] "Multum Information Services, Inc. Expert Review Panel"[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120349, 'Hydralazine', 'Propranolol', 'Minor', 'Hydralazine may increase serum levels of some oral beta blockers. The proposed mechanism is reduced hepatic blood flow resulting in decreased biotransformation of beta blockers that undergo extensive first-pass metabolism. The interaction is less likely to occur with sustained-release preparations. Renally excreted beta-blockers such as atenolol, carteolol, nadolol, or sotalol are not expected to interact. This combination generally tends to have beneficial effects and is used commonly in the treatment of hypertension. The patient''s clinical response should be monitored. A dosage adjustment for the beta blocker may be required when given concomitantly with hydralazine.', NULL, '-', NULL, '-', 'Absorption', 'Nebivolol, Ivabradine, Nebivolol, Nebivolol', 'Nitroprusside, Diazoxide, Deserpidine', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120487/', '[1] Schneck DW, Vary JE "Mechanism by which hydralazine increases propranolol bioavailability." Clin Pharmacol Ther 35 (1984): 447-53[2] Janku I, Perlik F, Tkaczykova M, Brodanova M "Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects." Eur J Clin Pharmacol 42 (1992): 337-40[3] Le Coz F, Sauleman P, Poirier JM, Cuche JL, Midavaine M, Rames A, Lecocq B, Jaillon P "Oral pharmacokinetics of bisoprolol in resting and exercising healthy volunteers." J Cardiovasc Pharmacol 18 (1991): 28-34[4] Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):[5] Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y "Pharmacokinetics of carteolol in patients with impaired renal function." Eur J Clin Pharmacol 43 (1992): 417-21[6] Piquette-Miller M, Foster RT, Kappagoda CT, Jamali F "Effect of aging on the pharmacokinetics of acebutolol enantiomers." J Clin Pharmacol 32 (1992): 148-56[7] "Product Information. Levatol (penbutolol)." Reed and Carnrick, Jersey City, NJ.[8] Morgan T "Clinical pharmacokinetics and pharmacodynamics of carvedilol." Clin Pharmacokinet 26 (1994): 335-46[9] "Product Information. Betapace (sotalol)." Berlex, Richmond, CA.[10] McTavish D, Campoli-Richards D, Sorkin EM "Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy." Drugs 45 (1993): 232-58[11] "Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals, Wilmington, DE.[12] "Product Information. Blocadren (timolol)." Merck & Co, Inc, West Point, PA.[13] "Product Information. Cartrol (carteolol)." Abbott Pharmaceutical, Abbott Park, IL.[14] McLean AJ, Skews H, Bobik A, Dudley FJ "Interaction between oral propranolol and hydralazine." Clin Pharmacol Ther 27 (1980): 726-32[15] Stagni G, Davis PJ, Ludden TM "Human pharmacokinetics of betaxolol enantiomers." J Pharm Sci 80 (1991): 321-4[16] "Product Information. Corgard (nadolol)." Bristol-Myers Squibb, Princeton, NJ.[17] "Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[18] McGourty JC, Silas JH, Fleming JJ, McBurney A, Ward JW "Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin." Clin Pharmacol Ther 38 (1985): 409-13[19] "Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc, Cost Mesa, CA.[20] McLean AJ, Wilhelm D, Heinzow BG "Stable oral availability of atenolol coadministered with hydralazine. Comparison with propranolol, metoprolol and other B-Adrenoceptor antagonists." Drugs 25 (1983): 131-5[21] Lindeberg S, Holm B, Lundborg P, Regardh CG, Sandstrom B "The effect of hydralazine on steady-state plasma concentrations of metoprolol in pregnant hypertensive women." Eur J Clin Pharmacol 35 (1988): 131-5[22] Byrne AJ, McNeil JJ, Harrison PM, Louis W, Tonkin AM, McLean AJ "Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions." Br J Clin Pharmacol 17 Suppl (1984): s45-50[23] Seffart G ed. "Drug Dosage in Renal Insufficiency." Dordrecht, South Holland, : Kluwer Academic Publishers (1991):[24] Smith RL "Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance." Eur J Clin Pharmacol 28 (1985): 77-84[25] "Product Information. Normodyne (labetalol)." Schering Laboratories, Kenilworth, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120350, 'Hydralazine', 'Quetiapine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120488/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120351, 'Hydralazine', 'Rasagiline', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Rauwolfia serpentina root, Reserpine, Deserpidine', 'Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Pramipexole, Amantadine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120489/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120352, 'Hydralazine', 'Rosuvastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Fenofibrate, Ezetimibe, Bempedoic acid, Niacin, Gemfibrozil, Fenofibric acid, Mipomersen, Evinacumab, Evolocumab, Dextrothyroxine, Probucol, More', 'Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120490/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120353, 'Hydralazine', 'Salsalate', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Ziconotide, Methoxyflurane', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120491/', '[1] Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120354, 'Hydralazine', 'Selegiline', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Ropinirole, Opicapone, Rotigotine, Tolcapone, Entacapone, Bromocriptine, Pergolide, Pramipexole, Amantadine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120492/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120355, 'Hydralazine', 'Selexipag', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120493/', '[1] "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC.[2] "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Buchdahl RM, Taylor P, Warner JD "Nebulised ribavirin for adenovirus pneumonia." Lancet 2 (1985): 1070-1[5] "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120356, 'Hydralazine', 'Simvastatin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, Glimepiride, More', 'Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120494/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120357, 'Hydralazine', 'Salicylic acid (sodium)', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120495/', '[1] Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120358, 'Hydralazine', 'Sulindac', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', 'Rabeprazole, Phenylbutazone, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Valdecoxib', 'Minoxidil, Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120496/', '[1] Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120359, 'Hydralazine', 'Telbivudine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120497/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120360, 'Hydralazine', 'Teniposide', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Topotecan, Irinotecan', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120498/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120361, 'Hydralazine', 'Teriflunomide', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120499/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120362, 'Hydralazine', 'Thalidomide', 'Moderate', 'Thalidomide can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Peripheral neuropathy is a common, potentially severe side effect of thalidomide that may be irreversible.', NULL, 'Caution is advised if thalidomide is used in combination with other neurotoxic agents.', NULL, 'Caution is advised if thalidomide is used in combination with other neurotoxic agents. All patients treated with thalidomide should be examined at monthly intervals for the first three months of therapy and periodically thereafter to detect early signs of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Electrophysiological testing may be performed at baseline and every six months during therapy to detect asymptomatic neuropathy. Consideration should be given to immediate discontinuation of thalidomide in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, More', 'Minoxidil, Nitroprusside, Diazoxide, Rauwolfia serpentina root, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120500/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6[3] "Product Information. Thalomid (thalidomide)." Celgene Corporation, Warren, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Accolate (zafirlukast)." Zeneca Pharmaceuticals, Wilmington, DE.[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120363, 'Hydralazine', 'Thiethylperazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120501/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120364, 'Hydralazine', 'Thiothixene', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120502/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120365, 'Hydralazine', 'Timolol', 'Minor', 'Hydralazine may increase serum levels of some oral beta blockers. The proposed mechanism is reduced hepatic blood flow resulting in decreased biotransformation of beta blockers that undergo extensive first-pass metabolism. The interaction is less likely to occur with sustained-release preparations. Renally excreted beta-blockers such as atenolol, carteolol, nadolol, or sotalol are not expected to interact. This combination generally tends to have beneficial effects and is used commonly in the treatment of hypertension. The patient''s clinical response should be monitored. A dosage adjustment for the beta blocker may be required when given concomitantly with hydralazine.', NULL, '-', NULL, '-', 'Absorption', 'Nebivolol, Latanoprost, Methazolamide, Neostigmine, Pilocarpine, Physostigmine, Acetylcholine, Diclofenamide, Bimatoprost, Travoprost, Acetazolamide, More', 'Minoxidil, Nitroprusside, Diazoxide, Deserpidine', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120503/', '[1] Schneck DW, Vary JE "Mechanism by which hydralazine increases propranolol bioavailability." Clin Pharmacol Ther 35 (1984): 447-53[2] Janku I, Perlik F, Tkaczykova M, Brodanova M "Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects." Eur J Clin Pharmacol 42 (1992): 337-40[3] Le Coz F, Sauleman P, Poirier JM, Cuche JL, Midavaine M, Rames A, Lecocq B, Jaillon P "Oral pharmacokinetics of bisoprolol in resting and exercising healthy volunteers." J Cardiovasc Pharmacol 18 (1991): 28-34[4] Hardman JG, Gilman AG, Limbird LE eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 9th ed." New York, NY: McGraw-Hill (1995):[5] Amemiya M, Tabei K, Furuya H, Sakairi Y, Asano Y "Pharmacokinetics of carteolol in patients with impaired renal function." Eur J Clin Pharmacol 43 (1992): 417-21[6] Piquette-Miller M, Foster RT, Kappagoda CT, Jamali F "Effect of aging on the pharmacokinetics of acebutolol enantiomers." J Clin Pharmacol 32 (1992): 148-56[7] "Product Information. Levatol (penbutolol)." Reed and Carnrick, Jersey City, NJ.[8] Morgan T "Clinical pharmacokinetics and pharmacodynamics of carvedilol." Clin Pharmacokinet 26 (1994): 335-46[9] "Product Information. Betapace (sotalol)." Berlex, Richmond, CA.[10] McTavish D, Campoli-Richards D, Sorkin EM "Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy." Drugs 45 (1993): 232-58[11] "Product Information. Brevibloc (esmolol)." DuPont Pharmaceuticals, Wilmington, DE.[12] "Product Information. Blocadren (timolol)." Merck & Co, Inc, West Point, PA.[13] "Product Information. Cartrol (carteolol)." Abbott Pharmaceutical, Abbott Park, IL.[14] McLean AJ, Skews H, Bobik A, Dudley FJ "Interaction between oral propranolol and hydralazine." Clin Pharmacol Ther 27 (1980): 726-32[15] Stagni G, Davis PJ, Ludden TM "Human pharmacokinetics of betaxolol enantiomers." J Pharm Sci 80 (1991): 321-4[16] "Product Information. Corgard (nadolol)." Bristol-Myers Squibb, Princeton, NJ.[17] "Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[18] McGourty JC, Silas JH, Fleming JJ, McBurney A, Ward JW "Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin." Clin Pharmacol Ther 38 (1985): 409-13[19] "Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc, Cost Mesa, CA.[20] McLean AJ, Wilhelm D, Heinzow BG "Stable oral availability of atenolol coadministered with hydralazine. Comparison with propranolol, metoprolol and other B-Adrenoceptor antagonists." Drugs 25 (1983): 131-5[21] Lindeberg S, Holm B, Lundborg P, Regardh CG, Sandstrom B "The effect of hydralazine on steady-state plasma concentrations of metoprolol in pregnant hypertensive women." Eur J Clin Pharmacol 35 (1988): 131-5[22] Byrne AJ, McNeil JJ, Harrison PM, Louis W, Tonkin AM, McLean AJ "Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions." Br J Clin Pharmacol 17 Suppl (1984): s45-50[23] Seffart G ed. "Drug Dosage in Renal Insufficiency." Dordrecht, South Holland, : Kluwer Academic Publishers (1991):[24] Smith RL "Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance." Eur J Clin Pharmacol 28 (1985): 77-84[25] "Product Information. Normodyne (labetalol)." Schering Laboratories, Kenilworth, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120366, 'Hydralazine', 'Tinidazole', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Tetracycline, Norfloxacin, Cefepime, Ciprofloxacin, Cefuroxime, Cefixime, Azithromycin, Amikacin, Levofloxacin, Ofloxacin, Tetracycline, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120504/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120367, 'Hydralazine', 'Tocilizumab', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Ustekinumab, Antithymocyte immunoglobulin (rabbit), Anifrolumab, Canakinumab, Secukinumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Methotrexate, Tacrolimus, Abatacept, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120505/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120368, 'Hydralazine', 'Tolmetin', 'Moderate', 'Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', NULL, 'Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.', 'Antagonism', 'Rabeprazole, Phenylbutazone, Misoprostol, Glucosamine, Chondroitin sulfate, Rofecoxib, Esomeprazole, Valdecoxib, Rabeprazole, Dimethyl sulfoxide, Phenylbutazone', 'Minoxidil, Nitroprusside, Diazoxide, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120506/', '[1] Cinquegrani MP, Liang CS "Indomethacin attenuates the hypotensive action of hydralazine." Clin Pharmacol Ther 39 (1986): 564-70', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120369, 'Hydralazine', 'Trabectedin', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Topotecan, Irinotecan', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120507/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120370, 'Hydralazine', 'Alimemazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Ketotifen, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Fexofenadine, More', 'Rauwolfia serpentina root, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120508/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120371, 'Hydralazine', 'Verteporfin', 'Moderate', 'Drugs that decrease clotting, vasoconstriction, or platelet aggregation may interfere with the therapeutic effect of verteporfin. These agents may antagonize the physiologic responses to local damage of neovascular endothelium induced by activated verteporfin, which include the release of procoagulant and vasoactive factors that result in vessel occlusion. However, the clinical significance is unknown.', NULL, 'If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy.', NULL, 'If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy. Otherwise, the potential for diminished efficacy of verteporfin should be considered.', 'Antagonism', 'Aflibercept, Bevacizumab', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120509/', '[1] "Product Information. Visudyne (verteporfin)" Valeant Pharmaceuticals, Costa Mesa, CA.[2] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120372, 'Hydralazine', 'Vinblastine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Topotecan, Irinotecan', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120510/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120373, 'Hydralazine', 'Vincristine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Topotecan, Irinotecan', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120511/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120374, 'Hydralazine', 'Vincristine (liposome)', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Topotecan, Irinotecan', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120512/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120375, 'Hydralazine', 'Vinorelbine', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Topotecan, Irinotecan', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120513/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120376, 'Hydralazine', 'Zafirlukast', 'Moderate', 'The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk factors include diabetes and age older than 60 years.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet.', NULL, 'Patients should be monitored closely for symptoms of neuropathy such as burning, tingling, pain, or numbness in the hands and feet. Since the development of peripheral neuropathy may be dose-related for many drugs, the recommended dosages should generally not be exceeded. Consideration should be given to dosage reduction or immediate discontinuation of these medications in patients who develop peripheral neuropathy to limit further damage.', 'Synergism', 'Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Oxtriphylline, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120514/', '[1] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[2] Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):[3] Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201[4] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120377, 'Hydralazine', 'Zalcitabine', 'Moderate', 'Zalcitabine can cause peripheral neuropathy in up to one-third of patients with advanced HIV disease, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or severity of nerve damage. Zalcitabine-related peripheral neuropathy is a sensorimotor neuropathy characterized initially by numbness and burning dysesthesia involving the distal extremities. These symptoms may be followed by sharp shooting pains or severe continuous burning pain if the drug is not withdrawn, and progress to severe pain requiring narcotic analgesics. The neuropathy is potentially irreversible. However, with prompt discontinuation of zalcitabine, it is usually slowly reversible, although symptoms may initially progress following discontinuation.', NULL, 'Use of zalcitabine with other drugs that have the potential to cause peripheral neuropathy should be avoided whenever possible.', NULL, 'Use of zalcitabine with other drugs that have the potential to cause peripheral neuropathy should be avoided whenever possible. Otherwise, careful monitoring is recommended for symptoms of neuropathy such as burning, tingling, pain, numbness, or weakness in the extremities, particularly in patients with a low CD4 cell count or diabetes. Since the development of peripheral neuropathy appears to be dose-related, the recommended dosage of zalcitabine should not be exceeded. Patients should be advised to promptly discontinue zalcitabine therapy and contact their physician if neuropathy develops. Therapy may be reinstituted following resolution of neuropathy symptoms, but dosage should be reduced to one-half the initially recommended dosage. Zalcitabine should be permanently discontinued in patients who develop severe peripheral neuropathy during treatment.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', 'Minoxidil, Nitroprusside, Diazoxide, Prazosin, Rauwolfia serpentina root, Reserpine, Clonidine, Guanethidine, Deserpidine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120515/', '[1] Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6[2] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.[3] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120378, 'Hydralazine', 'Zaleplon', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Quazepam, Ramelteon, Lemborexant, Ethchlorvynol, Zopiclone, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120516/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120379, 'Hydralazine', 'Ziprasidone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120517/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120380, 'Isosorbide mononitrate', 'Amoxapine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, Vilazodone, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Protriptyline, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120518/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120381, 'Isosorbide mononitrate', 'Oxybuprocaine (ophthalmic)', 'Moderate', 'Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.', 'Synergism', 'Nesiritide, Vericiguat', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120519/', '[1] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009): 837-45[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Hurricaine (benzocaine topical)." Beutlich, Waukegan, IL.[4] "Product Information. Chloraseptic (benzocaine-menthol topical)." Prestige Brands (formerly MedTech), Tarrytown, NY.[5] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011): 757-61[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Karim A, Ahmed S, Siddiqui R, Mattana J "Methemoglobinemia complicating topical lidocaine used during endoscopic procedures." Am J Med 111 (2001): 150-3', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120382, 'Isosorbide mononitrate', 'Butabarbital', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Thiopental, Amobarbital, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Methylphenobarbital, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120520/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120383, 'Isosorbide mononitrate', 'Chloral hydrate', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat', 'Suvorexant, Thiopental, Amobarbital, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Methylphenobarbital, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120521/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120384, 'Isosorbide mononitrate', 'Chlorpromazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120522/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120385, 'Isosorbide mononitrate', 'Dapsone', 'Moderate', 'Coadministration of oral or topical dapsone with other agents associated with methemoglobinemia may have additive effects and theoretically increase the risk of drug-induced methemoglobinemia. Oral and topical dapsone have been associated with methemoglobinemia, and the risk is increased in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency or congenital or idiopathic methemoglobinemia.', NULL, 'Concurrent use of oral or topical dapsone with other methemoglobinemia-inducing medications should be followed with monitoring for signs and symptoms of methemoglobinemia (e.', NULL, 'Concurrent use of oral or topical dapsone with other methemoglobinemia-inducing medications should be followed with monitoring for signs and symptoms of methemoglobinemia (e.g., cyanosis, hypoxia).', 'Synergism', 'Minocycline, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Azelaic acid, Adapalene, Clofazimine', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120523/', '[1] "Product Information. Aczone (dapsone topical)." QLT USA, Inc, Fort Collins, CO.[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120386, 'Isosorbide mononitrate', 'Cinchocaine (topical)', 'Moderate', 'Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.', 'Synergism', 'Nesiritide, Vericiguat', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120524/', '[1] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009): 837-45[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Hurricaine (benzocaine topical)." Beutlich, Waukegan, IL.[4] "Product Information. Chloraseptic (benzocaine-menthol topical)." Prestige Brands (formerly MedTech), Tarrytown, NY.[5] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011): 757-61[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Karim A, Ahmed S, Siddiqui R, Mattana J "Methemoglobinemia complicating topical lidocaine used during endoscopic procedures." Am J Med 111 (2001): 150-3', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120387, 'Isosorbide mononitrate', 'Dimenhydrinate', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120525/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120388, 'Isosorbide mononitrate', 'Epoprostenol', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120526/', '[1] "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC.[2] "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Buchdahl RM, Taylor P, Warner JD "Nebulised ribavirin for adenovirus pneumonia." Lancet 2 (1985): 1070-1[5] "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120389, 'Isosorbide mononitrate', 'Ergometrine', 'Moderate', 'Ergot alkaloids, by causing vasoconstriction, may theoretically antagonize the effects of nitrates. In addition, nitrates may increase splanchnic blood flow, resulting in decreased first-pass metabolism of dihydroergotamine and increased bioavailability.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Ergot alkaloids are considered contraindicated in patients with ischemic heart disease.', 'Antagonism', 'Nesiritide, Vericiguat', 'Dinoprostone, Oxytocin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120527/', '[1] Bobik A, Jennings G, Skews H, Esler M, McLean A "Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension." Clin Pharmacol Ther 30 (1981): 673-9[2] Raberger G, Schutz W, Zimpfer M, Kraupp O "The influence of dihydroergotamine on adenosine-induced and reactive coronary vasodilation. Interaction of dihydroergotamine and coronary vasodilation." Basic Res Cardiol 71 (1976): 645-51[3] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[7] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120390, 'Isosorbide mononitrate', 'Ergotamine', 'Moderate', 'Ergot alkaloids, by causing vasoconstriction, may theoretically antagonize the effects of nitrates. In addition, nitrates may increase splanchnic blood flow, resulting in decreased first-pass metabolism of dihydroergotamine and increased bioavailability.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Ergot alkaloids are considered contraindicated in patients with ischemic heart disease.', 'Antagonism', 'Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Ubrogepant, Naratriptan, Galcanezumab, Zolmitriptan, Atogepant, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120528/', '[1] Bobik A, Jennings G, Skews H, Esler M, McLean A "Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension." Clin Pharmacol Ther 30 (1981): 673-9[2] Raberger G, Schutz W, Zimpfer M, Kraupp O "The influence of dihydroergotamine on adenosine-induced and reactive coronary vasodilation. Interaction of dihydroergotamine and coronary vasodilation." Basic Res Cardiol 71 (1976): 645-51[3] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[7] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120391, 'Isosorbide mononitrate', 'Ertugliflozin', 'Moderate', 'Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.', NULL, 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.', NULL, 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.', 'Synergism', 'Vericiguat', 'Exenatide, Lixisenatide, Albiglutide, Acetohexamide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120529/', '[1] "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb, Princeton, NJ.[5] "Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals, Titusville, NJ.[6] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[9] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[10] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120392, 'Isosorbide mononitrate', 'Fluphenazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120530/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120393, 'Isosorbide mononitrate', 'Flurazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Thiopental, Amobarbital, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Methylphenobarbital, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120531/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120394, 'Isosorbide mononitrate', 'Fosinopril', 'Moderate', 'Angiotensin converting enzyme (ACE) inhibitors may enhance the vasodilatory and hypotensive effects of nitroglycerin. Data have also shown that captopril can prevent nitrate tolerance. ACE inhibitors can decrease systemic vascular resistance and cardiac work, further enhancing the effectiveness of nitroglycerin.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose. Blood pressure monitoring is advisable.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120532/', '[1] Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7[2] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[3] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[4] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120395, 'Isosorbide mononitrate', 'Garlic', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', 'Vericiguat', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120533/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120396, 'Isosorbide mononitrate', 'Haloperidol', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120534/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120397, 'Isosorbide mononitrate', 'Diamorphine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat', 'Acamprosate, Naltrexone, Disulfiram, Levacetylmethadol, Nalmefene', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120535/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120398, 'Isosorbide mononitrate', 'Hydromorphone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120536/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120399, 'Isosorbide mononitrate', 'Hydroxyzine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Halazepam', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120537/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120400, 'Isosorbide mononitrate', 'Iloperidone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat', 'Droperidol, Pimozide, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120538/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120401, 'Isosorbide mononitrate', 'Iloprost', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120539/', '[1] "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC.[2] "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Buchdahl RM, Taylor P, Warner JD "Nebulised ribavirin for adenovirus pneumonia." Lancet 2 (1985): 1070-1[5] "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120402, 'Isosorbide mononitrate', 'Imipramine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, Vilazodone, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Protriptyline, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120540/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120403, 'Isosorbide mononitrate', 'Licorice', 'Moderate', 'Licorice use has been associated with hypertension and may antagonize the effects of antihypertensive agents. Glycyrrhizic acid, a component of licorice, is hydrolyzed in the intestine to a metabolite (glycyrrhetinic acid) that causes mineralocorticoid and renin-suppressing effects.', NULL, 'Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products.', NULL, 'Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products. Even relatively moderate doses of licorice may be problematic in susceptible patients when ingested regularly for prolonged periods.', 'Antagonism', 'Vericiguat', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120541/', '[1] Cumming AM "Metabolic effects of licorice." Br Med J 1 (1977): 906[2] Epstein MT, Espiner EA, Donald RA, Hughes H "Effect of eating liquorice on the renin-angiotensin aldosterone axis in normal subjects." Br Med J 1 (1977): 488-90[3] Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR "Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age." Lancet 2 (1987): 821-4[4] Elinav E, Chajek-Shaul T "Licorice consumption causing severe hypokalemic paralysis." Mayo Clin Proc 78 (2003): 767-8[5] Rosseel M, Schoors D "Chewing gum and hypokalaemia." Lancet 341 (1993): 175[6] Clyburn EB, DiPette DJ "Hypertension induced by drugs and other substances." Semin Nephrol 15 (1995): 72-86[7] Lin SH, Yang SS, Chau T, Halperin ML "An unusual cause of hypokalemic paralysis: chronic licorice ingestion." Am J Med Sci 325 (2003): 153-6[8] de Klerk GJ, Nieuwenhuis MG, Beutler JJ "Lesson of the week: hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum." BMJ 314 (1997): 731[9] Nielsen I, Pedersen RS "Life-threatening hypokalaemia caused by liquorice ingestion." Lancet 1 (1984): 1305[10] Cumming AM, Boddy K, Brown JJ, et al "Severe hypokalaemia with paralysis induced by small doses of liquorice." Postgrad Med J 56 (1980): 526-9[11] Cumming A "Severe reduction of serum potassium induced by licorice." Nurs Times 72 (1976): 367-70[12] Epstein MT, Espiner EA, Donald RA, Hughes H "Liquorice toxicity and the renin-angiotensin-aldosterone axis in man." Br Med J 1 (1977): 209-10[13] Sigurjonsdottir HA, Franzson L, Manhem K, Ragnarsson J, Sigurdsson G, Wallerstedt S "Liquorice-induced rise in blood pressure: a linear dose-response relationship." J Hum Hypertens 15 (2001): 549-52[14] Edwards CR "Lessons from licorice." N Engl J Med 325 (1991): 1242-3[15] Ishikawa S, Kato M, Tokuda T, Momoi H, Sekijima Y, Higuchi M, Yanagisawa N "Licorice-induced hypokalemic myopathy and hypokalemic renal tubular damage in anorexia nervosa." Int J Eating Disorder 26 (1999): 111-4[16] Holmes AM, Young J, Marrott PK, Prentice E "Pseudohyperaldosteronism induced by habitual ingestion of liquorice." Postgrad Med J 46 (1970): 625-9[17] Bannister B, Ginsburg R, Shneerson J "Cardiac arrest due to liquorice-induced hypokalaemia." Br Med J 2 (1977): 738-9[18] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20[19] Farese RV, Biglieri EG, Shackleton CH, Irony I, Gomez-Fontes R "Licorice-induced hypermineralocorticoidism." N Engl J Med 325 (1991): 1223-7[20] Dellow EL, Unwin RJ, Honour JW "Pontefract cakes can be bad for you: refractory hypertension and liquorice excess." Nephrol Dial Transplant 14 (1999): 218-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120404, 'Isosorbide mononitrate', 'Linezolid', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Lefamulin, Fosfomycin, Tedizolid, Dalbavancin', 'Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120542/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120405, 'Isosorbide mononitrate', 'Lisinopril', 'Moderate', 'Angiotensin converting enzyme (ACE) inhibitors may enhance the vasodilatory and hypotensive effects of nitroglycerin. Data have also shown that captopril can prevent nitrate tolerance. ACE inhibitors can decrease systemic vascular resistance and cardiac work, further enhancing the effectiveness of nitroglycerin.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose. Blood pressure monitoring is advisable.', 'Synergism', 'Bempedoic acid', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120543/', '[1] Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7[2] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[3] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[4] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120406, 'Isosorbide mononitrate', 'Lofexidine', 'Moderate', 'The hypotensive effects of lofexidine and antihypertensive agents may be additive. Postural hypotension may occur.', NULL, 'Hemodynamic responses should be monitored during coadministration of lofexidine with antihypertensive agents, especially during the first few weeks of therapy.', NULL, 'Hemodynamic responses should be monitored during coadministration of lofexidine with antihypertensive agents, especially during the first few weeks of therapy.', 'Synergism', 'Nesiritide', 'Acamprosate, Naltrexone, Disulfiram, Levacetylmethadol, Nalmefene', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120544/', '[1] "Product Information. Lucemyra (lofexidine)." US WorldMeds LLC, Louisville , KY.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120407, 'Isosorbide mononitrate', 'Lorazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Halazepam', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120545/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120408, 'Isosorbide mononitrate', 'Loxapine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120546/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120409, 'Isosorbide mononitrate', 'Lumateperone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat', 'Droperidol, Pimozide, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120547/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120410, 'Isosorbide mononitrate', 'Lurasidone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat', 'Droperidol, Pimozide, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120548/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120411, 'Isosorbide mononitrate', 'Maprotiline', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, Vilazodone, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Protriptyline, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120549/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120412, 'Isosorbide mononitrate', 'Maraviroc', 'Moderate', 'Maraviroc may potentiate the hypotensive effect of some medications.', NULL, 'Caution is advised when maraviroc is prescribed to patients on concomitant medications known to lower blood pressure.', NULL, 'Caution is advised when maraviroc is prescribed to patients on concomitant medications known to lower blood pressure. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Vericiguat', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Zanamivir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120550/', '[1] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120413, 'Isosorbide mononitrate', 'Meperidine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120551/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120414, 'Isosorbide mononitrate', 'Meprobamate', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Halazepam, Suvorexant, Thiopental, Amobarbital, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120552/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120415, 'Isosorbide mononitrate', 'Mesoridazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120553/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120416, 'Isosorbide mononitrate', 'Methdilazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120554/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120417, 'Isosorbide mononitrate', 'Methocarbamol', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Chlorzoxazone, Chlormezanone', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120555/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120418, 'Isosorbide mononitrate', 'Methotrimeprazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat', 'Droperidol, Pimozide, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120556/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120419, 'Isosorbide mononitrate', 'Methylergometrine', 'Moderate', 'Ergot alkaloids, by causing vasoconstriction, may theoretically antagonize the effects of nitrates. In addition, nitrates may increase splanchnic blood flow, resulting in decreased first-pass metabolism of dihydroergotamine and increased bioavailability.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Ergot alkaloids are considered contraindicated in patients with ischemic heart disease.', 'Antagonism', 'Dinoprostone, Oxytocin', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120557/', '[1] Bobik A, Jennings G, Skews H, Esler M, McLean A "Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension." Clin Pharmacol Ther 30 (1981): 673-9[2] Raberger G, Schutz W, Zimpfer M, Kraupp O "The influence of dihydroergotamine on adenosine-induced and reactive coronary vasodilation. Interaction of dihydroergotamine and coronary vasodilation." Basic Res Cardiol 71 (1976): 645-51[3] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[7] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120420, 'Isosorbide mononitrate', 'Methysergide', 'Moderate', 'Ergot alkaloids, by causing vasoconstriction, may theoretically antagonize the effects of nitrates. In addition, nitrates may increase splanchnic blood flow, resulting in decreased first-pass metabolism of dihydroergotamine and increased bioavailability.', NULL, 'This combination should generally be avoided.', NULL, 'This combination should generally be avoided. Ergot alkaloids are considered contraindicated in patients with ischemic heart disease.', 'Antagonism', 'Frovatriptan, Rimegepant, Eptinezumab, Lasmiditan, Eletriptan, Rizatriptan, Ubrogepant, Naratriptan, Galcanezumab, Zolmitriptan, Atogepant, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120558/', '[1] Bobik A, Jennings G, Skews H, Esler M, McLean A "Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension." Clin Pharmacol Ther 30 (1981): 673-9[2] Raberger G, Schutz W, Zimpfer M, Kraupp O "The influence of dihydroergotamine on adenosine-induced and reactive coronary vasodilation. Interaction of dihydroergotamine and coronary vasodilation." Basic Res Cardiol 71 (1976): 645-51[3] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[6] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[7] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[8] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[11] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[12] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[13] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[16] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[19] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[20] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[21] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[22] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[23] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[27] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[28] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[29] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[30] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[31] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[32] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[33] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[34] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[35] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120421, 'Isosorbide mononitrate', 'Midazolam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Thiopental, Amobarbital, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Methylphenobarbital, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120559/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120422, 'Isosorbide mononitrate', 'Minoxidil (topical)', 'Moderate', 'Theoretically, topical administration of minoxidil may potentiate the hypotensive effects of systemic minoxidil and other vasodilators. Increased systemic absorption may occur when topical minoxidil is used in excess of normally recommended dosages or applied to compromised skin.', NULL, 'Patients prescribed topical minoxidil in combination with systemic vasodilators or peripherally-acting antiadrenergic agents should be monitored for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.', NULL, 'Patients prescribed topical minoxidil in combination with systemic vasodilators or peripherally-acting antiadrenergic agents should be monitored for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.', 'Synergism', 'Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Ivermectin, Caffeine, Cromoglicic acid, Abrocitinib, More', 'Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120560/', '[1] Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988): 481-5[2] "Product Information. Rogaine (minoxidil topical)." Johnson and Johnson/McNeil Consumer, Fort Washington, PA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120423, 'Isosorbide mononitrate', 'Mirtazapine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, Vilazodone, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Protriptyline, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120561/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120424, 'Isosorbide mononitrate', 'Moexipril', 'Moderate', 'Angiotensin converting enzyme (ACE) inhibitors may enhance the vasodilatory and hypotensive effects of nitroglycerin. Data have also shown that captopril can prevent nitrate tolerance. ACE inhibitors can decrease systemic vascular resistance and cardiac work, further enhancing the effectiveness of nitroglycerin.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose. Blood pressure monitoring is advisable.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120562/', '[1] Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7[2] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[3] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[4] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120425, 'Isosorbide mononitrate', 'Molindone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat', 'Droperidol, Pimozide, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120563/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120426, 'Isosorbide mononitrate', 'Nabilone', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Scopolamine, Rolapitant, Granisetron, Dolasetron', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120564/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120427, 'Isosorbide mononitrate', 'Nalbuphine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120565/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120428, 'Isosorbide mononitrate', 'Nefazodone', 'Moderate', 'Nefazodone may potentiate the hypotensive effect of many drugs including vasodilators and antihypertensive agents. Orthostatic hypotension may occur.', NULL, 'Caution and close monitoring for altered efficacy and safety are recommended if patients receive nefazodone with agents that can produce significant hypotension such as antihypertensive agents or vasodilators.', NULL, 'Caution and close monitoring for altered efficacy and safety are recommended if patients receive nefazodone with agents that can produce significant hypotension such as antihypertensive agents or vasodilators. Patients should be made aware of the possible side effects (e.g., dizziness, lightheadedness, orthostasis) and be cautioned about driving, operating machinery, or performing other hazardous tasks.', 'Synergism', 'Vericiguat', 'Desipramine, Vilazodone, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Protriptyline, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120566/', '[1] "Product Information. Serzone (nefazodone)." Bristol-Myers Squibb, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120429, 'Isosorbide mononitrate', 'Nesiritide', 'Moderate', 'The coadministration of nesiritide with intravenous vasodilators such as nitroglycerin, nitroprusside, and milrinone has not been evaluated. Theoretically, an increase in symptomatic hypotension may occur due to possible additive pharmacodynamic effects in the vasculature. A similar risk may exist during coadministration with oral vasodilators such as hydralazine and minoxidil and other agents with vasodilating effects.', NULL, 'Whether used alone or with other agents, nesiritide should be administered only in settings where blood pressure can be closely monitored.', NULL, 'Whether used alone or with other agents, nesiritide should be administered only in settings where blood pressure can be closely monitored. The dosage should be reduced or the drug discontinued in patients who develop hypotension.', 'Synergism', 'Nesiritide', 'Isosorbide mononitrate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120567/', '[1] "Product Information. Natrecore (nesiritide)" Scios Inc, Sunnyvale, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120430, 'Isosorbide mononitrate', 'Nortriptyline', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, Vilazodone, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Protriptyline, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120568/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120431, 'Isosorbide mononitrate', 'Olanzapine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120569/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120432, 'Isosorbide mononitrate', 'Oliceridine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat', 'Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120570/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120433, 'Isosorbide mononitrate', 'Olopatadine (nasal)', 'Moderate', 'Concurrent use of olopatadine nasal spray with alcohol or other central nervous system (CNS) depressants may result in additive impairment of mental alertness and performance. Somnolence has been reported in some patients using olopatadine nasal spray in clinical trials.', NULL, 'Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible.', NULL, 'Concomitant use of olopatadine nasal spray with alcohol or other CNS depressants should generally be avoided if possible. In the event that they are used together, patients should be counseled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.', 'Synergism', 'Nesiritide, Nitroglycerin, Vericiguat', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120571/', '[1] "Product Information. Patanase (olopatadine nasal)." Alcon Laboratories Inc, Fort Worth, TX.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120434, 'Isosorbide mononitrate', 'Opium', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat', 'Eluxadoline, Diphenoxylate, Difenoxin, Naltrexone, Tapentadol, Oxymorphone, Dezocine, Naloxone', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120572/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120435, 'Isosorbide mononitrate', 'Oxazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Halazepam', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120573/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120436, 'Isosorbide mononitrate', 'Ozanimod', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Vericiguat', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Abatacept, Upadacitinib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120574/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120437, 'Isosorbide mononitrate', 'Paraldehyde', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat', 'Suvorexant, Thiopental, Amobarbital, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Methylphenobarbital, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120575/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120438, 'Isosorbide mononitrate', 'Pentoxifylline', 'Moderate', 'Pentoxifylline may potentiate the action of hypotensive agents. Small decreases in blood pressure have been observed in some patients treated with pentoxifylline plus nifedipine or captopril. The mechanism of interaction has not been described.', NULL, 'Caution is advised if pentoxifylline is used in combination with hypotensive agents.', NULL, 'Caution is advised if pentoxifylline is used in combination with hypotensive agents. Periodic systemic blood pressure monitoring is recommended.', 'Synergism', 'Cyclandelate, Tolazoline, Phenoxybenzamine, Phentolamine, Isoxsuprine, Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, More', 'Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120576/', '[1] "Product Information. Trental (pentoxifylline)." Hoechst Marion-Roussel Inc, Kansas City, MO.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120439, 'Isosorbide mononitrate', 'Perphenazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120577/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120440, 'Isosorbide mononitrate', 'Phenelzine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, Vilazodone, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Protriptyline, More', 'Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120578/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120441, 'Isosorbide mononitrate', 'Procarbazine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Vericiguat', 'Pertuzumab, Olaparib, Rucaparib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, Pegaspargase, Ixazomib, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120579/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120442, 'Isosorbide mononitrate', 'Promazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120580/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120443, 'Isosorbide mononitrate', 'Propiomazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Suvorexant, Thiopental, Amobarbital, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Methylphenobarbital, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120581/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120444, 'Isosorbide mononitrate', 'Quazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat', 'Suvorexant, Thiopental, Amobarbital, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Methylphenobarbital, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120582/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120445, 'Isosorbide mononitrate', 'Quetiapine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat', 'Droperidol, Pimozide, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120583/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120446, 'Isosorbide mononitrate', 'Quinapril', 'Moderate', 'Angiotensin converting enzyme (ACE) inhibitors may enhance the vasodilatory and hypotensive effects of nitroglycerin. Data have also shown that captopril can prevent nitrate tolerance. ACE inhibitors can decrease systemic vascular resistance and cardiac work, further enhancing the effectiveness of nitroglycerin.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose. Blood pressure monitoring is advisable.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120584/', '[1] Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7[2] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[3] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[4] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120447, 'Isosorbide mononitrate', 'Ramipril', 'Moderate', 'Angiotensin converting enzyme (ACE) inhibitors may enhance the vasodilatory and hypotensive effects of nitroglycerin. Data have also shown that captopril can prevent nitrate tolerance. ACE inhibitors can decrease systemic vascular resistance and cardiac work, further enhancing the effectiveness of nitroglycerin.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose.', NULL, 'In general, this combination is used to clinical advantage; however, some manufacturers recommend that nitrates and other vasodilators should be discontinued before starting ACE inhibitors or resumed at a reduced dose. Blood pressure monitoring is advisable.', 'Synergism', 'Bempedoic acid', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120585/', '[1] Katz RJ, Levy WS, Buff L, Wasserman AG "Prevention of nitrate tolerance with angiotension converting enzyme inhibitors." Circulation 83 (1991): 1271-7[2] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[3] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[4] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120448, 'Isosorbide mononitrate', 'Rasagiline', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Vericiguat', 'Opicapone, Rotigotine, Tolcapone, Pergolide, Levodopa', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120586/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120449, 'Isosorbide mononitrate', 'Remimazolam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat', 'Suvorexant, Thiopental, Amobarbital, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Methylphenobarbital, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120587/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120450, 'Isosorbide mononitrate', 'Riociguat', 'Major', 'Coadministration of riociguat with organic nitrates or nitric oxide donors may cause significant hypotension, syncope, and myocardial ischemia. Riociguat stimulates soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system that binds with nitric oxide (NO) to catalyze the synthesis of cyclic guanosine monophosphate (cGMP). The resultant accumulation of cGMP in vascular smooth muscle cells leads to peripheral vasodilation.', NULL, 'Concomitant use of riociguat with organic nitrates (e.', NULL, 'Concomitant use of riociguat with organic nitrates (e.g., nitroglycerin) or nitric oxide donors (e.g., amyl nitrite) in any form is considered contraindicated.', 'Synergism', 'Macitentan, Metyrosine', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120588/', '[1] "Product Information. Adempas (riociguat)." Bayer Pharmaceutical Inc, West Haven, CT.[2] "Product Information. Adempas (riociguat)." Bayer Pharmaceutical Inc, West Haven, CT.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120451, 'Isosorbide mononitrate', 'Rosiglitazone', 'Moderate', 'The concomitant use of rosiglitazone with nitrates may increase the risk of myocardial ischemia. Results of clinical trials have suggested that rosiglitazone is associated with a higher risk of angina or myocardial infarction.', NULL, 'The concomitant use of rosiglitazone and nitrates should generally be avoided.', NULL, 'The concomitant use of rosiglitazone and nitrates should generally be avoided.', 'Synergism', 'Exenatide, Lixisenatide, Albiglutide, Acetohexamide, Guar gum, Pramlintide, Sitagliptin, Alogliptin, Liraglutide, Troglitazone, Semaglutide, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120589/', '[1] "Product Information. Avandia (rosiglitazone)" SmithKline Beecham, Philadelphia, PA.[2] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[3] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[4] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[5] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[6] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[7] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[8] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[9] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[12] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120452, 'Isosorbide mononitrate', 'Safinamide', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Vericiguat', 'Opicapone, Rotigotine, Tolcapone, Pergolide, Levodopa', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120590/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120453, 'Isosorbide mononitrate', 'Secobarbital', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Thiopental, Amobarbital, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Methylphenobarbital, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120591/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120454, 'Isosorbide mononitrate', 'Selegiline', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Vericiguat', 'Opicapone, Rotigotine, Tolcapone, Pergolide, Levodopa', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120592/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120455, 'Isosorbide mononitrate', 'Selexipag', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'Vericiguat', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120593/', '[1] "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC.[2] "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Buchdahl RM, Taylor P, Warner JD "Nebulised ribavirin for adenovirus pneumonia." Lancet 2 (1985): 1070-1[5] "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120456, 'Isosorbide mononitrate', 'Sildenafil', 'Major', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the hypotensive effect of organic nitrates. Severe hypotension, syncope, or myocardial ischemia may result from use of the combination. The mechanism involves peripheral vasodilation secondary to enhanced levels of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells, as PDE5 inhibitors prevent degradation of cGMP while nitrates promote its synthesis.', NULL, 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated.', NULL, 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated. A suitable time interval following sildenafil or vardenafil use for the safe administration of nitrates has not been determined. For patients treated with avanafil or tadalafil, at least 12 hours after the last dose of avanafil and 48 hours after the last dose of tadalafil are recommended before nitrate administration, should it be deemed medically necessary in a life-threatening situation. Even then, nitrates should only be administered under close medical supervision with appropriate hemodynamic monitoring. Patients should be advised to seek immediate medical attention if they experience anginal chest pain after taking a PDE5 inhibitor.', 'Synergism', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Methazolamide, Amphotericin B, Trichlormethiazide, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120594/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[4] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[5] "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation, Silver Spring, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120457, 'Isosorbide mononitrate', 'Tadalafil', 'Major', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the hypotensive effect of organic nitrates. Severe hypotension, syncope, or myocardial ischemia may result from use of the combination. The mechanism involves peripheral vasodilation secondary to enhanced levels of cyclic guanosine monophosphate (cGMP) in vascular smooth muscle cells, as PDE5 inhibitors prevent degradation of cGMP while nitrates promote its synthesis.', NULL, 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated.', NULL, 'The use of PDE5 inhibitors in patients receiving organic nitrates or other nitric oxide donors, either regularly or intermittently, is considered contraindicated. A suitable time interval following sildenafil or vardenafil use for the safe administration of nitrates has not been determined. For patients treated with avanafil or tadalafil, at least 12 hours after the last dose of avanafil and 48 hours after the last dose of tadalafil are recommended before nitrate administration, should it be deemed medically necessary in a life-threatening situation. Even then, nitrates should only be administered under close medical supervision with appropriate hemodynamic monitoring. Patients should be advised to seek immediate medical attention if they experience anginal chest pain after taking a PDE5 inhibitor.', 'Synergism', 'Fesoterodine, Pentosan polysulfate, Phenazopyridine, Acetohydroxamic acid, Trospium, Mirabegron, Yohimbine, Flavoxate, Darifenacin, Papaverine, Phenyl salicylate, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120595/', '[1] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[2] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[3] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[4] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[5] "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation, Silver Spring, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120458, 'Isosorbide mononitrate', 'Temazepam', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Thiopental, Amobarbital, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Methylphenobarbital, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120596/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120459, 'Isosorbide mononitrate', 'Tetrabenazine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Nesiritide, Vericiguat', 'Dextromethorphan, Valbenazine, Dalfampridine, Riluzole, Inotersen, Pitolisant, Amifampridine, Deutetrabenazine, Tafamidis', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120597/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120460, 'Isosorbide mononitrate', 'Tetracaine (topical)', 'Moderate', 'Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents.', NULL, 'Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.', 'Synergism', 'Nesiritide, Vericiguat', 'Zinc sulfate, Zinc acetate, Fluocinolone acetonide, Fluocinonide, Zinc chloride, Betamethasone, Fluorometholone, Zinc gluconate, Tripelennamine, Clemastine, Pheniramine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120598/', '[1] Guay J "Methemoglobinemia related to local anesthetics: a summary of 242 episodes." Anesth Analg 108 (2009): 837-45[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Hurricaine (benzocaine topical)." Beutlich, Waukegan, IL.[4] "Product Information. Chloraseptic (benzocaine-menthol topical)." Prestige Brands (formerly MedTech), Tarrytown, NY.[5] Skold A, Cosco DL, Klein R "Methemoglobinemia: pathogenesis, diagnosis, and management." South Med J 104 (2011): 757-61[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Karim A, Ahmed S, Siddiqui R, Mattana J "Methemoglobinemia complicating topical lidocaine used during endoscopic procedures." Am J Med 111 (2001): 150-3', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120461, 'Isosorbide mononitrate', 'Thallous Chloride', 'Moderate', 'Coadministration of certain drugs may alter the myocardial uptake of thallous chloride Tl-201 and interfere with results of myocardial imaging studies. Drugs that increase or decrease coronary blood flow or potassium uptake may alter the biodistribution of thallous chloride Tl-201.', NULL, 'Clinicians should be aware of possible diagnostic interference by these drugs.', NULL, 'Clinicians should be aware of possible diagnostic interference by these drugs.', 'Others', 'Nesiritide, Vericiguat', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120599/', '[1] "Product Information. Thallous Chloride Tl 201 (thallous chloride Tl-201)." GE Healthcare, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Nuclear Pharmacy Website. University of Arkansas for Medical Sciences. College of Pharmacy "Drug - Radiopharmaceutical Interactions. Available from: URL: http://nuclearpharmacy.uams.edu/nicki.html#tl." ([cited Feb2015]):', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120462, 'Isosorbide mononitrate', 'Thiethylperazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120600/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120463, 'Isosorbide mononitrate', 'Thioridazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120601/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120464, 'Isosorbide mononitrate', 'Thiothixene', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat', 'Droperidol, Pimozide, Pimavanserin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120602/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120465, 'Isosorbide mononitrate', 'Tizanidine', 'Major', 'Tizanidine may potentiate the hypotensive effect of some medications secondary to its alpha-2 adrenergic activity. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.', NULL, 'A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications.', NULL, 'A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications. Although single doses of less than 8 mg of tizanidine have not been shown effective for spasticity in controlled clinical studies, it may be prudent to initiate treatment with 4 mg doses and gradually increase in 2 to 4 mg increments until optimum effect is achieved. The dose can be repeated at 6 to 8 hour intervals as needed, up to a maximum of three doses in 24 hours and a total daily dosage of 36 mg. However, experience with single doses exceeding 8 mg and daily doses exceeding 24 mg is limited. Close monitoring for development of hypotension is recommended.', 'Synergism', 'Chlorzoxazone, Chlormezanone', 'Vericiguat', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120603/', '[1] "Product Information. Zanaflex (tizanidine)." Acorda Therapeutics, Hawthorne, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120466, 'Isosorbide mononitrate', 'Tranylcypromine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, Vilazodone, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Protriptyline, More', 'Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120604/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120467, 'Isosorbide mononitrate', 'Treprostinil', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Lepirudin, Urokinase, Cangrelor, Caplacizumab, Argatroban, Prasugrel, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120605/', '[1] "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC.[2] "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Buchdahl RM, Taylor P, Warner JD "Nebulised ribavirin for adenovirus pneumonia." Lancet 2 (1985): 1070-1[5] "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120468, 'Isosorbide mononitrate', 'Trifluoperazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120606/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120469, 'Isosorbide mononitrate', 'Triflupromazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120607/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120470, 'Isosorbide mononitrate', 'Alimemazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Nesiritide, Vericiguat', 'Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, Cyclizine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120608/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120471, 'Isosorbide mononitrate', 'Trimipramine', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Desipramine, Vilazodone, Desvenlafaxine, St. John''s Wort, Oxitriptan, Viloxazine, Vortioxetine, Milnacipran, Tryptophan, Levomilnacipran, Protriptyline, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120609/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120472, 'Isosorbide mononitrate', 'Verteporfin', 'Moderate', 'Drugs that decrease clotting, vasoconstriction, or platelet aggregation may interfere with the therapeutic effect of verteporfin. These agents may antagonize the physiologic responses to local damage of neovascular endothelium induced by activated verteporfin, which include the release of procoagulant and vasoactive factors that result in vessel occlusion. However, the clinical significance is unknown.', NULL, 'If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy.', NULL, 'If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy. Otherwise, the potential for diminished efficacy of verteporfin should be considered.', 'Antagonism', 'Aflibercept, Bevacizumab', 'Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120610/', '[1] "Product Information. Visudyne (verteporfin)" Valeant Pharmaceuticals, Costa Mesa, CA.[2] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120473, 'Isosorbide mononitrate', 'Zaleplon', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Thiopental, Amobarbital, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Methylphenobarbital, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120611/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120474, 'Isosorbide mononitrate', 'Ziprasidone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120612/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120475, 'Isosorbide mononitrate', 'Zolpidem', 'Moderate', 'Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents.', NULL, 'Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Suvorexant, Thiopental, Amobarbital, Butalbital, Eszopiclone, Ramelteon, Scopolamine, Tasimelteon, Methohexital, Lemborexant, Methylphenobarbital, More', 'Nesiritide, Vericiguat', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120613/', '[1] Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139[2] Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6[3] Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1[4] Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595[7] Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[11] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120476, 'Iopamidol', 'Amikacin (liposome)', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Tetracycline, Ganciclovir, Rifamycin, Oxytetracycline, Famciclovir, Sulfamethizole, Cefuroxime, Trifluridine, Benzylpenicillin, Ampicillin, Chloramphenicol, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120614/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120477, 'Iopamidol', 'Aminophylline', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120615/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120478, 'Iopamidol', 'Amoxapine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120616/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120479, 'Iopamidol', 'Amphotericin B (cholesteryl sulfate)', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, Vemurafenib, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120617/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120480, 'Iopamidol', 'Amphotericin B (liposomal)', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, Vemurafenib, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120618/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120481, 'Iopamidol', 'Bendroflumethiazide', 'Moderate', 'Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, Vemurafenib, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120619/', '[1] Briguori C, Marenzi G "Contrast-induced nephropathy: Pharmacological prophylaxis." Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R "Can we prevent acute kidney injury?" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS "Clinical practice. Preventing nephropathy induced by contrast medium." N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N "Contrast-induced nephropathy: a clinical and evidence-based approach." Circulation 113 (2006): 1799-806[5] "Product Information. Lasix (furosemide)." sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC "Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy." Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M "Potential deleterious effect of furosemide in radiocontrast nephropathy." Nephron 62 (1992): 413-5[8] Massicotte A "Contrast medium-induced nephropathy: strategies for prevention." Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D "What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography." Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. "Strategies to reduce the risk of contrast-induced nephropathy." Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G "Facts and fallacies concerning the prevention of contrast medium-induced nephropathy." Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D''Elia J, Silva P "Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents." N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. "A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation." J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ "Meta-analysis of frusemide to prevent or treat acute renal failure." BMJ 333 (2006): 420[15] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120482, 'Iopamidol', 'Benzthiazide', 'Moderate', 'Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, Vemurafenib, More', 'Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120620/', '[1] Briguori C, Marenzi G "Contrast-induced nephropathy: Pharmacological prophylaxis." Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R "Can we prevent acute kidney injury?" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS "Clinical practice. Preventing nephropathy induced by contrast medium." N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N "Contrast-induced nephropathy: a clinical and evidence-based approach." Circulation 113 (2006): 1799-806[5] "Product Information. Lasix (furosemide)." sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC "Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy." Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M "Potential deleterious effect of furosemide in radiocontrast nephropathy." Nephron 62 (1992): 413-5[8] Massicotte A "Contrast medium-induced nephropathy: strategies for prevention." Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D "What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography." Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. "Strategies to reduce the risk of contrast-induced nephropathy." Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G "Facts and fallacies concerning the prevention of contrast medium-induced nephropathy." Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D''Elia J, Silva P "Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents." N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. "A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation." J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ "Meta-analysis of frusemide to prevent or treat acute renal failure." BMJ 333 (2006): 420[15] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120483, 'Iopamidol', 'Bromfenac', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Fluocinolone acetonide, Salicylic acid, Fluorometholone', 'Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120621/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120484, 'Iopamidol', 'Carteolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', 'Latanoprost, Apraclonidine, Pilocarpine, Clonidine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Epinephrine, Brimonidine, Guanethidine, Levobunolol', 'Iodipamide, Iodamide, Tyropanoic acid, Iopanoic acid, Iopodic acid, Metrizamide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120622/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12[3] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[4] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120485, 'Iopamidol', 'Chlorpromazine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120623/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120486, 'Iopamidol', 'Cinoxacin', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120624/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120487, 'Iopamidol', 'Dexfenfluramine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Lorcaserin, Orlistat, Naltrexone', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120625/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120488, 'Iopamidol', 'Dezocine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Naloxone, Naltrexone', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120626/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120489, 'Iopamidol', 'Diflunisal', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Salicylic acid, Choline salicylate, Ziconotide', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120627/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120490, 'Iopamidol', 'Edetate disodium anhydrous', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120628/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120491, 'Iopamidol', 'Enoxacin', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120629/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120492, 'Iopamidol', 'Enzalutamide', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Relugolix, Bicalutamide, Degarelix, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120630/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120493, 'Iopamidol', 'Ephedrine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Homatropine, Methscopolamine, Scopolamine, Tropicamide, Phenylephrine, Ciclesonide, Mupirocin, Mometasone furoate, Budesonide, Mometasone, Epinephrine, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120631/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120494, 'Iopamidol', 'Ertapenem', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Cefepime, Aztreonam, Ceftazidime, Cefapirin, Cefoxitin, Cefprozil, Cefonicid, Cefuroxime, Cefoperazone, Cefditoren, Cefdinir, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120632/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120495, 'Iopamidol', 'Escitalopram', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120633/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120496, 'Iopamidol', 'Esmolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120634/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12[3] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[4] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120497, 'Iopamidol', 'Etacrynic acid', 'Moderate', 'Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.', 'Synergism', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120635/', '[1] Briguori C, Marenzi G "Contrast-induced nephropathy: Pharmacological prophylaxis." Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R "Can we prevent acute kidney injury?" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS "Clinical practice. Preventing nephropathy induced by contrast medium." N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N "Contrast-induced nephropathy: a clinical and evidence-based approach." Circulation 113 (2006): 1799-806[5] "Product Information. Lasix (furosemide)." sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC "Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy." Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M "Potential deleterious effect of furosemide in radiocontrast nephropathy." Nephron 62 (1992): 413-5[8] Massicotte A "Contrast medium-induced nephropathy: strategies for prevention." Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D "What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography." Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. "Strategies to reduce the risk of contrast-induced nephropathy." Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G "Facts and fallacies concerning the prevention of contrast medium-induced nephropathy." Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D''Elia J, Silva P "Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents." N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. "A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation." J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ "Meta-analysis of frusemide to prevent or treat acute renal failure." BMJ 333 (2006): 420[15] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120498, 'Iopamidol', 'Etidronic acid', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120636/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120499, 'Iopamidol', 'Etodolac', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120637/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120500, 'Iopamidol', 'Everolimus', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120638/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120501, 'Iopamidol', 'Fenfluramine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Lorcaserin, Orlistat, Naltrexone, Brivaracetam, Topiramate, Ezogabine, Cenobamate, Lamotrigine, Methylphenobarbital, Phenytoin, Ethosuximide, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120639/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120502, 'Iopamidol', 'Fenoprofen', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120640/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120503, 'Iopamidol', 'Fluphenazine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120641/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120504, 'Iopamidol', 'Flurbiprofen', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Tolazoline, Dimethyl sulfoxide, Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Chlorhexidine, Povidone-iodine, Fluocinolone acetonide, Salicylic acid, Fluorometholone', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120642/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120505, 'Iopamidol', 'Fluvoxamine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120643/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120506, 'Iopamidol', 'Foscarnet', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120644/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120507, 'Iopamidol', 'Furosemide', 'Moderate', 'Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, Vemurafenib, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120645/', '[1] Briguori C, Marenzi G "Contrast-induced nephropathy: Pharmacological prophylaxis." Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R "Can we prevent acute kidney injury?" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS "Clinical practice. Preventing nephropathy induced by contrast medium." N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N "Contrast-induced nephropathy: a clinical and evidence-based approach." Circulation 113 (2006): 1799-806[5] "Product Information. Lasix (furosemide)." sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC "Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy." Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M "Potential deleterious effect of furosemide in radiocontrast nephropathy." Nephron 62 (1992): 413-5[8] Massicotte A "Contrast medium-induced nephropathy: strategies for prevention." Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D "What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography." Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. "Strategies to reduce the risk of contrast-induced nephropathy." Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G "Facts and fallacies concerning the prevention of contrast medium-induced nephropathy." Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D''Elia J, Silva P "Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents." N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. "A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation." J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ "Meta-analysis of frusemide to prevent or treat acute renal failure." BMJ 333 (2006): 420[15] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120508, 'Iopamidol', 'Galantamine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Memantine, Ginkgo biloba, Aducanumab', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120646/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120509, 'Iopamidol', 'Gallium nitrate', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120647/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120510, 'Iopamidol', 'Gatifloxacin', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Tetracycline, Ganciclovir, Rifamycin, Oxytetracycline, Famciclovir, Sulfamethizole, Cefuroxime, Trifluridine, Benzylpenicillin, Ampicillin, Chloramphenicol, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120648/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120511, 'Iopamidol', 'Gemifloxacin', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120649/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120512, 'Iopamidol', 'Gentamicin', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Tetracycline, Ganciclovir, Rifamycin, Oxytetracycline, Famciclovir, Sulfamethizole, Cefuroxime, Trifluridine, Benzylpenicillin, Ampicillin, Chloramphenicol, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120650/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120513, 'Iopamidol', 'Givosiran', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Teduglutide, Lonafarnib, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120651/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120514, 'Iopamidol', 'Grepafloxacin', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120652/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120515, 'Iopamidol', 'Haloperidol', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120653/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120516, 'Iopamidol', 'Diamorphine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120654/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120517, 'Iopamidol', 'Hydroflumethiazide', 'Moderate', 'Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, Vemurafenib, More', 'Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120655/', '[1] Briguori C, Marenzi G "Contrast-induced nephropathy: Pharmacological prophylaxis." Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R "Can we prevent acute kidney injury?" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS "Clinical practice. Preventing nephropathy induced by contrast medium." N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N "Contrast-induced nephropathy: a clinical and evidence-based approach." Circulation 113 (2006): 1799-806[5] "Product Information. Lasix (furosemide)." sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC "Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy." Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M "Potential deleterious effect of furosemide in radiocontrast nephropathy." Nephron 62 (1992): 413-5[8] Massicotte A "Contrast medium-induced nephropathy: strategies for prevention." Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D "What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography." Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. "Strategies to reduce the risk of contrast-induced nephropathy." Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G "Facts and fallacies concerning the prevention of contrast medium-induced nephropathy." Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D''Elia J, Silva P "Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents." N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. "A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation." J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ "Meta-analysis of frusemide to prevent or treat acute renal failure." BMJ 333 (2006): 420[15] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120518, 'Iopamidol', 'Hydromorphone', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Naloxone, Naltrexone', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120656/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120519, 'Iopamidol', 'Ibutilide', 'Moderate', 'The use of iodine-containing contrast media for coronary angiography in patients treated with certain antiarrhythmics such as amiodarone may result in significant prolongation of the QT interval. These contrast agents can be arrhythmogenic when injected into the coronary arteries and may have additive effects on cardiac repolarization when coadministered with antiarrhythmic agents that prolong the QT interval.', NULL, 'Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.', NULL, 'Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents. Increased surveillance and ECG monitoring may be appropriate. Patients who receive outpatient angiographies should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of arrhythmia such as dizziness, palpitations, or syncope.', 'Synergism', 'Propafenone, Dronedarone, Tocainide, Flecainide, Bretylium, Moricizine', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120657/', '[1] Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U "Iohexol contrast medium induces QT prolongation in amiodarone patients." Br J Clin Pharmacol 58 (2004): 96-98[2] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[3] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120520, 'Iopamidol', 'Ifosfamide', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, More', 'Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120658/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120521, 'Iopamidol', 'Iloperidone', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120659/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120522, 'Iopamidol', 'Imipramine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120660/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120523, 'Iopamidol', 'Indapamide', 'Moderate', 'Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.', 'Synergism', 'Felodipine, Enalapril, Amlodipine, Moexipril, Verapamil, Ramipril, Lisinopril, Perindopril, Benazepril, Quinapril, Trandolapril, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120661/', '[1] Briguori C, Marenzi G "Contrast-induced nephropathy: Pharmacological prophylaxis." Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R "Can we prevent acute kidney injury?" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS "Clinical practice. Preventing nephropathy induced by contrast medium." N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N "Contrast-induced nephropathy: a clinical and evidence-based approach." Circulation 113 (2006): 1799-806[5] "Product Information. Lasix (furosemide)." sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC "Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy." Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M "Potential deleterious effect of furosemide in radiocontrast nephropathy." Nephron 62 (1992): 413-5[8] Massicotte A "Contrast medium-induced nephropathy: strategies for prevention." Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D "What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography." Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. "Strategies to reduce the risk of contrast-induced nephropathy." Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G "Facts and fallacies concerning the prevention of contrast medium-induced nephropathy." Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D''Elia J, Silva P "Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents." N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. "A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation." J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ "Meta-analysis of frusemide to prevent or treat acute renal failure." BMJ 333 (2006): 420[15] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120524, 'Iopamidol', 'Indomethacin', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Fluocinolone acetonide, Fludrocortisone, Fluorometholone, Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Fluocinolone acetonide, Salicylic acid, Fluorometholone, Tolazoline, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120662/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120525, 'Iopamidol', 'Interferon alfa-2a, Recombinant', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120663/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120526, 'Iopamidol', 'Interferon alfa-n1', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120664/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120527, 'Iopamidol', 'Interferon alfa-n3', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120665/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120528, 'Iopamidol', 'Interferon alfacon-1', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120666/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120529, 'Iopamidol', 'Iopanoic acid', 'Moderate', 'INTERVAL: Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents. The mechanism of interaction has not been described.', NULL, 'Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.', NULL, 'Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.', 'Others', 'Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Iodixanol, Ethiodized oil, Iothalamic acid, Ioxaglic acid, Iopromide, More', 'Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120667/', '[1] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.[2] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[3] "Product Information. Omniscan (gadodiamide)." Novation, Irving, TX.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120530, 'Iopamidol', 'Iopodic acid', 'Moderate', 'INTERVAL: Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents. The mechanism of interaction has not been described.', NULL, 'Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.', NULL, 'Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.', 'Others', 'Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide', 'Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Iodixanol, Ethiodized oil, Iothalamic acid, Ioxaglic acid, Iopromide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120668/', '[1] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.[2] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[3] "Product Information. Omniscan (gadodiamide)." Novation, Irving, TX.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120531, 'Iopamidol', 'Kanamycin', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Tetracycline, Ganciclovir, Rifamycin, Oxytetracycline, Famciclovir, Sulfamethizole, Cefuroxime, Trifluridine, Benzylpenicillin, Ampicillin, Chloramphenicol, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120669/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120532, 'Iopamidol', 'Ketoprofen', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120670/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120533, 'Iopamidol', 'Labetalol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120671/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12[3] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[4] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120534, 'Iopamidol', 'Levobetaxolol (ophthalmic)', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', 'Iodipamide, Iodamide, Tyropanoic acid, Iopanoic acid, Iopodic acid, Metrizamide', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120672/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12[3] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[4] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120535, 'Iopamidol', 'Levobunolol (ophthalmic)', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', 'Latanoprost, Apraclonidine, Pilocarpine, Clonidine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Epinephrine, Brimonidine, Guanethidine, Levobunolol', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120673/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12[3] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[4] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120536, 'Iopamidol', 'Levofloxacin', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Tinidazole, Tetracycline, Dexlansoprazole, Sucralfate, Misoprostol, Bismuth subcitrate potassium, Metronidazole, Rifabutin, Cimetidine, Esomeprazole, Nizatidine, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120674/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120537, 'Iopamidol', 'Levacetylmethadol', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Acamprosate, Lofexidine, Naltrexone, Varenicline, Disulfiram, Nalmefene, Nicotine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120675/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120538, 'Iopamidol', 'Levomilnacipran', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120676/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120539, 'Iopamidol', 'Levorphanol', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120677/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120540, 'Iopamidol', 'Lindane', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Disulfiram', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120678/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120541, 'Iopamidol', 'Lisdexamfetamine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Atomoxetine, Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120679/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120542, 'Iopamidol', 'Lithium carbonate', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120680/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120543, 'Iopamidol', 'Lomefloxacin', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Tetracycline, Ganciclovir, Rifamycin, Oxytetracycline, Famciclovir, Sulfamethizole, Cefuroxime, Trifluridine, Benzylpenicillin, Ampicillin, Chloramphenicol, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120681/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120544, 'Iopamidol', 'Loxapine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120682/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120545, 'Iopamidol', 'Lumateperone', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120683/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120546, 'Iopamidol', 'Lurasidone', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120684/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120547, 'Iopamidol', 'Lutetium Lu 177 dotatate', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120685/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120548, 'Iopamidol', 'Mannitol', 'Moderate', 'Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.', 'Synergism', 'Sorbitol, Sulfamethizole, Sodium citrate, Magnesium citrate, Sodium bicarbonate, Sodium chloride, Chlorhexidine, Alvimopan, Sorbitol, Tegaserod, Naloxegol, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120686/', '[1] Briguori C, Marenzi G "Contrast-induced nephropathy: Pharmacological prophylaxis." Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R "Can we prevent acute kidney injury?" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS "Clinical practice. Preventing nephropathy induced by contrast medium." N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N "Contrast-induced nephropathy: a clinical and evidence-based approach." Circulation 113 (2006): 1799-806[5] "Product Information. Lasix (furosemide)." sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC "Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy." Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M "Potential deleterious effect of furosemide in radiocontrast nephropathy." Nephron 62 (1992): 413-5[8] Massicotte A "Contrast medium-induced nephropathy: strategies for prevention." Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D "What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography." Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. "Strategies to reduce the risk of contrast-induced nephropathy." Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G "Facts and fallacies concerning the prevention of contrast medium-induced nephropathy." Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D''Elia J, Silva P "Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents." N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. "A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation." J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ "Meta-analysis of frusemide to prevent or treat acute renal failure." BMJ 333 (2006): 420[15] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120549, 'Iopamidol', 'Maprotiline', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120687/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120550, 'Iopamidol', 'Mazindol', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Lorcaserin, Orlistat, Naltrexone', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120688/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120551, 'Iopamidol', 'Meclofenamic acid', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120689/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120552, 'Iopamidol', 'Mefenamic acid', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120690/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120553, 'Iopamidol', 'Mefloquine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Artesunate, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, Sulfadoxine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120691/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120554, 'Iopamidol', 'Meloxicam', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Ropivacaine, Chloroprocaine, Levobupivacaine, Tetracaine, Bupivacaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, Misoprostol, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120692/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120555, 'Iopamidol', 'Meperidine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Naloxone, Naltrexone', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120693/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120556, 'Iopamidol', 'Mesoridazine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120694/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120557, 'Iopamidol', 'Metamfetamine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Atomoxetine, Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120695/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120558, 'Iopamidol', 'Methazolamide', 'Moderate', 'Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, Vemurafenib, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120696/', '[1] Briguori C, Marenzi G "Contrast-induced nephropathy: Pharmacological prophylaxis." Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R "Can we prevent acute kidney injury?" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS "Clinical practice. Preventing nephropathy induced by contrast medium." N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N "Contrast-induced nephropathy: a clinical and evidence-based approach." Circulation 113 (2006): 1799-806[5] "Product Information. Lasix (furosemide)." sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC "Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy." Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M "Potential deleterious effect of furosemide in radiocontrast nephropathy." Nephron 62 (1992): 413-5[8] Massicotte A "Contrast medium-induced nephropathy: strategies for prevention." Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D "What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography." Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. "Strategies to reduce the risk of contrast-induced nephropathy." Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G "Facts and fallacies concerning the prevention of contrast medium-induced nephropathy." Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D''Elia J, Silva P "Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents." N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. "A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation." J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ "Meta-analysis of frusemide to prevent or treat acute renal failure." BMJ 333 (2006): 420[15] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120559, 'Iopamidol', 'Methdilazine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120697/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120560, 'Iopamidol', 'Methotrimeprazine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120698/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120561, 'Iopamidol', 'Methoxyflurane', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Salicylic acid, Choline salicylate, Ziconotide', 'Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120699/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120562, 'Iopamidol', 'Methylprednisolone', 'Major', 'Coadministration of corticosteroids with iodinated contrast media by the intrathecal route may be associated with a high incidence of radiographic arachnoiditis. Meningitis and seizures may also occur.', NULL, 'Intrathecal coadministration of corticosteroids with iodinated contrast media is considered contraindicated.', NULL, 'Intrathecal coadministration of corticosteroids with iodinated contrast media is considered contraindicated.', 'Others', 'Clindamycin, Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Tretinoin, Erythromycin, Dapsone, Azelaic acid, Adapalene, Fludrocortisone, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120700/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.[3] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[4] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[5] Nelson DA, Landau WM "Intraspinal steroids: history, efficacy, accidentality, and controversy with review of United States Food and Drug Administration reports." J Neurol Neurosurg Psychiatry 70 (2001): 433-43', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120563, 'Iopamidol', 'Metipranolol (ophthalmic)', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', 'Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120701/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12[3] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[4] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120564, 'Iopamidol', 'Metoclopramide', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Cisapride', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, Diatrizoate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120702/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120565, 'Iopamidol', 'Metolazone', 'Moderate', 'Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, Vemurafenib, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120703/', '[1] Briguori C, Marenzi G "Contrast-induced nephropathy: Pharmacological prophylaxis." Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R "Can we prevent acute kidney injury?" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS "Clinical practice. Preventing nephropathy induced by contrast medium." N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N "Contrast-induced nephropathy: a clinical and evidence-based approach." Circulation 113 (2006): 1799-806[5] "Product Information. Lasix (furosemide)." sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC "Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy." Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M "Potential deleterious effect of furosemide in radiocontrast nephropathy." Nephron 62 (1992): 413-5[8] Massicotte A "Contrast medium-induced nephropathy: strategies for prevention." Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D "What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography." Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. "Strategies to reduce the risk of contrast-induced nephropathy." Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G "Facts and fallacies concerning the prevention of contrast medium-induced nephropathy." Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D''Elia J, Silva P "Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents." N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. "A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation." J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ "Meta-analysis of frusemide to prevent or treat acute renal failure." BMJ 333 (2006): 420[15] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120566, 'Iopamidol', 'Metoprolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', 'Felodipine, Amlodipine, Nifedipine, Ivabradine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120704/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12[3] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[4] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120567, 'Iopamidol', 'Mexiletine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Propafenone, Dronedarone, Tocainide, Flecainide, Bretylium, Moricizine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120705/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120568, 'Iopamidol', 'Milnacipran', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120706/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120569, 'Iopamidol', 'Mirtazapine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120707/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120570, 'Iopamidol', 'Molindone', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120708/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120571, 'Iopamidol', 'Morphine (liposomal)', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Naloxone, Naltrexone', 'Ioxilan, Iomeprol, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120709/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120572, 'Iopamidol', 'Moxifloxacin', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Tetracycline, Ganciclovir, Rifamycin, Oxytetracycline, Famciclovir, Sulfamethizole, Cefuroxime, Trifluridine, Benzylpenicillin, Ampicillin, Chloramphenicol, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120710/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120573, 'Iopamidol', 'Muromonab', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120711/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120574, 'Iopamidol', 'Nabumetone', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120712/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120575, 'Iopamidol', 'Nadolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120713/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12[3] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[4] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120576, 'Iopamidol', 'Nalbuphine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Naloxone, Naltrexone', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120714/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120577, 'Iopamidol', 'Nalidixic acid', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120715/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120578, 'Iopamidol', 'Nefazodone', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120716/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120579, 'Iopamidol', 'Nelarabine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Fluorouracil, Pemetrexed, Mercaptopurine, Cladribine, Trifluridine, Floxuridine, Gemcitabine, Pralatrexate, Cytarabine, Fludarabine, Decitabine, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120717/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120580, 'Iopamidol', 'Neomycin', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Rifamycin, Miconazole, Nystatin, Fidaxomicin, Rifaximin, Paromomycin, Chlorhexidine, Povidone-iodine, Tetracycline, Mupirocin, Rifamycin, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120718/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120581, 'Iopamidol', 'Neostigmine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ambenonium, Pilocarpine, Cevimeline, Pyridostigmine, Latanoprost, Apraclonidine, Pilocarpine, Clonidine, Acetylcholine, Bimatoprost, Travoprost, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120719/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120582, 'Iopamidol', 'Netilmicin', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Tetracycline, Ganciclovir, Rifamycin, Oxytetracycline, Famciclovir, Sulfamethizole, Cefuroxime, Trifluridine, Benzylpenicillin, Ampicillin, Chloramphenicol, More', 'Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120720/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120583, 'Iopamidol', 'Norfloxacin', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Tetracycline, Ganciclovir, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120721/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120584, 'Iopamidol', 'Nortriptyline', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120722/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120585, 'Iopamidol', 'Ofloxacin', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Tinidazole, Tetracycline, Cefepime, Fluconazole, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Tetracycline, Ganciclovir, More', 'Ioxilan, Iodipamide, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, Diatrizoate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120723/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120586, 'Iopamidol', 'Olanzapine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120724/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120587, 'Iopamidol', 'Oliceridine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Naloxone, Naltrexone', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120725/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120588, 'Iopamidol', 'Olsalazine', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Beclomethasone dipropionate, Budesonide, Cromoglicic acid, Prednisone', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120726/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120589, 'Iopamidol', 'Opium', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Loperamide, Eluxadoline, Diphenoxylate, Difenoxin, Naloxone, Naltrexone', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120727/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120590, 'Iopamidol', 'Oxamniquine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Triclabendazole, Praziquantel', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120728/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120591, 'Iopamidol', 'Oxtriphylline', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Omalizumab, Tezepelumab, Mercaptopurine, Benralizumab, Caffeine, Reslizumab, Montelukast, Dyphylline, Mepolizumab, Roflumilast, Pentoxifylline, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120729/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120592, 'Iopamidol', 'Oxymorphone', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Naloxone, Naltrexone', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120730/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120593, 'Iopamidol', 'Pamidronic acid', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120731/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120594, 'Iopamidol', 'Paroxetine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120732/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120595, 'Iopamidol', 'Peginterferon alfa-2a', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120733/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120596, 'Iopamidol', 'Peginterferon alfa-2b', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120734/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120597, 'Iopamidol', 'Peginterferon beta-1a', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Oprelvekin, Sipuleucel-T, Elapegademase, Ropeginterferon alfa-2b, Sargramostim, Histamine, Pegademase, Pegfilgrastim, Filgrastim, Glatiramer', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120735/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120598, 'Iopamidol', 'Pemoline', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Atomoxetine, Solriamfetol, Caffeine, Armodafinil, Citicoline, Modafinil', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120736/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120599, 'Iopamidol', 'Penbutolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120737/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12[3] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[4] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120600, 'Iopamidol', 'Penicillamine', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Auranofin, Aurothioglucose, Sodium aurothiomalate', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120738/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120601, 'Iopamidol', 'Perphenazine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120739/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120602, 'Iopamidol', 'Phendimetrazine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120740/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120603, 'Iopamidol', 'Phenelzine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120741/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120604, 'Iopamidol', 'Phenylbutazone', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide', 'Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120742/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120605, 'Iopamidol', 'Phenylpropanolamine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Pseudoephedrine, Phenylephrine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120743/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120606, 'Iopamidol', 'Physostigmine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Latanoprost, Apraclonidine, Pilocarpine, Clonidine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Epinephrine, Brimonidine, Guanethidine, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120744/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120607, 'Iopamidol', 'Pimozide', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120745/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120608, 'Iopamidol', 'Pindolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120746/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12[3] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[4] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120609, 'Iopamidol', 'Piperazine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Thiabendazole, Levamisole, Pyrantel, Ivermectin, Mebendazole, Albendazole', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120747/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120610, 'Iopamidol', 'Piroxicam', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide, Fluocinolone acetonide, Salicylic acid, Fluorometholone', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120748/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120611, 'Iopamidol', 'Plazomicin', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120749/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120612, 'Iopamidol', 'Polymyxin B', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Tetracycline, Rifamycin, Miconazole, Chloramphenicol, Chlorhexidine, Tetracycline, Chloramphenicol, Chlorhexidine, Tinidazole, Linezolid, Oritavancin, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120750/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120613, 'Iopamidol', 'Polythiazide', 'Moderate', 'Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, Vemurafenib, More', 'Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120751/', '[1] Briguori C, Marenzi G "Contrast-induced nephropathy: Pharmacological prophylaxis." Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R "Can we prevent acute kidney injury?" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS "Clinical practice. Preventing nephropathy induced by contrast medium." N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N "Contrast-induced nephropathy: a clinical and evidence-based approach." Circulation 113 (2006): 1799-806[5] "Product Information. Lasix (furosemide)." sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC "Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy." Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M "Potential deleterious effect of furosemide in radiocontrast nephropathy." Nephron 62 (1992): 413-5[8] Massicotte A "Contrast medium-induced nephropathy: strategies for prevention." Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D "What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography." Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. "Strategies to reduce the risk of contrast-induced nephropathy." Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G "Facts and fallacies concerning the prevention of contrast medium-induced nephropathy." Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D''Elia J, Silva P "Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents." N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. "A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation." J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ "Meta-analysis of frusemide to prevent or treat acute renal failure." BMJ 333 (2006): 420[15] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120614, 'Iopamidol', 'Prednisolone', 'Major', 'Coadministration of corticosteroids with iodinated contrast media by the intrathecal route may be associated with a high incidence of radiographic arachnoiditis. Meningitis and seizures may also occur.', NULL, 'Intrathecal coadministration of corticosteroids with iodinated contrast media is considered contraindicated.', NULL, 'Intrathecal coadministration of corticosteroids with iodinated contrast media is considered contraindicated.', 'Others', 'Mometasone furoate, Amcinonide, Budesonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluticasone, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluocinolone acetonide, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, Diatrizoate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120752/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.[3] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[4] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[5] Nelson DA, Landau WM "Intraspinal steroids: history, efficacy, accidentality, and controversy with review of United States Food and Drug Administration reports." J Neurol Neurosurg Psychiatry 70 (2001): 433-43', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120615, 'Iopamidol', 'Procainamide', 'Moderate', 'The use of iodine-containing contrast media for coronary angiography in patients treated with certain antiarrhythmics such as amiodarone may result in significant prolongation of the QT interval. These contrast agents can be arrhythmogenic when injected into the coronary arteries and may have additive effects on cardiac repolarization when coadministered with antiarrhythmic agents that prolong the QT interval.', NULL, 'Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.', NULL, 'Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents. Increased surveillance and ECG monitoring may be appropriate. Patients who receive outpatient angiographies should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of arrhythmia such as dizziness, palpitations, or syncope.', 'Synergism', 'Propafenone, Dronedarone, Tocainide, Flecainide, Bretylium, Moricizine', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120753/', '[1] Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U "Iohexol contrast medium induces QT prolongation in amiodarone patients." Br J Clin Pharmacol 58 (2004): 96-98[2] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[3] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120616, 'Iopamidol', 'Promazine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120754/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120617, 'Iopamidol', 'Propiomazine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, Butabarbital, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120755/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120618, 'Iopamidol', 'Propranolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', 'Felodipine, Amlodipine, Nifedipine, Ivabradine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120756/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12[3] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[4] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120619, 'Iopamidol', 'Protriptyline', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120757/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120620, 'Iopamidol', 'Quetiapine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, Diatrizoate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120758/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120621, 'Iopamidol', 'Quinidine', 'Moderate', 'The use of iodine-containing contrast media for coronary angiography in patients treated with certain antiarrhythmics such as amiodarone may result in significant prolongation of the QT interval. These contrast agents can be arrhythmogenic when injected into the coronary arteries and may have additive effects on cardiac repolarization when coadministered with antiarrhythmic agents that prolong the QT interval.', NULL, 'Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.', NULL, 'Caution is advised if iodine-containing contrast media are used for coronary angiography in patients treated with class IA (e.g., disopyramide, quinidine, procainamide) or class III (e.g., amiodarone, dofetilide, ibutilide, sotalol) antiarrhythmic agents. Increased surveillance and ECG monitoring may be appropriate. Patients who receive outpatient angiographies should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of arrhythmia such as dizziness, palpitations, or syncope.', 'Synergism', 'Propafenone, Dronedarone, Tocainide, Flecainide, Bretylium, Moricizine', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120759/', '[1] Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U "Iohexol contrast medium induces QT prolongation in amiodarone patients." Br J Clin Pharmacol 58 (2004): 96-98[2] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[3] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120622, 'Iopamidol', 'Remdesivir', 'Moderate', 'Coadministration of remdesivir with nephrotoxic agents may increase the plasma concentrations of its main metabolite, GS-441524, and the excipient, sulfobutylether-beta-cyclodextrin sodium (SBECD). Both GS-441524 and SBECD are primarily eliminated by the kidneys, thus renal impairment secondary to the use of nephrotoxic agents may reduce their clearance and increase the risk of accumulation.', NULL, 'Some authorities recommend avoiding the concomitant use of remdesivir with drugs that can reduce renal function.', NULL, 'Some authorities recommend avoiding the concomitant use of remdesivir with drugs that can reduce renal function. Caution is advised if remdesivir is used in patients who have recently received potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function (estimated glomerular filtration rate, or eGFR, for adult and pediatric patients older than 28 days; serum creatinine for full-term neonates at least 7 days up to 28 days old) should be evaluated prior to starting remdesivir and monitored daily during treatment or as clinically appropriate.', 'Excretion', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120760/', '[1] Gilead Sciences, Inc "About Remdesivir. Available from: URL: https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir." ([2020]):[2] European Medicines Agency "Summary on compassionate use. Remdesivir Gilead. Available from: URL: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf." ([2020 Apr 03]):[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] US Food and Drug Administration "Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM) Available from: URL: https://www.fda.gov/media/137566/download." ([2020, May 1]]):[5] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120623, 'Iopamidol', 'Remifentanil', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Halothane, Thiopental, Sodium oxybate, Isoflurane, Methohexital, Nitrous oxide, Desflurane, Propofol, Enflurane, Esketamine, Sevoflurane, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120761/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120624, 'Iopamidol', 'Rivastigmine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Memantine, Ginkgo biloba, Aducanumab', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120762/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120625, 'Iopamidol', 'Rofecoxib', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120763/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120626, 'Iopamidol', 'Salsalate', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Salicylic acid, Choline salicylate, Ziconotide', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120764/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120627, 'Iopamidol', 'Sertraline', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, Diatrizoate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120765/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120628, 'Iopamidol', 'Sibutramine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Lorcaserin, Orlistat, Naltrexone', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120766/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120629, 'Iopamidol', 'Sirolimus', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120767/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120630, 'Iopamidol', 'Iodide I-123', 'Moderate', 'INTERVAL: Iodine-containing products may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides. These effects may last up to 8 weeks.', NULL, 'Iodine preparations including expectorants, vitamins, topicals, and intravascular iodine-containing contrast media should be withheld for at least 2 to 4 weeks and possibly longer, and cholecystographic agents should be withheld for more than 4 weeks, prior to administration of sodium iodide I-131 or I-123.', NULL, 'Iodine preparations including expectorants, vitamins, topicals, and intravascular iodine-containing contrast media should be withheld for at least 2 to 4 weeks and possibly longer, and cholecystographic agents should be withheld for more than 4 weeks, prior to administration of sodium iodide I-131 or I-123.', 'Others', 'Iopanoic acid, Tyropanoic acid', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120768/', '[1] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Sodium Iodide I-123 (sodium iodide I-123)." GE Healthcare, Princeton, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120631, 'Iopamidol', 'Iodide I-131', 'Moderate', 'INTERVAL: Iodine-containing products may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides. These effects may last up to 8 weeks.', NULL, 'Iodine preparations including expectorants, vitamins, topicals, and intravascular iodine-containing contrast media should be withheld for at least 2 to 4 weeks and possibly longer, and cholecystographic agents should be withheld for more than 4 weeks, prior to administration of sodium iodide I-131 or I-123.', NULL, 'Iodine preparations including expectorants, vitamins, topicals, and intravascular iodine-containing contrast media should be withheld for at least 2 to 4 weeks and possibly longer, and cholecystographic agents should be withheld for more than 4 weeks, prior to administration of sodium iodide I-131 or I-123.', 'Others', 'Iopanoic acid, Tyropanoic acid', 'Ibritumomab tiuxetan, Tositumomab', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120769/', '[1] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Sodium Iodide I-123 (sodium iodide I-123)." GE Healthcare, Princeton, NJ.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120632, 'Iopamidol', 'Sotalol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', 'Felodipine, Amlodipine, Nifedipine, Ivabradine', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120770/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12[3] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[4] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120633, 'Iopamidol', 'Sparfloxacin', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120771/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120634, 'Iopamidol', 'Streptomycin', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Rifapentine, Trimethoprim, Rifampicin, Rifabutin, Isoniazid, Ethambutol, Ethionamide, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120772/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120635, 'Iopamidol', 'Streptozocin', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Temozolomide, Thiotepa, Carmustine, Cyclophosphamide, Busulfan, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120773/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120636, 'Iopamidol', 'Sulfasalazine', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, Vemurafenib, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120774/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120637, 'Iopamidol', 'Sulindac', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120775/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120638, 'Iopamidol', 'Tacrine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Memantine, Ginkgo biloba, Aducanumab', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120776/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120639, 'Iopamidol', 'Tacrolimus', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, Cromoglicic acid, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120777/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120640, 'Iopamidol', 'Tapentadol', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Naloxone, Naltrexone', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120778/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120641, 'Iopamidol', 'Telavancin', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Tinidazole, Linezolid, Oritavancin, Daptomycin, Metronidazole, Methenamine, Spectinomycin, Lefamulin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120779/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120642, 'Iopamidol', 'Temsirolimus', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Entrectinib, Imatinib, Pralsetinib, Dabrafenib, Asciminib, Acalabrutinib, Dacomitinib, Pexidartinib, Pacritinib, Tepotinib, Fedratinib, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120780/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120643, 'Iopamidol', 'Thiethylperazine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120781/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120644, 'Iopamidol', 'Thioridazine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120782/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120645, 'Iopamidol', 'Thiothixene', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120783/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120646, 'Iopamidol', 'Timolol', 'Moderate', 'Limited data suggest that patients receiving beta-blockers may have an increased risk of severe hypotensive and/or hypersensitivity reactions to parenteral iodinated contrast media. In addition, allergic/anaphylactoid reactions in these patients may be more difficult to treat.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media.', NULL, 'Patients who have received beta-blockers should be closely monitored for adverse reactions to iodinated contrast media. If anaphylaxis occurs, clinicians should be aware that beta-blockers may attenuate the response to epinephrine. Thus, larger doses of epinephrine may be necessary to overcome the bronchospasm, although such large doses can also cause excessive alpha-adrenergic stimulation resulting in hypertension, reflex bradycardia, heart block, and possible potentiation of bronchospasm. Alternative treatments recommended include vigorous supportive care (e.g., fluids) and the use of parenteral beta-agonists for bronchospasm and norepinephrine for hypotension.', 'Synergism', 'Latanoprost, Apraclonidine, Pilocarpine, Clonidine, Acetylcholine, Bimatoprost, Travoprost, Brinzolamide, Epinephrine, Brimonidine, Guanethidine, Levobunolol', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120784/', '[1] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[2] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12[3] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[4] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120647, 'Iopamidol', 'Tobramycin', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Tetracycline, Ganciclovir, Rifamycin, Oxytetracycline, Famciclovir, Sulfamethizole, Cefuroxime, Trifluridine, Benzylpenicillin, Ampicillin, Chloramphenicol, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120785/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120648, 'Iopamidol', 'Tolmetin', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine, Tolazoline, Dimethyl sulfoxide', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120786/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120649, 'Iopamidol', 'Torasemide', 'Moderate', 'Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, Vemurafenib, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120787/', '[1] Briguori C, Marenzi G "Contrast-induced nephropathy: Pharmacological prophylaxis." Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R "Can we prevent acute kidney injury?" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS "Clinical practice. Preventing nephropathy induced by contrast medium." N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N "Contrast-induced nephropathy: a clinical and evidence-based approach." Circulation 113 (2006): 1799-806[5] "Product Information. Lasix (furosemide)." sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC "Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy." Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M "Potential deleterious effect of furosemide in radiocontrast nephropathy." Nephron 62 (1992): 413-5[8] Massicotte A "Contrast medium-induced nephropathy: strategies for prevention." Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D "What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography." Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. "Strategies to reduce the risk of contrast-induced nephropathy." Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G "Facts and fallacies concerning the prevention of contrast medium-induced nephropathy." Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D''Elia J, Silva P "Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents." N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. "A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation." J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ "Meta-analysis of frusemide to prevent or treat acute renal failure." BMJ 333 (2006): 420[15] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120650, 'Iopamidol', 'Tranylcypromine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120788/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120651, 'Iopamidol', 'Triamterene', 'Moderate', 'Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.', 'Synergism', 'Eplerenone, Finerenone', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120789/', '[1] Briguori C, Marenzi G "Contrast-induced nephropathy: Pharmacological prophylaxis." Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R "Can we prevent acute kidney injury?" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS "Clinical practice. Preventing nephropathy induced by contrast medium." N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N "Contrast-induced nephropathy: a clinical and evidence-based approach." Circulation 113 (2006): 1799-806[5] "Product Information. Lasix (furosemide)." sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC "Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy." Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M "Potential deleterious effect of furosemide in radiocontrast nephropathy." Nephron 62 (1992): 413-5[8] Massicotte A "Contrast medium-induced nephropathy: strategies for prevention." Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D "What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography." Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. "Strategies to reduce the risk of contrast-induced nephropathy." Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G "Facts and fallacies concerning the prevention of contrast medium-induced nephropathy." Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D''Elia J, Silva P "Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents." N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. "A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation." J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ "Meta-analysis of frusemide to prevent or treat acute renal failure." BMJ 333 (2006): 420[15] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120652, 'Iopamidol', 'Trichlormethiazide', 'Moderate', 'Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Metronidazole, Simeprevir, Sulfadiazine, Lactic acid, Mitapivat, Clindamycin, Ciclopirox, Vemurafenib, More', 'Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120790/', '[1] Briguori C, Marenzi G "Contrast-induced nephropathy: Pharmacological prophylaxis." Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R "Can we prevent acute kidney injury?" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS "Clinical practice. Preventing nephropathy induced by contrast medium." N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N "Contrast-induced nephropathy: a clinical and evidence-based approach." Circulation 113 (2006): 1799-806[5] "Product Information. Lasix (furosemide)." sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC "Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy." Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M "Potential deleterious effect of furosemide in radiocontrast nephropathy." Nephron 62 (1992): 413-5[8] Massicotte A "Contrast medium-induced nephropathy: strategies for prevention." Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D "What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography." Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. "Strategies to reduce the risk of contrast-induced nephropathy." Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G "Facts and fallacies concerning the prevention of contrast medium-induced nephropathy." Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D''Elia J, Silva P "Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents." N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. "A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation." J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ "Meta-analysis of frusemide to prevent or treat acute renal failure." BMJ 333 (2006): 420[15] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120653, 'Iopamidol', 'Trifluoperazine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120791/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120654, 'Iopamidol', 'Triflupromazine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120792/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120655, 'Iopamidol', 'Alimemazine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120793/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120656, 'Iopamidol', 'Trimipramine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120794/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120657, 'Iopamidol', 'Trovafloxacin', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120795/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120658, 'Iopamidol', 'Tyropanoic acid', 'Moderate', 'INTERVAL: Renal toxicity has been reported in a few patients with liver dysfunction who were given an oral cholecystographic agent followed by intravenous contrast agents. The mechanism of interaction has not been described.', NULL, 'Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.', NULL, 'Administration of any intravascular contrast agent should be deferred for 48 hours in patients with hepatic or biliary disorders who have recently received an oral cholecystographic contrast agent.', 'Others', 'Iodipamide, Iodamide, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Metrizamide', 'Ioxilan, Iomeprol, Iodipamide, Ioversol, Iohexol, Iodamide, Iodixanol, Ethiodized oil, Iothalamic acid, Ioxaglic acid, Iopromide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120796/', '[1] "Product Information. Ultravist (iopromide)." Berlex, Richmond, CA.[2] "Product Information. Visipaque (iodixanol)." Nycomed Inc, Princeton, NJ.[3] "Product Information. Omniscan (gadodiamide)." Novation, Irving, TX.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120659, 'Iopamidol', 'Urea', 'Moderate', 'Forced diuresis during administration of radiocontrast agents may increase the risk of renal impairment in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy.', NULL, 'Whenever possible, alternative imaging techniques should be considered in patients who are at high risk for contrast-induced nephropathy. Otherwise, some experts recommend discontinuing diuretics 1 to 2 days before administration of contrast media, depending on the clinical feasibility of doing so. The smallest effective dose of a nonionic, hypo- or iso-osmolar contrast medium (e.g., iohexol, iodixanol, iopamidol) should be used, since the risk of nephropathy is increased with increasing contrast dose and/or osmolarity. Repeat procedures with contrast media, if necessary, should not occur until at least 72 hours after the previous contrast exposure and renal function has fully recovered. Although it is not necessary to measure the serum creatinine levels of every patient before contrast administration, measurements should generally be made in patients receiving contrast agent by intraarterial administration (which is associated with increased risk of nephropathy relative to intravenous administration) and patients with a history of kidney disease, proteinuria, kidney surgery, diabetes, hypertension, gout, or other risk factors for nephropathy. Creatinine measurements should be continued for 24 to 48 hours after administration of contrast medium. It is important that patients be adequately hydrated with either saline or sodium bicarbonate.', 'Synergism', 'Tromethamine', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120797/', '[1] Briguori C, Marenzi G "Contrast-induced nephropathy: Pharmacological prophylaxis." Kidney Int 69(S100) (2006): S30-S38[2] Venkataraman R "Can we prevent acute kidney injury?" Crit Care Med 36(4 Suppl) (2008): S166-71[3] Barrett BJ, Parfrey PS "Clinical practice. Preventing nephropathy induced by contrast medium." N Engl J Med 354 (2006): 379-86[4] Tepel M, Aspelin P, Lameire N "Contrast-induced nephropathy: a clinical and evidence-based approach." Circulation 113 (2006): 1799-806[5] "Product Information. Lasix (furosemide)." sanofi-aventis , Bridgewater, NJ.[6] Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC "Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy." Ann Intern Med 148 (2008): 284-94[7] Weinstein J-M, Heyman S, Brezis M "Potential deleterious effect of furosemide in radiocontrast nephropathy." Nephron 62 (1992): 413-5[8] Massicotte A "Contrast medium-induced nephropathy: strategies for prevention." Pharmacotherapy 28 (2008): 1140-50[9] Fishman EK, Reddan D "What are radiologists doing to prevent contrast-induced nephropathy (CIN) compared with measures supported by current evidence? A survey of European radiologists on CIN associated with computed tomography." Acta Radiol 49 (2008): 310-20[10] Stacul F, Adam A, Becker CR, et al. "Strategies to reduce the risk of contrast-induced nephropathy." Am J Cardiol 98(6S1) (2006): 59-77[11] Meschi M, Detrenis S, Musini S, Strada E, Savazzi G "Facts and fallacies concerning the prevention of contrast medium-induced nephropathy." Crit Care Med 34 (2006): 2060-80[12] Solomon R, Werner C, Mann D, D''Elia J, Silva P "Effects of saline, mannitol, and furosemide on acute decreases in renal function induced by radiocontrast agents." N Engl J Med 331 (1994): 1416-20[13] Stevens MA, McCullough PA, Tobin KJ, et al. "A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation." J Am Coll Cardiol 33 (1999): 403-11[14] Ho KM, Sheridan DJ "Meta-analysis of frusemide to prevent or treat acute renal failure." BMJ 333 (2006): 420[15] Costa N "Understanding contrast media." J Infus Nurs 27 (2004): 302-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120660, 'Iopamidol', 'Valaciclovir', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Maraviroc, Amprenavir, Simeprevir, Zanamivir, Cabotegravir, Lenacapavir, Telaprevir, Velpatasvir, More', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120798/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120661, 'Iopamidol', 'Valdecoxib', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Misoprostol, Chondroitin sulfate, Esomeprazole, Glucosamine', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120799/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120662, 'Iopamidol', 'Venlafaxine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, Diatrizoate', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120800/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120663, 'Iopamidol', 'Vilazodone', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120801/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120664, 'Iopamidol', 'Vortioxetine', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'St. John''s Wort, Oxitriptan, Viloxazine, Tryptophan, Esketamine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120802/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120665, 'Iopamidol', 'Ziprasidone', 'Major', 'Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient.', NULL, 'Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.', 'Synergism', 'Amisulpride, Droperidol, Pimavanserin', 'Ioxilan, Iodipamide, Ioversol, Iodamide, Iodixanol, Tyropanoic acid, Ethiodized oil, Iopanoic acid, Iopodic acid, Iothalamic acid, Ioxaglic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120803/', '[1] "Product Information. Amipaque (metrizamide)" Nycomed Inc, Princeton, NJ.[2] Hindmarsh T, Grepe A, Widen L "Metrizamide-phenothiazine interaction: report of a case with seizures following myelography." Acta Radiol Diagn (Stockh) 16 (1975): 129-35[3] "Product Information. Omnipaque 180 (iohexol)." Amersham Health, Princeton, NJ.[4] "Product Information. Osmovist 240 (iotrolan)." Berlex Canada Inc, Lachine, QC.[5] "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120666, 'Iopamidol', 'Zoledronic acid', 'Major', 'Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy.', NULL, 'Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.', 'Synergism', 'Tiludronic acid, Alendronic acid, Vosoritide, Denosumab, Cholecalciferol, Burosumab, Risedronic acid, Romosozumab', 'Ethiodized oil, Iopanoic acid, Tyropanoic acid, Iopodic acid', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120804/', '[1] Dubrovskaya Y, Prasad N, Lee Y, Esaian D, Figueroa DA, Tam VH "Risk factors for nephrotoxicity onset associated with polymyxin B therapy." J Antimicrob Chemother 70 (2015): 1903-7[2] Bentley ML, Corwin HL, Dasta J "Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies." Crit Care Med 38(6 Suppl) (2010): S169-74[3] Kellum JA, Leblanc M, Venkataraman R "Acute renal failure." BMJ Clin Evid 9 (2008): 2001[4] van den Berk G, Tonino S, de Fijter C, Smit W, Schultz MJ "Bench-to-bedside review: Preventative measures for contrast-induced nephropathy in critically ill patients." Crit Care 9 (2005): 361-70[5] Marcos LA, Camins BC, Ritchie DJ, Casabar E, Warren DK "Acute renal insufficiency during telavancin therapy in clinical practice." J Antimicrob Chemother 67 (2012): 723-6[6] Bansal R, Kaplan AA, Aflieco F "Contrast-Induced Nephropathy. Available from: URL: http://emedicine.medscape.com/article/246751-overview." ([2016, Jan 18]):[7] Bennett WM, Porter GA "Nephrotoxicity of common drugs used by urologists." Urol Clin North Am 17 (1990): 145-56', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120667, 'Isoxsuprine', 'Chlorpromazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120805/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120668, 'Isoxsuprine', 'Epoprostenol', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More', 'Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120806/', '[1] "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC.[2] "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Buchdahl RM, Taylor P, Warner JD "Nebulised ribavirin for adenovirus pneumonia." Lancet 2 (1985): 1070-1[5] "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120669, 'Isoxsuprine', 'Ertugliflozin', 'Moderate', 'Sodium-glucose co-transporter 2 (SGLT-2) inhibitors may potentiate the hypotensive effects of diuretics and other antihypertensive agents or vasodilators. Inhibition of glucose and sodium co-transport produces mild diuresis and transient natriuresis, resulting in intravascular volume contraction. Volume depletion-related adverse reactions including hypotension, postural dizziness, orthostatic hypotension, syncope, and dehydration can occur after initiating treatment with SGLT-2 inhibitors, and the risk may be increased with concomitant use of other agents that can lower blood pressure.', NULL, 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function.', NULL, 'Caution is advised if SGLT-2 inhibitors are coadministered with diuretics and other hypotensive agents, particularly in the elderly and patients with impaired renal function. Prior to initiating SGLT-2 inhibitors, volume status should be assessed and corrected, if necessary. Clinical and laboratory monitoring are recommended during therapy, including electrolytes, fluid status, renal function, and blood pressure. If volume depletion occurs, treatment with SGLT-2 inhibitors should be interrupted until the condition is corrected.', 'Synergism', 'Pentoxifylline', 'Glipizide, Acetohexamide, Guar gum, Pramlintide, Alogliptin, Rosuvastatin, Tolazamide, Dulaglutide, Exenatide, Tolbutamide, Miglitol, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120807/', '[1] "Product Information. Jardiance (empagliflozin)." Boehringer Ingelheim, Ridgefield, CT.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Farxiga (dapagliflozin)." Bristol-Myers Squibb, Princeton, NJ.[5] "Product Information. Invokana (canagliflozin)." Janssen Pharmaceuticals, Titusville, NJ.[6] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[7] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[8] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[9] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[10] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[11] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[12] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[15] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120670, 'Isoxsuprine', 'Fluphenazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120808/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120671, 'Isoxsuprine', 'Garlic', 'Minor', 'Garlic has been found in some studies to lower blood pressure and may theoretically potentiate the effects of hypotensive agents. A meta-analysis of 11 randomized, placebo-controlled studies showed a mean decrease of 4.6 mmHg for systolic blood pressure and no significant effect for diastolic blood pressure in subjects treated with garlic (most often garlic powder 600 to 900 mg/day, providing 3.6 to 5.4 mg of the active component allicin) compared to placebo.', NULL, '-', NULL, '-', 'Synergism', 'Pentoxifylline, Niacin', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120809/', '[1] Tattelman E "Health effects of garlic." Am Fam Physician 72 (2005): 103-6[2] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120672, 'Isoxsuprine', 'Haloperidol', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120810/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120673, 'Isoxsuprine', 'Iloperidone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120811/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120674, 'Isoxsuprine', 'Iloprost', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More', 'Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120812/', '[1] "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC.[2] "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Buchdahl RM, Taylor P, Warner JD "Nebulised ribavirin for adenovirus pneumonia." Lancet 2 (1985): 1070-1[5] "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120675, 'Isoxsuprine', 'Licorice', 'Moderate', 'Licorice use has been associated with hypertension and may antagonize the effects of antihypertensive agents. Glycyrrhizic acid, a component of licorice, is hydrolyzed in the intestine to a metabolite (glycyrrhetinic acid) that causes mineralocorticoid and renin-suppressing effects.', NULL, 'Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products.', NULL, 'Patients receiving antihypertensive therapy should avoid or limit the consumption of licorice-containing products. Even relatively moderate doses of licorice may be problematic in susceptible patients when ingested regularly for prolonged periods.', 'Antagonism', 'Pentoxifylline, Niacin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120813/', '[1] Cumming AM "Metabolic effects of licorice." Br Med J 1 (1977): 906[2] Epstein MT, Espiner EA, Donald RA, Hughes H "Effect of eating liquorice on the renin-angiotensin aldosterone axis in normal subjects." Br Med J 1 (1977): 488-90[3] Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edwards CR "Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age." Lancet 2 (1987): 821-4[4] Elinav E, Chajek-Shaul T "Licorice consumption causing severe hypokalemic paralysis." Mayo Clin Proc 78 (2003): 767-8[5] Rosseel M, Schoors D "Chewing gum and hypokalaemia." Lancet 341 (1993): 175[6] Clyburn EB, DiPette DJ "Hypertension induced by drugs and other substances." Semin Nephrol 15 (1995): 72-86[7] Lin SH, Yang SS, Chau T, Halperin ML "An unusual cause of hypokalemic paralysis: chronic licorice ingestion." Am J Med Sci 325 (2003): 153-6[8] de Klerk GJ, Nieuwenhuis MG, Beutler JJ "Lesson of the week: hypokalaemia and hypertension associated with use of liquorice flavoured chewing gum." BMJ 314 (1997): 731[9] Nielsen I, Pedersen RS "Life-threatening hypokalaemia caused by liquorice ingestion." Lancet 1 (1984): 1305[10] Cumming AM, Boddy K, Brown JJ, et al "Severe hypokalaemia with paralysis induced by small doses of liquorice." Postgrad Med J 56 (1980): 526-9[11] Cumming A "Severe reduction of serum potassium induced by licorice." Nurs Times 72 (1976): 367-70[12] Epstein MT, Espiner EA, Donald RA, Hughes H "Liquorice toxicity and the renin-angiotensin-aldosterone axis in man." Br Med J 1 (1977): 209-10[13] Sigurjonsdottir HA, Franzson L, Manhem K, Ragnarsson J, Sigurdsson G, Wallerstedt S "Liquorice-induced rise in blood pressure: a linear dose-response relationship." J Hum Hypertens 15 (2001): 549-52[14] Edwards CR "Lessons from licorice." N Engl J Med 325 (1991): 1242-3[15] Ishikawa S, Kato M, Tokuda T, Momoi H, Sekijima Y, Higuchi M, Yanagisawa N "Licorice-induced hypokalemic myopathy and hypokalemic renal tubular damage in anorexia nervosa." Int J Eating Disorder 26 (1999): 111-4[16] Holmes AM, Young J, Marrott PK, Prentice E "Pseudohyperaldosteronism induced by habitual ingestion of liquorice." Postgrad Med J 46 (1970): 625-9[17] Bannister B, Ginsburg R, Shneerson J "Cardiac arrest due to liquorice-induced hypokalaemia." Br Med J 2 (1977): 738-9[18] Richard CL, Jurgens TM "Effects of natural health products on blood pressure." Ann Pharmacother 39 (2005): 712-20[19] Farese RV, Biglieri EG, Shackleton CH, Irony I, Gomez-Fontes R "Licorice-induced hypermineralocorticoidism." N Engl J Med 325 (1991): 1223-7[20] Dellow EL, Unwin RJ, Honour JW "Pontefract cakes can be bad for you: refractory hypertension and liquorice excess." Nephrol Dial Transplant 14 (1999): 218-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120676, 'Isoxsuprine', 'Linezolid', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, Lefamulin, More', 'Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120814/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120677, 'Isoxsuprine', 'Loxapine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120815/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120678, 'Isoxsuprine', 'Lumateperone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120816/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120679, 'Isoxsuprine', 'Lurasidone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120817/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120680, 'Isoxsuprine', 'Maraviroc', 'Moderate', 'Maraviroc may potentiate the hypotensive effect of some medications.', NULL, 'Caution is advised when maraviroc is prescribed to patients on concomitant medications known to lower blood pressure.', NULL, 'Caution is advised when maraviroc is prescribed to patients on concomitant medications known to lower blood pressure. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Lamivudine, Paritaprevir, Glecaprevir, Tenofovir alafenamide, Simeprevir, Amprenavir, Cabotegravir, Valaciclovir, Zanamivir, Lenacapavir, Telaprevir, More', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120818/', '[1] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120681, 'Isoxsuprine', 'Mesoridazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120819/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120682, 'Isoxsuprine', 'Methdilazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120820/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120683, 'Isoxsuprine', 'Methotrimeprazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120821/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120684, 'Isoxsuprine', 'Minoxidil (topical)', 'Moderate', 'Theoretically, topical administration of minoxidil may potentiate the hypotensive effects of systemic minoxidil and other vasodilators. Increased systemic absorption may occur when topical minoxidil is used in excess of normally recommended dosages or applied to compromised skin.', NULL, 'Patients prescribed topical minoxidil in combination with systemic vasodilators or peripherally-acting antiadrenergic agents should be monitored for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.', NULL, 'Patients prescribed topical minoxidil in combination with systemic vasodilators or peripherally-acting antiadrenergic agents should be monitored for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache.', 'Synergism', 'Tacrolimus, Minoxidil, Deoxycholic acid, Magnesium sulfate, Glycopyrronium, Calcium gluconate, Pimecrolimus, Aminobenzoic acid, Finasteride, Ivermectin, Caffeine, More', 'Tolazoline, Phenoxybenzamine, Phentolamine, Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120822/', '[1] Leenen FH, Smith DL, Unger WP "Topical minoxidil: cardiac effects in bald men." Br J Clin Pharmacol 26 (1988): 481-5[2] "Product Information. Rogaine (minoxidil topical)." Johnson and Johnson/McNeil Consumer, Fort Washington, PA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120685, 'Isoxsuprine', 'Molindone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120823/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120686, 'Isoxsuprine', 'Nefazodone', 'Moderate', 'Nefazodone may potentiate the hypotensive effect of many drugs including vasodilators and antihypertensive agents. Orthostatic hypotension may occur.', NULL, 'Caution and close monitoring for altered efficacy and safety are recommended if patients receive nefazodone with agents that can produce significant hypotension such as antihypertensive agents or vasodilators.', NULL, 'Caution and close monitoring for altered efficacy and safety are recommended if patients receive nefazodone with agents that can produce significant hypotension such as antihypertensive agents or vasodilators. Patients should be made aware of the possible side effects (e.g., dizziness, lightheadedness, orthostasis) and be cautioned about driving, operating machinery, or performing other hazardous tasks.', 'Synergism', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More', 'Pentoxifylline', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120824/', '[1] "Product Information. Serzone (nefazodone)." Bristol-Myers Squibb, Princeton, NJ.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120687, 'Isoxsuprine', 'Nesiritide', 'Moderate', 'The coadministration of nesiritide with intravenous vasodilators such as nitroglycerin, nitroprusside, and milrinone has not been evaluated. Theoretically, an increase in symptomatic hypotension may occur due to possible additive pharmacodynamic effects in the vasculature. A similar risk may exist during coadministration with oral vasodilators such as hydralazine and minoxidil and other agents with vasodilating effects.', NULL, 'Whether used alone or with other agents, nesiritide should be administered only in settings where blood pressure can be closely monitored.', NULL, 'Whether used alone or with other agents, nesiritide should be administered only in settings where blood pressure can be closely monitored. The dosage should be reduced or the drug discontinued in patients who develop hypotension.', 'Synergism', 'Isosorbide mononitrate, Nitroglycerin, Isosorbide dinitrate', 'Cyclandelate, Niacin, Phentolamine, Phenoxybenzamine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120825/', '[1] "Product Information. Natrecore (nesiritide)" Scios Inc, Sunnyvale, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120688, 'Isoxsuprine', 'Ozanimod', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Pentoxifylline, Niacin', 'Golimumab, Cyclosporine, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120826/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120689, 'Isoxsuprine', 'Pentoxifylline', 'Moderate', 'Pentoxifylline may potentiate the action of hypotensive agents. Small decreases in blood pressure have been observed in some patients treated with pentoxifylline plus nifedipine or captopril. The mechanism of interaction has not been described.', NULL, 'Caution is advised if pentoxifylline is used in combination with hypotensive agents.', NULL, 'Caution is advised if pentoxifylline is used in combination with hypotensive agents. Periodic systemic blood pressure monitoring is recommended.', 'Synergism', 'Cyclandelate, Tolazoline, Phenoxybenzamine, Phentolamine, Isoxsuprine, Niacin, Theophylline, Omalizumab, Tezepelumab, Mercaptopurine, Aminophylline, More', 'Pentoxifylline', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120827/', '[1] "Product Information. Trental (pentoxifylline)." Hoechst Marion-Roussel Inc, Kansas City, MO.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120690, 'Isoxsuprine', 'Perphenazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120828/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120691, 'Isoxsuprine', 'Phenelzine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120829/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120692, 'Isoxsuprine', 'Procarbazine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120830/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120693, 'Isoxsuprine', 'Promazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120831/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120694, 'Isoxsuprine', 'Propiomazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120832/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120695, 'Isoxsuprine', 'Quetiapine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120833/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120696, 'Isoxsuprine', 'Rasagiline', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Ropinirole, Opicapone, Cabergoline, Tolcapone, Entacapone, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Amantadine, Levodopa', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120834/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120697, 'Isoxsuprine', 'Riociguat', 'Moderate', 'Riociguat may potentiate the action of antihypertensive agents and other vasodilators. Symptomatic hypotension may occur. Riociguat stimulates soluble guanylate cyclase (sGC), an enzyme in the cardiopulmonary system that binds with nitric oxide (NO) to catalyze the synthesis of cyclic guanosine monophosphate (cGMP). The resultant accumulation of cGMP in vascular smooth muscle cells leads to peripheral vasodilation and blood pressure decreases.', NULL, 'Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.', NULL, 'Caution is advised if riociguat is prescribed in combination with antihypertensive agents or other vasodilators.', 'Synergism', 'Bosentan, Ambrisentan, Macitentan, Metyrosine', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120835/', '[1] "Product Information. Adempas (riociguat)." Bayer Pharmaceutical Inc, West Haven, CT.[2] "Product Information. Adempas (riociguat)." Bayer Pharmaceutical Inc, West Haven, CT.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120698, 'Isoxsuprine', 'Safinamide', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Ropinirole, Opicapone, Cabergoline, Tolcapone, Entacapone, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Amantadine, Levodopa', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120836/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120699, 'Isoxsuprine', 'Selegiline', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Ropinirole, Opicapone, Cabergoline, Tolcapone, Entacapone, Rotigotine, Bromocriptine, Pergolide, Pramipexole, Amantadine, Levodopa', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120837/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120700, 'Isoxsuprine', 'Selexipag', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'Pentoxifylline, Niacin', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120838/', '[1] "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC.[2] "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Buchdahl RM, Taylor P, Warner JD "Nebulised ribavirin for adenovirus pneumonia." Lancet 2 (1985): 1070-1[5] "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120701, 'Isoxsuprine', 'Sildenafil', 'Moderate', 'Phosphodiesterase-5 (PDE5) inhibitors may potentiate the blood pressure-lowering effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can lead to peripheral vasodilation.', NULL, 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents.', NULL, 'Caution is advised if PDE5 inhibitors are prescribed in combination with antihypertensive agents. Patients receiving the combination should be advised to avoid rising abruptly from a sitting or recumbent position, especially following treatment initiation or a dosage increase, and to contact their doctor if they experience symptoms of hypotension such as dizziness, lightheadedness, fainting, or tachycardia.', 'Synergism', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Mitapivat, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120839/', '[1] "Product Information. Stendra (avanafil)." Vivus Inc, Mountain View, CA.[2] "Product Information. Viagra (sildenafil)." Pfizer US Pharmaceuticals, New York, NY.[3] "Product Information. Levitra (vardenafil)." Bayer, West Haven, CT.[4] Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, et al. "Effects of grapefruit juice on the pharmacokinetics of sildenafil." Clin Pharmacol Ther 71 (2002): 21-29', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120702, 'Isoxsuprine', 'Tadalafil', 'Minor', 'Based on their pharmacology, phosphodiesterase-5 (PDE5) inhibitors may conceivably potentiate the hypotensive effect of antihypertensive medications. These agents inhibit PDE5-mediated degradation of cyclic guanosine monophosphate (cGMP), which in vascular smooth muscles can cause peripheral vasodilation.', NULL, '-', NULL, '-', 'Synergism', 'Darifenacin, Ammonium chloride, Yohimbine, Papaverine, Oxybutynin, Dimethyl sulfoxide, Pentosan polysulfate, Calcium chloride, Trospium, Flavoxate, Magnesium hydroxide, More', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120840/', '[1] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[2] "Product Information. Rapaflo (silodosin)." Watson Pharmaceuticals, Corona, CA.[3] "Product Information. Cialis (tadalafil)." Lilly, Eli and Company, Indianapolis, IN.[4] "Product Information. Adcirca (tadalafil)." United Therapeutics Corporation, Silver Spring, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120703, 'Isoxsuprine', 'Thiethylperazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120841/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120704, 'Isoxsuprine', 'Thioridazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120842/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120705, 'Isoxsuprine', 'Thiothixene', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120843/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120706, 'Isoxsuprine', 'Tizanidine', 'Major', 'Tizanidine may potentiate the hypotensive effect of some medications secondary to its alpha-2 adrenergic activity. Pharmacologic studies have found tizanidine to possess between 1/10 to 1/50 of the potency of clonidine, a structurally similar agent, in lowering blood pressure.', NULL, 'A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications.', NULL, 'A lower initial dosage and cautious dosage titration should be considered when tizanidine is initiated in patients receiving hypotensive medications. Although single doses of less than 8 mg of tizanidine have not been shown effective for spasticity in controlled clinical studies, it may be prudent to initiate treatment with 4 mg doses and gradually increase in 2 to 4 mg increments until optimum effect is achieved. The dose can be repeated at 6 to 8 hour intervals as needed, up to a maximum of three doses in 24 hours and a total daily dosage of 36 mg. However, experience with single doses exceeding 8 mg and daily doses exceeding 24 mg is limited. Close monitoring for development of hypotension is recommended.', 'Synergism', 'Carisoprodol, Orphenadrine, Chlorzoxazone, Baclofen, Cyclobenzaprine, Methocarbamol, Chlormezanone', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120844/', '[1] "Product Information. Zanaflex (tizanidine)." Acorda Therapeutics, Hawthorne, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120707, 'Isoxsuprine', 'Tranylcypromine', 'Moderate', 'Monoamine oxidase inhibitors (MAOIs) may potentiate the hypotensive effect of some medications. MAOIs alone quite commonly produce orthostatic hypotension. This effect may stem from a gradual MAOI-induced accumulation of false neurotransmitters in peripheral adrenergic neurons that have minimal activity at alpha- and beta-adrenergic receptors, resulting in a functional block of sympathetic neurotransmission. The interaction has been reported with the concomitant use of beta-blockers.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment.', NULL, 'Caution is advised during coadministration of MAOIs and other medications with hypotensive effects, especially during the first few weeks of treatment. Close monitoring for development of hypotension is recommended. Ambulatory patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.', 'Synergism', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, St. John''s Wort, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Viloxazine, More', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120845/', '[1] Reggev A, Vollhardt BR "Bradycardia induced by an interaction between phenelzine and beta blockers." Psychosomatics 30 (1992): 106-8[2] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[3] Schulz R, Antonin KH, Hoffmann E, et al "Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline." Clin Pharmacol Ther 46 (1989): 528-36[4] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[5] Kronig MH, Roose SP, Walsh BT, Woodring S, Glassman AH "Blood pressure effects of phenelzine." J Clin Psychopharmacol 3 (1983): 307-10[6] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[7] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[8] "Product Information. Parnate (tranylcypromine)." SmithKline Beecham, Philadelphia, PA.[9] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[10] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[11] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[12] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[13] Golwyn DH, Sevlie CP "Monoamine oxidase inhibitor hypertensive crisis headache and orthostatic hypotension." J Clin Psychopharmacol 13 (1993): 77-8[14] "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.[15] "Product Information. Zyvox (linezolid)" Pharmacia and Upjohn, Kalamazoo, MI.[16] Zetin M, Plon L, DeAntonio M "MAOI reaction with powdered protein dietary supplement." J Clin Psychiatry 48 (1987): 499[17] "Product Information. Marplan (isocarboxazid)" Roche Laboratories, Nutley, NJ.[18] Pohl R, Balon R, Berchou R "Reaction to chicken nuggets in a patient taking an MAOI." Am J Psychiatry 145 (1988): 651[19] Martin TG "Serotonin syndrome." Ann Emerg Med 28 (1996): 520-6[20] Tailor SA, Shulman KI, Walker SE, Moss J, Gardner D "Hypertensive episode associated with phenelzine and tap beer--a reanalysis of the role of pressor amines in beer." J Clin Psychopharmacol 14 (1994): 5-14[21] Sweet RA, Liebowitz MR, Holt CS, Heimberg RG "Potential interactions between monoamine oxidase inhibitors and prescribed dietary supplements." J Clin Psychopharmacol 11 (1991): 331-2[22] "Product Information. Furoxone (furazolidone)." Roberts Pharmaceutical Corporation, Eatontown, NJ.[23] Domino EF, Selden EM "Red wine and reactions." J Clin Psychopharmacol 4 (1984): 173-4[24] Pettinger WA, Soyangco FG, Oates JA "Inhibition of monoamine oxidase in man by furazolidone." Clin Pharmacol Ther 9 (1968): 442-7[25] "Product Information. Nardil (phenelzine)." Parke-Dvis, Morris Plains, NJ.[26] Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6[27] De Vita VT, Hahn MA, Oliverio VT "Monoamine oxidase inhibition by a new carcinostatic agent, n-isopropyl-a-(2-methylhydrazino)-p-toluamide (MIH). (30590)." Proc Soc Exp Biol Med 120 (1965): 561-5[28] Maxwell MB "Reexamining the dietary restrictions with procarbazine (an MAOI)." Cancer Nurs 3 (1980): 451-7[29] Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31[30] Nuessle WF, Norman FC, Miller HE "Pickled herring and tranylcypromine reaction." JAMA 192 (1965): 142-3[31] Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62[32] Walker JI, Davidson J, Zung WWK "Patient compliance with MAO Inhibitor therapy." J Clin Psychiatry 45 (1984): 78-80', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120708, 'Isoxsuprine', 'Treprostinil', 'Moderate', 'Coadministration of medicines targeting the prostacyclin pathway (e.g., prostacyclin (PGI2), PGI2 analogs, or selective non-prostanoid prostacyclin IP receptor agonists) with diuretics, antihypertensive agents, or other vasodilators may potentiate the hypotensive effects of these agents. The mechanism involves the additive reduction in blood pressure due to the vasodilatory effects of PGI2, PGI2 analogs or selective non-prostanoid prostacyclin IP receptor agonists on the prostacyclin pathway.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently.', NULL, 'While therapies that target the prostacyclin pathway have been used in combination with diuretics, antihypertensives, or other vasodilators in the management of pulmonary arterial hypertension, caution is recommended if they must be administered concurrently. If these drugs are used together, it is generally recommended that blood pressure be measured more frequently until a stable blood pressure pattern is observed. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their doctor if they experience dizziness, lightheadedness, syncope, orthostatic hypotension, or tachycardia.', 'Synergism', 'Ticagrelor, Betrixaban, Apixaban, Cilostazol, Rivaroxaban, Clopidogrel, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, More', 'Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120846/', '[1] "Product Information. Flolan (epoprostenol)." Glaxo Wellcome, Research Triangle Park, NC.[2] "Product Information. Remodulin (treprostinil)." United Therapeutics Corp, Silver Spring, MD.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Buchdahl RM, Taylor P, Warner JD "Nebulised ribavirin for adenovirus pneumonia." Lancet 2 (1985): 1070-1[5] "Product Information. Ventavis (iloprost)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.[6] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.[7] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120709, 'Isoxsuprine', 'Trifluoperazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120847/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120710, 'Isoxsuprine', 'Triflupromazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120848/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120711, 'Isoxsuprine', 'Alimemazine', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, More', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120849/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120712, 'Isoxsuprine', 'Verteporfin', 'Moderate', 'Drugs that decrease clotting, vasoconstriction, or platelet aggregation may interfere with the therapeutic effect of verteporfin. These agents may antagonize the physiologic responses to local damage of neovascular endothelium induced by activated verteporfin, which include the release of procoagulant and vasoactive factors that result in vessel occlusion. However, the clinical significance is unknown.', NULL, 'If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy.', NULL, 'If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy. Otherwise, the potential for diminished efficacy of verteporfin should be considered.', 'Antagonism', 'Aflibercept, Bevacizumab', 'Pentoxifylline, Niacin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120850/', '[1] "Product Information. Visudyne (verteporfin)" Valeant Pharmaceuticals, Costa Mesa, CA.[2] "Product Information. Xatral (alfuzosin)." Sanofi-Synthelabo Canada Inc, Markham, ON.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120713, 'Isoxsuprine', 'Ziprasidone', 'Moderate', 'Phenothiazines and neuroleptic agents may potentiate the hypotensive effect of some medications secondary to their peripheral alpha-1 adrenergic blocking activity. Orthostatic hypotension and syncope associated with vasodilation may occur, particularly during initial dosing and/or parenteral administration of the phenothiazine or neuroleptic.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators.', NULL, 'Close clinical monitoring for development of hypotension is recommended if phenothiazines or neuroleptic agents are used in patients receiving antihypertensive medications or vasodilators. A lower starting dosage and slower titration of the phenothiazine or neuroleptic may be appropriate, especially in the elderly. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery.', 'Synergism', 'Droperidol, Pimozide, Pimavanserin', 'Pentoxifylline', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120851/', '[1] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[3] "Product Information. Clozaril (clozapine)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Risperdal (risperidone)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Abilify (aripiprazole)." Bristol-Myers Squibb, Princeton, NJ.[6] Markowitz JS, Wells BG, Carson WH "Interactions between antipsychotic and antihypertensive drugs." Ann Pharmacother 29 (1995): 603-9[7] Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30[8] "Product Information. Zyprexa (olanzapine)." Lilly, Eli and Company, Indianapolis, IN.[9] Fruncillo R, Gibbons W, Vlasses P, Ferguson R "Severe hypotension associated with concurrent clonidine and antipsychotic medication." Am J Psychiatry 142 (1985): 274[10] "Product Information. Geodon (ziprasidone)." Pfizer US Pharmaceuticals, New York, NY.[11] White WB "Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril." Arch Intern Med 146 (1986): 1833-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120714, 'Istradefylline', 'Amprenavir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120852/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120715, 'Istradefylline', 'Artesunate', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Mefloquine, Lumefantrine, Artemether, Pyrimethamine, Tafenoquine, Atovaquone, Hydroxychloroquine, Halofantrine, Quinine, Primaquine, Proguanil, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120853/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120716, 'Istradefylline', 'Berotralstat', 'Moderate', 'Coadministration with berotralstat may increase the plasma concentrations and effects of drugs that are substrates of CYP450 3A4 and/or 2D6. The mechanism is decreased clearance due to inhibition of CYP450 3A4 and 2D6 activity by berotralstat.', NULL, 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.', NULL, 'Caution is advised when berotralstat is coadministered with drugs that are substrates of CYP450 3A4 and/or 2D6, particularly those with a narrow therapeutic index including but not limited to thioridazine, pimozide, cyclosporine, and fentanyl.', 'Metabolism', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120854/', '[1] "Product Information. Orladeyo (berotralstat)." BioCryst Pharmaceuticals Inc, Durham, NC.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120717, 'Istradefylline', 'Boceprevir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120855/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120718, 'Istradefylline', 'Daunorubicin (liposomal)', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.', NULL, 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.', NULL, 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.', 'Absorption', 'Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin, Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120856/', '[1] "Product Information. Daunoxome (daunorubicin liposomal)." Nexstar Pharmaceuticals Inc, Boulder, CO.[2] "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.[3] "Multum Information Services, Inc. Expert Review Panel"[4] "Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120719, 'Istradefylline', 'Doxorubicin (liposomal)', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120857/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120720, 'Istradefylline', 'Enzalutamide', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended.', NULL, 'The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.', 'Metabolism', 'Darolutamide, Tamoxifen, Anastrozole, Letrozole, Toremifene, Fulvestrant, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120858/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[3] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120721, 'Istradefylline', 'Epirubicin', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120859/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120722, 'Istradefylline', 'Erlotinib', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120860/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120723, 'Istradefylline', 'Eslicarbazepine', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1. No data are available regarding the effects that other, less potent CYP450 3A4 inducers will have on the pharmacokinetics of istradefylline.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inducers.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inducers. Clinical monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy. Patients should be monitored for diminished therapeutic effects.', 'Metabolism', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120861/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.[3] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120724, 'Istradefylline', 'Etoposide', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Teniposide, Trabectedin, Cabazitaxel, Irinotecan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120862/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120725, 'Istradefylline', 'Etravirine', 'Moderate', 'Coadministration with etravirine may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by etravirine.', NULL, 'Caution is advised if etravirine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if etravirine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever etravirine is added to or withdrawn from therapy.', 'Metabolism', 'Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120863/', '[1] "Product Information. Intelence (etravirine)." Ortho Biotech Inc, Bridgewater, NJ.[2] "Product Information. Intelence (etravirine)." Ortho Biotech Inc, Bridgewater, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120726, 'Istradefylline', 'Everolimus', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the blood concentrations of everolimus following oral administration. Everolimus is a substrate of both the CYP450 3A4 isoenzyme and P-glycoprotein drug efflux transporter, thus their inhibition in the intestine can enhance the absorption of everolimus.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of everolimus therapy should be considered during coadministration with CYP450 3A4 and/or P-glycoprotein inhibitors, including adverse effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of everolimus therapy should be considered during coadministration with CYP450 3A4 and/or P-glycoprotein inhibitors, including adverse effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.', 'Absorption', 'Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120864/', '[1] "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.[2] "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.[4] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120727, 'Istradefylline', 'Fedratinib', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors. It is unknown if istradefylline will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120865/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120728, 'Istradefylline', 'Fexofenadine', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120866/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120729, 'Istradefylline', 'Fidaxomicin', 'Minor', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of fidaxomicin and its main metabolite, OP-1118, both of which are substrates of the intestinal efflux transporter. Theoretically, concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) due to P-gp inhibition.', NULL, '-', NULL, '-', 'Absorption', 'Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120867/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Dificid (fidaxomicin)." Optimer Pharmaceuticals, San Diego, CA.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Dificid (fidaxomicin)." Optimer Pharmaceuticals, San Diego, CA.[7] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120730, 'Istradefylline', 'Fluconazole', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors. It is unknown if istradefylline will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Tinidazole, Tetracycline, Cefepime, Norfloxacin, Metronidazole, Cefuroxime, Secnidazole, Cefixime, Azithromycin, Amikacin, Levofloxacin, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120868/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120731, 'Istradefylline', 'Fluvoxamine', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors. It is unknown if istradefylline will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120869/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120732, 'Istradefylline', 'Fosamprenavir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120870/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120733, 'Istradefylline', 'Fosaprepitant', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors. It is unknown if istradefylline will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120871/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120734, 'Istradefylline', 'Fosphenytoin', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended.', NULL, 'The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.', 'Metabolism', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120872/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[3] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120735, 'Istradefylline', 'Gilteritinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of gilteritinib, which is a substrate of both the isoenzyme and the efflux transporter.', NULL, 'Caution is advised when gilteritinib is used with CYP450 3A4 and/or P-gp inhibitors.', NULL, 'Caution is advised when gilteritinib is used with CYP450 3A4 and/or P-gp inhibitors. Patients should be monitored for adverse effects such as QT interval prolongation, pancreatitis, liver transaminase and bilirubin elevations, edema, infections and stomatitis, and the gilteritinib dosage adjusted as necessary in accordance with the product labeling.', 'Metabolism', 'Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120873/', '[1] "Product Information. Xospata (gilteritinib)." Astellas Pharma US, Inc, Deerfield, IL.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Xospata (gilteritinib)." Astellas Pharma US, Inc, Deerfield, IL.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120736, 'Istradefylline', 'Idarubicin', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.', NULL, 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.', NULL, 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.', 'Absorption', 'Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120874/', '[1] "Product Information. Daunoxome (daunorubicin liposomal)." Nexstar Pharmaceuticals Inc, Boulder, CO.[2] "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.[3] "Multum Information Services, Inc. Expert Review Panel"[4] "Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120737, 'Istradefylline', 'Idelalisib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120875/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120738, 'Istradefylline', 'Imatinib', 'Moderate', 'Coadministration with imatinib may increase the plasma concentrations of drugs that are substrates of CYP450 2C9, 2D6 and/or 3A4. The mechanism is decreased clearance due to inhibition of these isoenzymes by imatinib.', NULL, 'Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when imatinib is used concomitantly with drugs that undergo metabolism by CYP450 2C9, 2D6 and/or 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever imatinib is added to or withdrawn from therapy.', 'Metabolism', 'Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120876/', '[1] "Product Information. Gleevec (imatinib mesylate)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Gleevec (imatinib mesylate)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120739, 'Istradefylline', 'Indacaterol', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter.', NULL, '-', NULL, '-', 'Metabolism', 'Formoterol, Cromoglicic acid, Ipratropium, Isoprenaline, Tiotropium, Beclomethasone dipropionate, Terbutaline, Budesonide, Glycopyrronium, Aclidinium, Mometasone, More', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120877/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120740, 'Istradefylline', 'Indinavir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120878/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120741, 'Istradefylline', 'Itraconazole', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120879/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120742, 'Istradefylline', 'Ketoconazole', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Tamsulosin, Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Metronidazole, Simeprevir, Rosuvastatin, Sulfadiazine, Lactic acid, Methazolamide, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120880/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120743, 'Istradefylline', 'Lanreotide', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors. It is unknown if istradefylline will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Norethisterone, Nafarelin, Elagolix, Cetrorelix, Estradiol, Ganirelix, Gonadorelin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120881/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120744, 'Istradefylline', 'Lapatinib', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120882/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120745, 'Istradefylline', 'Larotrectinib', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120883/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120746, 'Istradefylline', 'Lefamulin', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 and/or P-gp may increase the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'Caution is advised when lefamulin is used with CYP450 3A4 and/or P-gp inhibitors.', NULL, 'Caution is advised when lefamulin is used with CYP450 3A4 and/or P-gp inhibitors. Patients should be monitored for increased adverse effects and seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Metabolism', 'Tinidazole, Linezolid, Bacitracin, Oritavancin, Polymyxin B, Daptomycin, Vancomycin, Metronidazole, Telavancin, Methenamine, Spectinomycin, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120884/', '[1] "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.[2] "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.[3] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.[4] "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120747, 'Istradefylline', 'Lemborexant', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120885/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120748, 'Istradefylline', 'Letermovir', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors. It is unknown if istradefylline will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120886/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120749, 'Istradefylline', 'Lonafarnib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120887/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120750, 'Istradefylline', 'Lorlatinib', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1. No data are available regarding the effects that other, less potent CYP450 3A4 inducers will have on the pharmacokinetics of istradefylline.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inducers.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inducers. Clinical monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy. Patients should be monitored for diminished therapeutic effects.', 'Metabolism', 'Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120888/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.[3] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120751, 'Istradefylline', 'Lusutrombopag', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Eltrombopag, Romiplostim, Fostamatinib, Avatrombopag, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120889/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120752, 'Istradefylline', 'Maraviroc', 'Moderate', 'Coadministration with inhibitors of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may increase the plasma concentrations of maraviroc, which is a substrate of both.', NULL, 'Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein.', NULL, 'Caution is advised when maraviroc is used with inhibitors of CYP450 3A4 and/or P-glycoprotein. Dosage adjustment for maraviroc may be necessary if an interaction is suspected.', 'Metabolism', 'Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120890/', '[1] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120753, 'Istradefylline', 'Miconazole', 'Moderate', 'Coadministration with miconazole may increase the plasma concentrations of drugs that are substrates of CYP450 3A4. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by miconazole, which is thought to be a relatively potent inhibitor of the isoenzyme. Although systemic absorption following mucous membrane exposure is limited, the potential for interaction with drugs metabolized by CYP450 3A4 cannot be ruled out.', NULL, 'Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if miconazole must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever miconazole is added to or withdrawn from therapy.', 'Metabolism', 'Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Caspofungin, Micafungin, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120891/', '[1] "Product Information. ORAVIG (miconazole)." Strativa Pharmaceuticals, a Division of Par Pharmaceuticals, Inc., Woodcliff Lake, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120754, 'Istradefylline', 'Mitotane', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended.', NULL, 'The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.', 'Metabolism', 'Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120892/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[3] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120755, 'Istradefylline', 'Mitoxantrone', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of mitoxantrone, which is a substrate of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor.', NULL, 'Caution is advised if mitoxantrone is prescribed in combination with a P-gp inhibitor.', NULL, 'Caution is advised if mitoxantrone is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.', 'Others', 'Valrubicin, Plicamycin, Ixabepilone, Bleomycin, Mitomycin, Dactinomycin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120893/', '[1] "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.[2] "Multum Information Services, Inc. Expert Review Panel"[3] "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.[4] "Multum Information Services, Inc. Expert Review Panel"[5] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120756, 'Istradefylline', 'Modafinil', 'Minor', 'Coadministration with modafinil (the racemate) or armodafinil (the R-enantiomer) may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. Modafinil and armodafinil are modest inducers of CYP450 3A4, and pharmacokinetic studies suggest that their effects may be primarily intestinal rather than hepatic. Thus, clinically significant interactions would most likely be expected with drugs that have low oral bioavailability due to significant intestinal CYP450 3A4-mediated first-pass metabolism (e.g., buspirone, cyclosporine, lovastatin, midazolam, saquinavir, simvastatin, sirolimus, tacrolimus, triazolam, calcium channel blockers). However, the potential for interaction should be considered with any drug metabolized by CYP450 3A4, especially given the high degree of interpatient variability with respect to CYP450-mediated metabolism. Pharmacologic response to these drugs may be altered and should be monitored more closely whenever modafinil or armodafinil is added to or withdrawn from therapy. Dosage adjustments may be required if an interaction is suspected.', NULL, '-', NULL, '-', 'Metabolism', 'Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120894/', '[1] Robertson P Jr, Hellriegel ET, Arora S, Nelson M "Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers." Clin Pharmacol Ther 71 (2002): 46-56[2] Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53[3] "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.[4] Robertson P, Decory HH, Madan A, Parkinson A "In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil." Drug Metab Dispos 28 (2000): 664-71[5] "Product Information. Nuvigil (armodafinil)." Cephalon Inc, West Chester, PA.[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[10] "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.[11] "Product Information. Nuvigil (armodafinil)." Cephalon Inc, West Chester, PA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120757, 'Istradefylline', 'Nafcillin', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1. No data are available regarding the effects that other, less potent CYP450 3A4 inducers will have on the pharmacokinetics of istradefylline.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inducers.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inducers. Clinical monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy. Patients should be monitored for diminished therapeutic effects.', 'Metabolism', 'Sulbactam, Oxacillin, Dicloxacillin, Piperacillin, Meticillin, Carbenicillin, Bacampicillin, Ticarcillin, Mezlocillin, Tazobactam, Cloxacillin, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120895/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.[3] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120758, 'Istradefylline', 'Naldemedine', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120896/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120759, 'Istradefylline', 'Naloxegol', 'Minor', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or weak inhibitors of CYP450 3A4 may increase the plasma concentrations of naloxegol, which is a substrate of both the efflux transporter and the isoenzyme.', NULL, '-', NULL, '-', 'Metabolism, Absorption', 'Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, More', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120897/', '[1] "Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] "Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] "Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[4] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120760, 'Istradefylline', 'Nefazodone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120898/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120761, 'Istradefylline', 'Nelfinavir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120899/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120762, 'Istradefylline', 'Nevirapine', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1. No data are available regarding the effects that other, less potent CYP450 3A4 inducers will have on the pharmacokinetics of istradefylline.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inducers.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inducers. Clinical monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy. Patients should be monitored for diminished therapeutic effects.', 'Metabolism', 'Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120900/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.[3] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120763, 'Istradefylline', 'Nilotinib', 'Moderate', 'Based on in vitro inhibition data, coadministration with nilotinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter and/or CYP450 2D6, CYP450 3A4, or UGT1A1 isoenzymes. The mechanism is decreased clearance via these routes due to inhibition by nilotinib.', NULL, 'Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when nilotinib is used concurrently with drugs that are known P-gp and/or CYP450 2D6, CYP450 3A4 or UGT1A1 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever nilotinib is added to or withdrawn from therapy.', 'Metabolism', 'Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120901/', '[1] "Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals, East Hanover, NJ.[2] "Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals, East Hanover, NJ.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120764, 'Istradefylline', 'Octreotide', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors. It is unknown if istradefylline will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Norethisterone, Nafarelin, Elagolix, Cetrorelix, Estradiol, Ganirelix, Gonadorelin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120902/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120765, 'Istradefylline', 'Paclitaxel (protein-bound)', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120903/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120766, 'Istradefylline', 'Pasireotide', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors. It is unknown if istradefylline will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Norethisterone, Nafarelin, Elagolix, Cetrorelix, Estradiol, Ganirelix, Gonadorelin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120904/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120767, 'Istradefylline', 'Pexidartinib', 'Moderate', 'Coadministration with moderate inducers of CYP450 3A4 may decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1. No data are available regarding the effects that other, less potent CYP450 3A4 inducers will have on the pharmacokinetics of istradefylline.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inducers.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inducers. Clinical monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inducer is added to or withdrawn from therapy. Patients should be monitored for diminished therapeutic effects.', 'Metabolism', 'Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120905/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.[3] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120768, 'Istradefylline', 'Phenytoin', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended.', NULL, 'The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.', 'Metabolism', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120906/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[3] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120769, 'Istradefylline', 'Pitolisant', 'Moderate', 'Coadministration with pitolisant may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Pitolisant is a borderline/weak inducer of CYP450 3A4.', NULL, 'Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.', NULL, 'Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates. Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary. It may be advisable to avoid concomitant use of pitolisant and CYP450 3A4 substrates with a narrow therapeutic index, if possible.', 'Metabolism', 'Dextromethorphan, Valbenazine, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Amifampridine, Deutetrabenazine, Tafamidis', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120907/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Wakix (pitolisant)." Harmony Biosciences, LLC, Plymouth Meeting, PA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120770, 'Istradefylline', 'Posaconazole', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120908/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120771, 'Istradefylline', 'Primidone', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended.', NULL, 'The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.', 'Metabolism', 'Suvorexant, Triazolam, Flurazepam, Methohexital, Methylphenobarbital, Zolpidem, Pentobarbital, Zaleplon, Dichloralphenazone, Valerian, Temazepam, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120909/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[3] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120772, 'Istradefylline', 'Prucalopride', 'Minor', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.', NULL, '-', NULL, '-', 'Others', 'Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Lactulose, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Magnesium oxide, Sodium sulfate, Linaclotide, More', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120910/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[3] "Product Information. Resotran (prucalopride)." Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[6] "Product Information. Resotran (prucalopride)." Janssen Pharmaceuticals, Titusville, NJ.[7] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120773, 'Istradefylline', 'Quinidine', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Amiodarone, Lidocaine, Tocainide, Propafenone, Procainamide, Flecainide, Disopyramide, Mexiletine, Dofetilide, Bretylium, Moricizine, Ibutilide', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120911/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120774, 'Istradefylline', 'Ranolazine', 'Moderate', 'Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the oral bioavailability of ranolazine, which has been shown in vitro to be a substrate of P-gp. Ranolazine can prolong the QT interval in a dose-dependent manner, thus increased plasma levels may potentiate the risk of ventricular arrhythmias including ventricular fibrillation and torsade de pointes.', NULL, 'Caution is advised if ranolazine is prescribed in combination with P-gp inhibitors.', NULL, 'Caution is advised if ranolazine is prescribed in combination with P-gp inhibitors. Pharmacologic response to ranolazine should be monitored more closely whenever a P-gp inhibitor is added to or withdrawn from therapy, and the ranolazine dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope.', 'Absorption', 'Alprostadil, Indomethacin, Ibuprofen, Ubidecarenone, Ivabradine, Adenosine, Regadenoson', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120912/', '[1] "Product Information. Ranexa (ranolazine)." Calmoseptine Inc, Huntington Beach, CA.[2] "Product Information. Ranexa (ranolazine)." Calmoseptine Inc, Huntington Beach, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120775, 'Istradefylline', 'Relugolix', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Norethisterone, Nafarelin, Elagolix, Cetrorelix, Estradiol, Ganirelix, Gonadorelin, Darolutamide, Tamoxifen, Anastrozole, Letrozole, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120913/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120776, 'Istradefylline', 'Ribociclib', 'Moderate', 'Coadministration with ribociclib may increase the plasma concentrations and pharmacologic effects of drugs that are substrates of CYP450 3A4. The proposed mechanism is decreased clearance due to ribociclib-mediated inhibition of CYP450 3A4 metabolism.', NULL, 'Caution is advised when ribociclib is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when ribociclib is used concomitantly with drugs that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever ribociclib is added to or withdrawn from therapy.', 'Metabolism', 'Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120914/', '[1] Rawden HC, Kokwaro GO, Ward SA, Edwards G "Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes." Br J Clin Pharmacol 49 (2000): 313-22[2] Trivier JM, Libersa C, Belloc C, Lhermitte M "Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P450 3A enzymes (first report)." Life Sci 52 (1993): pl91-6[3] Kane GC, Lipsky JJ "Drug-grapefruit juice interactions." Mayo Clin Proc 75 (2000): 933-42[4] Katoh M, Nakajima M, Yamazaki H, Yokoi T "Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport." Eur J Pharm Sci 12 (2001): 505-13[5] DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4[6] "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.[7] Yu DK "The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions." J Clin Pharmacol 39 (1999): 1203-11[8] Zhou XJ, Zhou-Pan XR, Gauthier T, Placidi M, Maurel P, Rahmani R "Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions." Biochem Pharmacol 45 (1993): 853-61[9] Nagy J, Schipper HG, Koopmans RP, Butter JJ, van Boxtel CJ, Kager PA "Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability." Am J Trop Med Hyg 66 (2002): 260-3[10] "Product Information. Kisqali (ribociclib)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120777, 'Istradefylline', 'Rifampicin', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended.', NULL, 'The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.', 'Metabolism', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120915/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[3] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120778, 'Istradefylline', 'Rifapentine', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended.', NULL, 'The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.', 'Metabolism', 'Capreomycin, Pyrazinamide, Rifamycin, Bedaquiline, Sulfamethoxazole, Streptomycin, Trimethoprim, Cycloserine, Isoniazid, Ethambutol, Pyridoxine, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120916/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[3] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120779, 'Istradefylline', 'Rifaximin', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Rifamycin, Kanamycin, Amphotericin B, Polymyxin B, Nystatin, Vancomycin, Streptomycin, Paromomycin, Neomycin, Tetracycline, Mupirocin, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120917/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120780, 'Istradefylline', 'Rimegepant', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of rimegepant. The proposed mechanism is decreased clearance due to inhibition of P-gp- and/or BCRP-mediated metabolism of rimegepant.', NULL, 'Coadministration of rimegepant with P-gp and/or BCRP inhibitors should be avoided.', NULL, 'Coadministration of rimegepant with P-gp and/or BCRP inhibitors should be avoided.', 'Metabolism', 'Frovatriptan, Dihydroergotamine, Eptinezumab, Lasmiditan, Atogepant, Eletriptan, Rizatriptan, Ubrogepant, Ergotamine, Clonidine, Naratriptan, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120918/', '[1] "Product Information. Nurtec ODT (rimegepant)." Biohaven Pharmaceuticals, New Haven, CT.[2] "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.[3] "Product Information. Nurtec ODT (rimegepant)." Biohaven Pharmaceuticals, New Haven, CT.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120781, 'Istradefylline', 'Ripretinib', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of ripretinib and its active metabolite, DP-5439. In vitro studies indicate that ripretinib and DP-5439 are substrates of the P-gp efflux transporter.', NULL, 'Until more information is available, caution is recommended when ripretinib is used concomitantly with drugs that are inhibitors of P-gp.', NULL, 'Until more information is available, caution is recommended when ripretinib is used concomitantly with drugs that are inhibitors of P-gp. Clinical and laboratory monitoring should be considered whenever a P-gp inhibitor is added to or withdrawn from therapy with ripretinib, and the dosage adjusted as necessary. Patients should be monitored for development of adverse effects such as nausea, vomiting, constipation, diarrhea, alopecia, arthralgia, myalgia, hypertension, cardiac dysfunction, and palmar-plantar erythrodysesthesia.', 'Absorption', 'Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120919/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Qinlock (ripretinib)." Deciphera Pharmaceuticals, Waltham, MA.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Qinlock (ripretinib)." Deciphera Pharmaceuticals, Waltham, MA.[5] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.[6] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[7] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[8] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[11] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[12] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[13] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[14] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[15] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[16] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[17] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[18] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[19] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[20] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[21] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[22] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[23] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[24] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[25] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[26] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[27] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[28] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[29] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[30] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[31] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[32] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[33] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[34] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[35] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[36] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[37] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120782, 'Istradefylline', 'Romidepsin', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of romidepsin, which is a substrate of the efflux transporter. Although there are no formal drug interaction studies, the interaction may increase the risk of hematologic toxicities such as anemia, leukopenia, and thrombocytopenia as well as electrocardiographic changes such as QT interval prolongation and T-wave and ST-segment changes.', NULL, 'Caution is advised if romidepsin is prescribed in combination with P-gp inhibitors.', NULL, 'Caution is advised if romidepsin is prescribed in combination with P-gp inhibitors. Pharmacologic response to romidepsin should be monitored more closely whenever a P-gp inhibitor is added to or withdrawn from therapy, and the romidepsin dosage adjusted as necessary. Patients should have complete blood cell counts, electrocardiograms, and serum electrolyte levels performed at baseline and regular intervals as recommended in the product labeling. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Absorption', 'Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120920/', '[1] "Product Information. Istodax (romidepsin)." Gloucester Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120783, 'Istradefylline', 'Selpercatinib', 'Moderate', 'Coadministration with selpercatinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by selpercatinib. The interaction may be particularly important for sensitive substrates or those that demonstrate a narrow therapeutic index.', NULL, 'Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when selpercatinib is used concomitantly with drugs that are substrates of CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever selpercatinib is added to or withdrawn from therapy. Patients should be monitored for the development of adverse effects.', 'Metabolism', 'Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120921/', '[1] "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company, Indianapolis, IN.[2] "Product Information. Retevmo (selpercatinib)." Lilly, Eli and Company, Indianapolis, IN.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120784, 'Istradefylline', 'Silodosin', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Tamsulosin, Terazosin, Alfuzosin, Tadalafil, Finasteride, Dutasteride, Solifenacin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120922/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120785, 'Istradefylline', 'Sirolimus', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Alteplase, Ascorbic acid, Vitamin A, Potassium Iodide, Acetylcysteine, Nandrolone, Heparin, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120923/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120786, 'Istradefylline', 'Somapacitan', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120924/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company, Indianapolis, IN.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120787, 'Istradefylline', 'Somatrem', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120925/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company, Indianapolis, IN.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120788, 'Istradefylline', 'Somatotropin', 'Moderate', 'Coadministration with human growth hormone may decrease the plasma concentrations of drugs that are metabolized by CYP450 3A4.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when human growth hormone is used concurrently with drugs that are known CYP450 3A4 substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever human growth hormone is added to or withdrawn from therapy.', 'Metabolism', 'Corticotropin, Mecasermin, Sermorelin, Tesamorelin, Thyrotropin alfa, Tetracosactide, Mecasermin rinfabate, Pegvisomant', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120926/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Zorbtive (somatropin)." Serono Laboratories Inc, Rockland, MA.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Humatrope (somatropin)." Lilly, Eli and Company, Indianapolis, IN.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120789, 'Istradefylline', 'St. John''s Wort', 'Major', 'Coadministration with potent inducers of CYP450 3A4 may significantly decrease the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended.', NULL, 'The use of istradefylline in combination with potent CYP450 3A4 inducers is not recommended. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible.', 'Metabolism', 'Citalopram, Sertraline, Maprotiline, Fluoxetine, Milnacipran, Vortioxetine, Levomilnacipran, Doxepin, Duloxetine, Isocarboxazid, Viloxazine, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120927/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John''s Wort." Am J Med 112 (2002): 507-8[3] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120790, 'Istradefylline', 'Stiripentol', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors. It is unknown if istradefylline will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Brivaracetam, Topiramate, Ezogabine, Lamotrigine, Methylphenobarbital, Ethosuximide, Lacosamide, Levetiracetam, Tiagabine, Oxcarbazepine, Ethotoin, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120928/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120791, 'Istradefylline', 'Telaprevir', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120929/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120792, 'Istradefylline', 'Telithromycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Dirithromycin, Lincomycin, Azithromycin, Clindamycin', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120930/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120793, 'Istradefylline', 'Telotristat ethyl', 'Moderate', 'Coadministration with telotristat ethyl may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4 and/or 2B6 isoenzymes. The proposed mechanism is accelerated clearance due to induction of CYP450 3A4 and/or 2B6 (in vitro) isoenzymes by telotristat ethyl.', NULL, 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered.', NULL, 'When drugs that are known substrates of CYP450 3A4 and/or 2B6 are coadministered with telotristat ethyl, the possibility of a diminished therapeutic response to those drugs should be considered. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs, particularly those with a narrow therapeutic range, whenever telotristat ethyl is added to or withdrawn from therapy.', 'Metabolism', NULL, NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120931/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.[3] "Product Information. Xermelo (telotristat ethyl)." Lexicon Pharmaceuticals, Inc., The Woodlands, TX.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120794, 'Istradefylline', 'Terfenadine', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Ketotifen, Mepyramine, Levocetirizine, Chlorcyclizine, Cetirizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Promethazine, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120932/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120795, 'Istradefylline', 'Ticagrelor', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Clopidogrel, Cilostazol, Iloprost, Rivaroxaban, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Warfarin, Caplacizumab, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120933/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120796, 'Istradefylline', 'Tipranavir', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Lamivudine, Glecaprevir, Simeprevir, Cabotegravir, Zanamivir, Valaciclovir, Velpatasvir, Rilpivirine, Dolutegravir, Oseltamivir, Acyclovir, More', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120934/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120797, 'Istradefylline', 'Topotecan', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Teniposide, Trabectedin, Cabazitaxel, Irinotecan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120935/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120798, 'Istradefylline', 'Troleandomycin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Dirithromycin, Lincomycin, Azithromycin, Clindamycin', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120936/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120799, 'Istradefylline', 'Tucatinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Entrectinib, Acalabrutinib, Dacomitinib, Avapritinib, Vemurafenib, Selumetinib, Vandetanib, Capmatinib, Ibrutinib, Tivozanib, Zanubrutinib, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120937/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120800, 'Istradefylline', 'Venetoclax', 'Major', 'Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter.', NULL, 'Concomitant use of venetoclax with P-gp inhibitors should generally be avoided.', NULL, 'Concomitant use of venetoclax with P-gp inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends that venetoclax dosage be reduced by at least 50%. The dosage used prior to initiating the P-gp inhibitor may be resumed 2 to 3 days after discontinuation of the inhibitor.', 'Absorption', 'Pertuzumab, Olaparib, Oxaliplatin, Rucaparib, Bortezomib, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Tazemetostat, Altretamine, Tagraxofusp, More', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120938/', '[1] "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Venclexta (venetoclax)." AbbVie US LLC, North Chicago, IL.[5] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120801, 'Istradefylline', 'Vinblastine', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Teniposide, Trabectedin, Cabazitaxel, Irinotecan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120939/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120802, 'Istradefylline', 'Vincristine', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Teniposide, Trabectedin, Cabazitaxel, Irinotecan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120940/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120803, 'Istradefylline', 'Vincristine (liposome)', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Teniposide, Trabectedin, Cabazitaxel, Irinotecan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120941/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120804, 'Istradefylline', 'Vinorelbine', 'Moderate', 'Coadministration with istradefylline may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein (P-gp) transporter. The proposed mechanism is inhibition of P-glycoprotein-mediated drug efflux by istradefylline.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when istradefylline is used concurrently with drugs that are known P-gp substrates, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever istradefylline is added to or withdrawn from therapy.', 'Others', 'Teniposide, Trabectedin, Cabazitaxel, Irinotecan', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120942/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120805, 'Istradefylline', 'Voriconazole', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse effects of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily.', NULL, 'The manufacturer suggests that the maximum dose of istradefylline when coadministered with potent CYP450 3A4 inhibitors be reduced to 20 mg once daily. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120943/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120806, 'Istradefylline', 'Voxelotor', 'Moderate', 'Coadministration with moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of istradefylline, which is primarily metabolized by CYP450 3A4 and 1A1.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if istradefylline is used with moderate CYP450 3A4 inhibitors. It is unknown if istradefylline will require a dosage adjustment if coadministered with a moderate CYP450 3A4 inhibitor. Clinical and laboratory monitoring of istradefylline should be considered whenever a moderate CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be monitored for adverse effects including dyskinesia, impulse control issues, dizziness, constipation, nausea, hallucinations, and insomnia.', 'Metabolism', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120944/', '[1] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[2] "Product Information. Nourianz (istradefylline)." Kyowa Kirin, Inc, Bedminster, NJ.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[15] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[21] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[27] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[28] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[29] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[30] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[31] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[32] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120807, 'Itraconazole', 'Acetohexamide', 'Minor', 'Itraconazole, a potent inhibitor of CYP450 3A4, does not appear to significantly affect the pharmacokinetics of available oral hypoglycemic agents, most of which are primarily metabolized by CYP450 2C8 (pioglitazone, rosiglitazone, repaglinide) or 2C9 (nateglinide, sulfonylureas). In most patients, no change in antidiabetic effect was reported. No specific precautions should be necessary during coadministration of most oral hypoglycemic agents with itraconazole. However, dosage adjustments may be necessary if an interaction is suspected.', NULL, '-', NULL, '-', 'Metabolism', 'Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Sitagliptin, Canagliflozin, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, More', 'Caspofungin, Micafungin, Amphotericin B, Posaconazole, Oteseconazole, Ketoconazole, Flucytosine, Anidulafungin', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120945/', '[1] Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ "Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone." Clin Pharmacol Ther 77 (2005): 404-14[2] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[3] Niemi M, Backman JT, Neuvonen M, Neuvonen PJ "Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide." Diabetologia 46 (2003): 347-51[4] Verspeelt J, Marynissen G, Gupta AK, De Doncker P "Safety of itraconazole in diabetic patients." Dermatology 198 (1999): 382-4[5] Miners JO, Birkett DJ "Cytochrome P4502C9: an enzyme of major importance in human drug metabolism." Br J Clin Pharmacol 45 (1998): 525-38[6] Niemi M, Backman JT, Juntti-Patinen L, Neuvonen M, Neuvonen PJ "Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide." Br J Clin Pharmacol 60 (2005): 208-17[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14[9] Komatsu K, Ito K, Nakajima Y, Kanamitsu S, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N, Sugiyama Y "Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments." Drug Metab Disposition 28 (2000): 475-81[10] Hatorp V, Hansen KT, Thomsen MS "Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide." J Clin Pharmacol 43 (2003): 649-60[11] Shon JH, Yoon YR, Kim MJ, et al. "Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism." Br J Clin Pharmacol 59 (2005): 552-63[12] Venkatakrishnan K, von Moltke LL, Greenblatt DJ "Effects of the antifungal agents on oxidative drug metabolism: clinical relevance." Clin Pharmacokinet 38 (2000): 111-80[13] Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT "Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes." Clin Pharmacol Ther 72 (2002): 326-32[14] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[15] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[16] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[17] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[18] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[20] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[23] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[24] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[25] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[26] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[27] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[28] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[29] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[30] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[31] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[32] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[33] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120808, 'Itraconazole', 'Aluminum hydroxide', 'Moderate', 'INTERVAL: The dissolution of itraconazole requires an acidic environment. Antacids and some aluminum, calcium, or magnesium containing salts decrease the acidity of the stomach and can reduce the bioavailability and subsequent therapeutic effect of itraconazole.', NULL, 'Separation of doses by two or more hours is recommended.', NULL, 'Separation of doses by two or more hours is recommended.', 'Absorption', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120946/', '[1] Carlson JA, Mann HJ, Canafax DM "Effect of pH on disintegration and dissolution of ketoconazole tablets." Am J Hosp Pharm 40 (1983): 1334-6[2] Brass C, Galgiani JN, Blaschke TF, et al "Disposition of ketoconazole, an oral antifungal, in humans." Antimicrob Agents Chemother 21 (1982): 151-8[3] Van der Meer JW, Keuning JJ "The influence of gastric acidity on the bio-availability of ketoconazole." J Antimicrob Chemother 6 (1980): 552-4[4] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[5] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[7] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[8] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[9] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[10] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[11] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[12] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[13] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[14] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[15] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120809, 'Itraconazole', 'Amphotericin B (cholesteryl sulfate)', 'Minor', 'Imidazole and triazole antifungal agents may antagonize the effects of amphotericin. The clinical significance is unknown. Caution is urged if combination therapy is necessary.', NULL, '-', NULL, '-', 'Antagonism', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Lactic acid, Methazolamide, Trichlormethiazide, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, More', 'Caspofungin, Anidulafungin, Amphotericin B, Oteseconazole', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120947/', '[1] "Product Information. Fungizone (amphotericin B)." Apothecon Inc, Plainsboro, NJ.[2] Saag MS, Powderly WG, Cloud GA, et al "Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis." N Engl J Med 326 (1992): 83-9[3] "Product Information. Ambisome (amphotericin B liposomal)" Nexstar Pharmaceuticals, San Dimas, CA.[4] "Product Information. Abelcet (amphotericin B)." Liposome Company Inc, The, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120810, 'Itraconazole', 'Amphotericin B (liposomal)', 'Minor', 'Imidazole and triazole antifungal agents may antagonize the effects of amphotericin. The clinical significance is unknown. Caution is urged if combination therapy is necessary.', NULL, '-', NULL, '-', 'Antagonism', 'Tinidazole, Ascorbic acid, Hydroflumethiazide, Chlorothiazide, Lactic acid, Methazolamide, Trichlormethiazide, Ciclopirox, Probenecid, Tioconazole, Brinzolamide, More', 'Caspofungin, Anidulafungin, Amphotericin B, Oteseconazole', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120948/', '[1] "Product Information. Fungizone (amphotericin B)." Apothecon Inc, Plainsboro, NJ.[2] Saag MS, Powderly WG, Cloud GA, et al "Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis." N Engl J Med 326 (1992): 83-9[3] "Product Information. Ambisome (amphotericin B liposomal)" Nexstar Pharmaceuticals, San Dimas, CA.[4] "Product Information. Abelcet (amphotericin B)." Liposome Company Inc, The, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120811, 'Itraconazole', 'Amprenavir', 'Moderate', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of itraconazole and ketoconazole, and vice versa. The mechanism is competitive inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of these agents.', NULL, 'Patients receiving amprenavir or fosamprenavir in combination with itraconazole or ketoconazole should be monitored for altered efficacy and safety of the drugs.', NULL, 'Patients receiving amprenavir or fosamprenavir in combination with itraconazole or ketoconazole should be monitored for altered efficacy and safety of the drugs. Amprenavir and fosamprenavir labeling states that dosage reduction of itraconazole and ketoconazole may be required in patients receiving more than 400 mg/day of either antifungal agent. High dosages of itraconazole or ketoconazole (greater than 200 mg/day) are not recommended during treatment with the fosamprenavir-ritonavir combination regimen.', 'Metabolism', 'Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Maribavir, More', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120949/', '[1] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[2] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[3] Polk RE, Crouch MA, Israel DS, et al. "Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men." Pharmacotherapy 19 (1999): 1378-84[4] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120812, 'Itraconazole', 'Anisindione', 'Moderate', 'Azole antifungal agents that are potent inhibitors of CYP450 3A4 such as itraconazole, ketoconazole, and posaconazole may increase the plasma concentrations and hypoprothrombinemic effect of warfarin. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of R(+) warfarin, the less biologically active of the two enantiomers of warfarin.', NULL, 'Patients receiving warfarin should be closely monitored during concomitant therapy with azole antifungal agents that are potent inhibitors of CYP450 3A4.', NULL, 'Patients receiving warfarin should be closely monitored during concomitant therapy with azole antifungal agents that are potent inhibitors of CYP450 3A4. The INR should be checked frequently and warfarin dosage adjusted accordingly, particularly following initiation, change of dosage, or discontinuation of azole antifungal therapy. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120950/', '[1] Brass C, Galgiani JN, Blaschke TF, et al "Disposition of ketoconazole, an oral antifungal, in humans." Antimicrob Agents Chemother 21 (1982): 151-8[2] Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83[3] Smith AG "Potentiation of oral anticoagulants by ketoconazole." Br Med J 288 (1984): 188-9[4] Yeh J, Soo S, Summerton C, Richardson C "Potentiation of action of warfarin by itraconazole." Br Med J 301 (1990): 669[5] Daneshmend TK, Warnock DW "Clinical pharmacokinetics of ketoconazole." Clin Pharmacokinet 14 (1988): 13-34[6] Visser LE, Penning-Van Beest FJ, Kasbergen AA, et al. "Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants." Clin Pharmacol Ther 71 (2002): 496-502[7] "Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals, Wilmington, DE.[8] Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36[9] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3[10] Suvarna R, Pirmohamed M, Henderson L "Possible interaction between warfarin and cranberry juice." BMJ 327 (2003): 1454[11] Sullivan DM, Ford MA, Boyden TW "Grapefruit juice and the response to warfarin." Am J Health Syst Pharm 55 (1998): 1581-3[12] Kempin SJ "Warfarin resistance caused by broccoli." N Engl J Med 308 (1983): 1229-30[13] Harrell CC, Kline SS "Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin." Jama J Am Med Assn 282 (1999): 1133-4[14] Beckey NP, Korman LB, Parra D "Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy." Pharmacotherapy 19 (1999): 1075-9[15] Grant P "Warfarin and cranberry juice: an interaction?" J Heart Valve Dis 13 (2004): 25-6[16] Ge B, Zhang Z, Zuo Z "Updates on the clinical evidenced herb-warfarin interactions." Evid Based Complement Alternat Med 2014 (2014): 957362[17] Westfall LK "An unrecognized cause of warfarin resistance." Drug Intell Clin Pharm 15 (1981): 131[18] Walker FB "Myocardial infarction after diet-induced warfarin resistance." Arch Intern Med 144 (1984): 2089-90[19] Kazmier FJ, Spittell JA Jr "Coumarin drug interactions." Mayo Clin Proc 45 (1970): 249-55[20] Pedersen FM, Hamberg O, Hess K, Ovesen L "The effect of dietary vitamin K on warfarin-induced anticoagulation." J Intern Med 229 (1991): 517-20[21] Zallman JA, Lee DP, Jeffrey PL "Liquid nutrition as a cause of warfarin resistance." Am J Hosp Pharm 38 (1981): 1174[22] Griffith LD, Olvey SE, Triplett WC "Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus." Crit Care Med 10 (1982): 799-800[23] Watson AJ, Pegg M, Green JR "Enteral feeds may antagonise warfarin." Br Med J 288 (1984): 557[24] Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83[25] Monterrey-Rodriguez J "Interaction between warfarin and mango fruit." Ann Pharmacother 36 (2002): 940-1[26] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[27] Griffiths AP, Beddall A, Pegler S "Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin." J R Soc Health 128 (2008): 324-6[28] Roberts D, Flanagan P "Case report: Cranberry juice and warfarin." Home Healthc Nurse 29 (2011): 92-7[29] Parr MD, Record KE, Griffith GL, et al "Effect of enteral nutrition on warfarin therapy." Clin Pharm 1 (1982): 274-6[30] Andersen P, Godal HC "Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K." Acta Med Scand 198 (1975): 269-70[31] Howard PA, Hannaman KN "Warfarin resistance linked to enteral nutrition products." J Am Diet Assoc 85 (1985): 713-5[32] Rindone JP, Murphy TW "Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding." Am J Ther 13 (2006): 283-4[33] Hamann GL, Campbell JD, George CM "Warfarin-cranberry juice interaction." Ann Pharmacother 45 (2011): e17[34] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT "Anticoagulation instability with life-threatening complication after dietary modification." Postgrad Med J 66 (1990): 855-7[35] Lee M, Schwartz RN, Sharifi R "Warfarin resistance and vitamin K." Ann Intern Med 94 (1981): 140-1[36] MacLeod SM, Sellers EM "Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants." Drugs 11 (1976): 461-70[37] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G "Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy." Eur J Clin Pharmacol 63 (2007): 565-70[38] Jarvis S, Li C, Bogle RG "Possible interaction between pomegranate juice and warfarin." Emerg Med J 27 (2010): 74-5[39] Kuykendall JR, Houle MD, Rhodes RS "Possible warfarin failure due to interaction with smokeless tobacco." Ann Pharmacother 38 (2004): 595-7[40] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[41] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines "Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm." ([2003 Sept]):[42] Karlson B, Leijd B, Hellstrom K "On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment." Acta Med Scand 220 (1986): 347-50[43] O''Reilly RA, Rytand DA ""Resistance" to warfarin due to unrecognized vitamin K supplementation." N Engl J Med 303 (1980): 160-1[44] Cambria-Kiely JA "Effect of soy milk on warfarin efficacy." Ann Pharmacother 36 (2002): 1893-6[45] Sansone-Parsons A, Krishna G, Calzetta A, et al. "Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers." Antimicrob Agents Chemother 50 (2006): 1881-3[46] Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P "Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole: Monitoring of Intraluminal and Plasma Drug Concentrations." Clin Pharmacokinet 50 (2011): 725-34[47] "Product Information. Noxafil (posaconazole)." Schering-Plough Corporation, Kenilworth, NJ.[48] Krishna G, Moton A, Ma L, Malavade D, Medlock M, McLeod J "Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastro-intestinal motility on absorption and pharmacokinetics of the antifungal posaconazole." 18th European Congress of Clinical Microbiology and Infectious Diseases April (2008): 20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120813, 'Itraconazole', 'Astemizole', 'Major', 'Coadministration with azole antifungal agents may significantly increase the plasma concentrations of astemizole. The proposed mechanism is azole inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of astemizole. High plasma levels of astemizole have been associated with prolongation of the QT interval on the ECG; ventricular arrhythmias including ventricular tachycardia and torsade de pointes; cardiac arrest; and sudden death.', NULL, 'The use of astemizole with most azole antifungal agents is considered contraindicated.', NULL, 'The use of astemizole with most azole antifungal agents is considered contraindicated. Some authorities consider concomitant administration of astemizole and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole (AU). Loratadine, cetirizine, or fexofenadine may be safer alternatives during therapy with azole antifungal agents.', 'Metabolism', 'Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120951/', '[1] Venkatakrishnan K, von Moltke LL, Greenblatt DJ "Effects of the antifungal agents on oxidative drug metabolism: clinical relevance." Clin Pharmacokinet 38 (2000): 111-80[2] "Product Information. Diflucan (fluconazole)." Roerig Division, New York, NY.[3] Smith SJ "Cardiovascular toxicity of antihistamines." Otolaryngol Head Neck Surg 111 Suppl (1994): 348-54[4] "Product Information. Sporonox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[5] Salata JJ, Jurkiewicz NK, Wallace AA, Stupienski RF, Guinosso PJ, Lynch JJ "Cardiac electrophysiological actions of the histamine h-1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine." Circ Res 76 (1995): 110-9[6] "Product Information. Hismanal (astemizole)." Janssen Pharmaceutica, Titusville, NJ.[7] Heidemann SM, Sarnaik AP "Arrhythmias after astemizole overdose." Pediatr Emerg Care 12 (1996): 102-4[8] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[9] Cerner Multum, Inc. "Australian Product Information." O 0[10] Snook J, Boothman-Burrell D, Watkins J, Colin-Jones D "Torsade de pointes ventricular tachycardia associated with astemizole overdose." Br J Clin Pract 42 (1988): 257-9[11] "Product Information. Diflucan (fluconazole)." Roerig Division, New York, NY.[12] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[13] Goss JE, Ramo BW, Blake K "Torsades de pointes associated with astemizole (hismanal) therapy." Arch Intern Med 153 (1993): 2705[14] Woosley RL "Cardiac actions of antihistamines." Annu Rev Pharmacol Toxicol 36 (1996): 233-52[15] Berul CI, Morad M "Regulation of potassium channels by nonsedating antihistamines." Circulation 91 (1995): 2220-5[16] Pratt CM, Mason J, Russell T, Reynolds R, Ahlbrandt R "Cardiovascular safety of fexofenadine HCl." Am J Cardiol 83 (1999): 1451-4[17] Tsai WC, Tsai LM, Chen JH "Combined use of astemizole and ketoconazole resulting in torsade de pointes." J Formos Med Assoc 96 (1997): 144-6[18] "Product Information. Nizoral (ketoconazole)." Janssen Pharmaceutica, Titusville, NJ. (1992):[19] Simons FE, Kesselman MS, Giddins NG, Pelech AN, Simons KJ "Astemizole-induced torsade de pointes." Lancet 2 (1988): 624[20] Craft TM "Torsade de pointes after astemizole overdose." Br Med J 292 (1986): 660[21] Vorperian VR, Zhou ZF, Mohammad S, Hoon TJ, Studenik C, January CT "Torsade de pointes with an antihistamine metabolite: potassium channel blockade with desmethylastemizole." J Am Coll Cardiol 28 (1996): 1556-61[22] Saviuc P, Danel V, Dixmerias F "Prolonged QT interval and torsade de pointes following astemizole overdose." J Toxicol Clin Toxicol 31 (1993): 121-5[23] Rao KA, Adlakha A, Vermaansil B, Meloy TD, Stanton MS "Torsades de pointes ventricular tachycardia associated with overdose of astemizole." Mayo Clin Proc 69 (1994): 589-93[24] "Product Information. Noxafil (posaconazole)." Schering-Plough Corporation, Kenilworth, NJ.[25] Ament PW, Paterson A "Drug interactions with the nonsedating antihistamines." Am Fam Physician 56 (1997): 223[26] Honig PK, Cantilena LR "Ketoconazole and fluconazole drug interactions." Arch Intern Med 154 (1994): 1038-41[27] "Product Information. Hismanal (astemizole)." Janssen Pharmaceutica, Titusville, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120814, 'Itraconazole', 'Bedaquiline', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of bedaquiline, which is primarily metabolized by CYP450 3A4 to its less active N-monodesmethyl metabolite, M2.', NULL, 'The concomitant use of potent CYP450 3A4 inhibitors such as clarithromycin, cobicistat, conivaptan, delavirdine, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents given systemically for more than 14 consecutive days should generally be avoided during treatment with bedaquiline unless the benefit is anticipated to outweigh the risk.', NULL, 'The concomitant use of potent CYP450 3A4 inhibitors such as clarithromycin, cobicistat, conivaptan, delavirdine, nefazodone, telithromycin, and most protease inhibitors and azole antifungal agents given systemically for more than 14 consecutive days should generally be avoided during treatment with bedaquiline unless the benefit is anticipated to outweigh the risk. Appropriate clinical monitoring for bedaquiline-related adverse reactions is recommended if coadministration is required. ECG, serum electrolytes (potassium, magnesium, calcium), and liver function tests (ALT, AST, alkaline phosphatase, bilirubin) should be monitored before starting bedaquiline therapy and periodically during treatment in accordance with the product labeling. Hypokalemia, hypomagnesemia, and hypocalcemia must be corrected prior to bedaquiline administration. Bedaquiline should be interrupted in patients who develop clinically significant ventricular arrhythmia or a QTcF interval greater than 500 msec confirmed by repeat ECG. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Metabolism', 'Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Streptomycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120952/', '[1] "Product Information. Sirturo (bedaquiline)." Janssen Pharmaceuticals, Titusville, NJ.[2] "Product Information. Sirturo (bedaquiline)." Janssen Pharmaceuticals, Titusville, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120815, 'Itraconazole', 'Bepridil', 'Major', 'Itraconazole exhibits a dose-related negative inotropic effect which may be additive to those of calcium channel blockers (CCBs). Theoretically, coadministration may potentiate the risk of ventricular dysfunction, congestive heart failure, and peripheral and pulmonary edema, particularly in patients with preexisting risk factors (e.g., a history of congestive heart failure; cardiac disease such as ischemic and valvular disease; significant pulmonary disease such as chronic obstructive pulmonary disorder; edematous disorders such as renal failure). In addition, both itraconazole and its major metabolite, hydroxyitraconazole, inhibit CYP450 3A4 metabolism and may interfere with the clearance of certain CCBs like the dihydropyridines (amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, nimodipine, nisoldipine), diltiazem, and verapamil. Significant increases of severalfold in felodipine and nifedipine plasma concentrations have been observed during coadministration with itraconazole, and there have been case reports of leg and ankle edema in patients treated with various itraconazole-dihydropyridine combinations. Itraconazole alone has also been associated with postmarketing reports of congestive heart failure, peripheral edema, and pulmonary edema in patients treated for onychomycosis and/or systemic fungal infections.', NULL, 'Caution is advised if itraconazole must be used concomitantly with CCBs.', NULL, 'Caution is advised if itraconazole must be used concomitantly with CCBs. Close monitoring of clinical response and tolerance is recommended, and patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis. Appropriate dosage adjustment of the CCB may be necessary when used with itraconazole. Some authorities consider concomitant administration of bepridil and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism, Synergism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120953/', '[1] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[2] Rosen T "Debilitating edema associated with itraconazole therapy." Arch Dermatol 130 (1994): 260-1[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Tailor SAN, Gupta AK, Walker SE, Shear NH "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 350-2[5] Jalava KM, Olkkola KT, Neuvonen PJ "Itraconazole greatly increases plasma concentrations and effects of felodipine." Clin Pharmacol Ther 61 (1997): 410-5[6] Tailor SAN "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 1374[7] Neuvonen PJ, Suhonen R "Itraconazole interacts with felodipine." J Am Acad Dermatol 33 (1995): 134-5[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[13] "Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.[14] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[15] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] "Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.[18] Fuhr U, Muller-Peltzer H, Kern R, et al. "Effects of grapefruit juice and smoking on verapamil concentrations in steady state." Eur J Clin Pharmacol 58 (2002): 45-53[19] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[20] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[21] "Product Information. Sular (nisoldipine)." Zeneca Pharmaceuticals, Wilmington, DE.[22] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[23] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[24] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[25] Ho PC, Ghose K, Saville D, Wanwimolruk S "Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers." Eur J Clin Pharmacol 56 (2000): 693-8[26] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[27] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[28] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[29] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[30] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[31] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[32] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[33] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[34] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[35] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[36] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120816, 'Itraconazole', 'Berotralstat', 'Major', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may significantly increase the plasma concentrations of berotralstat. Berotralstat is a substrate of both P-gp and BCRP.', NULL, 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors.', NULL, 'The dosage of berotralstat should be reduced to 110 mg once daily in patients requiring chronic coadministration with P-gp and/or BCRP inhibitors. Patients should be advised to contact their physician if they experience undue adverse effects of berotralstat such as abdominal pain, vomiting, or diarrhea. Patients should seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Absorption', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Flucytosine, Anidulafungin, Voriconazole', 'Hemin, Conestat alfa, Betibeglogene autotemcel, Hyaluronidase, Streptokinase, Human C1-esterase inhibitor, Crizanlizumab, Lanadelumab, Icatibant', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120954/', '[1] "Product Information. Orladeyo (berotralstat)." BioCryst Pharmaceuticals Inc, Durham, NC.[2] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[3] Ace LN, Jaffe JM, Kunka RL "Effect of food and an antacid on quinidine bioavailability." Biopharm Drug Dispos 4 (1983): 183-90[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] Ha HR, Chen J, Leuenberger PM, Freiburghaus AU, Follah F "In vitro inhibition of midazolam and quinidine metabolism by flavonoids." Eur J Clin Pharmacol 48 (1995): 367-71', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120817, 'Itraconazole', 'Boceprevir', 'Moderate', 'Coadministration of an azole antifungal agent and hepatitis C virus (HCV) NS3/4A protease inhibitor (boceprevir, telaprevir) may result in increased plasma concentrations of both drugs. The mechanism may involve both competitive and noncompetitive inhibition of CYP450 3A4, since these drugs are all substrates as well as inhibitors of the isoenzyme. Clinically, high plasma levels of an azole antifungal agent may increase the risk of QT interval prolongation and torsade de pointes arrhythmia.', NULL, 'Caution is advised if azole antifungal agents are used in combination with HCV NS3/4A protease inhibitors.', NULL, 'Caution is advised if azole antifungal agents are used in combination with HCV NS3/4A protease inhibitors. Dosage adjustments may be required. According to the product information for boceprevir and telaprevir, high dosages of ketoconazole and itraconazole (>200 mg/day) should be avoided.', 'Metabolism', 'Fluconazole, Caspofungin, Amphotericin B, Micafungin, Oteseconazole, Flucytosine, Anidulafungin', 'Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Maribavir, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120955/', '[1] "Product Information. Victrelis (boceprevir)." Schering-Plough Corporation, Kenilworth, NJ.[2] "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals, Cambridge, MA.[3] "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120818, 'Itraconazole', 'Calcium carbonate', 'Moderate', 'INTERVAL: The dissolution of itraconazole requires an acidic environment. Antacids and some aluminum, calcium, or magnesium containing salts decrease the acidity of the stomach and can reduce the bioavailability and subsequent therapeutic effect of itraconazole.', NULL, 'Separation of doses by two or more hours is recommended.', NULL, 'Separation of doses by two or more hours is recommended.', 'Absorption', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole', 'Calcium glucoheptonate, Calcium lactate, Calcium chloride, Calcium gluconate, Calcium glubionate anhydrous, Calcium citrate, Calcium Phosphate, Ascorbic acid, Calcium chloride, Calcium citrate, Calcium acetate, Calcium Phosphate', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120956/', '[1] Carlson JA, Mann HJ, Canafax DM "Effect of pH on disintegration and dissolution of ketoconazole tablets." Am J Hosp Pharm 40 (1983): 1334-6[2] Brass C, Galgiani JN, Blaschke TF, et al "Disposition of ketoconazole, an oral antifungal, in humans." Antimicrob Agents Chemother 21 (1982): 151-8[3] Van der Meer JW, Keuning JJ "The influence of gastric acidity on the bio-availability of ketoconazole." J Antimicrob Chemother 6 (1980): 552-4[4] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[5] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[7] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[8] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[9] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[10] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[11] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[12] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[13] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[14] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[15] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120819, 'Itraconazole', 'Cerivastatin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of HMG-CoA reductase inhibitors (statins) that are substrates of the isoenzyme. High levels of HMG-CoA reductase inhibitory activity in plasma is associated with an increased risk of musculoskeletal toxicity. Myopathy manifested as muscle pain and/or weakness associated with grossly elevated creatine kinase exceeding ten times the upper limit of normal has been reported occasionally. Rhabdomyolysis has also occurred rarely, which may be accompanied by acute renal failure secondary to myoglobinuria and may result in death.', NULL, 'The benefits of using azole antifungal agents with statins that are substrates of CYP450 3A4 should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis.', NULL, 'The benefits of using azole antifungal agents with statins that are substrates of CYP450 3A4 should be carefully weighed against the potentially increased risk of myopathy including rhabdomyolysis. If coadministration is required, a lower initial and maintenance dosage of the statin should be considered. Close monitoring for musculoskeletal toxicity is recommended, particularly during the initial months of therapy and following a dosage increase of either drug. Pitavastatin, pravastatin, and rosuvastatin may be safer alternatives, since they are not metabolized by CYP450 3A4. Fluvastatin may also be used with azole antifungal agents except fluconazole and voriconazole, both of which can inhibit fluvastatin metabolism via CYP450 2C9. Alternatively, an interruption of the statin may be considered during treatment with an azole antifungal agent. All patients receiving statin therapy should be advised to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by fever, malaise and/or dark colored urine. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed.', 'Metabolism', 'Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, More', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120957/', '[1] Watkins JL, Atkinson BJ, Pagliaro LC "Rhabdomyolysis in a prostate cancer patient taking ketoconazole and simvastatin: case report and review of the literature." Ann Pharmacother 45 (2011): e9[2] Lomaestro BM, Piatek MA "Update on drug interactions with azole antifungal agents." Ann Pharmacother 32 (1998): 915-28[3] Gilad R, Lampl Y "Rhabdomyolysis induced by simvastatin and ketoconazole treatment." Clin Neuropharmacol 22 (1999): 295-7[4] Itakura H, Vaughn D, Haller DG, O''Dwyer PJ "Rhabdomyolysis from cytochrome p-450 interaction of ketoconazole and simvastatin in prostate cancer." J Urol 169 (2003): 613[5] Kantola T, Kivisto KT, Neuvonen PJ "Effect of itraconazole on the pharmacokinetics of atorvastatin." Clin Pharmacol Ther 64 (1998): 58-65[6] Kantola T, Kivisto KT, Neuvonen PJ "Effect of itraconazole on cerivastatin pharmacokinetics." Eur J Clin Pharmacol 54 (1999): 851-5[7] Neuvonen PJ, Backman JT, Niemi M "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet 47 (2008): 463-74[8] Kivisto KT, Kantola T, Neuvonen PJ "Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin." Br J Clin Pharmacol 46 (1998): 49-53[9] Neuvonen PJ, Jalava KM "Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 60 (1996): 54-61[10] Lees RS, Lees AM "Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole." N Engl J Med 333 (1995): 664-5[11] Horn M "Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals." Arch Dermatol 132 (1996): 1254[12] Akram K, Rao S, Parker M "A lesson for everyone in drug-drug interactions." Int J Cardiol 118 (2007): e19-20[13] Neuvonen PJ, Kantola T, Kivisto KT "Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole." Clin Pharmacol Ther 63 (1998): 332-41[14] Stein CA, Goel S, Ghavamian R "Hepatitis and rhabdomyolysis in a patient with hormone refractory prostate cancer on ketoconazole and concurrent lovastatin therapy." Invest New Drugs 25 (2007): 277-8[15] Richter WO, Jacob BG, Schwandt P "Interaction between fibre and lovastatin." Lancet 338 (1991): 706[16] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[17] Boberg M, Angerbauer R, Fey P, Kanhai WK, Karl W, Kern A, Ploschke J, Radtke M "Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P45 isozymes involved." Drug Metab Dispos 25 (1997): 321-31[18] "Product Information. Lipitor (atorvastatin)." Parke-Davis, Morris Plains, NJ.[19] McMillan K "Considerations in the formulary selection of hydroxymethylglutaryl coenzyme a reductase inhibitors." Am J Health Syst Pharm 53 (1996): 2206-14[20] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[21] Neuvonen PJ, Backman JT, Niemi M "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet 47 (2008): 463-74', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120820, 'Itraconazole', 'Cisapride', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of cisapride, which is primarily metabolized by the isoenzyme. The use of cisapride has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels of the drug may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes as well as cardiac arrest and sudden death.', NULL, 'Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of cisapride, the concomitant use with most azole antifungal agents is considered contraindicated.', NULL, 'Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of cisapride, the concomitant use with most azole antifungal agents is considered contraindicated. Some authorities consider concomitant administration of cisapride and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120958/', '[1] "Product Information. Diflucan (fluconazole)." Roerig Division, New York, NY.[2] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[3] Bedford TA, Rowbotham DJ "Cisapride: drug interactions of clinical significance." Drug Saf 15 (1996): 167-75[4] Gray VS "Syncopal episodes associated with cisapride and concurrent drugs." Ann Pharmacother 32 (1998): 648-51[5] "Product Information. Nizoral (ketoconazole)." Janssen Pharmaceutica, Titusville, NJ. (1992):[6] "Product Information. Sporonox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[7] "Product Information. Noxafil (posaconazole)." Schering-Plough Corporation, Kenilworth, NJ.[8] "Product Information. Propulsid (cisapride)." Janssen Pharmaceutica, Titusville, NJ.[9] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[10] Desta Z, Soukhova N, Mahal SK, Flockhart DA "Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies." Drug Metab Dispos 28 (2000): 789-800[11] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[12] Bran S, Murray WA, Hirsch IB, Palmer JP "Long QT syndrome during high-dose cisapride." Arch Intern Med 155 (1995): 765-8[13] Lewin MB, Bryant RM, Fenrich AL, Grifka RG "Cisapride-induced long QT interval." J Pediatr 128 (1996): 279-81[14] Cerner Multum, Inc. "Australian Product Information." O 0[15] Michalets EL, Williams CR "Drug interactions with cisapride: clinical implications." Clin Pharmacokinet 39 (2000): 49-75[16] Lewin MB, Bryant RM, Fenrich AL, Grifka RG "Cisapride-induced long QT interval." J Pediatr 128 (1996): 279-81[17] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[18] Kivisto KT, Lilja TJ, Backman JT, Neuvonen PJ "Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride." Clin Pharmacol Ther 66 (1999): 448-53[19] Michalets EL, Williams CR "Drug interactions with cisapride: clinical implications." Clin Pharmacokinet 39 (2000): 49-75[20] Hill SL, Evangelista JK, Pizzi AM, Mobassaleh M, Fulton DR, Berul CI "Proarrhythmia associated with cisapride in children." Pediatrics 101 (1998): 1053-6[21] Bran S, Murray WA, Hirsch IB, Palmer JP "Long QT syndrome during high-dose cisapride." Arch Intern Med 155 (1995): 765-8[22] Gross AS, Goh YD, Addison RS, Shenfield GM "Influence of grapefruit juice on cisapride pharmacokinetics." Clin Pharmacol Ther 65 (1999): 395-401[23] Offman EM, Freeman DJ, Dresser GK, Munoz C, Bend JR, Bailey DG "Red wine-cisapride interaction: Comparison with grapefruit juice." Clin Pharmacol Ther 70 (2001): 17-23[24] "Product Information. Propulsid (cisapride)." Janssen Pharmaceutica, Titusville, NJ.[25] Desta Z, Soukhova N, Mahal SK, Flockhart DA "Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies." Drug Metab Dispos 28 (2000): 789-800', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120821, 'Itraconazole', 'Conjugated estrogens (topical)', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Bazedoxifene', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120959/', '[1] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ "Pregnancy associated with a combined oral contraceptive and itraconazole." N Z Med J 106 (1993): 436[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120822, 'Itraconazole', 'Copanlisib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 and P-glycoprotein (P-gp) may increase the plasma concentrations of copanlisib, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'The manufacturer recommends reducing the copanlisib dose to 45 mg when concomitant use with potent CYP450 3A4 inhibitors cannot be avoided.', NULL, 'The manufacturer recommends reducing the copanlisib dose to 45 mg when concomitant use with potent CYP450 3A4 inhibitors cannot be avoided.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120960/', '[1] "Product Information. Aliqopa (copanlisib)." Bayer Pharmaceutical Inc, West Haven, CT.[2] "Product Information. Aliqopa (copanlisib)." Bayer Pharmaceutical Inc, West Haven, CT.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120823, 'Itraconazole', 'Dapsone', 'Moderate', 'Coadministration with itraconazole may significantly increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by itraconazole.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever itraconazole is added to or withdrawn from therapy. Some authorities recommend avoiding concomitant use of nevirapine from 2 weeks before and during treatment with itraconazole.', 'Metabolism', 'Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Azelaic acid, Adapalene, Clofazimine', 'Micafungin, Caspofungin, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120961/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Kaukonen KM, Olkkola KT, Neuvonen PJ "Itraconazole increases plasma concentrations of quinidine." Clin Pharmacol Ther 62 (1997): 510-7[3] Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44[4] Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH "Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor." Drug Metab Dispos 24 (1996): 307-14[5] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[7] Tailor SAN "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 1374[8] Gillies J, Hung KA, Fitzsimons E, Soutar R "Severe vincristine toxicity in combination with itraconazole." Clin Lab Haematol 20 (1998): 123-4[9] Lukkari E, Juhakoski A, Aranko K, Neuvonen PJ "Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite." Eur J Clin Pharmacol 52 (1997): 403-6[10] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[11] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[12] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[13] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[14] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[15] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[16] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[17] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[18] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[19] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120824, 'Itraconazole', 'Dexamethasone (nasal)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'Fluconazole, Caspofungin, Amphotericin B, Micafungin, Oteseconazole, Flucytosine, Anidulafungin', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120962/', '[1] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD "Case of psychosis due to prednisone-clarithromycin interaction." Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM "Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction." J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ "Impact of ketoconazole on the metabolism of prednisolone." Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR "Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals." J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ "Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone." Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML "The use of macrolide antibiotic substances in the treatment of asthma." J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH "Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma." Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. "Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects." Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone." Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G "Steroid-induced mania in an adolescent: risk factors and management." Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J "Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers." J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[30] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120825, 'Itraconazole', 'Dicoumarol', 'Moderate', 'Azole antifungal agents that are potent inhibitors of CYP450 3A4 such as itraconazole, ketoconazole, and posaconazole may increase the plasma concentrations and hypoprothrombinemic effect of warfarin. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of R(+) warfarin, the less biologically active of the two enantiomers of warfarin.', NULL, 'Patients receiving warfarin should be closely monitored during concomitant therapy with azole antifungal agents that are potent inhibitors of CYP450 3A4.', NULL, 'Patients receiving warfarin should be closely monitored during concomitant therapy with azole antifungal agents that are potent inhibitors of CYP450 3A4. The INR should be checked frequently and warfarin dosage adjusted accordingly, particularly following initiation, change of dosage, or discontinuation of azole antifungal therapy. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.', 'Metabolism', 'Iloprost, Lepirudin, Acenocoumarol, Urokinase, Cangrelor, Dipyridamole, Caplacizumab, Argatroban, Prasugrel, Desirudin, Eptifibatide, More', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120963/', '[1] Brass C, Galgiani JN, Blaschke TF, et al "Disposition of ketoconazole, an oral antifungal, in humans." Antimicrob Agents Chemother 21 (1982): 151-8[2] Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83[3] Smith AG "Potentiation of oral anticoagulants by ketoconazole." Br Med J 288 (1984): 188-9[4] Yeh J, Soo S, Summerton C, Richardson C "Potentiation of action of warfarin by itraconazole." Br Med J 301 (1990): 669[5] Daneshmend TK, Warnock DW "Clinical pharmacokinetics of ketoconazole." Clin Pharmacokinet 14 (1988): 13-34[6] Visser LE, Penning-Van Beest FJ, Kasbergen AA, et al. "Overanticoagulation associated with combined use of antifungal agents and coumarin anticoagulants." Clin Pharmacol Ther 71 (2002): 496-502[7] "Product Information. Coumadin (warfarin)." DuPont Pharmaceuticals, Wilmington, DE.[8] Guo LQ, Yamazoe Y "Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines." Acta Pharmacol Sin 25 (2004): 129-36[9] Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3[10] Suvarna R, Pirmohamed M, Henderson L "Possible interaction between warfarin and cranberry juice." BMJ 327 (2003): 1454[11] Sullivan DM, Ford MA, Boyden TW "Grapefruit juice and the response to warfarin." Am J Health Syst Pharm 55 (1998): 1581-3[12] Kempin SJ "Warfarin resistance caused by broccoli." N Engl J Med 308 (1983): 1229-30[13] Harrell CC, Kline SS "Vitamin K-supplemented snacks containing olestra: Implication for patients taking warfarin." Jama J Am Med Assn 282 (1999): 1133-4[14] Beckey NP, Korman LB, Parra D "Effect of the moderate consumption of olestra in patients receiving long-term warfarin therapy." Pharmacotherapy 19 (1999): 1075-9[15] Grant P "Warfarin and cranberry juice: an interaction?" J Heart Valve Dis 13 (2004): 25-6[16] Ge B, Zhang Z, Zuo Z "Updates on the clinical evidenced herb-warfarin interactions." Evid Based Complement Alternat Med 2014 (2014): 957362[17] Westfall LK "An unrecognized cause of warfarin resistance." Drug Intell Clin Pharm 15 (1981): 131[18] Walker FB "Myocardial infarction after diet-induced warfarin resistance." Arch Intern Med 144 (1984): 2089-90[19] Kazmier FJ, Spittell JA Jr "Coumarin drug interactions." Mayo Clin Proc 45 (1970): 249-55[20] Pedersen FM, Hamberg O, Hess K, Ovesen L "The effect of dietary vitamin K on warfarin-induced anticoagulation." J Intern Med 229 (1991): 517-20[21] Zallman JA, Lee DP, Jeffrey PL "Liquid nutrition as a cause of warfarin resistance." Am J Hosp Pharm 38 (1981): 1174[22] Griffith LD, Olvey SE, Triplett WC "Increasing prothrombin times in a warfarin-treated patient upon withdrawal of ensure plus." Crit Care Med 10 (1982): 799-800[23] Watson AJ, Pegg M, Green JR "Enteral feeds may antagonise warfarin." Br Med J 288 (1984): 557[24] Wells PS, Holbrook AM, Crowther NR, Hirsh J "Interactions of warfarin with drugs and food." Ann Intern Med 121 (1994): 676-83[25] Monterrey-Rodriguez J "Interaction between warfarin and mango fruit." Ann Pharmacother 36 (2002): 940-1[26] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[27] Griffiths AP, Beddall A, Pegler S "Fatal haemopericardium and gastrointestinal haemorrhage due to possible interaction of cranberry juice with warfarin." J R Soc Health 128 (2008): 324-6[28] Roberts D, Flanagan P "Case report: Cranberry juice and warfarin." Home Healthc Nurse 29 (2011): 92-7[29] Parr MD, Record KE, Griffith GL, et al "Effect of enteral nutrition on warfarin therapy." Clin Pharm 1 (1982): 274-6[30] Andersen P, Godal HC "Predictable reduction in anticoagulant activity of warfarin by small amounts of vitamin K." Acta Med Scand 198 (1975): 269-70[31] Howard PA, Hannaman KN "Warfarin resistance linked to enteral nutrition products." J Am Diet Assoc 85 (1985): 713-5[32] Rindone JP, Murphy TW "Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding." Am J Ther 13 (2006): 283-4[33] Hamann GL, Campbell JD, George CM "Warfarin-cranberry juice interaction." Ann Pharmacother 45 (2011): e17[34] Chow WH, Chow TC, Tse TM, Tai YT, Lee WT "Anticoagulation instability with life-threatening complication after dietary modification." Postgrad Med J 66 (1990): 855-7[35] Lee M, Schwartz RN, Sharifi R "Warfarin resistance and vitamin K." Ann Intern Med 94 (1981): 140-1[36] MacLeod SM, Sellers EM "Pharmacodynamic and pharmacokinetic drug interactions with coumarin anticoagulants." Drugs 11 (1976): 461-70[37] Brandin H, Myrberg O, Rundlof T, Arvidsson AK, Brenning G "Adverse effects by artificial grapefruit seed extract products in patients on warfarin therapy." Eur J Clin Pharmacol 63 (2007): 565-70[38] Jarvis S, Li C, Bogle RG "Possible interaction between pomegranate juice and warfarin." Emerg Med J 27 (2010): 74-5[39] Kuykendall JR, Houle MD, Rhodes RS "Possible warfarin failure due to interaction with smokeless tobacco." Ann Pharmacother 38 (2004): 595-7[40] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[41] MHRA. Mediciines and Healthcare products Regulatory Agency. Committee on Safety of Medicines "Possible interaction between warfarin and cranberry juice. Available from: URL: http://medicines.mhra.gov.uk/ourwork/monitorsafequalmed/currentproblems/currentproblems.htm." ([2003 Sept]):[42] Karlson B, Leijd B, Hellstrom K "On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment." Acta Med Scand 220 (1986): 347-50[43] O''Reilly RA, Rytand DA ""Resistance" to warfarin due to unrecognized vitamin K supplementation." N Engl J Med 303 (1980): 160-1[44] Cambria-Kiely JA "Effect of soy milk on warfarin efficacy." Ann Pharmacother 36 (2002): 1893-6[45] Sansone-Parsons A, Krishna G, Calzetta A, et al. "Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers." Antimicrob Agents Chemother 50 (2006): 1881-3[46] Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P "Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole: Monitoring of Intraluminal and Plasma Drug Concentrations." Clin Pharmacokinet 50 (2011): 725-34[47] "Product Information. Noxafil (posaconazole)." Schering-Plough Corporation, Kenilworth, NJ.[48] Krishna G, Moton A, Ma L, Malavade D, Medlock M, McLeod J "Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastro-intestinal motility on absorption and pharmacokinetics of the antifungal posaconazole." 18th European Congress of Clinical Microbiology and Infectious Diseases April (2008): 20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120826, 'Itraconazole', 'Dienestrol (topical)', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120964/', '[1] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ "Pregnancy associated with a combined oral contraceptive and itraconazole." N Z Med J 106 (1993): 436[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120827, 'Itraconazole', 'Diethylstilbestrol', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Histrelin, Megestrol acetate, Leuprolide, Bicalutamide, Triptorelin, Bazedoxifene', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120965/', '[1] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ "Pregnancy associated with a combined oral contraceptive and itraconazole." N Z Med J 106 (1993): 436[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120828, 'Itraconazole', 'Doxorubicin (liposomal)', 'Moderate', 'Coadministration with itraconazole may significantly increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by itraconazole.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever itraconazole is added to or withdrawn from therapy. Some authorities recommend avoiding concomitant use of nevirapine from 2 weeks before and during treatment with itraconazole.', 'Metabolism', 'Dactinomycin, Mitomycin, Valrubicin, Plicamycin', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120966/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Kaukonen KM, Olkkola KT, Neuvonen PJ "Itraconazole increases plasma concentrations of quinidine." Clin Pharmacol Ther 62 (1997): 510-7[3] Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44[4] Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH "Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor." Drug Metab Dispos 24 (1996): 307-14[5] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[7] Tailor SAN "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 1374[8] Gillies J, Hung KA, Fitzsimons E, Soutar R "Severe vincristine toxicity in combination with itraconazole." Clin Lab Haematol 20 (1998): 123-4[9] Lukkari E, Juhakoski A, Aranko K, Neuvonen PJ "Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite." Eur J Clin Pharmacol 52 (1997): 403-6[10] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[11] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[12] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[13] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[14] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[15] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[16] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[17] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[18] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[19] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120829, 'Itraconazole', 'Echinacea', 'Moderate', 'Coadministration with echinacea may alter the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4. Echinacea appears to inhibit intestinal CYP450 3A4, which would lead to an increase in oral midazolam (a sensitive 3A4 substrate) bioavailability; however, plasma levels of midazolam following oral administration do not appear to be affected by echinacea. In contrast, it appears that echinacea may also induce hepatic CYP450 3A4; thereby increasing the hepatic clearance of drugs that are substrates of CYP450 3A4.', NULL, 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines.', NULL, 'In general, patients should be advised to consult their healthcare provider before using any herbal or alternative medicines. If echinacea is prescribed with a drug that is a CYP450 3A4 substrate, the possibility of an altered (increased or decreased) therapeutic response should be considered. Patients should be monitored more closely following the addition or withdrawal of echinacea and the dosage of the CYP450 3A4 substrate adjusted as necessary.', 'Metabolism', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120967/', '[1] Gorski JC, Huang SM, Pinto A, et al. "The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo." Clin Pharmacol Ther 75 (2004): 89-100[2] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120830, 'Itraconazole', 'Entrectinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of entrectinib, which is primarily metabolized by the isoenzyme. Increased exposure to entrectinib may increase the risk and/or severity of adverse effects such as cognitive impairment, mood disorders, dizziness, sleep disturbances, liver enzyme elevations, hyperuricemia, congestive heart failure, edema, myocarditis, QT prolongation, vision problems, anemia, and neutropenia.', NULL, 'Concomitant use of entrectinib with potent (or moderate) CYP450 3A4 inhibitors should be avoided when possible.', NULL, 'Concomitant use of entrectinib with potent (or moderate) CYP450 3A4 inhibitors should be avoided when possible. If coadministration is necessary, the dosage of entrectinib should be reduced to 100 mg once daily for adults and pediatrics patients (12 years and older) with a body surface area (BSA) greater than 1.5 m2. Following discontinuation, and after an appropriate washout period of the CYP450 3A4 inhibitor (i.e., 3 to 5 half-lives), the entrectinib dosage taken prior to initiating the CYP450 3A4 inhibitor may be resumed. For pediatric patients with a body surface area of 1.5 m2 or less, concomitant use of entrectinib with potent (or moderate) CYP450 3A4 inhibitors should be avoided.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120968/', '[1] "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120831, 'Itraconazole', 'Enzalutamide', 'Moderate', 'Coadministration with enzalutamide may decrease the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-glycoprotein (P-gp) efflux transporter. The proposed mechanism involves accelerated clearance via these routes due to enzalutamide-mediated induction. The resulting plasma concentrations will depend on the sensitivity of the affected drugs to these isoenzymes.', NULL, 'Caution is advised when enzalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-gp, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised when enzalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever enzalutamide is added to or withdrawn from therapy.', 'Metabolism', 'Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Anastrozole, Fulvestrant, Letrozole, Abarelix, Flutamide, Bicalutamide, Degarelix, Nilutamide, Aminoglutethimide, Exemestane', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120969/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Xtandi (enzalutamide)." Astellas Pharma US, Inc, Deerfield, IL.[3] Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120832, 'Itraconazole', 'Epirubicin', 'Moderate', 'The concomitant or sequential use of epirubicin with agents known to induce hepatotoxicity may potentiate the risk of liver injury. Epirubicin undergoes elimination through the hepatobiliary system.', NULL, 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', NULL, 'Caution and clinical and laboratory monitoring for signs of liver injury are advisable before, during, or after use of epirubicin with other agents that are potentially hepatotoxic.', 'Synergism', 'Dactinomycin, Mitomycin, Valrubicin, Plicamycin', 'Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120970/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Ellence (epirubicin)" Pharmacia and Upjohn, Kalamazoo, MI.[4] "Product Information. Hivid (zalcitabine)." Roche Laboratories, Nutley, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120833, 'Itraconazole', 'Eplerenone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and risk of adverse reactions of eplerenone, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of eplerenone with potent CYP450 3A4 inhibitors is considered contraindicated.', NULL, 'Concomitant use of eplerenone with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities consider concomitant administration of eplerenone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'Amiloride, Triamterene', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120971/', '[1] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[2] "Product Information. Inspra (eplerenone)." Searle, Chicago, IL.[3] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120834, 'Itraconazole', 'Eravacycline', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of eravacycline, which undergoes oxidation by CYP450 3A4 and flavin monoxygenase (FMO).', NULL, '-', NULL, '-', 'Metabolism', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Tetracycline, Oxytetracycline, Omadacycline, Demeclocycline, Sarecycline, Tigecycline', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120972/', '[1] "Product Information. Xerava (eravacycline)." Tetraphase Pharmaceuticals, Inc, Watertown, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120835, 'Itraconazole', 'Erdafitinib', 'Major', 'Coadministration of erdafitinib with potent inhibitors of CYP450 2C9 or 3A4 may increase the plasma concentrations and risk of toxicity of erdafitinib, which is a substrate of these isoenzymes.', NULL, 'Coadministration of erdafitinib with potent inhibitors of CYP450 2C9 or 3A4 should generally be avoided.', NULL, 'Coadministration of erdafitinib with potent inhibitors of CYP450 2C9 or 3A4 should generally be avoided. If concomitant use is unavoidable, patients should be closely monitored for the development of adverse effects. Dosage adjustments as well as clinical and laboratory monitoring of erdafitinib should be considered whenever a CYP450 2C9 or 3A4 inhibitor is added to or withdrawn from therapy.', 'Metabolism', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120973/', '[1] "Product Information. Balversa (erdafitinib)." Janssen Products, LP, Horsham, PA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120836, 'Itraconazole', 'Ergometrine', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. Clinical ergotism has been reported, which can lead to gangrene and myocardial infarction in severe cases.', NULL, 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with itraconazole, ketoconazole, posaconazole, or voriconazole is considered contraindicated.', NULL, 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with itraconazole, ketoconazole, posaconazole, or voriconazole is considered contraindicated. Some authorities consider concomitant administration of ergot derivatives and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole. Use with other azole antifungal agents, including fluconazole at high multiple doses, should probably be avoided if possible.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Misoprostol, Dinoprostone, Oxytocin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120974/', '[1] Hayton AC "Precipitation of acute ergotism by triacetyloleandomycin." N Z Med J 69 (1969): 42[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7[4] "Product Information. Migranal (dihydroergotamine nasal)." Novartis Pharmaceuticals, East Hanover, NJ.[5] Liaudet L, Buclin T, Jaccard C, Eckert P "Severe ergotism associated with interaction between ritonavir and ergotamine." Br Med J 318 (1999): 771[6] Eadie MJ "Clinically significant drug interactions with agents specific for migraine attacks." Cns Drugs 15 (2001): 105-18[7] Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3[8] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R "Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy." Ann Vasc Surg 7 (1993): 291-6[9] "Product Information. Cafergot (caffeine-ergotamine)." Novartis Pharmaceuticals, East Hanover, NJ.[10] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C "Dihydroergotamine-erythromycin-induced ergotism." Ann Intern Med 109 (1988): 249[11] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[12] Srisuma S, Lavonas EJ, Wananukul W "Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors." Clin Toxicol (Phila) (2014): 1-4[13] Matthews NT, Havill JH "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J 89 (1979): 476-7[14] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207[15] "Product Information. Noxafil (posaconazole)." Schering-Plough Corporation, Kenilworth, NJ.[16] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F "Clinical ergotism induced by ritonavir." Scand J Infect Dis 33 (2001): 788-9[17] Montero A, Giovannoni AG, Tvrde PL "Leg ischemia in a patient receiving ritonavir and ergotamine." Ann Intern Med 130 (1999): 329[18] Mortier E, Pouchet J, Vinceneux P, Lalande M "Ergotism related to interaction between nelfinavir and ergotamine." Am J Med 110 (2001): 594[19] Bird PA, Sturgess AD "Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction." Aust N Z J Med 30 (2000): 635-6[20] Liaudet L "Severe ergotism associated with interaction between ritonavir and ergotamine." BMJ 318 (1999): 771[21] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W "Cerebral ergotism under treatment with ergotamine and ritonavir." Neurology 57 (2001): 743-4[22] Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6[23] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[24] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP "Ergotism related to concurrent administration of ergotamine tartrate and indinavir." JAMA 281 (1999): 987[25] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW "Fatal ergotism induced by an HIV protease inhibitor." Headache 42 (2002): 694-5[26] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[27] Horowitz RS, Dart RC, Gomez HF "Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction." Arch Intern Med 156 (1996): 456-8[28] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[29] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[30] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[31] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[32] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[33] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[34] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[35] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[36] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[37] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[38] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[39] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[40] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[41] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[42] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[43] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[44] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[45] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[46] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[47] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[48] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[49] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[50] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[51] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[52] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[53] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[54] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[55] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[56] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[57] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[58] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[59] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[60] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[61] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120837, 'Itraconazole', 'Ergotamine', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. Clinical ergotism has been reported, which can lead to gangrene and myocardial infarction in severe cases.', NULL, 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with itraconazole, ketoconazole, posaconazole, or voriconazole is considered contraindicated.', NULL, 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with itraconazole, ketoconazole, posaconazole, or voriconazole is considered contraindicated. Some authorities consider concomitant administration of ergot derivatives and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole. Use with other azole antifungal agents, including fluconazole at high multiple doses, should probably be avoided if possible.', 'Metabolism', 'Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Fremanezumab', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120975/', '[1] Hayton AC "Precipitation of acute ergotism by triacetyloleandomycin." N Z Med J 69 (1969): 42[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7[4] "Product Information. Migranal (dihydroergotamine nasal)." Novartis Pharmaceuticals, East Hanover, NJ.[5] Liaudet L, Buclin T, Jaccard C, Eckert P "Severe ergotism associated with interaction between ritonavir and ergotamine." Br Med J 318 (1999): 771[6] Eadie MJ "Clinically significant drug interactions with agents specific for migraine attacks." Cns Drugs 15 (2001): 105-18[7] Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3[8] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R "Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy." Ann Vasc Surg 7 (1993): 291-6[9] "Product Information. Cafergot (caffeine-ergotamine)." Novartis Pharmaceuticals, East Hanover, NJ.[10] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C "Dihydroergotamine-erythromycin-induced ergotism." Ann Intern Med 109 (1988): 249[11] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[12] Srisuma S, Lavonas EJ, Wananukul W "Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors." Clin Toxicol (Phila) (2014): 1-4[13] Matthews NT, Havill JH "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J 89 (1979): 476-7[14] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207[15] "Product Information. Noxafil (posaconazole)." Schering-Plough Corporation, Kenilworth, NJ.[16] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F "Clinical ergotism induced by ritonavir." Scand J Infect Dis 33 (2001): 788-9[17] Montero A, Giovannoni AG, Tvrde PL "Leg ischemia in a patient receiving ritonavir and ergotamine." Ann Intern Med 130 (1999): 329[18] Mortier E, Pouchet J, Vinceneux P, Lalande M "Ergotism related to interaction between nelfinavir and ergotamine." Am J Med 110 (2001): 594[19] Bird PA, Sturgess AD "Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction." Aust N Z J Med 30 (2000): 635-6[20] Liaudet L "Severe ergotism associated with interaction between ritonavir and ergotamine." BMJ 318 (1999): 771[21] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W "Cerebral ergotism under treatment with ergotamine and ritonavir." Neurology 57 (2001): 743-4[22] Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6[23] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[24] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP "Ergotism related to concurrent administration of ergotamine tartrate and indinavir." JAMA 281 (1999): 987[25] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW "Fatal ergotism induced by an HIV protease inhibitor." Headache 42 (2002): 694-5[26] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[27] Horowitz RS, Dart RC, Gomez HF "Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction." Arch Intern Med 156 (1996): 456-8[28] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[29] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[30] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[31] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[32] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[33] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[34] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[35] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[36] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[37] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[38] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[39] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[40] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[41] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[42] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[43] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[44] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[45] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[46] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[47] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[48] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[49] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[50] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[51] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[52] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[53] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[54] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[55] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[56] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[57] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[58] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[59] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[60] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[61] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120838, 'Itraconazole', 'Erlotinib', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of erlotinib, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if erlotinib must be used with potent CYP450 3A4 inhibitors.', NULL, 'Caution is advised if erlotinib must be used with potent CYP450 3A4 inhibitors. A dosage reduction or temporary interruption of therapy should be considered in patients who experience undue adverse effects of erlotinib such as severe diarrhea (i.e., that which is unresponsive to loperamide or results in dehydration), severe skin reactions, or severe liver function test abnormalities.', 'Metabolism', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120976/', '[1] Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7[2] "Product Information. Tarceva (erlotinib)." Genentech, South San Francisco, CA.[3] Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7[4] "Product Information. Tarceva (erlotinib)." Genentech, South San Francisco, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120839, 'Itraconazole', 'Escitalopram', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 is not expected to significantly affect the pharmacokinetics of citalopram or escitalopram, both of which are partially metabolized by the isoenzyme. Administration of racemic citalopram (40 mg) in combination with the potent CYP450 3A4 inhibitor ketoconazole (200 mg) decreased the ketoconazole peak plasma concentration (Cmax) by 21% and systemic exposure (AUC) by 10%, but did not significantly affect the pharmacokinetics of citalopram.', NULL, '-', NULL, '-', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Phenelzine, Duloxetine, Desipramine, Tranylcypromine, Trimipramine, Desvenlafaxine, Maprotiline, Fluoxetine, St. John''s Wort, Isocarboxazid, Oxitriptan, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120977/', '[1] "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.[2] "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120840, 'Itraconazole', 'Esterified estrogens', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120978/', '[1] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ "Pregnancy associated with a combined oral contraceptive and itraconazole." N Z Med J 106 (1993): 436[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120841, 'Itraconazole', 'Estradiol (topical)', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Megestrol acetate, Bazedoxifene, Prasterone, Methyltestosterone, Megestrol acetate, Estetrol, Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, More', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120979/', '[1] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ "Pregnancy associated with a combined oral contraceptive and itraconazole." N Z Med J 106 (1993): 436[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120842, 'Itraconazole', 'Estrone', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Bazedoxifene', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120980/', '[1] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ "Pregnancy associated with a combined oral contraceptive and itraconazole." N Z Med J 106 (1993): 436[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120843, 'Itraconazole', 'Estrone sulfate', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120981/', '[1] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ "Pregnancy associated with a combined oral contraceptive and itraconazole." N Z Med J 106 (1993): 436[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120844, 'Itraconazole', 'Estrone sulfate (topical)', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120982/', '[1] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ "Pregnancy associated with a combined oral contraceptive and itraconazole." N Z Med J 106 (1993): 436[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120845, 'Itraconazole', 'Eszopiclone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of both zopiclone and its pharmacologically active S(-) enantiomer, eszopiclone. Zopiclone has been shown in vitro to be metabolized by CYP450 3A4 and CYP450 2C8, while eszopiclone is primarily metabolized by CYP450 3A4 and 2E1 via demethylation and oxidation.', NULL, 'Due to increased risk of next-day psychomotor impairment, the dosages of eszopiclone and zopiclone should be reduced when used with potent CYP450 3A4 inhibitors.', NULL, 'Due to increased risk of next-day psychomotor impairment, the dosages of eszopiclone and zopiclone should be reduced when used with potent CYP450 3A4 inhibitors. The manufacturers recommend that total dose of eszopiclone not exceed 2 mg. An initial dose of 3.75 mg is recommended for zopiclone, which may be increased up to 5 mg if clinically indicated. Patients should be advised to avoid driving or operating hazardous machinery until they know how these medications affect them, preferably at least 12 hours after administration of the hypnotic.', 'Metabolism', 'Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, Paraldehyde, More', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120983/', '[1] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[2] "Product Information. Imovane (zopiclone)." Rhone-Poulenc Rorer Canada Inc, Laval, IN.[3] Alderman CP, Gebauer MG, Gilbert AL, Condon JT "Possible interaction of zopiclone and nefazodone." Ann Pharmacother 35 (2001): 1378-80[4] Becquemont L, Mouajjah S, Escaffre O, Beaune P, Funck-Bretano C, Jaillon P "Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism." Drug Metab Dispos 27 (1999): 1068-73[5] "Product Information. Lunesta (eszopiclone)." Sepracor Inc, Marlborough, MA.[6] "Product Information. Lunesta (eszopiclone)." Sepracor Inc, Marlborough, MA.[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120846, 'Itraconazole', 'Ethosuximide', 'Moderate', 'Coadministration with itraconazole may significantly increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by itraconazole.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever itraconazole is added to or withdrawn from therapy. Some authorities recommend avoiding concomitant use of nevirapine from 2 weeks before and during treatment with itraconazole.', 'Metabolism', 'Brivaracetam, Topiramate, Ezogabine, Paramethadione, Methsuximide, Fenfluramine, Eslicarbazepine, Lamotrigine, Phensuximide, Methylphenobarbital, Phenacemide, More', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Ketoconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120984/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Kaukonen KM, Olkkola KT, Neuvonen PJ "Itraconazole increases plasma concentrations of quinidine." Clin Pharmacol Ther 62 (1997): 510-7[3] Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44[4] Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH "Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor." Drug Metab Dispos 24 (1996): 307-14[5] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[7] Tailor SAN "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 1374[8] Gillies J, Hung KA, Fitzsimons E, Soutar R "Severe vincristine toxicity in combination with itraconazole." Clin Lab Haematol 20 (1998): 123-4[9] Lukkari E, Juhakoski A, Aranko K, Neuvonen PJ "Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite." Eur J Clin Pharmacol 52 (1997): 403-6[10] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[11] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[12] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[13] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[14] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[15] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[16] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[17] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[18] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[19] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120847, 'Itraconazole', 'Ethotoin', 'Moderate', 'Phenytoin and other hydantoins may reduce itraconazole serum levels by up to 90%. The mechanism appears to be enhanced first-pass metabolism and hepatic enzyme metabolism (CYP450 3A4) of itraconazole. Itraconazole therapy may fail. Ketoconazole is affected in a similar manner. In addition, itraconazole may increase the plasma concentrations of phenytoin.', NULL, 'Coadministration of phenytoin or other hydantoins with itraconazole or ketoconazole should be avoided from 2 weeks before and during treatment with itraconazole or ketoconazole.', NULL, 'Coadministration of phenytoin or other hydantoins with itraconazole or ketoconazole should be avoided from 2 weeks before and during treatment with itraconazole or ketoconazole. Some experts suggest that if concomitant use is unavoidable, a dosage increase for itraconazole or ketoconazole should be considered. In addition, monitoring of phenytoin concentrations is recommended and the dosage adjusted if needed. Fluconazole is eliminated unchanged by the kidneys and may be a more appropriate antifungal agent, depending on the patient''s condition.', 'Metabolism', 'Brivaracetam, Topiramate, Ezogabine, Paramethadione, Methsuximide, Fenfluramine, Eslicarbazepine, Lamotrigine, Phensuximide, Methylphenobarbital, Phenacemide, More', 'Caspofungin, Micafungin, Amphotericin B, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120985/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Ozuna J, Friel P "Effect of enteral tube feeding on serum phenytoin levels." J Neurosurg Nurs 16 (1984): 289-91[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.[9] Doak KK, Haas CE, Dunnigan KJ, et al. "Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings." Pharmacotherapy 18 (1998): 637-45[10] Haley CJ, Nelson J "Phenytoin-enteral feeding interaction." DICP 23 (1989): 796-8[11] Rodman DP, Stevenson TL, Ray TR "Phenytoin malabsorption after jejunostomy tube delivery." Pharmacotherapy 15 (1995): 801-5[12] Faraji B, Yu PP "Serum phenytoin levels of patients on gastrostomy tube feeding." J Neurosci Nurs 30 (1998): 55-9[13] Au Yeung SC, Ensom MH "Phenytoin and enteral feedings: does evidence support an interaction?" Ann Pharmacother 34 (2000): 896-905[14] Sandor P, Sellers EM, Dumbrell M, Khouw V "Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics." Clin Pharmacol Ther 30 (1981): 390-7[15] Sellers EM, Holloway MR "Drug kinetics and alcohol ingestion." Clin Pharmacokinet 3 (1978): 440-52[16] Guidry JR, Eastwood TF, Curry SC "Phenytoin absorption in volunteers receiving selected enteral feedings." West J Med 150 (1989): 659-61[17] Holtz L, Milton J, Sturek JK "Compatibility of medications with enteral feedings." JPEN J Parenter Enteral Nutr 11 (1987): 183-6[18] Marvel ME, Bertino JS "Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension." JPEN J Parenter Enteral Nutr 15 (1991): 316-8[19] Fleisher D, Sheth N, Kou JH "Phenytoin interaction with enteral feedings administered through nasogastric tubes." JPEN J Parenter Enteral Nutr 14 (1990): 513-6[20] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM "Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability." Epilepsia 28 (1987): 706-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120848, 'Itraconazole', 'Etonogestrel', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Megestrol acetate, Estetrol', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120986/', '[1] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ "Pregnancy associated with a combined oral contraceptive and itraconazole." N Z Med J 106 (1993): 436[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120849, 'Itraconazole', 'Etoposide', 'Moderate', 'Coadministration with itraconazole may significantly increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by itraconazole.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever itraconazole is added to or withdrawn from therapy. Some authorities recommend avoiding concomitant use of nevirapine from 2 weeks before and during treatment with itraconazole.', 'Metabolism', 'Topotecan, Teniposide', 'Micafungin, Miconazole, Oteseconazole, Ketoconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120987/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Kaukonen KM, Olkkola KT, Neuvonen PJ "Itraconazole increases plasma concentrations of quinidine." Clin Pharmacol Ther 62 (1997): 510-7[3] Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44[4] Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH "Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor." Drug Metab Dispos 24 (1996): 307-14[5] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[7] Tailor SAN "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 1374[8] Gillies J, Hung KA, Fitzsimons E, Soutar R "Severe vincristine toxicity in combination with itraconazole." Clin Lab Haematol 20 (1998): 123-4[9] Lukkari E, Juhakoski A, Aranko K, Neuvonen PJ "Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite." Eur J Clin Pharmacol 52 (1997): 403-6[10] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[11] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[12] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[13] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[14] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[15] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[16] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[17] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[18] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[19] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120850, 'Itraconazole', 'Etravirine', 'Moderate', 'Coadministration of etravirine and itraconazole or ketoconazole may result in increased plasma concentrations of etravirine and decreased plasma concentration of the azole antifungal agent. Etravirine is a substrate as well as inducer of CYP450 3A4, while itraconazole and ketoconazole are both substrates and potent inhibitors of CYP450 3A4. Theoretically, itraconazole and ketoconazole can inhibit the metabolism of etravirine, and etravirine can induce the metabolism of the azole antifungal agents.', NULL, 'Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with itraconazole or ketoconazole.', NULL, 'Because safety data regarding increased etravirine exposures are limited, caution is advised if etravirine is prescribed in combination with itraconazole or ketoconazole. In addition, dosage adjustments may be required for the azole antifungal agent, depending on other coadministered drugs.', 'Metabolism', 'Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Maribavir, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120988/', '[1] "Product Information. Intelence (etravirine)." Ortho Biotech Inc, Bridgewater, NJ.[2] "Product Information. Intelence (etravirine)." Ortho Biotech Inc, Bridgewater, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120851, 'Itraconazole', 'Everolimus', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 and P-glycoprotein may significantly increase the plasma concentrations of everolimus following oral administration. Everolimus is a substrate of both the CYP450 3A4 isoenzyme and P-glycoprotein drug efflux transporter, thus their inhibition in the intestine can enhance the absorption of everolimus. The risk of side effects such as pneumonitis, stomatitis, infection, dyspnea, diarrhea, anemia, leucopenia, thrombocytopenia, hyperglycemia, and hyperlipidemia may be increased.', NULL, 'Concomitant use of everolimus with potent inhibitors of CYP450 3A4 and P-glycoprotein should generally be avoided.', NULL, 'Concomitant use of everolimus with potent inhibitors of CYP450 3A4 and P-glycoprotein should generally be avoided. Some authorities recommend avoiding concomitant use of everolimus during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'Flucytosine, Anidulafungin, Caspofungin, Oteseconazole', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib, Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120989/', '[1] "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[4] Homma S, Takahashi KI, Nihei S, Kato F, Sugihara S, Nunoda S "The successful management of respiratory complications with long-term, low-dose macrolide administration in pediatric heart transplant recipients." Int Heart J (2014):[5] "Product Information. Afinitor (everolimus)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120852, 'Itraconazole', 'Fedratinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of fedratinib, which is a substrate of the isoenzyme. The risk of adverse reactions such as anemia, thrombocytopenia, diarrhea, nausea, vomiting, and liver (ALT, AST) and pancreatic (amylase, lipase) enzyme elevations may increase.', NULL, 'Coadministration of fedratinib with potent CYP450 3A4 inhibitors should be avoided.', NULL, 'Coadministration of fedratinib with potent CYP450 3A4 inhibitors should be avoided. However, if coadministration with a potent CYP450 3A4 inhibitor is necessary, the manufacturer recommends that the dose of fedratinib be reduced to 200 mg once daily. Patients should be advised to notify their health care professional if signs and symptoms of anemia, thrombocytopenia, or gastrointestinal, hepatic, or pancreatic toxicity develop. Further dosage adjustment may be required based on patient tolerance and response. When/if concomitant therapy with a potent CYP450 3A4 inhibitor is ceased, the dose of fedratinib should first be increased to 300 mg once daily for two weeks an then increased to 400 mg once daily thereafter as tolerated.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120990/', '[1] "Product Information. Inrebic (fedratinib)." Celgene Corporation, Summit, NJ.[2] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[3] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[6] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[7] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[8] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[9] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[10] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[11] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[12] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[13] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[14] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[15] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[16] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[19] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[20] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[21] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[22] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[23] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[24] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[25] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[26] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[28] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[30] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[31] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[32] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[33] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120853, 'Itraconazole', 'Felodipine', 'Major', 'Coadministration with itraconazole or ketoconazole may significantly increase the plasma concentrations of felodipine. The proposed mechanism is decreased first-pass metabolism and hepatic clearance of felodipine due to inhibition of CYP450 3A4.There have been case reports of leg and ankle edema in patients treated with itraconazole and dihydropyridine calcium channel blockers. Pharmacodynamically, itraconazole exhibits a dose-related negative inotropic effect, which may be additive to those of calcium channel blockers (CCBs). It is conceivable that coadministration may potentiate the risk of ventricular dysfunction, congestive heart failure, and peripheral and pulmonary edema, particularly in patients with preexisting risk factors (e.g., a history of congestive heart failure; cardiac disease such as ischemic and valvular disease; significant pulmonary disease such as chronic obstructive pulmonary disorder; edematous disorders such as renal failure). Itraconazole alone has also been associated with postmarketing reports of congestive heart failure, peripheral edema, and pulmonary edema in patients treated for onychomycosis and/or systemic fungal infections.', NULL, 'Because the alterations in felodipine pharmacokinetics cannot be feasibly managed by dosage reduction, concomitant use with itraconazole or ketoconazole is considered contraindicated.', NULL, 'Because the alterations in felodipine pharmacokinetics cannot be feasibly managed by dosage reduction, concomitant use with itraconazole or ketoconazole is considered contraindicated. Some authorities state that coadministration with felodipine is considered contraindicated during and for 2 weeks after treatment with itraconazole (AU).', 'Metabolism', 'Nebivolol, Bisoprolol, Sotalol, Clevidipine, Moexipril, Perindopril, Bisoprolol, Benazepril, Trandolapril, Captopril, Fosinopril, Indapamide', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120991/', '[1] Neuvonen PJ, Suhonen R "Itraconazole interacts with felodipine." J Am Acad Dermatol 33 (1995): 134-5[2] Tailor SAN "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 1374[3] Tailor SAN, Gupta AK, Walker SE, Shear NH "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 350-2[4] Rosen T "Debilitating edema associated with itraconazole therapy." Arch Dermatol 130 (1994): 260-1[5] Jalava KM, Olkkola KT, Neuvonen PJ "Itraconazole greatly increases plasma concentrations and effects of felodipine." Clin Pharmacol Ther 61 (1997): 410-5[6] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[7] "Product Information. Nizoral (ketoconazole)." Janssen Pharmaceutica, Titusville, NJ. (1992):[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[13] "Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.[14] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[15] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] "Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.[18] Fuhr U, Muller-Peltzer H, Kern R, et al. "Effects of grapefruit juice and smoking on verapamil concentrations in steady state." Eur J Clin Pharmacol 58 (2002): 45-53[19] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[20] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[21] "Product Information. Sular (nisoldipine)." Zeneca Pharmaceuticals, Wilmington, DE.[22] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[23] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[24] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[25] Ho PC, Ghose K, Saville D, Wanwimolruk S "Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers." Eur J Clin Pharmacol 56 (2000): 693-8[26] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120854, 'Itraconazole', 'Fesoterodine', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of fesoterodine''s active metabolite, 5-hydroxymethyl tolterodine, which is partially metabolized by the isoenzyme. The possibility of prolonged and/or increased pharmacologic effects of fesoterodine should be considered. Because 5-hydroxymethyl tolterodine is also metabolized by CYP450 2D6, the clinical significance of the interaction may be greater in patients who are CYP450 2D6-deficient, or so-called poor metabolizers of CYP450 2D6 who may rely more on the 3A4 metabolic pathway for clearance of the drug.', NULL, 'The dosage of fesoterodine should not exceed 4 mg/day when used with potent CYP450 3A4 inhibitors.', NULL, 'The dosage of fesoterodine should not exceed 4 mg/day when used with potent CYP450 3A4 inhibitors. Close clinical and laboratory monitoring is advised whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to contact their physician if they experience potential adverse effects of fesoterodine such as irregular heartbeat, blurry vision, difficulty urinating, dry mouth, headache, drowsiness, dizziness, gastrointestinal upset, or constipation. The product labeling for itraconazole (a potent CYP450 3A4 inhibitor) states that concomitant use with fesoterodine is contraindicated in patients with moderate to severe renal or hepatic impairment during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120992/', '[1] "Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Sporonox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Toviaz (fesoterodine)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120855, 'Itraconazole', 'Fexofenadine', 'Minor', 'Coadministration with ketoconazole has been shown to significantly increase the oral bioavailability of fexofenadine. The proposed mechanism is ketoconazole inhibition of the intestinal efflux of fexofenadine via P-glycoprotein transporter. No studies have been performed using other azole antifungal agents, but similar results are possible given their similarities to ketoconazole. Fexofenadine had no effect on the pharmacokinetics of ketoconazole.', NULL, '-', NULL, '-', 'Absorption', 'Mepyramine, Levocetirizine, Chlorcyclizine, Acrivastine, Triprolidine, Tripelennamine, Azelastine, Dexbrompheniramine, Clemastine, Doxylamine, Meclizine, More', 'Caspofungin, Micafungin, Amphotericin B, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120993/', '[1] "Product Information. Allegra-D (fexofenadine-pseudoephedrine)." Chattem Consumer Products, Chattanooga, TN.[2] "Product Information. Allegra (fexofenadine)." Hoechst Marion-Roussel Inc, Kansas City, MO.[3] Bailey DG, Dresser GK, Munoz C, Freemar DJ, Kim RB "Reduction of fexofenadine bioavailability by fruit juices." Clin Pharmacol Ther 69 (2001): PI-82[4] Dresser GK, Bailey DG, Leake BF, et al. "Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine." Clin Pharmacol Ther 71 (2002): 11-20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120856, 'Itraconazole', 'Fidaxomicin', 'Minor', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of fidaxomicin and its main metabolite, OP-1118, both of which are substrates of the intestinal efflux transporter. Theoretically, concentrations of fidaxomicin and OP-1118 may also be decreased at the site of action (i.e., gastrointestinal tract) due to P-gp inhibition.', NULL, '-', NULL, '-', 'Absorption', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole', 'Rifamycin, Kanamycin, Polymyxin B, Streptomycin, Rifaximin, Paromomycin, Neomycin', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120994/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Dificid (fidaxomicin)." Optimer Pharmaceuticals, San Diego, CA.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] "Product Information. Dificid (fidaxomicin)." Optimer Pharmaceuticals, San Diego, CA.[7] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120857, 'Itraconazole', 'Finasteride', 'Moderate', 'Coadministration with itraconazole may significantly increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by itraconazole.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever itraconazole is added to or withdrawn from therapy. Some authorities recommend avoiding concomitant use of nevirapine from 2 weeks before and during treatment with itraconazole.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, Aminobenzoic acid, Caffeine, Cromoglicic acid, Abrocitinib, Dupilumab, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120995/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Kaukonen KM, Olkkola KT, Neuvonen PJ "Itraconazole increases plasma concentrations of quinidine." Clin Pharmacol Ther 62 (1997): 510-7[3] Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44[4] Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH "Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor." Drug Metab Dispos 24 (1996): 307-14[5] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[7] Tailor SAN "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 1374[8] Gillies J, Hung KA, Fitzsimons E, Soutar R "Severe vincristine toxicity in combination with itraconazole." Clin Lab Haematol 20 (1998): 123-4[9] Lukkari E, Juhakoski A, Aranko K, Neuvonen PJ "Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite." Eur J Clin Pharmacol 52 (1997): 403-6[10] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[11] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[12] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[13] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[14] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[15] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[16] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[17] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[18] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[19] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120858, 'Itraconazole', 'Flibanserin', 'Major', 'Coadministration with moderate and potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of flibanserin, which is primarily metabolized by CYP450 3A4 and, to a lesser extent, by CYP450 2C19. High plasma levels of flibanserin may increase the risk of severe hypotension, syncope, and central nervous system depression.', NULL, 'Concomitant use of flibanserin with moderate or potent CYP450 3A4 inhibitors is considered contraindicated.', NULL, 'Concomitant use of flibanserin with moderate or potent CYP450 3A4 inhibitors is considered contraindicated. When initiating flibanserin following treatment with a moderate or potent CYP450 3A4 inhibitor, the manufacturer recommends waiting until 2 weeks after the last dose of CYP450 3A4 inhibitor. Conversely, if a moderate or potent CYP450 3A4 inhibitor is required during flibanserin therapy, flibanserin should be discontinued at least 2 days before starting the CYP450 3A4 inhibitor.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Ritodrine, Bremelanotide, Cabergoline', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120996/', '[1] "Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals, Raleigh, NC.[2] "Product Information. Addyi (flibanserin)." Sprout Pharmaceuticals, Raleigh, NC.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120859, 'Itraconazole', 'Fludrocortisone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'Fluocinolone acetonide, Fluocinolone acetonide, Fluorometholone', 'Micafungin, Caspofungin, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120997/', '[1] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD "Case of psychosis due to prednisone-clarithromycin interaction." Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM "Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction." J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ "Impact of ketoconazole on the metabolism of prednisolone." Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR "Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals." J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ "Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone." Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML "The use of macrolide antibiotic substances in the treatment of asthma." J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH "Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma." Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. "Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects." Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone." Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G "Steroid-induced mania in an adolescent: risk factors and management." Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J "Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers." J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[30] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120860, 'Itraconazole', 'Flunisolide (nasal)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'Mupirocin, Mometasone furoate, Epinephrine, Vitamin A, Ephedrine, Olopatadine, Ipratropium, Cromoglicic acid, Hyaluronic acid, Nedocromil, Phenylephrine, More', 'Fluconazole, Caspofungin, Amphotericin B, Micafungin, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120998/', '[1] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD "Case of psychosis due to prednisone-clarithromycin interaction." Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM "Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction." J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ "Impact of ketoconazole on the metabolism of prednisolone." Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR "Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals." J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ "Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone." Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML "The use of macrolide antibiotic substances in the treatment of asthma." J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH "Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma." Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. "Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects." Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone." Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G "Steroid-induced mania in an adolescent: risk factors and management." Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J "Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers." J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[30] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120861, 'Itraconazole', 'Fluorometholone (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'Mometasone furoate, Fluorometholone, Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Salicylic acid, More', 'Fluconazole, Caspofungin, Amphotericin B, Micafungin, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/120999/', '[1] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD "Case of psychosis due to prednisone-clarithromycin interaction." Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM "Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction." J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ "Impact of ketoconazole on the metabolism of prednisolone." Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR "Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals." J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ "Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone." Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML "The use of macrolide antibiotic substances in the treatment of asthma." J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH "Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma." Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. "Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects." Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone." Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G "Steroid-induced mania in an adolescent: risk factors and management." Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J "Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers." J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[30] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120862, 'Itraconazole', 'Fluticasone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the systemic exposure to fluticasone following intranasal administration or oral inhalation. Fluticasone undergoes extensive first-pass and systemic metabolism via CYP450 3A4, thus inhibition of the isoenzyme may significantly increase systemic bioavailability of the drug. However, the extent of interaction may depend on route of fluticasone administration and the specific formulation.', NULL, 'Concomitant use of most orally inhaled fluticasone preparations with potent CYP450 3A4 inhibitors is not recommended unless the potential benefit outweighs the risk of systemic side effects.', NULL, 'Concomitant use of most orally inhaled fluticasone preparations with potent CYP450 3A4 inhibitors is not recommended unless the potential benefit outweighs the risk of systemic side effects. Alternatives to fluticasone should be considered whenever possible. A less potent, less lipophilic, and/or shorter-acting agent such as beclomethasone or flunisolide may be appropriate. The lowest effective dosage of orally inhaled corticosteroid should be used, and further adjustments made as necessary according to therapeutic response and tolerance. Intranasal fluticasone and fluticasone furoate-vilanterol oral inhalation powder may be used cautiously in combination with potent CYP450 3A4 inhibitors except ritonavir.', 'Metabolism', 'Micafungin, Caspofungin, Oteseconazole, Flucytosine, Anidulafungin', 'Mometasone furoate, Umeclidinium, Aclidinium, Glycopyrronium, Ipratropium, Cromoglicic acid, Revefenacin, Nedocromil, Beclomethasone dipropionate, Mometasone furoate, Amcinonide, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121000/', '[1] "Product Information. Veramyst (fluticasone nasal)." GlaxoSmithKline, Research Triangle Park, NC.[2] Valin N, De Castro N, Garrait V, Bergeron A, Bouche C, Molina JM "Iatrogenic Cushing''s syndrome in HIV-infected patients receiving ritonavir and inhaled fluticasone: description of 4 new cases and review of the literature." J Int Assoc Physicians AIDS Care 8 (2009): 113-21[3] "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical, Abbott Park, IL.[4] Lonnebo A, Grahnen A, Jansson B, Brundin RM, Lingandersson A, Eckernas SA "An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers." Eur J Clin Pharmacol 49 (1996): 459-63[5] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[6] Nocent C, Raherison C, Dupon M, Taytard A "Unexpected effects of inhaled fluticasone in an HIV patient with asthma." J Asthma 41 (2004): 793-5[7] Li AM "Ritonavir and fluticasone: Beware of this potentially fatal combination." J Pediatr 148 (2006): 294-5[8] Woods DR, Arun CS, Corris PA, Perros P "Cushing''s syndrome without excess cortisol." BMJ 332 (2006): 469-70[9] Jinno S, Goshima C "Progression of Kaposi sarcoma associated with iatrogenic Cushing syndrome in a person with HIV/AIDS." AIDS Read 18 (2008): 100-4[10] Boorsma M, Andersson N, Larsson P, Ullman A "Assessment of the relative systemic potency of inihaled fluticasone and budesonide." Eur Respir J 9 (1996): 1427-32[11] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[12] Schmid C, Naef R, Speich R, Boehler A "Addition of inhaled fluticasone propionate to systemic immunosuppression after lung transplantation: Cushing''s Syndrome in patients on itraconazole comedication." Transplantation 76 (2003): 263-4[13] Daveluy A, Raignoux C, Miremont-Salame G, et al. "Drug interactions between inhaled corticosteroids and enzymatic inhibitors." Eur J Clin Pharmacol (2009):[14] Pessanha TM, Campos JM, Barros AC, Pone MV, Garrido JR, Pone SM "Iatrogenic Cushing''s syndrome in a adolescent with AIDSs on ritonavir and inhaled fluticasone. case report and literature review." AIDS 21 (2007): 529-32[15] Rouanet I, Peyriere H, Mauboussin JM, Vincent D "Cushing''s syndrome in a patient treated by ritonavir/lopinavir and inhaled fluticasone." HIV Med 4 (2003): 149-50[16] Todd GR, Acerini CL, Ross-Russell, Zahra S, Warner JT, McCance D "Survey of adrenal crisis associated witwh inhaled corticosteroids in the United Kingdom." Arch Dis Child 87 (2002): 457-61[17] Lipworth BJ "Systemic adverse effects of inhaled corticosteroid therapy - A systematic review and meta-analysis." Arch Intern Med 159 (1999): 941-55[18] Grahnen A, Eckernas SA, Brundin RM, Ling-Andersson A "An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers." Br J Clin Pharmacol 38 (1994): 521-5[19] Pearce RE, Leeder JS, Kearns GL "Biotransformation of fluticasone: in vitro characterization." Drug Metab Dispos 34 (2006): 1035-40[20] Vassiliadi D, Tsagarakis S "Unusual causes of Cushing''s syndrome." Arq Bras Endocrinol Metabol 51 (2007): 1245-52[21] Bernecker C, West TB, Mansmann G, Scherbaum WA, Willenberg HS "Hypercortisolism caused by ritonavir associated inhibition of CYP 3A4 under inhalative glucocorticoid therapy. 2 case reports and a review of the literature." Exp Clin Endocrinol Diabetes 120 (2012): 125-7[22] Fardon TC, Lee DK, Haggart K, McFarlane LC, Lipworth BJ "Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate." Am J Respir Crit Care Med 170 (2004): 960-6[23] Parmar JS, Howell T, Kelly J, Bilton D "Profound adrenal suppression secondary to treatment with low dose inhaled steroids and itraconazole in allergic bronchopulmonary aspergillosis in cystic fibrosis." Thorax 57 (2002): 749-50[24] "Product Information. Flonase (fluticasone)." Glaxo Wellcome, Research Triangle Park, NC.[25] Brus R "Effects of high-dose inhaled corticosteroids on plasma cortisol consentrations in healthy adults." Arch Intern Med 159 (1999): 1903-8[26] Arrington-Sanders R, Hutton N, Siberry GK "Ritonavir-fluticasone interaction causing Cushing syndrome in HIV-infected children and adolescents." Pediatr Infect Dis J 25 (2006): 1044-1048[27] "Product Information. Breo Ellipta (fluticasone-vilanterol)." GlaxoSmithKline, Research Triangle Park, NC.[28] Kedem E, Shahar E, Hassoun G, Pollack S "Iatrogenic Cushing''s syndrome due to coadministration of ritonavir and inhaled budesonide in an asthmatic human immunodeficiency virus infected patient." J Asthma 47 (2010): 830-1[29] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[30] Molimard M, Girodet PO, Pollet C, et al. "Inhaled corticosteroids and adrenal insufficiency: prevalence and clinical presentation." Drug Saf 31 (2008): 769-74[31] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[32] Kempsford R, Norris V, Siederer S "Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD." Pulm Pharmacol Ther 26 (2013): 256-64[33] Sastre J "Pharmacology of fluticasone propionate." J Investig Allergol Clin Immunol 7 (1997): 382-4[34] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[35] Johnson SR, Marion AA, Vrchoticky T, Emmanuel PJ, Lujan-Zilbermann J "Cushing syndrome with secondary adrenal insufficiency from concomitant therapy with ritonavir and fluticasone." J Pediatr 148 (2006): 386-388[36] Kelly HW "Comparison of inhaled corticosteroids." Ann Pharmacother 32 (1998): 220-32[37] "Product Information. Flovent (fluticasone)." Glaxo Wellcome, Research Triangle Park, NC.[38] Gillett MJ, Cameron PU, Nguyen HV, Hurley DM, Mallal SA "Iatrogenic Cushing''s syndrome in an HIV-infected patient treated with ritonavir and inhaled fluticasone." AIDS 19 (2005): 740-1[39] Naef R, Schmid C, Hofer M, Minder S, Speich R, Boehler A "Itraconazole comedication increases systemic levels of inhaled fluticasone in lung transplant recipients." Respiration 74 (2007): 418-22[40] Foisy MM, Yakiwchuk EM, Chiu I, Singh AE "Adrenal suppression and Cushing''s syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature." HIV Med 9 (2008): 389-96', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120863, 'Itraconazole', 'Fluvoxamine', 'Moderate', 'Coadministration with fluvoxamine may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to competitive inhibition of CYP450 3A4 activity by fluvoxamine.', NULL, 'Caution is advised if fluvoxamine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if fluvoxamine must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fluvoxamine is added to or withdrawn from therapy.', 'Metabolism', 'Phenelzine, Duloxetine, Desipramine, Tranylcypromine, Trimipramine, Desvenlafaxine, Maprotiline, Fluoxetine, St. John''s Wort, Isocarboxazid, Oxitriptan, More', 'Caspofungin, Micafungin, Amphotericin B, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121001/', '[1] "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.[2] Damkier P, Hansen LL, Brosen K "Effect of fluvoxamine on the pharmacokinetics of quinidine." Eur J Clin Pharmacol 55 (1999): 451-6[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120864, 'Itraconazole', 'Fosamprenavir', 'Moderate', 'Coadministration with amprenavir or its prodrug, fosamprenavir, may increase the plasma concentrations of itraconazole and ketoconazole, and vice versa. The mechanism is competitive inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of these agents.', NULL, 'Patients receiving amprenavir or fosamprenavir in combination with itraconazole or ketoconazole should be monitored for altered efficacy and safety of the drugs.', NULL, 'Patients receiving amprenavir or fosamprenavir in combination with itraconazole or ketoconazole should be monitored for altered efficacy and safety of the drugs. Amprenavir and fosamprenavir labeling states that dosage reduction of itraconazole and ketoconazole may be required in patients receiving more than 400 mg/day of either antifungal agent. High dosages of itraconazole or ketoconazole (greater than 200 mg/day) are not recommended during treatment with the fosamprenavir-ritonavir combination regimen.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Maribavir, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121002/', '[1] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.[2] "Product Information. Agenerase (amprenavir)." Glaxo Wellcome, Research Triangle Pk, NC.[3] Polk RE, Crouch MA, Israel DS, et al. "Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men." Pharmacotherapy 19 (1999): 1378-84[4] "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120865, 'Itraconazole', 'Fosaprepitant', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of aprepitant, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors.', NULL, 'Caution is advised if aprepitant is prescribed in combination with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, idelalisib, nefazodone, telithromycin, cobicistat, delavirdine, and protease inhibitors. Pharmacologic response to aprepitant should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. In addition, many CYP450 3A4 inhibitors are also substrates of the isoenzyme, thus pharmacologic response to these agents should also be monitored during coadministration with aprepitant.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121003/', '[1] "Product Information. Emend for Injection (fosaprepitant)." Merck & Company Inc, West Point, PA.[2] "Product Information. Emend (aprepitant)." Merck & Company Inc, West Point, PA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120866, 'Itraconazole', 'Fosphenytoin', 'Moderate', 'Phenytoin and other hydantoins may reduce itraconazole serum levels by up to 90%. The mechanism appears to be enhanced first-pass metabolism and hepatic enzyme metabolism (CYP450 3A4) of itraconazole. Itraconazole therapy may fail. Ketoconazole is affected in a similar manner. In addition, itraconazole may increase the plasma concentrations of phenytoin.', NULL, 'Coadministration of phenytoin or other hydantoins with itraconazole or ketoconazole should be avoided from 2 weeks before and during treatment with itraconazole or ketoconazole.', NULL, 'Coadministration of phenytoin or other hydantoins with itraconazole or ketoconazole should be avoided from 2 weeks before and during treatment with itraconazole or ketoconazole. Some experts suggest that if concomitant use is unavoidable, a dosage increase for itraconazole or ketoconazole should be considered. In addition, monitoring of phenytoin concentrations is recommended and the dosage adjusted if needed. Fluconazole is eliminated unchanged by the kidneys and may be a more appropriate antifungal agent, depending on the patient''s condition.', 'Metabolism', 'Micafungin, Amphotericin B, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Brivaracetam, Topiramate, Ezogabine, Paramethadione, Methsuximide, Fenfluramine, Eslicarbazepine, Lamotrigine, Phensuximide, Methylphenobarbital, Phenacemide, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121004/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Ozuna J, Friel P "Effect of enteral tube feeding on serum phenytoin levels." J Neurosurg Nurs 16 (1984): 289-91[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.[9] Doak KK, Haas CE, Dunnigan KJ, et al. "Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings." Pharmacotherapy 18 (1998): 637-45[10] Haley CJ, Nelson J "Phenytoin-enteral feeding interaction." DICP 23 (1989): 796-8[11] Rodman DP, Stevenson TL, Ray TR "Phenytoin malabsorption after jejunostomy tube delivery." Pharmacotherapy 15 (1995): 801-5[12] Faraji B, Yu PP "Serum phenytoin levels of patients on gastrostomy tube feeding." J Neurosci Nurs 30 (1998): 55-9[13] Au Yeung SC, Ensom MH "Phenytoin and enteral feedings: does evidence support an interaction?" Ann Pharmacother 34 (2000): 896-905[14] Sandor P, Sellers EM, Dumbrell M, Khouw V "Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics." Clin Pharmacol Ther 30 (1981): 390-7[15] Sellers EM, Holloway MR "Drug kinetics and alcohol ingestion." Clin Pharmacokinet 3 (1978): 440-52[16] Guidry JR, Eastwood TF, Curry SC "Phenytoin absorption in volunteers receiving selected enteral feedings." West J Med 150 (1989): 659-61[17] Holtz L, Milton J, Sturek JK "Compatibility of medications with enteral feedings." JPEN J Parenter Enteral Nutr 11 (1987): 183-6[18] Marvel ME, Bertino JS "Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension." JPEN J Parenter Enteral Nutr 15 (1991): 316-8[19] Fleisher D, Sheth N, Kou JH "Phenytoin interaction with enteral feedings administered through nasogastric tubes." JPEN J Parenter Enteral Nutr 14 (1990): 513-6[20] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM "Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability." Epilepsia 28 (1987): 706-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120867, 'Itraconazole', 'Fostamatinib', 'Major', 'Coadministration of fostamatinib with potent inhibitors of CYP450 3A4 may significantly increase exposure to the active metabolite known as R406, the predominant moiety in the systemic circulation following fostamatinib administration. Fostamatinib is metabolized in the gut by alkaline phosphatase to R406, which then undergoes oxidation via CYP450 3A4 and glucuronidation via UGT1A9. Increased exposure to R406 may result in increased risk of adverse effects such as diarrhea, hepatotoxicity, hypertension, and neutropenia.', NULL, 'Patients should be monitored for toxicities of fostamatinib during concomitant use of potent CYP450 3A4 inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.', NULL, 'Patients should be monitored for toxicities of fostamatinib during concomitant use of potent CYP450 3A4 inhibitors, and the fostamatinib dosage adjusted as necessary in accordance with the product labeling.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Eltrombopag, Romiplostim, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121005/', '[1] "Product Information. Tavalisse (fostamatinib)." Rigel Pharmaceuticals, South San Francisco, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120868, 'Itraconazole', 'Fostemsavir', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4, P-glycoprotein (P-gp), and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of temsavir, the active moiety of fostemsavir. Increased temsavir exposure may increase the risk of QT prolongation.', NULL, 'No dosage adjustments are recommended for fostemsavir when used with potent CYP450 3A4, P-gp, and/or BCRP inhibitors.', NULL, 'No dosage adjustments are recommended for fostemsavir when used with potent CYP450 3A4, P-gp, and/or BCRP inhibitors. It may be advisable to monitor patients for increased adverse effects such as QT prolongation during coadministration, particularly in the elderly and patients with risk factors for torsade de pointes.', 'Metabolism, Absorption', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Maribavir, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121006/', '[1] "Product Information. Rukobia (fostemsavir)." ViiV Healthcare, Research Triangle Park, NC.[2] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120869, 'Itraconazole', 'Galantamine', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of galantamine, which is partially metabolized by the isoenzyme.', NULL, 'Pharmacologic response to galantamine should be monitored more closely whenever a potent CYP450 3A4 inhibitor (e.', NULL, 'Pharmacologic response to galantamine should be monitored more closely whenever a potent CYP450 3A4 inhibitor (e.g., clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors) is added to or withdrawn from therapy, and the galantamine dosage adjusted as necessary. Patients should be advised to notify their physician if they experience excessive cholinergic symptoms such as severe nausea, vomiting, GI cramping, salivation, lacrimation, sweating, dizziness, or syncope.', 'Metabolism', 'Rivastigmine, Aducanumab, Memantine, Ginkgo biloba, Tacrine', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121007/', '[1] "Product Information. Reminyl (galantamine)" Janssen Pharmaceuticals, Titusville, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120870, 'Itraconazole', 'Gefitinib', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of gefitinib, which is primarily metabolized by the isoenzyme. According to the product labeling, administration of gefitinib (250 mg single dose) with the potent inhibitor itraconazole (200 mg once a day for 12 days) increased the mean gefitinib systemic exposure (AUC) by 88% in healthy male volunteers.', NULL, 'Caution is advised if gefitinib is administered with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.', NULL, 'Caution is advised if gefitinib is administered with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors. Pharmacologic response to gefitinib should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the dosage adjusted as necessary. Patients should be advised to contact their physician if they experience possible symptoms of gefitinib toxicity such as severe diarrhea, nausea, dyspnea, cough, and fever.', 'Metabolism', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121008/', '[1] Li J, Zhao M, He P, Hidalgo M, Baker SD "Differential metabolism of gefitinib and erlotinib by human cytochrome p450 enzymes." Clin Cancer Res 13 (2007): 3731-7[2] "Product Information. Iressa (gefitinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120871, 'Itraconazole', 'Gilteritinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of gilteritinib, which is primarily metabolized by the isoenzyme. Increased exposure to gilteritinib may increase the risk of serious adverse effects such as QT interval prolongation, pancreatitis, liver transaminase and bilirubin elevations, edema, infections, and stomatitis.', NULL, 'Concomitant use of gilteritinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of gilteritinib with potent CYP450 3A4 inhibitors should generally be avoided. Alternative agents with no or minimal CYP450 3A4 inhibitory potential are recommended whenever possible. Otherwise, close monitoring for increased adverse effects is advisable, including more frequent ECG monitoring. Gilteritinib treatment should be interrupted or dosage reduced in patients with serious or life-threatening toxicity in accordance with the product labeling.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121009/', '[1] "Product Information. Xospata (gilteritinib)." Astellas Pharma US, Inc, Deerfield, IL.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120872, 'Itraconazole', 'Glasdegib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of glasdegib, which is primarily metabolized by the isoenzyme. Increased exposure to glasdegib may increase the risk of serious adverse effects such as QT interval prolongation, anemia, febrile neutropenia, thrombocytopenia, hemorrhage, edema, and mucositis.', NULL, 'Concomitant use of glasdegib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of glasdegib with potent CYP450 3A4 inhibitors should generally be avoided. Alternative agents with no or minimal CYP450 3A4 inhibitory potential are recommended whenever possible. Otherwise, close monitoring for increased adverse effects is advisable, including more frequent ECG monitoring.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Selinexor, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121010/', '[1] "Product Information. Daurismo (glasdegib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] "Product Information. Daurismo (glasdegib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120873, 'Itraconazole', 'Glipizide', 'Minor', 'Itraconazole, a potent inhibitor of CYP450 3A4, does not appear to significantly affect the pharmacokinetics of available oral hypoglycemic agents, most of which are primarily metabolized by CYP450 2C8 (pioglitazone, rosiglitazone, repaglinide) or 2C9 (nateglinide, sulfonylureas). In most patients, no change in antidiabetic effect was reported. No specific precautions should be necessary during coadministration of most oral hypoglycemic agents with itraconazole. However, dosage adjustments may be necessary if an interaction is suspected.', NULL, '-', NULL, '-', 'Metabolism', 'Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Sitagliptin, Canagliflozin, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, More', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Ketoconazole, Flucytosine, Anidulafungin', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121011/', '[1] Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ "Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone." Clin Pharmacol Ther 77 (2005): 404-14[2] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[3] Niemi M, Backman JT, Neuvonen M, Neuvonen PJ "Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide." Diabetologia 46 (2003): 347-51[4] Verspeelt J, Marynissen G, Gupta AK, De Doncker P "Safety of itraconazole in diabetic patients." Dermatology 198 (1999): 382-4[5] Miners JO, Birkett DJ "Cytochrome P4502C9: an enzyme of major importance in human drug metabolism." Br J Clin Pharmacol 45 (1998): 525-38[6] Niemi M, Backman JT, Juntti-Patinen L, Neuvonen M, Neuvonen PJ "Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide." Br J Clin Pharmacol 60 (2005): 208-17[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14[9] Komatsu K, Ito K, Nakajima Y, Kanamitsu S, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N, Sugiyama Y "Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments." Drug Metab Disposition 28 (2000): 475-81[10] Hatorp V, Hansen KT, Thomsen MS "Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide." J Clin Pharmacol 43 (2003): 649-60[11] Shon JH, Yoon YR, Kim MJ, et al. "Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism." Br J Clin Pharmacol 59 (2005): 552-63[12] Venkatakrishnan K, von Moltke LL, Greenblatt DJ "Effects of the antifungal agents on oxidative drug metabolism: clinical relevance." Clin Pharmacokinet 38 (2000): 111-80[13] Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT "Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes." Clin Pharmacol Ther 72 (2002): 326-32[14] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[15] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[16] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[17] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[18] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[20] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[23] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[24] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[25] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[26] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[27] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[28] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[29] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[30] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[31] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[32] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[33] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120874, 'Itraconazole', 'Glyburide', 'Minor', 'Itraconazole, a potent inhibitor of CYP450 3A4, does not appear to significantly affect the pharmacokinetics of available oral hypoglycemic agents, most of which are primarily metabolized by CYP450 2C8 (pioglitazone, rosiglitazone, repaglinide) or 2C9 (nateglinide, sulfonylureas). In most patients, no change in antidiabetic effect was reported. No specific precautions should be necessary during coadministration of most oral hypoglycemic agents with itraconazole. However, dosage adjustments may be necessary if an interaction is suspected.', NULL, '-', NULL, '-', 'Metabolism', 'Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Sitagliptin, Canagliflozin, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, More', 'Micafungin, Caspofungin, Posaconazole, Oteseconazole, Ketoconazole, Flucytosine, Anidulafungin', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121012/', '[1] Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ "Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone." Clin Pharmacol Ther 77 (2005): 404-14[2] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[3] Niemi M, Backman JT, Neuvonen M, Neuvonen PJ "Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide." Diabetologia 46 (2003): 347-51[4] Verspeelt J, Marynissen G, Gupta AK, De Doncker P "Safety of itraconazole in diabetic patients." Dermatology 198 (1999): 382-4[5] Miners JO, Birkett DJ "Cytochrome P4502C9: an enzyme of major importance in human drug metabolism." Br J Clin Pharmacol 45 (1998): 525-38[6] Niemi M, Backman JT, Juntti-Patinen L, Neuvonen M, Neuvonen PJ "Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide." Br J Clin Pharmacol 60 (2005): 208-17[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14[9] Komatsu K, Ito K, Nakajima Y, Kanamitsu S, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N, Sugiyama Y "Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments." Drug Metab Disposition 28 (2000): 475-81[10] Hatorp V, Hansen KT, Thomsen MS "Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide." J Clin Pharmacol 43 (2003): 649-60[11] Shon JH, Yoon YR, Kim MJ, et al. "Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism." Br J Clin Pharmacol 59 (2005): 552-63[12] Venkatakrishnan K, von Moltke LL, Greenblatt DJ "Effects of the antifungal agents on oxidative drug metabolism: clinical relevance." Clin Pharmacokinet 38 (2000): 111-80[13] Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT "Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes." Clin Pharmacol Ther 72 (2002): 326-32[14] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[15] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[16] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[17] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[18] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[20] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[23] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[24] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[25] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[26] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[27] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[28] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[29] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[30] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[31] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[32] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[33] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120875, 'Itraconazole', 'Granisetron', 'Moderate', 'Coadministration with itraconazole may significantly increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by itraconazole.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever itraconazole is added to or withdrawn from therapy. Some authorities recommend avoiding concomitant use of nevirapine from 2 weeks before and during treatment with itraconazole.', 'Metabolism', 'Nabilone, Scopolamine, Dronabinol, Rolapitant, Dolasetron, Palonosetron', 'Micafungin, Caspofungin, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121013/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Kaukonen KM, Olkkola KT, Neuvonen PJ "Itraconazole increases plasma concentrations of quinidine." Clin Pharmacol Ther 62 (1997): 510-7[3] Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44[4] Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH "Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor." Drug Metab Dispos 24 (1996): 307-14[5] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[7] Tailor SAN "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 1374[8] Gillies J, Hung KA, Fitzsimons E, Soutar R "Severe vincristine toxicity in combination with itraconazole." Clin Lab Haematol 20 (1998): 123-4[9] Lukkari E, Juhakoski A, Aranko K, Neuvonen PJ "Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite." Eur J Clin Pharmacol 52 (1997): 403-6[10] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[11] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[12] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[13] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[14] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[15] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[16] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[17] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[18] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[19] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120876, 'Itraconazole', 'Grepafloxacin', 'Moderate', 'Based on in vitro inhibition data, coadministration with grepafloxacin may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by grepafloxacin.', NULL, 'Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if grepafloxacin must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever grepafloxacin is added to or withdrawn from therapy.', 'Metabolism', 'Enoxacin, Levofloxacin, Norfloxacin, Nalidixic acid, Gemifloxacin, Lomefloxacin, Cinoxacin, Trovafloxacin, Delafloxacin, Sparfloxacin', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121014/', '[1] "Product Information. Raxar (grepafloxacin)." Glaxo Wellcome, Research Triangle Park, NC.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120877, 'Itraconazole', 'Guanfacine', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of guanfacine, which is primarily metabolized by the isoenzyme. The risk of adverse reactions such as hypotension, bradycardia, and sedation may increase.', NULL, 'Caution and dosage adjustment are advised when guanfacine is administered with potent and moderate CYP450 3A4 inhibitors.', NULL, 'Caution and dosage adjustment are advised when guanfacine is administered with potent and moderate CYP450 3A4 inhibitors. For extended-release guanfacine, the manufacturers recommend reducing the dosage to half the recommended level during concomitant use . Further dosage adjustments may be required based on patient tolerance and response.', 'Metabolism', 'Rauwolfia serpentina root, Reserpine, Methyldopa, Deserpidine', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121015/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Intuniv (guanfacine)." Shire US Inc, Florence, KY.[3] "Product Information. Tenex (guanfacine)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Intuniv (guanfacine)." Shire US Inc, Florence, KY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120878, 'Itraconazole', 'Halofantrine', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of halofantrine, resulting in an increased risk of QT interval prolongation and ventricular arrhythmias. The mechanism is inhibition of CYP450 3A4, the isoenzyme responsible for the metabolic clearance of halofantrine. Halofantrine has been associated with QT interval prolongation, ventricular arrhythmias, and sudden death, even at recommended dosages.', NULL, 'Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors.', NULL, 'Caution and close monitoring is recommended if halofantrine is prescribed with CYP450 3A4 inhibitors, particularly potent ones like itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors. The manufacturer recommends performing an ECG before initiating halofantrine therapy and cardiac monitoring during and for 8 to 12 hours after completion of therapy.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Artesunate, Mefloquine, Lumefantrine, Tafenoquine, Primaquine, Proguanil, Sulfadoxine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121016/', '[1] Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Bretano C "Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine." Clin Pharmacol Ther 72 (2002): 514-23[2] Giao PT, de Vries PJ "Pharmacokinetic interactions of antimalarial agents." Clin Pharmacokinet 40 (2001): 343-73[3] "Product Information. Halfan (halofantrine)." GlaxoSmithKline, Philadelphia, PA.[4] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7[5] Baune B, Flinois JP, Furlan V, et al. "Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5." J Pharm Pharmacol 51 (1999): 419-26[6] Giao PT, de Vries PJ "Pharmacokinetic interactions of antimalarial agents." Clin Pharmacokinet 40 (2001): 343-73[7] "Product Information. Halfan (halofantrine)." GlaxoSmithKline, Philadelphia, PA.[8] Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7[9] Charbit B, Becquemont L, Lepere B, Peytavin G, Funck-Bretano C "Pharmacokinetic and pharmacodynamic interaction between grapefruit juice and halofantrine." Clin Pharmacol Ther 72 (2002): 514-23[10] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120879, 'Itraconazole', 'Haloperidol', 'Moderate', 'Itraconazole, a potent inhibitor of CYP450 3A4, may increase the plasma concentrations of haloperidol. Haloperidol and reduced haloperidol have been shown to be substrates of CYP450 3A4 and to a lesser extent of CYP450 2D6. Metabolic inhibition and reduced haloperidol clearance may result in increased neurologic side effects.', NULL, 'When coadministration of itraconazole and haloperidol is necessary, monitoring for adverse effects and a reduction in the haloperidol dosage should be considered.', NULL, 'When coadministration of itraconazole and haloperidol is necessary, monitoring for adverse effects and a reduction in the haloperidol dosage should be considered. Patients should be advised to notify their doctor if they experience extrapyramidal symptoms, drowsiness, slurred speech, agitation, restlessness, or irregular heartbeats.', 'Metabolism', 'Chlorpromazine, Mesoridazine, Methotrimeprazine, Promazine, Fluphenazine, Asenapine, Perphenazine, Thiothixene, Thioridazine, Clozapine, Trifluoperazine, More', 'Micafungin, Caspofungin, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121017/', '[1] Yasui N, Kondo T, Otani K, Furukori H, Mihara K, Suzuki A, Kaneko S, Inoue Y "Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: In vivo evidence of the involvement of CYP3A4 for haloperidol metabolism." J Clin Psychopharmacol 19 (1999): 149-54[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[4] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[6] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[7] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[8] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[9] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[10] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[11] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[12] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[13] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[14] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[15] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120880, 'Itraconazole', 'Hydroxychloroquine', 'Moderate', 'Coadministration with moderate or strong inhibitors of CYP450 2C8 or CYP450 3A4 may increase the plasma concentration of hydroxychloroquine and the risk of toxicities such as QT interval prolongation and ventricular arrhythmias.', NULL, 'Caution and close monitoring is recommended whenever hydroxychloroquine or chloroquine is used concomitantly with a moderate or strong CYP450 3A4 or 2C8 inhibitor.', NULL, 'Caution and close monitoring is recommended whenever hydroxychloroquine or chloroquine is used concomitantly with a moderate or strong CYP450 3A4 or 2C8 inhibitor. Clinical and laboratory monitoring should be considered whenever a moderate or strong CYP450 3A4 or 2C8 inhibitor is added to or withdrawn from therapy with hydroxychloroquine or chloroquine, and the dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitations, irregular heartbeat, shortness of breath, or syncope.', 'Metabolism', 'Micafungin, Caspofungin, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Artesunate, Mefloquine, Lumefantrine, Tafenoquine, Primaquine, Proguanil, Sulfadoxine', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121018/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.[3] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120881, 'Itraconazole', 'Ibrutinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ibrutinib, which is primarily metabolized by the isoenzyme.', NULL, 'The use of ibrutinib in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics should generally be avoided, particularly those that are intended for chronic administration.', NULL, 'The use of ibrutinib in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics should generally be avoided, particularly those that are intended for chronic administration. Some authorities recommend avoiding concomitant use of ibrutinib during and for 2 weeks after treatment with itraconazole. Alternative agents with no or minimal CYP450 3A4 inhibitory potential are recommended whenever possible. If no alternatives exist and the CYP450 3A4 inhibitor is used short-term for 7 days or less, consider interrupting or delaying initiation of ibrutinib treatment until therapy with the inhibitor is complete. Patients should be closely monitored for signs of ibrutinib toxicity such as myelosuppression, bleeding, infection, and renal impairment.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121019/', '[1] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[2] "Product Information. Imbruvica (ibrutinib)." Pharmacyclics Inc, Sunnyvale, CA.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] "Product Information. Imbruvica (ibrutinib)." Pharmacyclics Inc, Sunnyvale, CA.[6] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120882, 'Itraconazole', 'Idarubicin', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of daunorubicin and idarubicin, both of which are substrates of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor, in attempt to overcome multidrug resistance in MDR1-overexpressing tumors.', NULL, 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor.', NULL, 'Caution is advised if daunorubicin or idarubicin is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.', 'Absorption', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Dactinomycin, Mitomycin, Valrubicin, Plicamycin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121020/', '[1] "Product Information. Daunoxome (daunorubicin liposomal)." Nexstar Pharmaceuticals Inc, Boulder, CO.[2] "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.[3] "Multum Information Services, Inc. Expert Review Panel"[4] "Product Information. Cerubidine (daunorubicin)." Wyeth-Ayerst Laboratories, Philadelphia, PA.[5] "Product Information. Incivek (telaprevir)." Vertex Pharmaceuticals, Cambridge, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120883, 'Itraconazole', 'Idelalisib', 'Moderate', 'Coadministration of idelalisib with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. The use of idelalisib has been associated with elevations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) greater than 5 times the upper limit of normal. Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of idelalisib, which is a substrate of both the isoenzyme and efflux transporter.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents such as azole antifungal agents, macrolide antibiotics, nefazodone, ritonavir, and telithromycin should be avoided whenever possible.', NULL, 'The use of idelalisib with other potentially hepatotoxic agents such as azole antifungal agents, macrolide antibiotics, nefazodone, ritonavir, and telithromycin should be avoided whenever possible. In addition, these agents are potent CYP450 3A4/P-gp inhibitors and may increase the toxicity of idelalisib. Caution is advised if coadministration is required. Patients should be closely monitored for hepatotoxicity and other toxicities of idelalisib such as diarrhea, colitis, intestinal perforation, pneumonitis, neutropenia and thrombocytopenia, and the dosing adjusted or interrupted as necessary. Patients should have serum ALT, AST, and bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling. Permanent discontinuation of idelalisib is recommended in those who experience recurrent hepatotoxicity following dosage reduction. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Metabolism, Synergism', 'Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121021/', '[1] "Product Information. Zydelig (idelalisib)." Gilead Sciences, Foster City, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120884, 'Itraconazole', 'Ifosfamide', 'Moderate', 'Coadministration with itraconazole may significantly increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by itraconazole.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever itraconazole is added to or withdrawn from therapy. Some authorities recommend avoiding concomitant use of nevirapine from 2 weeks before and during treatment with itraconazole.', 'Metabolism', 'Micafungin, Caspofungin, Miconazole, Posaconazole, Oteseconazole, Ketoconazole, Flucytosine, Anidulafungin, Voriconazole', 'Temozolomide, Streptozocin, Chlorambucil, Lomustine, Dacarbazine, Mechlorethamine, Bendamustine, Melphalan flufenamide, Uracil mustard', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121022/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Kaukonen KM, Olkkola KT, Neuvonen PJ "Itraconazole increases plasma concentrations of quinidine." Clin Pharmacol Ther 62 (1997): 510-7[3] Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44[4] Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH "Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor." Drug Metab Dispos 24 (1996): 307-14[5] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[7] Tailor SAN "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 1374[8] Gillies J, Hung KA, Fitzsimons E, Soutar R "Severe vincristine toxicity in combination with itraconazole." Clin Lab Haematol 20 (1998): 123-4[9] Lukkari E, Juhakoski A, Aranko K, Neuvonen PJ "Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite." Eur J Clin Pharmacol 52 (1997): 403-6[10] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[11] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[12] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[13] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[14] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[15] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[16] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[17] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[18] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[19] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120885, 'Itraconazole', 'Iloperidone', 'Major', 'Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may increase the plasma concentrations of iloperidone, which is a substrate of the isoenzymes.', NULL, 'The dosage of iloperidone should be reduced by one-half when administered concomitantly with potent CYP450 3A4 inhibitors (e.', NULL, 'The dosage of iloperidone should be reduced by one-half when administered concomitantly with potent CYP450 3A4 inhibitors (e.g., itraconazole, ketoconazole, voriconazole, nefazodone, delavirdine, protease inhibitors, clarithromycin, telithromycin) and/or potent CYP450 2D6 inhibitors (e.g., dacomitinib, fluoxetine, paroxetine, quinidine). Patients should be advised to seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope. Following discontinuation of the potent CYP450 3A4 or 2D6 inhibitor, the iloperidone dosage should be returned to the previous level.', 'Metabolism', 'Micafungin, Caspofungin, Oteseconazole, Flucytosine, Anidulafungin', 'Chlorpromazine, Mesoridazine, Methotrimeprazine, Promazine, Fluphenazine, Asenapine, Perphenazine, Thiothixene, Thioridazine, Clozapine, Trifluoperazine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121023/', '[1] "Product Information. Fanapt (iloperidone)." Vanda Pharmaceuticals Inc, Rockville, MD.[2] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[3] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[4] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[5] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120886, 'Itraconazole', 'Imatinib', 'Moderate', 'Imatinib is a substrate of the CYP450 3A4 isoenzyme as well as a potent competitive inhibitor of the CYP450 2C9, 2D6 and 3A4 isoenzymes. Some drugs that are known inhibitors of CYP450 3A4 are also metabolized by one or more of the isoenzymes inhibited by imatinib. Theoretically, coadministration of imatinib with those drugs may result in mutually elevated plasma drug concentrations due to competitive and noncompetitive inhibition of CYP450 activities.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of imatinib, including serious adverse effects such as edema, hematologic toxicity and immunosuppression, should be considered during concomitant therapy, particularly with potent CYP450 3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, nefazodone, and erythromycin.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of imatinib, including serious adverse effects such as edema, hematologic toxicity and immunosuppression, should be considered during concomitant therapy, particularly with potent CYP450 3A4 inhibitors such as ketoconazole, itraconazole, ritonavir, nefazodone, and erythromycin. In addition, clinical and laboratory monitoring for potentially increased pharmacologic effects of coadministered medications is recommended, especially those with a narrow therapeutic range.', 'Metabolism', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Flucytosine, Micafungin, Caspofungin, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121024/', '[1] "Product Information. Gleevec (imatinib mesylate)." Novartis Pharmaceuticals, East Hanover, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Gleevec (imatinib mesylate)." Novartis Pharmaceuticals, East Hanover, NJ.[4] Cerner Multum, Inc. "Australian Product Information." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120887, 'Itraconazole', 'Imipramine', 'Moderate', 'The coadministration with azole antifungal agents may increase the plasma concentrations of some tricyclic antidepressants (TCAs). Elevated TCA levels may result in CNS toxicity, anticholinergic symptoms, and QT interval prolongation. The mechanism is decreased TCA clearance due to azole-related inhibition of the CYP450 3A4 isoenzyme, which is partially responsible for the metabolism of TCAs like amitriptyline, clomipramine, imipramine, and possibly others.', NULL, 'During concomitant therapy with azole antifungal agents, patients stabilized on their TCA regimen should be observed for increased pharmacologic response to the TCA, and the dosage adjusted accordingly if necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients stabilized on their TCA regimen should be observed for increased pharmacologic response to the TCA, and the dosage adjusted accordingly if necessary. Serum TCA levels should be monitored following initiation or discontinuation of azole antifungal therapy. Patients should be advised to notify their caregiver if they experience excessive dry mouth, visual disturbances, urinary retention, dizziness, syncope, fast or irregular heartbeat, constipation, or seizures.', 'Metabolism', 'Phenelzine, Duloxetine, Desipramine, Tranylcypromine, Trimipramine, Desvenlafaxine, Maprotiline, Fluoxetine, St. John''s Wort, Isocarboxazid, Oxitriptan, More', 'Caspofungin, Micafungin, Amphotericin B, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121025/', '[1] Dorsey ST, Biblio LA "Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline." Am J Emerg Med 18 (2000): 227-9[2] Gannon RH "Fluconazole-nortriptyline drug interaction." Ann Pharmacother 26 (1992): 1456[3] Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E "Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects." Br J Clin Pharmacol 43 (1997): 315-8[4] Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E "Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects." Br J Clin Pharmacol 43 (1997): 315-8[5] Robinson RF, Nahata MC, Olshefski RS "Syncope associated with concurrent amitriptyline and fluconazole therapy." Ann Pharmacother 34 (2000): 1406-9[6] Newberry DL, Bass SN, Mbanefo CO "A fluconazole/amitriptyline drug interaction in three male adults." Clin Infect Dis 24 (1997): 270-1', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120888, 'Itraconazole', 'Indacaterol', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein may increase the systemic exposure to indacaterol following oral inhalation, as it is a substrate of both the isoenzyme and efflux transporter.', NULL, '-', NULL, '-', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Mometasone furoate, Terbutaline, Umeclidinium, Aclidinium, Glycopyrronium, Epinephrine, Olodaterol, Cromoglicic acid, Ipratropium, Orciprenaline, Pirbuterol, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121026/', '[1] "Product Information. Arcapta Neohaler (indacaterol)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120889, 'Itraconazole', 'Indinavir', 'Moderate', 'Coadministration with itraconazole may significantly increase the plasma concentrations of indinavir. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by itraconazole.', NULL, 'The manufacturer recommends that the indinavir dose be reduced to 600 mg every 8 hours during concurrent administration.', NULL, 'The manufacturer recommends that the indinavir dose be reduced to 600 mg every 8 hours during concurrent administration. The patient should be monitored for the therapeutic and adverse effects of indinavir, and dosage adjustments should be made as necessary.', 'Metabolism', 'Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Maribavir, More', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121027/', '[1] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[2] Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S "Single-dose pharmacokinetics of indinavir and the effect of food." Antimicrob Agents Chemother 42 (1998): 332-8[3] Shelton MJ, Wynn HE, Newitt RG, DiFrancesco R "Effects of grapefruit juice on pharmacokinetic exposure to indinavir in HIV-positive subjects." J Clin Pharmacol 41 (2001): 435-42[4] "Product Information. Crixivan (indinavir)." Merck & Co, Inc, West Point, PA.[5] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[7] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[8] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[9] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[10] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[11] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[12] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[13] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[14] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120890, 'Itraconazole', 'Irinotecan (liposomal)', 'Major', 'Coadministration with certain azole antifungal agents may significantly increase the plasma concentrations of irinotecan and its active metabolite, SN-38. CYP450 3A4 is the isoenzyme responsible for the metabolic conversion of irinotecan to its inactive metabolite, APC. Inhibition of APC formation results in more irinotecan metabolism to SN-38, an active and toxic metabolite. High plasma levels of irinotecan and SN-38 may increase the risk of potentially fatal toxicities such as severe diarrhea, neutropenia, sepsis, and thromboembolism.', NULL, 'Concomitant use of irinotecan with ketoconazole or itraconazole is considered contraindicated.', NULL, 'Concomitant use of irinotecan with ketoconazole or itraconazole is considered contraindicated. Ketoconazole should be discontinued for at least one week before initiation of treatment with irinotecan, and itraconazole should be discontinued for up to two weeks before. Some authorities consider concomitant administration of irinotecan to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'Topotecan, Teniposide', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121028/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] "Product Information. Onivyde (irinotecan liposomal)." Merrimack Pharmaceuticals, Cambridge, MA.[3] Phansalker S, Desai AA, Bell D, et al "High-priority drug-drug interactions for use in electronic health records." J Am Med Inform Assoc 19 (2012): 735-43[4] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] "Product Information. Nizoral (ketoconazole)." Janssen Pharmaceutica, Titusville, NJ. (1992):[8] "Product Information. Camptosar (irinotecan)." Pharmacia and Upjohn, Kalamazoo, MI.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120891, 'Itraconazole', 'Isoniazid', 'Moderate', 'The concomitant administration of potent CYP450 3A4 inducers may significantly reduce itraconazole and ketoconazole serum levels. The mechanism appears to be enhanced first-pass metabolism and hepatic enzyme metabolism (CYP450 3A4) of the antifungal agents. Antifungal therapy may fail.', NULL, 'Coadministration of potent CYP450 3A4 inducers with itraconazole or ketoconazole should be avoided.', NULL, 'Coadministration of potent CYP450 3A4 inducers with itraconazole or ketoconazole should be avoided. Some authorities recommend avoiding concomitant therapy with potent CYP450 3A4 inducers from 2 weeks before and during treatment with itraconazole. Fluconazole is eliminated unchanged by the kidneys and may be a more appropriate antifungal agent, depending on the patient''s condition.', 'Metabolism', 'Capreomycin, Pyrazinamide, Rifamycin, Sulfamethoxazole, Streptomycin, Cycloserine, Pyridoxine, Ethionamide, Pretomanid, Aminosalicylic acid', 'Micafungin, Caspofungin, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121029/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Nizoral (ketoconazole)." Janssen Pharmaceutica, Titusville, NJ.[3] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120892, 'Itraconazole', 'Ivabradine', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivabradine, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of ivabradine with potent CYP450 3A4 inhibitors is considered contraindicated.', NULL, 'Concomitant use of ivabradine with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities consider concomitant administration of ivabradine and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Adenosine, Regadenoson, Ubidecarenone, Nebivolol, Bisoprolol, Sotalol', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121030/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[4] "Product Information. Corlanor (ivabradine)." Amgen USA, Thousand Oaks, CA.[5] "Product Information. Corlanor (ivabradine)." Amgen USA, Thousand Oaks, CA.[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[9] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120893, 'Ivermectin', 'Itraconazole', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of ivermectin and the risk of adverse effects. The proposed mechanism, based on in vitro data, is decreased clearance due to inhibition of CYP450 3A4, the primary isoenzyme responsible for the metabolic clearance of ivermectin.', NULL, 'Caution is advised when ivermectin must be used concomitantly with potent CYP450 3A4 inhibitors.', NULL, 'Caution is advised when ivermectin must be used concomitantly with potent CYP450 3A4 inhibitors. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever a potent CYP450 3A4 inhibitor is added to or withdrawn from therapy.', 'Metabolism', 'Thiabendazole, Levamisole, Pyrantel, Piperazine, Mebendazole, Minoxidil, Deoxycholic acid, Calcium gluconate, Magnesium sulfate, Glycopyrronium, Pimecrolimus, More', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121031/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Zeng Z, Andrew NW, Arison BH, Luffer-Atlas D, Wang RW "Identification of cytochrome P4503A4 as the major enzyme responsible for the metabolism of ivermectin by human liver microsomes." Xenobiotica 28 (1998): 313-21[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120894, 'Itraconazole', 'Ivosidenib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivosidenib, which is primarily metabolized by the isoenzyme. Coadministration with ivosidenib may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4, including many of the known potent inhibitors of the isoenzyme such as clarithromycin, conivaptan, delavirdine, idelalisib, itraconazole, ketoconazole, nefazodone, posaconazole, telithromycin, and all protease inhibitors. Ivosidenib is an inducer of CYP450 3A4 and induces its own metabolism following multiple dosing.', NULL, 'Concomitant use of ivosidenib with potent CYP450 3A4 inhibitors, particularly those that are also substrates of CYP450 3A4, should generally be avoided.', NULL, 'Concomitant use of ivosidenib with potent CYP450 3A4 inhibitors, particularly those that are also substrates of CYP450 3A4, should generally be avoided. If coadministration is required, a reduction of the ivosidenib dosage to 250 mg once daily is recommended. Following discontinuation of the potent inhibitor for at least 5 half-lives, ivosidenib therapy should be returned to the recommended dosage of 500 mg once daily. Monitoring of electrocardiograms and electrolytes should be conducted regularly.', 'Metabolism', 'Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Selinexor, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121032/', '[1] "Product Information. Tibsovo (ivosidenib)." Agios Pharmaceuticals, Cambridge, MA.[2] "Product Information. Tibsovo (ivosidenib)." Agios Pharmaceuticals, Cambridge, MA.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120895, 'Itraconazole', 'Ixabepilone', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ixabepilone, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of ixabepilone with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of ixabepilone with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is necessary, a reduction of the ixabepilone dosage to 20 mg/m2 should be considered. Based on pharmacokinetic studies, this dosage is predicted to adjust the ixabepilone systemic exposure (AUC) to the range observed without inhibitors. However, clinical data are lacking. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the ixabepilone dosage is adjusted upward to the indicated dosage.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Dactinomycin, Mitomycin, Valrubicin, Plicamycin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121033/', '[1] "Product Information. Ixempra (ixabepilone)." Bristol-Myers Squibb, Princeton, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Ixempra (ixabepilone)." Bristol-Myers Squibb, Princeton, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120896, 'Itraconazole', 'Lansoprazole', 'Moderate', 'Proton pump inhibitors may decrease the gastrointestinal absorption of the azole antifungal agents, itraconazole and ketoconazole, both of which require an acidic environment for dissolution. By increasing gastric pH and reducing the acidity, proton pump inhibitors can decrease bioavailability of the azoles by 75% to 80%.', NULL, 'If coadministration is necessary, an acidic pH may be produced with two capsules of glutamic acid hydrochloride administered 15 minutes before the azole dose.', NULL, 'If coadministration is necessary, an acidic pH may be produced with two capsules of glutamic acid hydrochloride administered 15 minutes before the azole dose. Administration with an acidic beverage such as Coca-Cola(R) or Pepsi(R) may also help. However, clinicians should still consider the possibility of a reduced or subtherapeutic antifungal effect. It may be appropriate to switch to an agent like fluconazole or terbinafine whose absorption is not affected by stomach pH.', 'Absorption', 'Tinidazole, Levofloxacin, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Amoxicillin', 'Flucytosine, Anidulafungin, Micafungin, Oteseconazole', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121034/', '[1] Piscitelli SC, Goss TF, Wilton JH, D''Andrea DT, Goldstein H, Schentag JJ "Effects of ranitidine and sucralfate on ketoconazole bioavailability." Antimicrob Agents Chemother 35 (1991): 1765-71[2] "Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc, Deerfield, IL.[3] Bottiger Y, Tybring G, Gotharson E, Bertilsson L "Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin." Clin Pharmacol Ther 62 (1997): 384-91[4] "Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America, Lincolnshire, IL.[5] Carlson JA, Mann HJ, Canafax DM "Effect of pH on disintegration and dissolution of ketoconazole tablets." Am J Hosp Pharm 40 (1983): 1334-6[6] Jaruratanasirikul S, Sriwiriyajan S "Effect of omeprazole on the pharmacokinetics of itraconazole." Eur J Clin Pharmacol 54 (1998): 159-61[7] Van der Meer JW, Keuning JJ "The influence of gastric acidity on the bio-availability of ketoconazole." J Antimicrob Chemother 6 (1980): 552-4[8] "Product Information. Nexium (esomeprazole)" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[9] "Product Information. Aciphex (rabeprazole)" Janssen Pharmaceuticals, Titusville, NJ.[10] "Product Information. Protonix (pantoprazole)" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Chin TWF, Loeb M, Fong IW "Effects of an acidic beverage (coca-cola) on absorption of ketoconazole." Antimicrob Agents Chemother 39 (1995): 1671-5[12] "Product Information. Prilosec (omeprazole)." Merck & Co, Inc, West Point, PA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120897, 'Itraconazole', 'Lanthanum carbonate', 'Moderate', 'INTERVAL: Theoretically, lanthanum carbonate may chelate with certain drugs in the gastrointestinal tract, resulting in reduced oral bioavailability of those drugs during coadministration.', NULL, 'To minimize the potential for interaction, drugs that are known to interact with antacids (e.', NULL, 'To minimize the potential for interaction, drugs that are known to interact with antacids (e.g., ACE inhibitors, beta blockers, bisphosphonates, coumarin derivatives, digitalis glycosides, fluoroquinolones, iron, phenytoin, rifampin, tetracyclines, thyroid preparations, valproic acid) should not be taken within 2 hours of administration of lanthanum carbonate according to the product labeling.', 'Absorption', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Difelikefalin, Deferoxamine, Levoleucovorin, Arginine, Methionine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121035/', '[1] "Product Information. Seysara (sarecycline)." Allergan Inc, Irvine, CA.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] "Product Information. Fosrenol (lanthanum carbonate)." Shire US Inc, Florence, KY.[5] "Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc., Boston, MA.[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120898, 'Itraconazole', 'Lapatinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lapatinib, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of lapatinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of lapatinib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of lapatinib during and for 2 weeks after treatment with itraconazole. If coadministration is required, the manufacturer recommends reducing the lapatinib dosage to 500 mg once a day. However, clinical data are lacking. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the lapatinib dosage is adjusted upward to the indicated dosage (i.e., 1250 mg once a day).', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121036/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[6] "Product Information. Tykerb (lapatinib)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120899, 'Itraconazole', 'Larotrectinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of larotrectinib, which is primarily metabolized by the isoenzyme. Increased exposure to larotrectinib may increase the risk of adverse effects such as neurotoxicity (delirium, dysarthria, dizziness, gait disturbance, paresthesia, encephalopathy, memory impairment, tremor) and hepatotoxicity (elevations in liver transaminases).', NULL, 'Concomitant use of larotrectinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of larotrectinib with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends reducing the larotrectinib dose by 50%. After the inhibitor has been discontinued for 3 to 5 elimination half-lives, the larotrectinib dose that was taken prior to initiating the inhibitor may be resumed.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121037/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc, West Haven, CT.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[6] "Product Information. Vitrakvi (larotrectinib)." Bayer Pharmaceutical Inc, West Haven, CT.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120900, 'Itraconazole', 'Lefamulin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 and/or P-gp may significantly increase the plasma concentrations of lefamulin, which is a substrate of both the isoenzyme and efflux transporter. Coadministration of intravenous lefamulin with oral ketoconazole increased mean lefamulin Cmax and AUC by 6% and 31%, respectively. Increased exposure to lefamulin may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Concomitant use of lefamulin with potent inhibitors of CYP450 3A4 and/or P-gp should generally be avoided.', NULL, 'Concomitant use of lefamulin with potent inhibitors of CYP450 3A4 and/or P-gp should generally be avoided.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Tinidazole, Bacitracin, Polymyxin B, Oritavancin, Daptomycin, Telavancin, Methenamine, Spectinomycin, Nitrofurantoin, Fosfomycin, Tedizolid, Dalbavancin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121038/', '[1] "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Xenleta (lefamulin)." Nabriva Therapeutics US, Inc., King of Prussia, PA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120901, 'Itraconazole', 'Leflunomide', 'Major', 'The recent, concomitant, or subsequent use (without the recommended leflunomide washout period or procedure) of other agents known to induce hepatotoxicity may potentiate the risk of liver injury associated with leflunomide. The risk is thought to extend to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.', NULL, 'Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.', NULL, 'Caution is advised if leflunomide or teriflunomide must be used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice), and vice versa. Liver enzymes and bilirubin should be measured prior to initiation of leflunomide/teriflunomide therapy and at least monthly for the first six months of treatment and every 6 to 8 weeks thereafter. Patients with preexisting liver disease or elevated baseline liver enzymes (i.e., ALT greater than two times ULN) should not receive leflunomide or teriflunomide. Patients who develop elevated serum ALT greater than three times ULN while receiving these medications should discontinue treatment and be given washout procedures with cholestyramine or activated charcoal to accelerate elimination of leflunomide''s active metabolite from plasma, which otherwise may take up to two years. Follow-up monitoring should be conducted at least weekly until the ALT value is within normal range, and washout procedures repeated as necessary. All patients treated with leflunomide or teriflunomide should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121039/', '[1] EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions. Available from URL: http://www.eudra.org/emea.html." ([1999 Sept 2]):[2] "Product Information. Arava (leflunomide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120902, 'Itraconazole', 'Lemborexant', 'Major', 'Coadministration with potent or moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of lemborexant, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of lemborexant with potent or moderate CYP450 3A4 inhibitors should be avoided.', NULL, 'Concomitant use of lemborexant with potent or moderate CYP450 3A4 inhibitors should be avoided.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, Paraldehyde, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121040/', '[1] "Product Information. Dayvigo (lemborexant)." Eisai Inc, Woodcliff Lake, NJ.[2] "Product Information. Dayvigo (lemborexant)." Eisai Inc, Woodcliff Lake, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120903, 'Itraconazole', 'Levamlodipine', 'Major', 'Itraconazole exhibits a dose-related negative inotropic effect which may be additive to those of calcium channel blockers (CCBs). Theoretically, coadministration may potentiate the risk of ventricular dysfunction, congestive heart failure, and peripheral and pulmonary edema, particularly in patients with preexisting risk factors (e.g., a history of congestive heart failure; cardiac disease such as ischemic and valvular disease; significant pulmonary disease such as chronic obstructive pulmonary disorder; edematous disorders such as renal failure). In addition, both itraconazole and its major metabolite, hydroxyitraconazole, inhibit CYP450 3A4 metabolism and may interfere with the clearance of certain CCBs like the dihydropyridines (amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, nimodipine, nisoldipine), diltiazem, and verapamil. Significant increases of severalfold in felodipine and nifedipine plasma concentrations have been observed during coadministration with itraconazole, and there have been case reports of leg and ankle edema in patients treated with various itraconazole-dihydropyridine combinations. Itraconazole alone has also been associated with postmarketing reports of congestive heart failure, peripheral edema, and pulmonary edema in patients treated for onychomycosis and/or systemic fungal infections.', NULL, 'Caution is advised if itraconazole must be used concomitantly with CCBs.', NULL, 'Caution is advised if itraconazole must be used concomitantly with CCBs. Close monitoring of clinical response and tolerance is recommended, and patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis. Appropriate dosage adjustment of the CCB may be necessary when used with itraconazole. Some authorities consider concomitant administration of bepridil and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism, Synergism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Clevidipine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121041/', '[1] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[2] Rosen T "Debilitating edema associated with itraconazole therapy." Arch Dermatol 130 (1994): 260-1[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Tailor SAN, Gupta AK, Walker SE, Shear NH "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 350-2[5] Jalava KM, Olkkola KT, Neuvonen PJ "Itraconazole greatly increases plasma concentrations and effects of felodipine." Clin Pharmacol Ther 61 (1997): 410-5[6] Tailor SAN "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 1374[7] Neuvonen PJ, Suhonen R "Itraconazole interacts with felodipine." J Am Acad Dermatol 33 (1995): 134-5[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[13] "Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.[14] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[15] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] "Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.[18] Fuhr U, Muller-Peltzer H, Kern R, et al. "Effects of grapefruit juice and smoking on verapamil concentrations in steady state." Eur J Clin Pharmacol 58 (2002): 45-53[19] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[20] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[21] "Product Information. Sular (nisoldipine)." Zeneca Pharmaceuticals, Wilmington, DE.[22] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[23] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[24] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[25] Ho PC, Ghose K, Saville D, Wanwimolruk S "Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers." Eur J Clin Pharmacol 56 (2000): 693-8[26] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[27] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[28] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[29] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[30] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[31] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[32] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[33] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[34] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[35] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[36] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120904, 'Itraconazole', 'Levobupivacaine', 'Moderate', 'Coadministration with inhibitors of CYP450 1A2 and/or 3A4 may increase the plasma concentrations of levobupivacaine, which is primarily metabolized by these isoenzymes.', NULL, 'Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.', NULL, 'Caution may be advisable if levobupivacaine is administered to patients receiving inhibitors of CYP450 1A2 (e.g., quinolones, deferasirox, mexiletine, propafenone, ticlopidine, zileuton) or CYP450 3A4 (e.g., azole antifungals, macrolide antibiotics, protease inhibitors, kinase inhibitors, aprepitant, conivaptan, cyclosporine, delavirdine, diltiazem, nefazodone, verapamil). Particular caution and dosage adjustment of levobupivacaine may be warranted during concomitant use of both a CYP450 1A2 inhibitor and a CYP450 3A4 inhibitor, or a drug that inhibits both isoenzymes (e.g., fluvoxamine). Patients should be monitored for early signs and symptoms of central nervous system toxicity such as dizziness, drowsiness, lightheadedness, anxiety, restlessness, incoherent speech, tremors, twitching, numbness and tingling of the mouth and lips, metallic taste, tinnitus, and blurred vision, as well as more serious reactions including convulsions, hypotension, arrhythmias, and cardiorespiratory depression.', 'Metabolism', 'Chloroprocaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121042/', '[1] "Product Information. Chirocaine (levobupivacaine)" Organon, West Orange, NJ.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120905, 'Itraconazole', 'Levacetylmethadol', 'Major', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and duration of action of levomethadyl acetate, which is a substrate of the isoenzyme. High plasma levels of levomethadyl acetate may increase the risk of QT interval prolongation, which is thought to be associated with serious cardiac events such as ventricular arrhythmias (e.g., torsade de pointes, ventricular tachycardia), cardiac arrest, and sudden death. Cases of QT prolongation and torsade de pointes have been reported with levomethadyl acetate alone during postmarketing use.', NULL, 'Concomitant use of levomethadyl acetate with CYP450 3A4 inhibitors is considered contraindicated.', NULL, 'Concomitant use of levomethadyl acetate with CYP450 3A4 inhibitors is considered contraindicated.', 'Metabolism', 'Micafungin, Caspofungin, Oteseconazole, Flucytosine, Anidulafungin', 'Diamorphine, Acamprosate, Lofexidine, Varenicline, Disulfiram, Nalmefene, Nicotine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121043/', '[1] "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.[2] "Product Information. Orlaam (levomethadyl acetate)" Roxanne Laboratories Inc, Columbus, OH.[3] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120906, 'Itraconazole', 'Levomilnacipran', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of levomilnacipran, which is primarily metabolized by the isoenzyme.', NULL, 'The dosage of levomilnacipran should not exceed 80 mg once daily when used with potent CYP450 3A4 inhibitors.', NULL, 'The dosage of levomilnacipran should not exceed 80 mg once daily when used with potent CYP450 3A4 inhibitors.', 'Metabolism', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Phenelzine, Duloxetine, Desipramine, Tranylcypromine, Trimipramine, Desvenlafaxine, Maprotiline, Fluoxetine, St. John''s Wort, Isocarboxazid, Oxitriptan, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121044/', '[1] "Product Information. Fetzima (levomilnacipran)." Forest Pharmaceuticals, St. Louis, MO.[2] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.[3] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[4] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.[5] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120907, 'Itraconazole', 'Levonorgestrel', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Megestrol acetate, Estetrol, Megestrol acetate', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121045/', '[1] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ "Pregnancy associated with a combined oral contraceptive and itraconazole." N Z Med J 106 (1993): 436[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120908, 'Itraconazole', 'Lomitapide', 'Major', 'Coadministration with potent and moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lomitapide, which is primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of lomitapide with potent or moderate inhibitors of CYP450 3A4 is considered contraindicated.', NULL, 'Concomitant use of lomitapide with potent or moderate inhibitors of CYP450 3A4 is considered contraindicated. Some authorities consider concomitant administration of lomitapide and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121046/', '[1] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[2] "Product Information. Juxtapid (lomitapide)." Aegerion Pharmaceuticals Inc, Cambridge, MA.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Juxtapid (lomitapide)." Aegerion Pharmaceuticals Inc, Cambridge, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120909, 'Itraconazole', 'Lonafarnib', 'Major', 'Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lonafarnib.', NULL, 'Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inhibitors is considered contraindicated.', NULL, 'Concomitant use of lonafarnib with potent or moderate CYP450 3A4 inhibitors is considered contraindicated.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121047/', '[1] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.[2] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120910, 'Itraconazole', 'Lorlatinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of lorlatinib, which has been found to be metabolized primarily by CYP450 3A4 and UGT1A4 in vitro. Increased exposure to lorlatinib may increase the risk of central nervous system adverse effects (e.g., seizures, hallucinations, changes in cognitive function, mood disorders, mental status changes, sleep impairment), hyperlipidemia (hypercholesterolemia and hypertriglyceridemia), PR interval prolongation and atrioventricular (AV) block, and interstitial lung disease/pneumonitis.', NULL, 'Concomitant use of lorlatinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of lorlatinib with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, the initial dosage of lorlatinib should be reduced from 100 mg orally once daily to 75 mg orally once daily. In patients who have had a dosage reduction to 75 mg orally once daily due to adverse reactions, the lorlatinib dosage should be further reduced to 50 mg orally once daily upon initiation of a potent CYP450 3A4 inhibitor. After 3 plasma half-lives following discontinuation of the potent CYP450 3A4 inhibitor, the lorlatinib dosage may be increased to that used prior to initiation of the inhibitor.', 'Metabolism', 'Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121048/', '[1] "Product Information. Lorbrena (lorlatinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Lorbrena (lorlatinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120911, 'Itraconazole', 'Loteprednol (ophthalmic)', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'Fluconazole, Caspofungin, Amphotericin B, Micafungin, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121049/', '[1] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD "Case of psychosis due to prednisone-clarithromycin interaction." Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM "Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction." J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ "Impact of ketoconazole on the metabolism of prednisolone." Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR "Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals." J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ "Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone." Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML "The use of macrolide antibiotic substances in the treatment of asthma." J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH "Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma." Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. "Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects." Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone." Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G "Steroid-induced mania in an adolescent: risk factors and management." Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J "Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers." J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[30] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120912, 'Itraconazole', 'Lovastatin', 'Major', 'Itraconazole increases the plasma concentrations of some HMG-CoA reductase inhibitors and may increase the risk of rhabdomyolysis. The mechanism has been reported to be inhibition of hepatic CYP450 3A4 enzymes responsible for HMG-CoA reductase inhibitor metabolism. Itraconazole greatly increases levels of lovastatin and its active metabolite, lovastatin acid and significantly increases simvastatin levels.', NULL, 'The concurrent use of itraconazole with lovastatin and simvastatin is considered contraindicated by the manufacturer.', NULL, 'The concurrent use of itraconazole with lovastatin and simvastatin is considered contraindicated by the manufacturer. Some authorities consider concomitant administration of lovastatin or simvastatin and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole. When concomitant use of an azole antifungal and an HMG-CoA reductase inhibitor is required, pravastatin which is not metabolized by CYP450 enzymes, or fluvastatin which is metabolized by CYP450 2C9, are recommended.', 'Metabolism', 'Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, More', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121050/', '[1] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[2] Neuvonen PJ, Kantola T, Kivisto KT "Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole." Clin Pharmacol Ther 63 (1998): 332-41[3] Holtzman CW, Wiggins BS, Spinler SA "Role of P-glycoprotein in statin drug interactions." Pharmacotherapy 26 (2006): 1601-7[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Kivisto KT, Kantola T, Neuvonen PJ "Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin." Br J Clin Pharmacol 46 (1998): 49-53[7] Neuvonen PJ, Jalava KM "Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 60 (1996): 54-61[8] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[9] Lees RS, Lees AM "Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole." N Engl J Med 333 (1995): 664-5[10] Lomaestro BM, Piatek MA "Update on drug interactions with azole antifungal agents." Ann Pharmacother 32 (1998): 915-28[11] Horn M "Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals." Arch Dermatol 132 (1996): 1254[12] Richter WO, Jacob BG, Schwandt P "Interaction between fibre and lovastatin." Lancet 338 (1991): 706[13] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[14] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[15] "Product Information. Mevacor (lovastatin)." Merck & Co, Inc, West Point, PA.[16] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[17] Neuvonen PJ, Backman JT, Niemi M "Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin." Clin Pharmacokinet 47 (2008): 463-74[18] Thompson PD, Clarkson P, Karas RH "Statin-associated myopathy." JAMA 289 (2003): 1681-90[19] "Product Information. Zocor (simvastatin)." Merck & Co, Inc, West Point, PA.[20] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[21] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[22] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[23] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[24] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[25] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[26] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[27] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[28] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[29] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120913, 'Itraconazole', 'Lumateperone', 'Major', 'Coadministration with strong or moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of lumateperone, which is metabolized by the isoenzyme in vitro.', NULL, 'Coadministration of strong or moderate CYP450 3A4 inhibitors with lumateperone should be avoided.', NULL, 'Coadministration of strong or moderate CYP450 3A4 inhibitors with lumateperone should be avoided.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Chlorpromazine, Mesoridazine, Methotrimeprazine, Promazine, Fluphenazine, Asenapine, Perphenazine, Thiothixene, Thioridazine, Clozapine, Trifluoperazine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121051/', '[1] "Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc., New York, NY.[2] "Product Information. Caplyta (lumateperone)." Intra-Cellular Therapies, Inc., New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120914, 'Itraconazole', 'Lurasidone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of lurasidone and its active metabolite, both of which are primarily metabolized by the isoenzyme.', NULL, 'Concomitant use of lurasidone with potent CYP450 3A4 inhibitors is considered contraindicated.', NULL, 'Concomitant use of lurasidone with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities consider concomitant administration of lurasidone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Chlorpromazine, Mesoridazine, Methotrimeprazine, Promazine, Fluphenazine, Asenapine, Perphenazine, Thiothixene, Thioridazine, Clozapine, Trifluoperazine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121052/', '[1] "Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[2] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] "Product Information. Latuda (lurasidone)." Sunovion Pharmaceuticals Inc, Marlborough, MA.[8] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[9] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[10] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120915, 'Itraconazole', 'Lurbinectedin', 'Major', 'Coadministration with a strong CYP450 3A4 inhibitor is predicted to increase lurbinectedin systemic exposure, which may increase the incidence and severity of adverse reactions to lurbinectedin, such as myelosuppression and hepatotoxicity.', NULL, 'Concomitant use of lurbinectedin and strong CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of lurbinectedin and strong CYP450 3A4 inhibitors should generally be avoided.', 'Metabolism', 'Caspofungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Selinexor, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121053/', '[1] "Product Information. Zepzelca (lurbinectedin)." Jazz Pharmaceuticals, Palo Alto, CA.[2] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.[3] "Product Information. Zepzelca (lurbinectedin)." Jazz Pharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120916, 'Itraconazole', 'Lusutrombopag', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) may increase the plasma concentrations of lusutrombopag, which is a substrate of both efflux transporter proteins.', NULL, 'Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors.', NULL, 'Caution is advised if lusutrombopag is prescribed in combination with P-gp and/or BCRP inhibitors. Pharmacologic response to lusutrombopag should be monitored more closely following initiation, discontinuation, or change of dosage of the concomitant P-gp or BCRP inhibitor.', 'Distribution', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Flucytosine, Anidulafungin, Voriconazole', 'Eltrombopag, Romiplostim, Emicizumab, Coagulation factor VIIa Recombinant Human, Coagulation factor X human, Phylloquinone, Anti-inhibitor coagulant complex, Antihemophilic factor, human recombinant, Fibrinogen human, Epinephrine, Coagulation Factor IX Human', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121054/', '[1] EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000366.jsp&mid=WC0b01ac058067c852" ([2013 - ]):', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120917, 'Itraconazole', 'Macitentan', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of macitentan, which is primarily metabolized by the isoenzyme. Macitentan was well tolerated with or without ketoconazole in the study, and there were no relevant differences in safety parameters between the treatments.', NULL, 'According to the product labeling, concomitant use of macitentan with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics should generally be avoided.', NULL, 'According to the product labeling, concomitant use of macitentan with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics should generally be avoided. Alternative treatment options for pulmonary arterial hypertension are recommended when potent CYP450 3A4 inhibitors are needed as part of HIV treatment.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Metyrosine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121055/', '[1] "Product Information. Opsumit (macitentan)." Actelion Pharmaceuticals US Inc, South San Francisco, CA.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120918, 'Itraconazole', 'Magaldrate', 'Moderate', 'INTERVAL: The dissolution of itraconazole requires an acidic environment. Antacids and some aluminum, calcium, or magnesium containing salts decrease the acidity of the stomach and can reduce the bioavailability and subsequent therapeutic effect of itraconazole.', NULL, 'Separation of doses by two or more hours is recommended.', NULL, 'Separation of doses by two or more hours is recommended.', 'Absorption', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121056/', '[1] Carlson JA, Mann HJ, Canafax DM "Effect of pH on disintegration and dissolution of ketoconazole tablets." Am J Hosp Pharm 40 (1983): 1334-6[2] Brass C, Galgiani JN, Blaschke TF, et al "Disposition of ketoconazole, an oral antifungal, in humans." Antimicrob Agents Chemother 21 (1982): 151-8[3] Van der Meer JW, Keuning JJ "The influence of gastric acidity on the bio-availability of ketoconazole." J Antimicrob Chemother 6 (1980): 552-4[4] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[5] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[7] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[8] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[9] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[10] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[11] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[12] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[13] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[14] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[15] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120919, 'Itraconazole', 'Magnesium carbonate', 'Moderate', 'INTERVAL: The dissolution of itraconazole requires an acidic environment. Antacids and some aluminum, calcium, or magnesium containing salts decrease the acidity of the stomach and can reduce the bioavailability and subsequent therapeutic effect of itraconazole.', NULL, 'Separation of doses by two or more hours is recommended.', NULL, 'Separation of doses by two or more hours is recommended.', 'Absorption', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole', 'Hydroxocobalamin, Fomepizole, Ipecac, Nitrous acid, Dexrazoxane, Oxygen, Difelikefalin, Deferoxamine, Levoleucovorin, Arginine, Methionine, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121057/', '[1] Carlson JA, Mann HJ, Canafax DM "Effect of pH on disintegration and dissolution of ketoconazole tablets." Am J Hosp Pharm 40 (1983): 1334-6[2] Brass C, Galgiani JN, Blaschke TF, et al "Disposition of ketoconazole, an oral antifungal, in humans." Antimicrob Agents Chemother 21 (1982): 151-8[3] Van der Meer JW, Keuning JJ "The influence of gastric acidity on the bio-availability of ketoconazole." J Antimicrob Chemother 6 (1980): 552-4[4] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[5] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[7] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[8] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[9] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[10] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[11] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[12] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[13] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[14] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[15] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120920, 'Itraconazole', 'Magnesium hydroxide', 'Moderate', 'INTERVAL: The dissolution of itraconazole requires an acidic environment. Antacids and some aluminum, calcium, or magnesium containing salts decrease the acidity of the stomach and can reduce the bioavailability and subsequent therapeutic effect of itraconazole.', NULL, 'Separation of doses by two or more hours is recommended.', NULL, 'Separation of doses by two or more hours is recommended.', 'Absorption', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121058/', '[1] Carlson JA, Mann HJ, Canafax DM "Effect of pH on disintegration and dissolution of ketoconazole tablets." Am J Hosp Pharm 40 (1983): 1334-6[2] Brass C, Galgiani JN, Blaschke TF, et al "Disposition of ketoconazole, an oral antifungal, in humans." Antimicrob Agents Chemother 21 (1982): 151-8[3] Van der Meer JW, Keuning JJ "The influence of gastric acidity on the bio-availability of ketoconazole." J Antimicrob Chemother 6 (1980): 552-4[4] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[5] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[7] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[8] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[9] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[10] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[11] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[12] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[13] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[14] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[15] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120921, 'Itraconazole', 'Maraviroc', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of maraviroc, which is primarily metabolized by the isoenzyme. Patients with severe renal impairment or end-stage renal disease (CrCl <30 mL/min) given maraviroc in combination with potent CYP450 3A4 inhibitors may have an increased risk of postural hypotension due to increased maraviroc exposure.', NULL, 'Maraviroc should be administered at a dosage of 150 mg twice daily during coadministration with potent CYP450 3A4 inhibitors, including most protease inhibitors except tipranavir plus ritonavir.', NULL, 'Maraviroc should be administered at a dosage of 150 mg twice daily during coadministration with potent CYP450 3A4 inhibitors, including most protease inhibitors except tipranavir plus ritonavir. This dosage is recommended whether or not a concomitant CYP450 3A4 inducer (e.g., efavirenz, rifampin, carbamazepine, phenobarbital, phenytoin) is given. Patients with moderate hepatic impairment who receive 150 mg with a potent CYP450 3A4 inhibitor should be monitored closely for maraviroc-associated adverse events. Maraviroc is contraindicated for use in combination with potent CYP450 3A4 inhibitors in patients with severe renal impairment or end-stage renal disease (CrCl <30 mL/min).', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Maribavir, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121059/', '[1] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120922, 'Itraconazole', 'Medroxyprogesterone acetate', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Megestrol acetate, Estetrol, Megestrol acetate, Megestrol acetate, Histrelin, Megestrol acetate, Leuprolide, Bicalutamide, Triptorelin', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121060/', '[1] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ "Pregnancy associated with a combined oral contraceptive and itraconazole." N Z Med J 106 (1993): 436[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120923, 'Itraconazole', 'Meloxicam', 'Moderate', 'Coadministration with itraconazole may decrease the plasma concentrations and therapeutic effects of meloxicam. The mechanism for this interaction has not been delineated.', NULL, 'Caution and monitoring of pharmacologic response to meloxicam is recommended whenever itraconazole is added to or withdrawn from therapy, and the meloxicam dosage adjusted as necessary.', NULL, 'Caution and monitoring of pharmacologic response to meloxicam is recommended whenever itraconazole is added to or withdrawn from therapy, and the meloxicam dosage adjusted as necessary.', 'Antagonism', 'Chloroprocaine, Tetracaine, Mepivacaine, Procaine, Prilocaine, Articaine, Etidocaine, Fenoprofen, Meclofenamic acid, Ketorolac, Phenylbutazone, More', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121061/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[3] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[4] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[5] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[6] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[7] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[8] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[9] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[10] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[11] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[12] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120924, 'Itraconazole', 'Mephenytoin', 'Moderate', 'Phenytoin and other hydantoins may reduce itraconazole serum levels by up to 90%. The mechanism appears to be enhanced first-pass metabolism and hepatic enzyme metabolism (CYP450 3A4) of itraconazole. Itraconazole therapy may fail. Ketoconazole is affected in a similar manner. In addition, itraconazole may increase the plasma concentrations of phenytoin.', NULL, 'Coadministration of phenytoin or other hydantoins with itraconazole or ketoconazole should be avoided from 2 weeks before and during treatment with itraconazole or ketoconazole.', NULL, 'Coadministration of phenytoin or other hydantoins with itraconazole or ketoconazole should be avoided from 2 weeks before and during treatment with itraconazole or ketoconazole. Some experts suggest that if concomitant use is unavoidable, a dosage increase for itraconazole or ketoconazole should be considered. In addition, monitoring of phenytoin concentrations is recommended and the dosage adjusted if needed. Fluconazole is eliminated unchanged by the kidneys and may be a more appropriate antifungal agent, depending on the patient''s condition.', 'Metabolism', 'Brivaracetam, Topiramate, Ezogabine, Paramethadione, Methsuximide, Fenfluramine, Eslicarbazepine, Lamotrigine, Phensuximide, Methylphenobarbital, Phenacemide, More', 'Caspofungin, Micafungin, Amphotericin B, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121062/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Ozuna J, Friel P "Effect of enteral tube feeding on serum phenytoin levels." J Neurosurg Nurs 16 (1984): 289-91[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.[9] Doak KK, Haas CE, Dunnigan KJ, et al. "Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings." Pharmacotherapy 18 (1998): 637-45[10] Haley CJ, Nelson J "Phenytoin-enteral feeding interaction." DICP 23 (1989): 796-8[11] Rodman DP, Stevenson TL, Ray TR "Phenytoin malabsorption after jejunostomy tube delivery." Pharmacotherapy 15 (1995): 801-5[12] Faraji B, Yu PP "Serum phenytoin levels of patients on gastrostomy tube feeding." J Neurosci Nurs 30 (1998): 55-9[13] Au Yeung SC, Ensom MH "Phenytoin and enteral feedings: does evidence support an interaction?" Ann Pharmacother 34 (2000): 896-905[14] Sandor P, Sellers EM, Dumbrell M, Khouw V "Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics." Clin Pharmacol Ther 30 (1981): 390-7[15] Sellers EM, Holloway MR "Drug kinetics and alcohol ingestion." Clin Pharmacokinet 3 (1978): 440-52[16] Guidry JR, Eastwood TF, Curry SC "Phenytoin absorption in volunteers receiving selected enteral feedings." West J Med 150 (1989): 659-61[17] Holtz L, Milton J, Sturek JK "Compatibility of medications with enteral feedings." JPEN J Parenter Enteral Nutr 11 (1987): 183-6[18] Marvel ME, Bertino JS "Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension." JPEN J Parenter Enteral Nutr 15 (1991): 316-8[19] Fleisher D, Sheth N, Kou JH "Phenytoin interaction with enteral feedings administered through nasogastric tubes." JPEN J Parenter Enteral Nutr 14 (1990): 513-6[20] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM "Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability." Epilepsia 28 (1987): 706-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120925, 'Itraconazole', 'Methylergometrine', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. Clinical ergotism has been reported, which can lead to gangrene and myocardial infarction in severe cases.', NULL, 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with itraconazole, ketoconazole, posaconazole, or voriconazole is considered contraindicated.', NULL, 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with itraconazole, ketoconazole, posaconazole, or voriconazole is considered contraindicated. Some authorities consider concomitant administration of ergot derivatives and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole. Use with other azole antifungal agents, including fluconazole at high multiple doses, should probably be avoided if possible.', 'Metabolism', 'Misoprostol, Dinoprostone, Oxytocin', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121063/', '[1] Hayton AC "Precipitation of acute ergotism by triacetyloleandomycin." N Z Med J 69 (1969): 42[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7[4] "Product Information. Migranal (dihydroergotamine nasal)." Novartis Pharmaceuticals, East Hanover, NJ.[5] Liaudet L, Buclin T, Jaccard C, Eckert P "Severe ergotism associated with interaction between ritonavir and ergotamine." Br Med J 318 (1999): 771[6] Eadie MJ "Clinically significant drug interactions with agents specific for migraine attacks." Cns Drugs 15 (2001): 105-18[7] Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3[8] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R "Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy." Ann Vasc Surg 7 (1993): 291-6[9] "Product Information. Cafergot (caffeine-ergotamine)." Novartis Pharmaceuticals, East Hanover, NJ.[10] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C "Dihydroergotamine-erythromycin-induced ergotism." Ann Intern Med 109 (1988): 249[11] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[12] Srisuma S, Lavonas EJ, Wananukul W "Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors." Clin Toxicol (Phila) (2014): 1-4[13] Matthews NT, Havill JH "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J 89 (1979): 476-7[14] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207[15] "Product Information. Noxafil (posaconazole)." Schering-Plough Corporation, Kenilworth, NJ.[16] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F "Clinical ergotism induced by ritonavir." Scand J Infect Dis 33 (2001): 788-9[17] Montero A, Giovannoni AG, Tvrde PL "Leg ischemia in a patient receiving ritonavir and ergotamine." Ann Intern Med 130 (1999): 329[18] Mortier E, Pouchet J, Vinceneux P, Lalande M "Ergotism related to interaction between nelfinavir and ergotamine." Am J Med 110 (2001): 594[19] Bird PA, Sturgess AD "Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction." Aust N Z J Med 30 (2000): 635-6[20] Liaudet L "Severe ergotism associated with interaction between ritonavir and ergotamine." BMJ 318 (1999): 771[21] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W "Cerebral ergotism under treatment with ergotamine and ritonavir." Neurology 57 (2001): 743-4[22] Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6[23] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[24] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP "Ergotism related to concurrent administration of ergotamine tartrate and indinavir." JAMA 281 (1999): 987[25] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW "Fatal ergotism induced by an HIV protease inhibitor." Headache 42 (2002): 694-5[26] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[27] Horowitz RS, Dart RC, Gomez HF "Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction." Arch Intern Med 156 (1996): 456-8[28] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[29] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[30] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[31] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[32] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[33] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[34] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[35] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[36] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[37] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[38] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[39] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[40] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[41] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[42] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[43] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[44] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[45] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[46] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[47] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[48] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[49] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[50] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[51] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[52] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[53] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[54] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[55] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[56] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[57] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[58] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[59] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[60] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[61] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120926, 'Itraconazole', 'Methylprednisolone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of methylprednisolone. Various CYP450 3A4 inhibitors including clarithromycin, diltiazem, erythromycin, itraconazole, ketoconazole, mibefradil, nefazodone, and troleandomycin have been shown to increase methylprednisolone systemic exposure (AUC) by approximately 100% to 300%, with increased adrenal suppression as evidenced by reduced plasma cortisol levels.', NULL, 'The possibility of increased corticosteroid effects should be considered when methylprednisolone is used with potent CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered when methylprednisolone is used with potent CYP450 3A4 inhibitors. Coadministration is not recommended unless the potential benefit to the patient outweighs the risk. If concomitant use is necessary, a 50% reduction in methylprednisolone dosage has been recommended by some investigators. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if methylprednisolone is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression. Signs and symptoms of adrenal insufficiency include anorexia, hypoglycemia, nausea, vomiting, weight loss, muscle wasting, fatigue, weakness, dizziness, postural hypotension, depression, and adrenal crisis manifested as inability to respond to stress (e.g., illness, infection, surgery, trauma).', 'Metabolism', 'Vitamin A, Isotretinoin, Chloramphenicol, Fluorometholone, Azelaic acid, Adapalene, Fluocinolone acetonide, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, More', 'Micafungin, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121064/', '[1] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[2] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[3] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[6] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[7] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[8] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[9] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[10] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[13] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[14] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[15] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[16] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[17] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[18] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[19] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[20] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[21] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[22] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[23] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[24] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[25] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[26] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[27] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[28] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[29] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[30] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[31] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[32] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[33] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[34] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[35] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[36] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[37] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[38] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[39] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[40] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[41] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[42] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120927, 'Itraconazole', 'Methysergide', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 including azole antifungal agents may significantly increase the plasma concentrations of ergot derivatives, which are primarily metabolized by the isoenzyme. Clinical ergotism has been reported, which can lead to gangrene and myocardial infarction in severe cases.', NULL, 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with itraconazole, ketoconazole, posaconazole, or voriconazole is considered contraindicated.', NULL, 'Given the potential for ergot toxicity characterized by peripheral vasospasm, ischemia, thrombosis, tachycardia and hypertension, concomitant use of ergot derivatives with itraconazole, ketoconazole, posaconazole, or voriconazole is considered contraindicated. Some authorities consider concomitant administration of ergot derivatives and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole. Use with other azole antifungal agents, including fluconazole at high multiple doses, should probably be avoided if possible.', 'Metabolism', 'Frovatriptan, Eptinezumab, Lasmiditan, Rizatriptan, Naratriptan, Galcanezumab, Zolmitriptan, Sumatriptan, Erenumab, Fremanezumab', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121065/', '[1] Hayton AC "Precipitation of acute ergotism by triacetyloleandomycin." N Z Med J 69 (1969): 42[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D "Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir." Postgrad Med J 75 (1999): 546-7[4] "Product Information. Migranal (dihydroergotamine nasal)." Novartis Pharmaceuticals, East Hanover, NJ.[5] Liaudet L, Buclin T, Jaccard C, Eckert P "Severe ergotism associated with interaction between ritonavir and ergotamine." Br Med J 318 (1999): 771[6] Eadie MJ "Clinically significant drug interactions with agents specific for migraine attacks." Cns Drugs 15 (2001): 105-18[7] Ausband SC, Goodman PE "An unusual case of clarithromycin associated ergotism." J Emerg Med 4 (2001): 411-3[8] Ghali R, De Lean J, Douville Y, Noel HP, Labbe R "Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy." Ann Vasc Surg 7 (1993): 291-6[9] "Product Information. Cafergot (caffeine-ergotamine)." Novartis Pharmaceuticals, East Hanover, NJ.[10] Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C "Dihydroergotamine-erythromycin-induced ergotism." Ann Intern Med 109 (1988): 249[11] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[12] Srisuma S, Lavonas EJ, Wananukul W "Ergotism and factitious hypotension associated with interaction of ergotamine with CYP3A4 inhibitors." Clin Toxicol (Phila) (2014): 1-4[13] Matthews NT, Havill JH "Ergotism with therapeutic doses of ergotamine tartrate." N Z Med J 89 (1979): 476-7[14] Caballero-Granado FJ, Viciana P, Cordero E, Gomez-Vera MJ, del Nozal M, Lopez-Cortes LF "Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient." Antimicrob Agents Chemother 41 (1997): 1207[15] "Product Information. Noxafil (posaconazole)." Schering-Plough Corporation, Kenilworth, NJ.[16] Vila A, Mykietiuk A, Bonvehi P, Temporiti E, Uruena A, Herrera F "Clinical ergotism induced by ritonavir." Scand J Infect Dis 33 (2001): 788-9[17] Montero A, Giovannoni AG, Tvrde PL "Leg ischemia in a patient receiving ritonavir and ergotamine." Ann Intern Med 130 (1999): 329[18] Mortier E, Pouchet J, Vinceneux P, Lalande M "Ergotism related to interaction between nelfinavir and ergotamine." Am J Med 110 (2001): 594[19] Bird PA, Sturgess AD "Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin - ergotamine drug interaction." Aust N Z J Med 30 (2000): 635-6[20] Liaudet L "Severe ergotism associated with interaction between ritonavir and ergotamine." BMJ 318 (1999): 771[21] Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W "Cerebral ergotism under treatment with ergotamine and ritonavir." Neurology 57 (2001): 743-4[22] Francis H, Tyndall A, Webb J "Severe vascular spasm due to erythromycin-ergotamine interaction." Clin Rheumatol 3 (1984): 243-6[23] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[24] Rosenthal E, Sala F, Chichmanian RM, Batt M, Cassuto JP "Ergotism related to concurrent administration of ergotamine tartrate and indinavir." JAMA 281 (1999): 987[25] Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW "Fatal ergotism induced by an HIV protease inhibitor." Headache 42 (2002): 694-5[26] "Product Information. D.H.E. 45 (dihydroergotamine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.[27] Horowitz RS, Dart RC, Gomez HF "Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction." Arch Intern Med 156 (1996): 456-8[28] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[29] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[30] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[31] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[32] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[33] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[34] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[35] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[36] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[37] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[38] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[39] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[40] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[41] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[42] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[43] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[44] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[45] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[46] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[47] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[48] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[49] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[50] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[51] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[52] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[53] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[54] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[55] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[56] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[57] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[58] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[59] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[60] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[61] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120928, 'Itraconazole', 'Midazolam', 'Major', 'Coadministration with itraconazole or ketoconazole may significantly increase the plasma concentrations and pharmacologic effects of benzodiazepines that are primarily metabolized by CYP450 3A4. The mechanism is increased bioavailability and/or decreased clearance due to inhibition of intestinal and hepatic CYP450 3A4 by the azole antifungal agents. Pharmacodynamic changes associated with the interaction include increased and prolonged sedation, enhanced benzodiazepine-related EEG effects, and increased impairment of psychomotor performance. The interaction is subject to a high degree of interpatient variability.', NULL, 'The concomitant use of itraconazole or ketoconazole with alprazolam, oral midazolam, and triazolam is considered contraindicated.', NULL, 'The concomitant use of itraconazole or ketoconazole with alprazolam, oral midazolam, and triazolam is considered contraindicated. Some authorities consider concomitant administration of triazolam or oral midazolam and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole. Fluconazole and miconazole are weaker inhibitors of CYP450 3A4 but may still cause the interaction, while terbinafine is not an inhibitor of CYP450 3A4 and has been shown to have no effect on the pharmacokinetics of midazolam and triazolam. Alternatively, benzodiazepines that are not metabolized by CYP450 3A4 (e.g., lorazepam, oxazepam, temazepam) may be considered in patients requiring itraconazole or ketoconazole.', 'Metabolism', 'Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, Paraldehyde, More', 'Flucytosine, Anidulafungin, Micafungin, Oteseconazole', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121066/', '[1] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[2] Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ "The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin." Eur J Clin Pharmacol 54 (1998): 53-8[3] Wrighton SA, Ring BJ "Inhibition of human CYP3A catalyzed 1''-hydroxy midazolam formation by ketoconazole, nifedipine, erythromycin, cimetidine, and nizatidine." Pharm Res 11 (1994): 921-4[4] Neuvonen PJ, Varhe A, Olkkola KT "The effect of ingestion time interval on the interaction between itraconazole and triazolam." Clin Pharmacol Ther 60 (1996): 326-31[5] Tsunoda SM, Velez RL, vonMoltke LL, Greenblatt DJ "Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole." Clin Pharmacol Ther 66 (1999): 461-71[6] Greenblatt DJ, Vonmoltke LL, Harmatz JS, Harrel LM, Tobias S, Shader RI, Wright CE "Interaction of triazolam and ketoconazole." Lancet 345 (1995): 191[7] "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[8] Vonmoltke LL, Greenblatt DJ, Schmider J, Duan SX, Wright CE, Harmatz JS, Shader RI "Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents." J Clin Pharmacol 36 (1996): 783-91[9] Vonmoltke LL, Greenblatt DJ, Cotreaubibbo MM, Harmatz JS, Shader RI "Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine." Br J Clin Pharmacol 38 (1994): 23-31[10] Brown MW, Maldonado AL, Meredith CG, Speeg KV "Effect of ketoconazole on hepatic oxidative drug metabolism." Clin Pharmacol Ther 37 (1985): 290-7[11] "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[12] "Product Information. Sporonox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[13] Cerner Multum, Inc. "Australian Product Information." O 0[14] "Product Information. Versed (midazolam)." Roche Laboratories, Nutley, NJ.[15] Varhe A, Olkkola KT, Neuvonen PJ "Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole." Clin Pharmacol Ther 56 (1994): 601-7[16] Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K "Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam." Psychopharmacology 139 (1998): 269-73[17] Olkkola KT, Backman JT, Neuvonen PJ "Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole." Clin Pharmacol Ther 55 (1994): 481-5[18] Greenblatt DJ, Wright CE, vonMoltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Counihan M, Tobias S, Shader RI "Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences." Clin Pharmacol Ther 64 (1998): 237-47[19] Ahonen J, Olkkola KT, Neuvonen PJ "Lack of effect of antimycotic itraconazole on the pharmacokinetics or pharmacodynamics of temazepam." Ther Drug Monit 18 (1996): 124-7[20] Ahonen J, Olkkola KT, Neuvonen PJ "Effect of itraconazole and terbinafine on the pharmacokinetics and pharmacodynamics of midazolam in healthy volunteers." Br J Clin Pharmacol 40 (1995): 270-2[21] Varhe A, Olkkola KT, Neuvonen PJ "Fluconazole, but not terbinafine, enhances the effects of triazolam by inhibiting its metabolism." Br J Clin Pharmacol 41 (1996): 319-23[22] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[23] Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krahenbuhl S "Interaction between grapefruit juice and midazolam in humans." Clin Pharmacol Ther 58 (1995): 20-8[24] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[25] "Product Information. Valium (diazepam)." Roche Laboratories, Nutley, NJ.[26] "Product Information. Xanax (alprazolam)." Pharmacia and Upjohn, Kalamazoo, MI.[27] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[28] "Product Information. Halcion (triazolam)." Pharmacia and Upjohn, Kalamazoo, MI.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120929, 'Itraconazole', 'Midostaurin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of midostaurin and its active metabolites, which are all substrates of the isoenzyme. The increase in midostaurin concentrations may be particularly pronounced when CYP450 3A4 inhibitors are administered during the first week of midostaurin administration.', NULL, 'Concomitant use of midostaurin with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of midostaurin with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, patients should be closely monitored for increased adverse reactions (e.g., nausea, vomiting, diarrhea, edema, hyperglycemia, hyperuricemia, QT prolongation, neutropenia, lymphopenia, thrombocytopenia, anemia), especially during the first week of consecutive midostaurin administration in patients with advanced systemic mastocytosis and during the first week of midostaurin administration in each cycle of chemotherapy in patients with acute myeloid leukemia.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121067/', '[1] Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34[2] "Product Information. Rydapt (midostaurin)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Rydapt (midostaurin)." Novartis Pharmaceuticals, East Hanover, NJ.[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120930, 'Itraconazole', 'Mifepristone', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of mifepristone, which is primarily metabolized by the isoenzyme. The clinical impact of this interaction has not been studied.', NULL, 'Due to its potent antiglucocorticoid effects and potential to cause dose-related prolongation of the QT interval, extreme caution is advised when mifepristone is prescribed in combination with strong CYP450 3A4 inhibitors such as, but not limited to, itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, delavirdine, nefazodone, telithromycin, and protease inhibitors.', NULL, 'Due to its potent antiglucocorticoid effects and potential to cause dose-related prolongation of the QT interval, extreme caution is advised when mifepristone is prescribed in combination with strong CYP450 3A4 inhibitors such as, but not limited to, itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, conivaptan, delavirdine, nefazodone, telithromycin, and protease inhibitors. When used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing''s syndrome, the dosage of mifepristone should be limited to 300 mg/day and used only when necessary.', 'Metabolism', 'Raloxifene, Prasterone, Danazol, Bazedoxifene', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121068/', '[1] "Product Information. Korlym (mifepristone)." Corcept Therapeutics Incorporated, Menlo Park, CA.[2] "Product Information. Mifeprex (mifepristone)" Danco Laboratories, New York, NY.[3] "Product Information. Korlym (mifepristone)." Corcept Therapeutics Incorporated, Menlo Park, CA.[4] "Product Information. Mifeprex (mifepristone)" Danco Laboratories, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120931, 'Itraconazole', 'Mipomersen', 'Major', 'Coadministration of mipomersen with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Mipomersen can cause elevations in serum transaminases and hepatic steatosis.', NULL, 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.', NULL, 'Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, lomitapide, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Mipomersen has not been studied with other LDL-lowering agents that can also increase hepatic fat, thus concomitant use is not recommended. Patients treated with mipomersen should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Gemfibrozil, Fenofibric acid, Pitavastatin, Evinacumab, Evolocumab, Probucol, Dextrothyroxine, Cholestyramine, Clofibrate, Colestipol, Bempedoic acid, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121069/', '[1] "Product Information. Kynamro (mipomersen)." Genzyme Corporation, Cambridge, MA.[2] "Product Information. Kynamro (mipomersen)." Genzyme Corporation, Cambridge, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120932, 'Itraconazole', 'Mirabegron', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of mirabegron, which has been shown in vitro to be a substrate of the isoenzyme. However, in vivo results indicate that CYP450 3A4 may play a limited role in the overall elimination. No dosage adjustment is recommended when mirabegron is administered in combination with ketoconazole and probably other CYP450 3A4 inhibitors.', NULL, '-', NULL, '-', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Apomorphine, Pentosan polysulfate, Calcium chloride, Phenazopyridine, Acetohydroxamic acid, Trospium, Yohimbine, Flavoxate, Papaverine, Phenyl salicylate, Ammonium chloride, Dimethyl sulfoxide', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121070/', '[1] "Product Information. Myrbetriq (mirabegron)." Astellas Pharma US, Inc, Deerfield, IL.[2] "Product Information. Myrbetriq (mirabegron)." Astellas Pharma US, Inc, Deerfield, IL.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120933, 'Itraconazole', 'Mirtazapine', 'Moderate', 'Coadministration of mirtazapine with drugs that inhibit one or more of its metabolic pathways may result in increased plasma concentrations of mirtazapine. In vitro data from human liver microsomes indicate that CYP450 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite, while CYP450 3A4 is primarily responsible for the formation of the N-desmethyl and N-oxide metabolites.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of mirtazapine should be considered during coadministration of drugs that inhibit CYP450 1A2, 2D6 and/or 3A4.', NULL, 'The possibility of prolonged and/or increased pharmacologic effects of mirtazapine should be considered during coadministration of drugs that inhibit CYP450 1A2, 2D6 and/or 3A4. Therapeutic response to mirtazapine should be monitored more closely following initiation, discontinuation, or dosing change of CYP450 inhibitors, and the mirtazapine dosage adjusted as necessary.', 'Metabolism', 'Phenelzine, Duloxetine, Desipramine, Tranylcypromine, Trimipramine, Desvenlafaxine, Maprotiline, Fluoxetine, St. John''s Wort, Isocarboxazid, Oxitriptan, More', 'Micafungin, Caspofungin, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121071/', '[1] Sitsen JM, Maris FA, Timmer CJ "Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects." Eur J Clin Pharmacol 56 (2000): 389-94[2] "Product Information. Remeron (mirtazapine)." Organon, West Orange, NJ.[3] Stormer E, von Moltke LL, Shader RI, Greenblatt DJ "Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4" Drug Metab Dispos 28 (2000): 1168-75[4] Okubo M, Murayama N, Miura J, Chiba Y, Yamazaki H "Effects of cytochrome P450 2D6 and 3A5 genotypes and possible coadministered medicines on the metabolic clearance of antidepressant mirtazapine in Japanese patients." Biochem Pharmacol 93 (2015): 104-9[5] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120934, 'Itraconazole', 'Mitoxantrone', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of mitoxantrone, which is a substrate of the efflux transporter also known as ABCB1 or MDR1. The interaction has been studied with cyclosporine, a potent P-gp inhibitor.', NULL, 'Caution is advised if mitoxantrone is prescribed in combination with a P-gp inhibitor.', NULL, 'Caution is advised if mitoxantrone is prescribed in combination with a P-gp inhibitor. Patients should be closely monitored for increased adverse effects including cardiotoxicity and myelosuppression.', 'Others', 'Flucytosine, Micafungin, Anidulafungin, Miconazole', 'Dactinomycin, Mitomycin, Valrubicin, Plicamycin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121072/', '[1] "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.[2] "Multum Information Services, Inc. Expert Review Panel"[3] "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.[4] "Multum Information Services, Inc. Expert Review Panel"[5] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120935, 'Itraconazole', 'Modafinil', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of modafinil (the racemate) and armodafinil (the R-enantiomer), which are both partially metabolized by the isoenzyme. Conversely, the plasma levels of some of these inhibitors may decrease, since many of them are also substrates of CYP450 3A4, and modafinil and armodafinil have been found to be modest inducers of CYP450 3A4. The clinical significance of this potential interaction is unknown. Clinical monitoring for altered effects of modafinil and armodafinil as well as the CYP450 3A4 inhibitor may be appropriate following addition or withdrawal of one or the other drug.', NULL, '-', NULL, '-', 'Metabolism', 'Amphetamine, Pemoline, Atomoxetine, Metamfetamine, Lisdexamfetamine, Solriamfetol, Caffeine, Methylphenidate, Dexmethylphenidate, Dextroamphetamine, Citicoline', 'Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121073/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Nuvigil (armodafinil)." Cephalon Inc, West Chester, PA.[3] "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.[4] "Product Information. Provigil (modafinil)." Cephalon, Inc, West Chester, PA.[5] "Product Information. Nuvigil (armodafinil)." Cephalon Inc, West Chester, PA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120936, 'Itraconazole', 'Naldemedine', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of naldemedine, which is primarily metabolized by CYP450 3A4 to nor-naldemedine and to a minor extent by UGT1A3 to naldemedine 3-G. Both metabolites have demonstrated antagonistic activity for opioid receptors, but with less potency than the parent drug. Increased exposure to naldemedine may precipitate opioid withdrawal symptoms such as hyperhidrosis, lacrimation, rhinorrhea, chills, diarrhea, abdominal pain, anxiety, insomnia, irritability, restlessness, and yawning.', NULL, 'Caution is advised during concomitant use of naldemedine with potent inhibitors of CYP450 3A4.', NULL, 'Caution is advised during concomitant use of naldemedine with potent inhibitors of CYP450 3A4. Patients should be closely monitored for potential opioid withdrawal symptoms as well as other adverse effects of naldemedine.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Sodium sulfate, Linaclotide, Plecanatide, Magnesium citrate, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121074/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Symproic (naldemedine)." Shionogi USA Inc, Florham Park, NJ.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] "Product Information. Symproic (naldemedine)." Shionogi USA Inc, Florham Park, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120937, 'Itraconazole', 'Naloxegol', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of naloxegol, which is primarily metabolized by the isoenzyme. Increased exposure to naloxegol may precipitate opioid withdrawal symptoms such as hyperhidrosis, lacrimation, rhinorrhea, chills, diarrhea, abdominal pain, anxiety, insomnia, irritability, restlessness, and yawning.', NULL, 'Concomitant use of naloxegol with potent CYP450 3A4 inhibitors such as clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and protease inhibitors is considered contraindicated.', NULL, 'Concomitant use of naloxegol with potent CYP450 3A4 inhibitors such as clarithromycin, telithromycin, itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and protease inhibitors is considered contraindicated. Some authorities consider concomitant administration of naloxegol and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Sodium sulfate, Linaclotide, Plecanatide, Magnesium citrate, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121075/', '[1] "Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] "Product Information. Movantik (naloxegol)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[7] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120938, 'Itraconazole', 'Naltrexone', 'Moderate', 'Coadministration of naltrexone with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Naltrexone, especially in larger than recommended doses (more than 50 mg/day), has been associated with hepatocellular injury, hepatitis, and elevations in liver transaminases and bilirubin. Other potential causative or contributory etiologies identified include preexisting alcoholic liver disease, hepatitis B and/or C infection, and concomitant usage of other hepatotoxic drugs.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.', NULL, 'The use of naltrexone with other potentially hepatotoxic agents should be avoided whenever possible (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Periodic monitoring of hepatic function is advisable.', 'Synergism', 'Oxymorphone, Tapentadol, Meperidine, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Nalbuphine, Dihydrocodeine, Naloxone, Codeine, More', 'Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121076/', '[1] "Product Information. ReVia (naltrexone)." DuPont Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120939, 'Itraconazole', 'Nateglinide', 'Minor', 'Itraconazole, a potent inhibitor of CYP450 3A4, does not appear to significantly affect the pharmacokinetics of available oral hypoglycemic agents, most of which are primarily metabolized by CYP450 2C8 (pioglitazone, rosiglitazone, repaglinide) or 2C9 (nateglinide, sulfonylureas). In most patients, no change in antidiabetic effect was reported. No specific precautions should be necessary during coadministration of most oral hypoglycemic agents with itraconazole. However, dosage adjustments may be necessary if an interaction is suspected.', NULL, '-', NULL, '-', 'Metabolism', 'Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Sitagliptin, Canagliflozin, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, More', 'Caspofungin, Micafungin, Amphotericin B, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121077/', '[1] Jaakkola T, Backman JT, Neuvonen M, Neuvonen PJ "Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone." Clin Pharmacol Ther 77 (2005): 404-14[2] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[3] Niemi M, Backman JT, Neuvonen M, Neuvonen PJ "Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide." Diabetologia 46 (2003): 347-51[4] Verspeelt J, Marynissen G, Gupta AK, De Doncker P "Safety of itraconazole in diabetic patients." Dermatology 198 (1999): 382-4[5] Miners JO, Birkett DJ "Cytochrome P4502C9: an enzyme of major importance in human drug metabolism." Br J Clin Pharmacol 45 (1998): 525-38[6] Niemi M, Backman JT, Juntti-Patinen L, Neuvonen M, Neuvonen PJ "Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide." Br J Clin Pharmacol 60 (2005): 208-17[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14[9] Komatsu K, Ito K, Nakajima Y, Kanamitsu S, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N, Sugiyama Y "Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments." Drug Metab Disposition 28 (2000): 475-81[10] Hatorp V, Hansen KT, Thomsen MS "Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide." J Clin Pharmacol 43 (2003): 649-60[11] Shon JH, Yoon YR, Kim MJ, et al. "Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism." Br J Clin Pharmacol 59 (2005): 552-63[12] Venkatakrishnan K, von Moltke LL, Greenblatt DJ "Effects of the antifungal agents on oxidative drug metabolism: clinical relevance." Clin Pharmacokinet 38 (2000): 111-80[13] Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT "Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes." Clin Pharmacol Ther 72 (2002): 326-32[14] Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72[15] Jerntorp P, Almer LO "Chlorpropamide-alcohol flushing in relation to macroangiopathy and peripheral neuropathy in non-insulin dependent diabetes." Acta Med Scand 656 (1981): 33-6[16] "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.[17] "Position Statement: evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes related complications. American Diabetes Association." Diabetes Care 25(Suppl 1) (2002): S50-S60[18] "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.[19] Jerntorp P, Almer LO, Holin H, et al "Plasma chlorpropamide: a critical factor in chlorpropamide-alcohol flush." Eur J Clin Pharmacol 24 (1983): 237-42[20] Hartling SG, Faber OK, Wegmann ML, Wahlin-Boll E, Melander A "Interaction of ethanol and glipizide in humans." Diabetes Care 10 (1987): 683-6[21] Barnett AH, Spiliopoulos AJ, Pyke DA, et al "Metabolic studies in chlorpropamide-alcohol flush positive and negative type 2 (non-insulin dependent) diabetic patients with and without retinopathy." Diabetologia 24 (1983): 213-5[22] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[23] "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.[24] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[25] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[26] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[27] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[28] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[29] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[30] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[31] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[32] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[33] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120940, 'Itraconazole', 'Nefazodone', 'Moderate', 'Coadministration with itraconazole may significantly increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by itraconazole.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever itraconazole is added to or withdrawn from therapy. Some authorities recommend avoiding concomitant use of nevirapine from 2 weeks before and during treatment with itraconazole.', 'Metabolism', 'Phenelzine, Duloxetine, Desipramine, Tranylcypromine, Trimipramine, Desvenlafaxine, Maprotiline, Fluoxetine, St. John''s Wort, Isocarboxazid, Oxitriptan, More', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121078/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Kaukonen KM, Olkkola KT, Neuvonen PJ "Itraconazole increases plasma concentrations of quinidine." Clin Pharmacol Ther 62 (1997): 510-7[3] Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44[4] Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH "Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor." Drug Metab Dispos 24 (1996): 307-14[5] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[7] Tailor SAN "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 1374[8] Gillies J, Hung KA, Fitzsimons E, Soutar R "Severe vincristine toxicity in combination with itraconazole." Clin Lab Haematol 20 (1998): 123-4[9] Lukkari E, Juhakoski A, Aranko K, Neuvonen PJ "Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite." Eur J Clin Pharmacol 52 (1997): 403-6[10] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[11] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[12] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[13] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[14] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[15] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[16] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[17] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[18] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[19] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120941, 'Itraconazole', 'Nelfinavir', 'Moderate', 'Coadministration with nelfinavir may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by nelfinavir.', NULL, 'Caution is advised if nelfinavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if nelfinavir must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever nelfinavir is added to or withdrawn from therapy.', 'Metabolism', 'Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Maribavir, More', 'Micafungin, Amphotericin B, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121079/', '[1] "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc, La Jolla, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120942, 'Itraconazole', 'Neratinib', 'Major', 'Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of neratinib, which is primarily metabolized by the isoenzyme.', NULL, 'Given the potential for increased risk of toxicity, concomitant use of neratinib with potent or moderate inhibitors of CYP450 3A4 should generally be avoided.', NULL, 'Given the potential for increased risk of toxicity, concomitant use of neratinib with potent or moderate inhibitors of CYP450 3A4 should generally be avoided.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121080/', '[1] "Product Information. Nerlynx (neratinib)." Puma Biotechnology, Inc., Los Angeles, CA.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] "Product Information. Nerlynx (neratinib)." Puma Biotechnology, Inc., Los Angeles, CA.[6] Abbas R, Hug BA, Leister C, Burns J, Sonnichsen D "Pharmacokinetics of oral neratinib during co-administration of ketoconazole in healthy subjects." Br J Clin Pharmacol 71 (2011): 522-7[7] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120943, 'Itraconazole', 'Nevirapine', 'Moderate', 'Coadministration with itraconazole may significantly increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by itraconazole.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever itraconazole is added to or withdrawn from therapy. Some authorities recommend avoiding concomitant use of nevirapine from 2 weeks before and during treatment with itraconazole.', 'Metabolism', 'Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Maribavir, More', 'Micafungin, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121081/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Kaukonen KM, Olkkola KT, Neuvonen PJ "Itraconazole increases plasma concentrations of quinidine." Clin Pharmacol Ther 62 (1997): 510-7[3] Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44[4] Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH "Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor." Drug Metab Dispos 24 (1996): 307-14[5] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[7] Tailor SAN "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 1374[8] Gillies J, Hung KA, Fitzsimons E, Soutar R "Severe vincristine toxicity in combination with itraconazole." Clin Lab Haematol 20 (1998): 123-4[9] Lukkari E, Juhakoski A, Aranko K, Neuvonen PJ "Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite." Eur J Clin Pharmacol 52 (1997): 403-6[10] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[11] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[12] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[13] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[14] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[15] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[16] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[17] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[18] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[19] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120944, 'Itraconazole', 'Nicardipine', 'Major', 'Itraconazole exhibits a dose-related negative inotropic effect which may be additive to those of calcium channel blockers (CCBs). Theoretically, coadministration may potentiate the risk of ventricular dysfunction, congestive heart failure, and peripheral and pulmonary edema, particularly in patients with preexisting risk factors (e.g., a history of congestive heart failure; cardiac disease such as ischemic and valvular disease; significant pulmonary disease such as chronic obstructive pulmonary disorder; edematous disorders such as renal failure). In addition, both itraconazole and its major metabolite, hydroxyitraconazole, inhibit CYP450 3A4 metabolism and may interfere with the clearance of certain CCBs like the dihydropyridines (amlodipine, felodipine, isradipine, lacidipine, nicardipine, nifedipine, nimodipine, nisoldipine), diltiazem, and verapamil. Significant increases of severalfold in felodipine and nifedipine plasma concentrations have been observed during coadministration with itraconazole, and there have been case reports of leg and ankle edema in patients treated with various itraconazole-dihydropyridine combinations. Itraconazole alone has also been associated with postmarketing reports of congestive heart failure, peripheral edema, and pulmonary edema in patients treated for onychomycosis and/or systemic fungal infections.', NULL, 'Caution is advised if itraconazole must be used concomitantly with CCBs.', NULL, 'Caution is advised if itraconazole must be used concomitantly with CCBs. Close monitoring of clinical response and tolerance is recommended, and patients should be advised to seek medical attention if they experience edema or swelling of the lower extremities; sudden, unexplained weight gain; difficulty breathing; chest pain or tightness; or hypotension as indicated by dizziness, fainting, or orthostasis. Appropriate dosage adjustment of the CCB may be necessary when used with itraconazole. Some authorities consider concomitant administration of bepridil and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism, Synergism', 'Clevidipine', 'Micafungin, Caspofungin, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121082/', '[1] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[2] Rosen T "Debilitating edema associated with itraconazole therapy." Arch Dermatol 130 (1994): 260-1[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Tailor SAN, Gupta AK, Walker SE, Shear NH "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 350-2[5] Jalava KM, Olkkola KT, Neuvonen PJ "Itraconazole greatly increases plasma concentrations and effects of felodipine." Clin Pharmacol Ther 61 (1997): 410-5[6] Tailor SAN "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 1374[7] Neuvonen PJ, Suhonen R "Itraconazole interacts with felodipine." J Am Acad Dermatol 33 (1995): 134-5[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[9] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[10] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[11] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[12] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[13] "Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.[14] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[15] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[16] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[17] "Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.[18] Fuhr U, Muller-Peltzer H, Kern R, et al. "Effects of grapefruit juice and smoking on verapamil concentrations in steady state." Eur J Clin Pharmacol 58 (2002): 45-53[19] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[20] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[21] "Product Information. Sular (nisoldipine)." Zeneca Pharmaceuticals, Wilmington, DE.[22] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[23] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[24] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[25] Ho PC, Ghose K, Saville D, Wanwimolruk S "Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers." Eur J Clin Pharmacol 56 (2000): 693-8[26] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[27] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[28] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[29] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[30] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[31] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[32] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[33] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[34] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[35] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[36] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120945, 'Itraconazole', 'Nilotinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of nilotinib, which is primarily metabolized by the isoenzyme. Because nilotinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.', NULL, 'Concomitant use of nilotinib with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics should generally be avoided.', NULL, 'Concomitant use of nilotinib with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics should generally be avoided. Some authorities recommend avoiding concomitant use of nilotinib during and for 2 weeks after treatment with itraconazole. Should treatment with a potent inhibitor be required, the manufacturer recommends that nilotinib therapy be withheld temporarily. If concomitant use is unavoidable, a reduction of the nilotinib dosage to 400 mg once daily should be considered. Based on pharmacokinetic studies, this dosage is predicted to adjust the nilotinib systemic exposure (AUC) to the range observed without inhibitors. However, clinical data are lacking. Patients should have frequent ECGs and be monitored for arrhythmias when QT interval is prolonged. A QTc interval exceeding 480 msec will require suspension of nilotinib therapy and immediate action to correct any concomitant risk factors before resuming treatment. Patients should be advised to seek prompt medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, lightheadedness, fainting, palpitation, irregular heart rhythm, shortness of breath, or syncope.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121083/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals, East Hanover, NJ.[3] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[4] "Product Information. Tasigna (nilotinib)." Novartis Pharmaceuticals, East Hanover, NJ.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[6] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120946, 'Itraconazole', 'Nimodipine', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations and blood pressure lowering effect of nimodipine, which is primarily metabolized by CYP450 3A4 in the intestinal mucosa and liver.', NULL, 'The use of nimodipine in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics is considered contraindicated because of a risk of significant hypotension.', NULL, 'The use of nimodipine in combination with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics is considered contraindicated because of a risk of significant hypotension.', 'Metabolism', 'Clevidipine', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121084/', '[1] "Product Information. Nimotop (nimodipine)." Bayer, West Haven, CT.[2] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[3] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[4] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[5] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[6] "Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.[7] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[8] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[9] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[10] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[11] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[12] Fuhr U, Muller-Peltzer H, Kern R, et al. "Effects of grapefruit juice and smoking on verapamil concentrations in steady state." Eur J Clin Pharmacol 58 (2002): 45-53[13] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[14] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[15] "Product Information. Sular (nisoldipine)." Zeneca Pharmaceuticals, Wilmington, DE.[16] Ho PC, Ghose K, Saville D, Wanwimolruk S "Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers." Eur J Clin Pharmacol 56 (2000): 693-8[17] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[18] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[19] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[20] "Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.[21] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[22] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120947, 'Itraconazole', 'Nintedanib', 'Moderate', 'Coadministration with inhibitors of P-glycoprotein (P-gp) and CYP450 3A4 may increase the plasma concentrations of nintedanib, which is a substrate of the efflux transporter and a minor substrate of the isoenzyme.', NULL, 'Caution is advised if nintedanib is prescribed in combination with P-gp and CYP450 3A4 inhibitors.', NULL, 'Caution is advised if nintedanib is prescribed in combination with P-gp and CYP450 3A4 inhibitors. Pharmacologic response to nintedanib should be monitored more closely whenever a CYP450 3A4/P-gp inhibitor is added to or withdrawn from therapy, and the nintedanib dosing adjusted or interrupted as necessary in accordance with the product labeling. Patients should be closely monitored for increased adverse effects such as liver enzyme and bilirubin elevations, diarrhea, nausea, vomiting, gastrointestinal perforation, bleeding, and arterial thromboembolic events (e.g., myocardial infarction).', 'Metabolism', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121085/', '[1] "Product Information. Ofev (nintedanib)." Boehringer Ingelheim, Ridgefield, CT.[2] "Product Information. Ofev (nintedanib)." Boehringer Ingelheim, Ridgefield, CT.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120948, 'Itraconazole', 'Niraparib', 'Moderate', 'Coadministration with potent inhibitors of P-glycoprotein (P-gp) may increase the bioavailability of niraparib, which is a substrate of the efflux transporter. Increased levels of niraparib may lead to increased incidence of hematological toxicity (e.g., thrombocytopenia, anemia, neutropenia) and/or cardiovascular toxicity (e.g., hypertension, hypertensive crisis).', NULL, 'Pharmacologic response to niraparib should be monitored more closely whenever a potent P-gp inhibitor is added to or withdrawn from therapy, and the niraparib dosage adjusted as necessary.', NULL, 'Pharmacologic response to niraparib should be monitored more closely whenever a potent P-gp inhibitor is added to or withdrawn from therapy, and the niraparib dosage adjusted as necessary.', 'Absorption', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole', 'Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Selinexor, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121086/', '[1] "Product Information. Zejula (niraparib)." Tesaro Inc., Waltham, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120949, 'Itraconazole', 'Nisoldipine', 'Major', 'Coadministration with ketoconazole or itraconazole may significantly increase the plasma concentrations of nisoldipine. The proposed mechanism is decreased first-pass metabolism and hepatic clearance of nisoldipine due to inhibition of CYP450 3A4. Although not studied, itraconazole is expected to interact similarly, since it is a known potent inhibitor of CYP450 3A4.There have been case reports of leg and ankle edema in patients treated with itraconazole and dihydropyridine calcium channel blockers. Pharmacodynamically, itraconazole exhibits a dose-related negative inotropic effect, which may be additive to those of calcium channel blockers (CCBs). It is conceivable that coadministration may potentiate the risk of ventricular dysfunction, congestive heart failure, and peripheral and pulmonary edema, particularly in patients with preexisting risk factors (e.g., a history of congestive heart failure; cardiac disease such as ischemic and valvular disease; significant pulmonary disease such as chronic obstructive pulmonary disorder; edematous disorders such as renal failure).', NULL, 'Because the alterations in nisoldipine pharmacokinetics cannot be feasibly managed by dosage reduction, concomitant use with ketoconazole or itraconazole is considered contraindicated.', NULL, 'Because the alterations in nisoldipine pharmacokinetics cannot be feasibly managed by dosage reduction, concomitant use with ketoconazole or itraconazole is considered contraindicated. Some authorities consider concomitant administration of nisoldipine and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'Clevidipine', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121087/', '[1] "Product Information. Nizoral (ketoconazole)." Janssen Pharmaceutica, Titusville, NJ. (1992):[2] Jalava KM, Olkkola KT, Neuvonen PJ "Itraconazole greatly increases plasma concentrations and effects of felodipine." Clin Pharmacol Ther 61 (1997): 410-5[3] Rosen T "Debilitating edema associated with itraconazole therapy." Arch Dermatol 130 (1994): 260-1[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Tailor SAN "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 1374[6] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[7] Heinig R, Adelmann HG, Ahr G "The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine." Eur J Clin Pharmacol 55 (1999): 57-60[8] Tailor SAN, Gupta AK, Walker SE, Shear NH "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 350-2[9] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[10] Neuvonen PJ, Suhonen R "Itraconazole interacts with felodipine." J Am Acad Dermatol 33 (1995): 134-5[11] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[12] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[13] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[14] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[15] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[16] "Product Information. Procardia (nifedipine)." Pfizer US Pharmaceuticals, New York, NY.[17] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[18] Edgar B, Bailey D, Bergstrand R, Johnsson G, Regardh CG "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics of felodipine--and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[19] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[20] "Product Information. Plendil (felodipine)." Merck & Co, Inc, West Point, PA.[21] Fuhr U, Muller-Peltzer H, Kern R, et al. "Effects of grapefruit juice and smoking on verapamil concentrations in steady state." Eur J Clin Pharmacol 58 (2002): 45-53[22] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[24] "Product Information. Sular (nisoldipine)." Zeneca Pharmaceuticals, Wilmington, DE.[25] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[26] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[27] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[28] Ho PC, Ghose K, Saville D, Wanwimolruk S "Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers." Eur J Clin Pharmacol 56 (2000): 693-8[29] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120950, 'Itraconazole', 'Nitisinone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of and exposure to, nitisinone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of nitisinone, which has been shown in in vitro studies to be metabolized by this isoenzyme.', NULL, 'Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors.', NULL, 'Until more information is available, caution is advised if nitisinone is used concomitantly with CYP450 3A4 inhibitors. Pharmacologic response to nitisinone should be monitored whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the nitisinone dosage adjusted as necessary. Patients should be monitored for the development of adverse effects.', 'Metabolism', 'Teduglutide, Fosdenopterin, Miglustat, Imiglucerase, Asfotase alfa, Glycerol phenylbutyrate, Pegvaliase, Triethylenetetramine, Sapropterin, Zinc acetate, Phenylbutyric acid, More', 'Caspofungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121088/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[3] Canadian Pharmacists Association "e-CPS. Available from: URL: http://www.pharmacists.ca/function/Subscriptions/ecps.cfm?link=eCPS_quikLink."[4] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[5] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[6] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[7] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[8] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[9] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[10] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[11] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[12] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[13] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[14] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[15] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[16] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[17] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[18] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[19] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[20] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[21] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[22] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[23] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[24] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[25] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[26] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[27] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[28] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[29] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[30] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[31] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[32] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[33] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[34] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[35] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[36] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[37] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[38] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[39] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[40] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[41] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[42] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[43] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[44] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[45] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[46] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[47] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[48] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[49] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[50] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[51] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[52] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[53] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[54] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[55] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[56] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[57] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[58] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[59] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[60] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[61] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[62] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[63] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[64] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[65] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[66] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[67] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120951, 'Itraconazole', 'Nizatidine', 'Moderate', 'INTERVAL: Oral H2 antagonists may significantly decrease the plasma concentration of oral itraconazole capsules. The mechanism is related to an increase in gastric pH resulting in a decrease in absorption of the antifungal. Clinical monitoring of patient response is recommended.', NULL, 'H2 antagonists should be taken at least 2 hours after itraconazole.', NULL, 'H2 antagonists should be taken at least 2 hours after itraconazole. If necessary, an acidic pH may be produced by administration with an acidic beverage such as Coca-Cola(R) or Pepsi(R). However, clinicians should still consider the possibility of a reduced or subtherapeutic antifungal effect. It may be appropriate to switch to itraconazole oral solution or an agent like fluconazole or terbinafine whose absorption is not affected by stomach pH.', 'Absorption', 'Tinidazole, Levofloxacin, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Amoxicillin', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121089/', '[1] Blum RA, D''Andrea DT, Florentino BM, et al "Increased gastric pH and the bioavailability of fluconazole and ketoconazole." Ann Intern Med 114 (1991): 755-7[2] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[3] "Product Information. Sporonox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[4] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[5] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[7] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[8] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[9] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[10] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[11] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[12] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[13] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[14] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120952, 'Itraconazole', 'Norgestrel', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Megestrol acetate, Megestrol acetate, Estetrol', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121090/', '[1] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ "Pregnancy associated with a combined oral contraceptive and itraconazole." N Z Med J 106 (1993): 436[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120953, 'Itraconazole', 'Nortriptyline', 'Moderate', 'The coadministration with azole antifungal agents may increase the plasma concentrations of some tricyclic antidepressants (TCAs). Elevated TCA levels may result in CNS toxicity, anticholinergic symptoms, and QT interval prolongation. The mechanism is decreased TCA clearance due to azole-related inhibition of the CYP450 3A4 isoenzyme, which is partially responsible for the metabolism of TCAs like amitriptyline, clomipramine, imipramine, and possibly others.', NULL, 'During concomitant therapy with azole antifungal agents, patients stabilized on their TCA regimen should be observed for increased pharmacologic response to the TCA, and the dosage adjusted accordingly if necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients stabilized on their TCA regimen should be observed for increased pharmacologic response to the TCA, and the dosage adjusted accordingly if necessary. Serum TCA levels should be monitored following initiation or discontinuation of azole antifungal therapy. Patients should be advised to notify their caregiver if they experience excessive dry mouth, visual disturbances, urinary retention, dizziness, syncope, fast or irregular heartbeat, constipation, or seizures.', 'Metabolism', 'Phenelzine, Duloxetine, Desipramine, Tranylcypromine, Trimipramine, Desvenlafaxine, Maprotiline, Fluoxetine, St. John''s Wort, Isocarboxazid, Oxitriptan, More', 'Caspofungin, Micafungin, Amphotericin B, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121091/', '[1] Dorsey ST, Biblio LA "Prolonged QT interval and torsades de pointes caused by the combination of fluconazole and amitriptyline." Am J Emerg Med 18 (2000): 227-9[2] Gannon RH "Fluconazole-nortriptyline drug interaction." Ann Pharmacother 26 (1992): 1456[3] Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E "Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects." Br J Clin Pharmacol 43 (1997): 315-8[4] Spina E, Avenoso A, Campo GM, Scordo MG, Caputi AP, Perucca E "Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects." Br J Clin Pharmacol 43 (1997): 315-8[5] Robinson RF, Nahata MC, Olshefski RS "Syncope associated with concurrent amitriptyline and fluconazole therapy." Ann Pharmacother 34 (2000): 1406-9[6] Newberry DL, Bass SN, Mbanefo CO "A fluconazole/amitriptyline drug interaction in three male adults." Clin Infect Dis 24 (1997): 270-1', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120954, 'Itraconazole', 'Olaparib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the isoenzyme. Increased exposure to olaparib may increase the risk of adverse effects such as hematologic toxicity, nausea, vomiting, diarrhea, anorexia, dyspepsia, and abdominal pain or discomfort.', NULL, 'Concomitant use of olaparib with potent CYP450 3A4 inhibitors should be avoided whenever possible.', NULL, 'Concomitant use of olaparib with potent CYP450 3A4 inhibitors should be avoided whenever possible. Some authorities recommend avoiding concomitant use of olaparib during and for 2 weeks after treatment with itraconazole. If coadministration is required, dose reductions are recommended as follows: the olaparib tablet dosage should be reduced to 100 mg twice a day; the olaparib capsule dosage should be reduced to 150 mg twice a day. Specific dose recommendations for each formulation should be followed as the tablet and capsule formulations are not interchangeable due to differences in bioavailability. Once the CYP450 3A4 inhibitor has been discontinued for 3 to 5 elimination half-lives, the usual olaparib dose should be resumed.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Selinexor, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121092/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[5] "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[6] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[7] Cerner Multum, Inc. "Australian Product Information." O 0[8] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[9] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120955, 'Itraconazole', 'Oliceridine', 'Major', 'Coadministration with moderate or potent inhibitors of CYP450 2D6 and/or 3A4 may increase the plasma concentrations and adverse opioid effects of oliceridine, which is primarily metabolized by both isoenzymes in vitro. In addition, oliceridine concentrations may decrease following discontinuation of a concomitant moderate or potent CYP450 2D6 or 3A4 inhibitor, possibly resulting in decreased opioid efficacy or withdrawal syndrome. The effect of a CYP450 2D6 inhibitor on the pharmacokinetics of oliceridine has not been studied. However, it may be similar to that reported in CYP450 2D6 poor metabolizers, whose plasma clearance of oliceridine is reduced by approximately 50% compared to those who are nonpoor CYP450 2D6 metabolizers.', NULL, 'Caution is recommended if oliceridine is used in combination with moderate or potent inhibitors of CYP450 2D6 or 3A4.', NULL, 'Caution is recommended if oliceridine is used in combination with moderate or potent inhibitors of CYP450 2D6 or 3A4. If concomitant use is considered necessary, patients may require less frequent dosing of oliceridine and should be closely monitored for respiratory depression, sedation, and QT prolongation. If a moderate or potent CYP450 2D6 or 3A4 inhibitor is discontinued, an increase of the oliceridine dosage may be considered while monitoring for signs of opioid withdrawal until stable drug effects are achieved.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Oxymorphone, Tapentadol, Meperidine, Dezocine, Opium, Dextropropoxyphene, Pentazocine, Nalbuphine, Dihydrocodeine, Naloxone, Codeine', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121093/', '[1] "Product Information. Olinvyk (oliceridine)." Trevena Inc, Chesterbrook, PA.[2] "Product Information. Olinvyk (oliceridine)." Trevena Inc, Chesterbrook, PA.[3] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[4] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[5] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[6] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[7] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[8] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[9] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[10] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[11] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[12] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[13] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[14] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[15] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[16] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[17] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[18] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[19] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[21] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[22] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[23] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[24] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[25] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[26] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[27] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[28] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[29] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[30] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[31] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[32] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[33] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[34] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120956, 'Itraconazole', 'Osilodrostat', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of osilodrostat, which is partially metabolized by the isoenzyme. Clinically, high plasma levels of osilodrostat may increase the risk of adverse effects such as hypocortisolism (which may lead to life-threatening adrenal insufficiency), QT prolongation (which may increase the risk of ventricular arrhythmias including torsade de pointes and sudden death), and elevated androgen and 11-deoxycorticosterone levels (the latter of which may activate mineralocorticoid receptors and cause hypokalemia, edema, and hypertension).', NULL, 'The manufacturer recommends reducing the dosage of osilodrostat by one-half during concomitant use of a potent CYP450 3A4 inhibitor.', NULL, 'The manufacturer recommends reducing the dosage of osilodrostat by one-half during concomitant use of a potent CYP450 3A4 inhibitor. Further dosage adjustments should be based on clinical response and tolerance. Patients should have regular monitoring of 24-hour urine free cortisol and serum or plasma cortisol during treatment, as well as regular evaluations for signs and symptoms of hypocortisolism such as nausea, vomiting, abdominal pain, loss of appetite, fatigue, dizziness, hypotension, abnormal electrolyte levels, and hypoglycemia. Decrease dosing or temporarily discontinue osilodrostat if patients experience symptoms of hypocortisolism or if urine free cortisol levels fall below the target range or there is a rapid decrease in cortisol levels. Stop osilodrostat and administer exogenous glucocorticoid replacement therapy if patients have symptoms of adrenal insufficiency and serum or plasma cortisol levels are below target range. Osilodrostat therapy may be restarted at a lower dosage when symptoms have resolved and cortisol values are within target range. Additionally, an electrocardiogram and serum electrolyte levels should also be obtained prior to initiating osilodrostat therapy and periodically thereafter.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121094/', '[1] "Product Information. Isturisa (osilodrostat)." Recordati Rare Diseases Inc, Lebanon, NJ.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120957, 'Itraconazole', 'Osimertinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of osimertinib, which has been shown in vitro to be primarily metabolized by the isoenzyme. However, no pharmacokinetic data are available from drug interaction studies. Because osimertinib is associated with concentration-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.', NULL, 'Concomitant use of osimertinib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of osimertinib with potent CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, close monitoring for adverse effects such as diarrhea, QT prolongation, torsade de pointes arrhythmia, and cardiomyopathy (e.g., cardiac failure, pulmonary edema, ejection fraction decreases) is recommended, and the osimertinib dosage adjusted accordingly or treatment discontinued as necessary.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121095/', '[1] "Product Information. Tagrisso (osimertinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120958, 'Itraconazole', 'Ospemifene', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of ospemifene, which is partially metabolized by the isoenzyme.', NULL, 'Caution is advised when ospemifene is used with potent CYP450 3A4 inhibitors.', NULL, 'Caution is advised when ospemifene is used with potent CYP450 3A4 inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain, shortness of breath, and pain or swelling in the arms or legs.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Raloxifene, Prasterone, Danazol, Bazedoxifene', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121096/', '[1] "Product Information. Osphena (ospemifene)." Shionogi USA Inc, Florham Park, NJ.[2] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.[3] "Product Information. Osphena (ospemifene)." Shionogi USA Inc, Florham Park, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120959, 'Itraconazole', 'Oxcarbazepine', 'Moderate', 'Coadministration with oxcarbazepine may decrease the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is accelerated clearance due to induction of CYP450 3A4 activity by oxcarbazepine.', NULL, 'Caution is advised if oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if oxcarbazepine must be used concurrently with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever oxcarbazepine is added to or withdrawn from therapy.', 'Metabolism', 'Brivaracetam, Topiramate, Ezogabine, Paramethadione, Methsuximide, Fenfluramine, Eslicarbazepine, Lamotrigine, Phensuximide, Methylphenobarbital, Phenacemide, More', 'Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121097/', '[1] Rosche J, Froscher W, Abendroth D, Liebel J "Possible oxcarbazepine interaction with cyclosporine serum levels: A single case study." Clin Neuropharmacol 24 (2001): 113-6[2] "Product Information. Trileptal (oxcarbazepine)" Novartis Pharmaceuticals, East Hanover, NJ.[3] Zaccara G, Gangemi PF, Bendoni L, Menge GP, Schwabe S, Monza GC "Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine." Ther Drug Monit 15 (1993): 39-42[4] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[5] "Product Information. Ambien (zolpidem)." sanofi-aventis, Bridgewater, NJ.[6] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[7] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[8] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[9] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120960, 'Itraconazole', 'Paclitaxel (protein-bound)', 'Moderate', 'Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate of these isoenzymes.', NULL, 'Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.', NULL, 'Clinicians should consider the potential for interaction with drugs that inhibit CYP450 2C8 and/or 3A4 and monitor for evidence of dose-related toxicities of paclitaxel during coadministration, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121098/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Bergmann TK, Filppula AM, Launiainen T, Nielsen F, Backman J, Brosen K "Neurotoxicity and low paclitaxel clearance associated with concomitant clopidogrel therapy in a 60 year old Caucasian woman with ovarian carcinoma." Br J Clin Pharmacol (2015):[3] Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J "Drug interactions of paclitaxel metabolism in human liver microsomes." J Chemother 15 (2003): 266-74[4] Spencer CM, Faulds D "Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer." Drugs 48 (1994): 794-847[5] "Product Information. Abraxane (paclitaxel protein-bound)." American Pharmaceutical Partners, Schaumberg, IL.[6] "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.[7] Jamis-Dow CA, Klecker RW, Katki AG, Collins JM "Metabolism of Taxol by human liver microsomes and effect of inhibitors (Meeting abstract)." Proc Annu Meet Am Assoc Cancer Res 34 (1993): a21981993[8] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[9] "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.[10] Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27[11] Cerner Multum, Inc. "Australian Product Information." O 0[12] Yong WP, Wang LZ, Tham LS, et al. "A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers." Cancer Chemother Pharmacol 62 (2008): 243-51[13] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[14] Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91[15] Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ "Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report." Br J Clin Pharmacol (2011):[16] McInnes GT, Brodie MJ "Drug interactions that matter: a critical reappraisal." Drugs 36 (1988): 83-110[17] Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J "Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel." Cancer Biol Ther 5 (2006): 833-9', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120961, 'Itraconazole', 'Palbociclib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of palbociclib, which is a substrate of the isoenzyme. The risk of adverse effects such as infections, neutropenia, leukopenia, anemia, thrombocytopenia, anorexia, nausea, vomiting, diarrhea, stomatitis, alopecia, asthenia, peripheral neuropathy, and epistaxis may be increased.', NULL, 'Concomitant use of palbociclib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of palbociclib with potent CYP450 3A4 inhibitors should generally be avoided. Alternative agents with no or minimal CYP450 3A4 inhibitory potential are recommended whenever possible. If no alternatives exist, consider reducing the palbociclib dosage to 75 mg once daily. Following discontinuation of the potent CYP450 3A4 inhibitor, the palbociclib dosage should be returned (after 3 to 5 half-lives of the inhibitor) to that used prior to initiation of the inhibitor.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121099/', '[1] "Product Information. Ibrance (palbociclib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Ibrance (palbociclib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120962, 'Itraconazole', 'Panobinostat', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of panobinostat, which is partially metabolized by the isoenzyme.', NULL, 'For the treatment of multiple myeloma in combination with bortezomib and dexamethasone, the dose of panobinostat should be reduced to 10 mg when coadministered with potent CYP450 3A4 inhibitors.', NULL, 'For the treatment of multiple myeloma in combination with bortezomib and dexamethasone, the dose of panobinostat should be reduced to 10 mg when coadministered with potent CYP450 3A4 inhibitors.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Selinexor, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121100/', '[1] Hamberg P, Woo MM, Chen LC, et al. "Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor." Cancer Chemother Pharmacol 68 (2011): 805-13[2] "Product Information. Farydak (panobinostat)." Novartis Pharmaceuticals, East Hanover, NJ.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] "Product Information. Farydak (panobinostat)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120963, 'Itraconazole', 'Pantoprazole', 'Moderate', 'Proton pump inhibitors may decrease the gastrointestinal absorption of the azole antifungal agents, itraconazole and ketoconazole, both of which require an acidic environment for dissolution. By increasing gastric pH and reducing the acidity, proton pump inhibitors can decrease bioavailability of the azoles by 75% to 80%.', NULL, 'If coadministration is necessary, an acidic pH may be produced with two capsules of glutamic acid hydrochloride administered 15 minutes before the azole dose.', NULL, 'If coadministration is necessary, an acidic pH may be produced with two capsules of glutamic acid hydrochloride administered 15 minutes before the azole dose. Administration with an acidic beverage such as Coca-Cola(R) or Pepsi(R) may also help. However, clinicians should still consider the possibility of a reduced or subtherapeutic antifungal effect. It may be appropriate to switch to an agent like fluconazole or terbinafine whose absorption is not affected by stomach pH.', 'Absorption', 'Tinidazole, Levofloxacin, Tetracycline, Misoprostol, Bismuth subcitrate potassium, Amoxicillin', 'Flucytosine, Anidulafungin, Micafungin, Oteseconazole', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121101/', '[1] Piscitelli SC, Goss TF, Wilton JH, D''Andrea DT, Goldstein H, Schentag JJ "Effects of ranitidine and sucralfate on ketoconazole bioavailability." Antimicrob Agents Chemother 35 (1991): 1765-71[2] "Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc, Deerfield, IL.[3] Bottiger Y, Tybring G, Gotharson E, Bertilsson L "Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin." Clin Pharmacol Ther 62 (1997): 384-91[4] "Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America, Lincolnshire, IL.[5] Carlson JA, Mann HJ, Canafax DM "Effect of pH on disintegration and dissolution of ketoconazole tablets." Am J Hosp Pharm 40 (1983): 1334-6[6] Jaruratanasirikul S, Sriwiriyajan S "Effect of omeprazole on the pharmacokinetics of itraconazole." Eur J Clin Pharmacol 54 (1998): 159-61[7] Van der Meer JW, Keuning JJ "The influence of gastric acidity on the bio-availability of ketoconazole." J Antimicrob Chemother 6 (1980): 552-4[8] "Product Information. Nexium (esomeprazole)" Astra-Zeneca Pharmaceuticals, Wilmington, DE.[9] "Product Information. Aciphex (rabeprazole)" Janssen Pharmaceuticals, Titusville, NJ.[10] "Product Information. Protonix (pantoprazole)" Wyeth-Ayerst Laboratories, Philadelphia, PA.[11] Chin TWF, Loeb M, Fong IW "Effects of an acidic beverage (coca-cola) on absorption of ketoconazole." Antimicrob Agents Chemother 39 (1995): 1671-5[12] "Product Information. Prilosec (omeprazole)." Merck & Co, Inc, West Point, PA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120964, 'Itraconazole', 'Paricalcitol', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of paricalcitol, which is partially metabolized by the isoenzyme.', NULL, 'Caution is advised when paricalcitol is used with potent CYP450 3A4 inhibitors.', NULL, 'Caution is advised when paricalcitol is used with potent CYP450 3A4 inhibitors. Serum calcium and phosphorus levels should be monitored closely. If clinically significant hypercalcemia develops, the paricalcitol dose should be reduced or interrupted and support therapy administered.', 'Metabolism', 'Etelcalcetide, Doxercalciferol, Salmon calcitonin, Calcifediol', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121102/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical, Abbott Park, IL.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120965, 'Itraconazole', 'Pazopanib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of pazopanib, which is primarily metabolized by the isoenzyme. Although not studied, the interaction may increase the risk of QT interval prolongation and torsade de pointes arrhythmia as well as severe and fatal hepatotoxicity associated with the use of pazopanib.', NULL, 'Concomitant use of pazopanib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of pazopanib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of pazopanib during and for 2 weeks after treatment with itraconazole. If coadministration is unavoidable, a reduction of the pazopanib dosage to 400 mg once daily should be considered. Based on pharmacokinetic studies, this dosage is predicted to adjust the pazopanib systemic exposure (AUC) to the range observed without inhibitors. However, clinical data are lacking. Patients should have liver function tests (ALT, AST, bilirubin), electrocardiograms, and serum electrolyte levels performed at baseline and regular intervals as recommended in the product labeling. Further dosage reductions may be needed if adverse effects occur during therapy. Patients should be advised to notify their physician if they experience signs and symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice. In addition, they should seek medical attention if they experience symptoms that could indicate the occurrence of torsade de pointes such as dizziness, palpitations, or syncope. Following discontinuation of the potent CYP450 3A4 inhibitor, a washout period of approximately one week should be allowed before the pazopanib dosage is adjusted upward.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121103/', '[1] "Product Information. Votrient (pazopanib)." GlaxoSmithKline, Research Triangle Park, NC.[2] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Votrient (pazopanib)." GlaxoSmithKline, Research Triangle Park, NC.[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[6] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120966, 'Itraconazole', 'Pegaspargase', 'Moderate', 'Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.', NULL, 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.', NULL, 'The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.', 'Synergism', 'Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Selinexor, More', 'Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121104/', '[1] "Product Information. Oncaspar (pegaspargase)." Rhone-Poulenc Rorer, Collegeville, PA.[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Bodmer M, Sulz M, Stadlmann S, Droll A, Terracciano L, Krahenbuhl S "Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase." Digestion 74 (2006): epub[4] Cerner Multum, Inc "ANVISA Bulrio Eletrnico. Available from: URL: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp." O 0 (2015):[5] "Product Information. Elspar (asparaginase)." Merck & Co, Inc, West Point, PA.[6] Christ TN, Stock W, Knoebel RW "Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen." J Oncol Pharm Pract 24 (2018): 299-308[7] Lu G, Karur V, Herrington JD, Walker MG "Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine" Proc (Bayl Univ Med Cent) 29 (2016): 46-7[8] Jenkins R, Perlin E "Severe hepatotoxicity from Escherichia coli L-asparaginase." J Natl Med Assoc 79 (1987): 775-9[9] "Product Information. Asparlas (calaspargase pegol)." Servier, Boston, MA.[10] Burke PW, Aldoss I, Lunning MA, et.al "High-grade PEGylated asparaginase-related hepatotoxicity occurrence in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not necessarily predict recurrent hepatotoxicity in subsequent cycles." Blood 122 (2013): 2671[11] "Product Information. Erwinaze (asparaginase Erwinia chrysanthemi)." EUSA Pharma, Newtown, PA.[12] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[13] Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120967, 'Itraconazole', 'Peginterferon beta-1a', 'Moderate', 'Coadministration of beta interferons with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Use of beta interferons has been associated with rare cases of liver injury, including autoimmune hepatitis and severe liver damage leading to hepatic failure, some of which required transplantation.', NULL, 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.', NULL, 'The risk of hepatic injury should be considered when beta interferons are used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; other interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.', 'Synergism', 'Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Interferon alfa-n1, Oprelvekin, Sipuleucel-T, Elapegademase, Peginterferon alfa-2a, Ropeginterferon alfa-2b, Interferon alfacon-1, Sargramostim, Histamine, Aldesleukin, Pegademase, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121105/', '[1] "Product Information. Plegridy (peginterferon beta-1a)." Biogen Idec Inc, Cambridge, MA.[2] "Product Information. Betaseron (interferon beta-1b)." Berlex, Richmond, CA.[3] "Product Information. Rebif (interferon beta-1a)." Serono Laboratories Inc, Norwell, MA.[4] "Product Information. Avonex (interferon beta-1a)." Biogen, Cambridge, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120968, 'Itraconazole', 'Pemigatinib', 'Major', 'Coadministration with potent or moderate inhibitors of CYP450 3A4 may increase the plasma concentrations of pemigatinib, which is primarily metabolized by the isoenzyme in vitro.', NULL, 'Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inhibitors should be avoided.', NULL, 'Concomitant use of pemigatinib with potent or moderate CYP450 3A4 inhibitors should be avoided. If coadministration is required, a reduction in the dosage of pemigatinib is recommended.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121106/', '[1] "Product Information. Pemazyre (pemigatinib)." Incyte Corporation, Wilmington, DE.[2] "Product Information. Pemazyre (pemigatinib)." Incyte Corporation, Wilmington, DE.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120969, 'Itraconazole', 'Perampanel', 'Minor', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of perampanel, which is primarily metabolized by the isoenzyme. In a clinical study, ketoconazole 400 mg daily for 10 days resulted in an increase in perampanel AUC by 20% and half-life by 15%.', NULL, '-', NULL, '-', 'Metabolism', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Brivaracetam, Topiramate, Ezogabine, Paramethadione, Methsuximide, Fenfluramine, Eslicarbazepine, Lamotrigine, Phensuximide, Methylphenobarbital, Phenacemide, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121107/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7[6] "Product Information. Fycompa (perampanel)." Eisai Inc, Teaneck, NJ.[7] Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman''s the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):[8] "Product Information. Rexulti (brexpiprazole)." Otsuka American Pharmaceuticals Inc, Rockville, MD.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120970, 'Itraconazole', 'Pexidartinib', 'Major', 'Coadministration of pexidartinib with strong CYP450 3A4 inhibitors and/or uridine diphosphate glucuronosyltransferase (UGT) inhibitors may significantly increase the plasma concentrations and the incidence and severity of adverse effects of pexidartinib, including potentially fatal hepatotoxicity. The proposed mechanism is inhibition of CYP450 3A4 and/or UGT, the primary isoenzymes responsible for the metabolic clearance of pexidartinib.', NULL, 'The use of pexidartinib with strong CYP450 3A4 inhibitors and/or UGT inhibitors should generally be avoided.', NULL, 'The use of pexidartinib with strong CYP450 3A4 inhibitors and/or UGT inhibitors should generally be avoided. If concomitant use is required, the dose of pexidartinib should be reduced according to the manufacturer''s recommendations. If concomitant use of a strong CYP450 3A4 inhibitor or UGT inhibitor is discontinued, the dose of pexidartinib may be increased, after 3 plasma half-lives of the strong CYP450 3A4 inhibitor or UGT inhibitor, to the dose that was used prior to starting the strong CYP450 3A4 inhibitor or UGT inhibitor.', 'Metabolism', 'Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121108/', '[1] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.[2] "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.[3] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120971, 'Itraconazole', 'Phenytoin', 'Moderate', 'Phenytoin and other hydantoins may reduce itraconazole serum levels by up to 90%. The mechanism appears to be enhanced first-pass metabolism and hepatic enzyme metabolism (CYP450 3A4) of itraconazole. Itraconazole therapy may fail. Ketoconazole is affected in a similar manner. In addition, itraconazole may increase the plasma concentrations of phenytoin.', NULL, 'Coadministration of phenytoin or other hydantoins with itraconazole or ketoconazole should be avoided from 2 weeks before and during treatment with itraconazole or ketoconazole.', NULL, 'Coadministration of phenytoin or other hydantoins with itraconazole or ketoconazole should be avoided from 2 weeks before and during treatment with itraconazole or ketoconazole. Some experts suggest that if concomitant use is unavoidable, a dosage increase for itraconazole or ketoconazole should be considered. In addition, monitoring of phenytoin concentrations is recommended and the dosage adjusted if needed. Fluconazole is eliminated unchanged by the kidneys and may be a more appropriate antifungal agent, depending on the patient''s condition.', 'Metabolism', 'Brivaracetam, Topiramate, Ezogabine, Paramethadione, Methsuximide, Fenfluramine, Eslicarbazepine, Lamotrigine, Phensuximide, Methylphenobarbital, Phenacemide, More', 'Flucytosine, Anidulafungin, Micafungin, Oteseconazole', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121109/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] "Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.[5] Cerner Multum, Inc. "Australian Product Information." O 0[6] Ozuna J, Friel P "Effect of enteral tube feeding on serum phenytoin levels." J Neurosurg Nurs 16 (1984): 289-91[7] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[8] "Product Information. Dilantin (phenytoin)." Parke-Davis, Morris Plains, NJ.[9] Doak KK, Haas CE, Dunnigan KJ, et al. "Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings." Pharmacotherapy 18 (1998): 637-45[10] Haley CJ, Nelson J "Phenytoin-enteral feeding interaction." DICP 23 (1989): 796-8[11] Rodman DP, Stevenson TL, Ray TR "Phenytoin malabsorption after jejunostomy tube delivery." Pharmacotherapy 15 (1995): 801-5[12] Faraji B, Yu PP "Serum phenytoin levels of patients on gastrostomy tube feeding." J Neurosci Nurs 30 (1998): 55-9[13] Au Yeung SC, Ensom MH "Phenytoin and enteral feedings: does evidence support an interaction?" Ann Pharmacother 34 (2000): 896-905[14] Sandor P, Sellers EM, Dumbrell M, Khouw V "Effect of short- and long-term alcohol use on phenytoin kinetics in chronic alcoholics." Clin Pharmacol Ther 30 (1981): 390-7[15] Sellers EM, Holloway MR "Drug kinetics and alcohol ingestion." Clin Pharmacokinet 3 (1978): 440-52[16] Guidry JR, Eastwood TF, Curry SC "Phenytoin absorption in volunteers receiving selected enteral feedings." West J Med 150 (1989): 659-61[17] Holtz L, Milton J, Sturek JK "Compatibility of medications with enteral feedings." JPEN J Parenter Enteral Nutr 11 (1987): 183-6[18] Marvel ME, Bertino JS "Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension." JPEN J Parenter Enteral Nutr 15 (1991): 316-8[19] Fleisher D, Sheth N, Kou JH "Phenytoin interaction with enteral feedings administered through nasogastric tubes." JPEN J Parenter Enteral Nutr 14 (1990): 513-6[20] Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM "Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability." Epilepsia 28 (1987): 706-12', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120972, 'Itraconazole', 'Pimavanserin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of pimavanserin, which is primarily metabolized by the isoenzyme. High plasma levels of pimavanserin may increase the risk of QT interval prolongation, which has been associated with ventricular arrhythmias including torsade de pointes and sudden death.', NULL, 'Pimavanserin dosage should be reduced to 10 mg once a day when used with potent CYP450 3A4 inhibitors.', NULL, 'Pimavanserin dosage should be reduced to 10 mg once a day when used with potent CYP450 3A4 inhibitors.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Chlorpromazine, Mesoridazine, Methotrimeprazine, Promazine, Fluphenazine, Asenapine, Perphenazine, Thiothixene, Thioridazine, Clozapine, Trifluoperazine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121110/', '[1] "Product Information. Nuplazid (pimavanserin)." Accelis Pharma, East Windsor, NJ.[2] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120973, 'Itraconazole', 'Pimecrolimus (topical)', 'Minor', 'Theoretically, coadministration with CYP450 3A inhibitors may increase the plasma concentrations of pimecrolimus, which has been shown in vitro to undergo metabolism by this subfamily of hepatic microsomal enzymes. Although clinically significant drug interactions are not expected due to minimal systemic absorption of topically administered pimecrolimus, the possibility cannot be ruled out.', NULL, '-', NULL, '-', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121111/', '[1] "Product Information. Elidel (pimecrolimus topical)." Novartis Pharmaceuticals, East Hanover, NJ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120974, 'Itraconazole', 'Pimozide', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of pimozide, which is partially metabolized by the isoenzyme. The use of pimozide has been associated with dose-related prolongation of the QT interval, thus elevated plasma levels of the drug may potentiate the risk of ventricular arrhythmias such as ventricular tachycardia and torsade de pointes as well as cardiac arrest and sudden death.', NULL, 'Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of pimozide, concomitant use with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors is considered contraindicated.', NULL, 'Given the potential for serious and life-threatening adverse cardiac events associated with increased plasma levels of pimozide, concomitant use with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, conivaptan, idelalisib, nefazodone, cobicistat, delavirdine, and most protease inhibitors is considered contraindicated. Some authorities consider concomitant administration of lurasidone and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole. With respect to less potent CYP450 3A4 inhibitors, the manufacturers recommend that they also not be used with pimozide.', 'Metabolism', 'Chlorpromazine, Mesoridazine, Methotrimeprazine, Promazine, Fluphenazine, Asenapine, Perphenazine, Thiothixene, Thioridazine, Clozapine, Trifluoperazine, More', 'Micafungin, Caspofungin, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121112/', '[1] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[2] Glassman AH, Bigger JT Jr "Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death." Am J Psychiatry 158 (2001): 1774-82[3] Flockhart DA, Drici MD, Kerbusch T, et al "Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with tourette syndrome." J Clin Psychopharmacol 20 (2000): 317-24[4] Mangum EM, Graham KK "Lopinavir-Ritonavir: a new protease inhibitor." Pharmacotherapy 21 (2001): 1352-63[5] Desta Z, Kerbusch T, Flockhart DA "Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)." Clin Pharmacol Ther 65 (1999): 10-20[6] Cerner Multum, Inc. "Australian Product Information." O 0[7] "Product Information. Orap Tablets (pimozide)." Gate Pharmaceuticals, Sellersville, PA.[8] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[9] Krahenbuhl S, Sauter B, Kupferschmidt H, Krause M, Wyss PA, Meier PJ "Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication." Am J Med Sci 309 (1995): 315-6[10] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[11] "Product Information. Orap Tablets (pimozide)." Gate Pharmaceuticals, Sellersville, PA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120975, 'Itraconazole', 'Pitolisant', 'Moderate', 'Coadministration with pitolisant may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4. Pitolisant is a borderline/weak inducer of CYP450 3A4.', NULL, 'Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates.', NULL, 'Caution is advised when pitolisant is used in combination with sensitive CYP450 3A4 substrates. Clinical and laboratory monitoring may be appropriate whenever pitolisant is added to or withdrawn from therapy, and dosage adjustments made if necessary. It may be advisable to avoid concomitant use of pitolisant and CYP450 3A4 substrates with a narrow therapeutic index, if possible.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Dextromethorphan, Dalfampridine, Sodium oxybate, Riluzole, Tetrabenazine, Inotersen, Amifampridine, Deutetrabenazine, Tafamidis', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121113/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Wakix (pitolisant)." Harmony Biosciences, LLC, Plymouth Meeting, PA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120976, 'Itraconazole', 'Polatuzumab vedotin', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase exposure to unconjugated monomethyl auristatin E (MMAE), the anti-mitotic and cytotoxic component of polatuzumab vedotin. Polatuzumab vedotin is an antibody-drug conjugate (ADC) that releases MMAE via proteolytic cleavage, and MMAE has been shown in vitro to be primarily metabolized by CYP450 3A4.', NULL, 'Caution is advised when polatuzumab vedotin is used concomitantly with potent CYP450 3A4 inhibitors.', NULL, 'Caution is advised when polatuzumab vedotin is used concomitantly with potent CYP450 3A4 inhibitors. Patients should be closely monitored for development or exacerbation of toxicities such as peripheral neuropathy, myelosuppression, opportunistic infections, tumor lysis syndrome and hepatotoxicity, and the dosing of polatuzumab vedotin adjusted or withheld as necessary in accordance with the product labeling.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Pertuzumab, Cetuximab, Avelumab, Panitumumab, Obinutuzumab, Bevacizumab, Necitumumab, Dostarlimab, Ramucirumab, Atezolizumab, Amivantamab, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121114/', '[1] "Product Information. Polivy (polatuzumab vedotin)." Genentech, South San Francisco, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120977, 'Itraconazole', 'Pomalidomide', 'Moderate', 'Coadministration with potent inhibitors of CYP450 1A2, CYP450 3A4, and P-glycoprotein may increase the plasma concentrations of pomalidomide, which has been shown to be primarily metabolized by these isoenzymes and also a substrate of the efflux transporter. Pomalidomide exposure is increased when given with a strong CYP450 1A2 inhibitor (e.g., fluvoxamine) in the presence of a strong CYP450 3A4 and P-gp inhibitor (e.g., ketoconazole). Coadministration with ketoconazole alone did not have a clinically significant effect on exposure to pomalidomide.', NULL, 'The use of pomalidomide with potent inhibitors of CYP450 1A2 (e.', NULL, 'The use of pomalidomide with potent inhibitors of CYP450 1A2 (e.g., ciprofloxacin, fluvoxamine, tiabendazole) in the presence of strong CYP450 3A4 and P-gp inhibitors should generally be avoided. If coadministration is considered clinically necessary, the pomalidomide dose should be reduced by 50%. Dose reduction may also be required if pomalidomide is given with a strong inhibitor of CYP450 1A2 in the absence of a coadministered CYP450 3A4 and P-gp inhibitor. Patients should be monitored for occurrence of pomalidomide-related side effects, including nausea, diarrhea, and neutropenia.', 'Metabolism', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Golimumab, Ustekinumab, Antithymocyte immunoglobulin (rabbit), Tocilizumab, Secukinumab, Canakinumab, Anifrolumab, Ravulizumab, Diroximel fumarate, Mycophenolic acid, Abatacept, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121115/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] "Product Information. Pomalyst (pomalidomide)." QLT Phototherapeutics Inc, Vancouver, AZ.[3] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[6] "Product Information. Pomalyst (pomalidomide)." QLT Phototherapeutics Inc, Vancouver, AZ.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120978, 'Itraconazole', 'Ponatinib', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of ponatinib, which is a substrate of the isoenzyme.', NULL, 'Caution is recommended if concomitant use is required, and the recommended starting dosage of ponatinib should be reduced to 30 mg once daily.', NULL, 'Caution is recommended if concomitant use is required, and the recommended starting dosage of ponatinib should be reduced to 30 mg once daily. Patients may be at increased risk for adverse effects such as thromboembolism, ischemia, congestive heart failure, hypertension, hepatotoxicity, pancreatitis, myelosuppression, hemorrhage, and fluid retention.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121116/', '[1] "Product Information. Iclusig (ponatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Iclusig (ponatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120979, 'Itraconazole', 'Porfimer sodium', 'Moderate', 'Concomitant use of porfimer with drugs known to cause photosensitivity may increase the risk of a photosensitivity reaction. Photosensitivity with porfimer is due to residual drug being present in the skin. Patients treated with porfimer will be photosensitive for at least 30 days.', NULL, 'Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient''s hepatic and/or renal function.', NULL, 'Concomitant use of photosensitizing agents with porfimer should be avoided for at least 30 days and maybe up to 90 days or longer depending on patient''s hepatic and/or renal function.', 'Synergism', 'Pertuzumab, Oxaliplatin, Tisagenlecleucel, Aminolevulinic acid, Omacetaxine mepesuccinate, Altretamine, Tagraxofusp, Ixazomib, Enasidenib, Mitotane, Selinexor, More', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121117/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Photofrin (porfimer)." Sanofi Winthrop Pharmaceuticals, New York, NY.[3] Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivityan update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47[4] Hoffman GA, Gradl G, Schulz M, Haidinger G, Tanew A, Weber B "The frequency of photosensitizing drug dispensings in Austria and Germany: A correlation with their photosensitizing potential based on published literature." J Eur Acad Dermatol Venereol 34 (2020): 589-600[5] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[6] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120980, 'Itraconazole', 'Posaconazole', 'Moderate', 'Coadministration with posaconazole may significantly increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by posaconazole.', NULL, 'Caution is advised if posaconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if posaconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever posaconazole is added to or withdrawn from therapy.', 'Metabolism', 'Micafungin, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Flucytosine, Anidulafungin, Oteseconazole, Itraconazole', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121118/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Product Information. Sonata (zaleplon)" Wyeth-Ayerst Laboratories, Philadelphia, PA.[3] Sansone-Parsons A, Krishna G, Calzetta A, et al. "Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers." Antimicrob Agents Chemother 50 (2006): 1881-3[4] Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P "Effect of pH and Comedication on Gastrointestinal Absorption of Posaconazole: Monitoring of Intraluminal and Plasma Drug Concentrations." Clin Pharmacokinet 50 (2011): 725-34[5] "Product Information. Noxafil (posaconazole)." Schering-Plough Corporation, Kenilworth, NJ.[6] Krishna G, Moton A, Ma L, Malavade D, Medlock M, McLeod J "Effect of gastric pH, dosing regimen and prandial state, food and meal timing relative to dose, and gastro-intestinal motility on absorption and pharmacokinetics of the antifungal posaconazole." 18th European Congress of Clinical Microbiology and Infectious Diseases April (2008): 20', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120981, 'Itraconazole', 'Pralsetinib', 'Major', 'Coadministration with a combined P-glycoprotein (P-gp) and potent CYP450 3A inhibitor may significantly increase the plasma concentrations of pralsetinib, which is primarily metabolized by the CYP450 3A isoenzyme. In vitro studies have shown pralsetinib is a time-dependent inhibitor of CYP450 3A4/5 isoenzymes and a P-gp inhibitor at clinically relevant concentrations.', NULL, 'Concomitant use of pralsetinib with a combined P-gp and potent CYP450 3A inhibitor should be avoided when possible.', NULL, 'Concomitant use of pralsetinib with a combined P-gp and potent CYP450 3A inhibitor should be avoided when possible. Following discontinuation of the combined P-gp and potent CYP450 3A inhibitor, and after an appropriate washout period (3 to 5 elimination half-lives), the pralsetinib dose taken prior to initiating the combined P-gp and potent CYP450 3A4 inhibitor may be resumed.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121119/', '[1] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation, Cambridge, MA.[2] "Product Information. Gavreto (pralsetinib)." Blueprint Medicines Corporation, Cambridge, MA.[3] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120982, 'Itraconazole', 'Praziquantel', 'Moderate', 'Coadministration with itraconazole may significantly increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme. The mechanism is decreased clearance due to inhibition of CYP450 3A4 activity by itraconazole.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range.', NULL, 'Caution is advised if itraconazole must be used concomitantly with medications that undergo metabolism by CYP450 3A4, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever itraconazole is added to or withdrawn from therapy. Some authorities recommend avoiding concomitant use of nevirapine from 2 weeks before and during treatment with itraconazole.', 'Metabolism', 'Triclabendazole, Oxamniquine', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Ketoconazole, Flucytosine, Anidulafungin, Voriconazole', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121120/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] Kaukonen KM, Olkkola KT, Neuvonen PJ "Itraconazole increases plasma concentrations of quinidine." Clin Pharmacol Ther 62 (1997): 510-7[3] Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44[4] Chiba M, Hensleigh M, Nishime JA, Balani SK, Lin JH "Role of cytochrome P450 3A4 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor." Drug Metab Dispos 24 (1996): 307-14[5] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[7] Tailor SAN "Peripheral edema due to nifedipine-itraconazole interaction: a case report." Arch Dermatol 132 (1996): 1374[8] Gillies J, Hung KA, Fitzsimons E, Soutar R "Severe vincristine toxicity in combination with itraconazole." Clin Lab Haematol 20 (1998): 123-4[9] Lukkari E, Juhakoski A, Aranko K, Neuvonen PJ "Itraconazole moderately increases serum concentrations of oxybutynin but does not affect those of the active metabolite." Eur J Clin Pharmacol 52 (1997): 403-6[10] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[11] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[12] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[13] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[14] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[15] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[16] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[17] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[18] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[19] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120983, 'Itraconazole', 'Prednisolone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'Mometasone furoate, Amcinonide, Fluocinolone acetonide, Hydrocortisone butyrate, Fluocinonide, Fluorometholone, Clobetasol, Beclomethasone dipropionate, Fluocinolone acetonide, Fluorometholone, Mometasone furoate, More', 'Micafungin, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121121/', '[1] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD "Case of psychosis due to prednisone-clarithromycin interaction." Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM "Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction." J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ "Impact of ketoconazole on the metabolism of prednisolone." Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR "Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals." J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ "Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone." Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML "The use of macrolide antibiotic substances in the treatment of asthma." J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH "Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma." Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. "Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects." Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone." Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G "Steroid-induced mania in an adolescent: risk factors and management." Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J "Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers." J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[30] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120984, 'Itraconazole', 'Prednisone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of corticosteroids, which are primarily metabolized by the isoenzyme. The interaction has been reported with potent inhibitors such as clarithromycin, erythromycin, itraconazole, nefazodone, cobicistat, and ritonavir during concomitant use of various corticosteroids, including inhaled, nasal, and ophthalmic formulations. Systemic corticosteroid adverse effects may occur following intensive or long-term continuous ophthalmic corticosteroid therapy. Cushing''s syndrome and adrenal insufficiency have been attributed to the interaction.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors.', NULL, 'The possibility of increased corticosteroid effects should be considered during coadministration with potent and moderate CYP450 3A4 inhibitors. When indicated for intranasal or inhalational use, alternative corticosteroids such as beclomethasone, which is less dependent on CYP450 3A4 metabolism, should be considered, particularly if long term treatment is required. Patients should be monitored for signs and symptoms of hypercorticism such as acne, striae, thinning of the skin, easy bruising, moon facies, dorsocervical "buffalo" hump, truncal obesity, increased appetite, acute weight gain, edema, hypertension, hirsutism, hyperhidrosis, proximal muscle wasting and weakness, glucose intolerance, exacerbation of preexisting diabetes, depression, and menstrual disorders. Other systemic glucocorticoid effects may include adrenal suppression, immunosuppression, posterior subcapsular cataracts, glaucoma, bone loss, and growth retardation in children and adolescents. Following extensive use with a potent CYP450 3A4 inhibitor, a progressive dosage reduction may be required over a longer period if the corticosteroid is to be withdrawn from therapy, as there may be a significant risk of adrenal suppression.', 'Metabolism', 'Beclomethasone dipropionate, Balsalazide, Cromoglicic acid, Olsalazine', 'Flucytosine, Anidulafungin, Micafungin, Oteseconazole', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121122/', '[1] Edsbacker S, Andersson T "Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn''s disease." Clin Pharmacokinet 43 (2004): 803-21[2] Finkenbine RD, Frye MD "Case of psychosis due to prednisone-clarithromycin interaction." Gen Hosp Psychiat 20 (1998): 325-6[3] Soldatos G, Sztal-Mazer S, Woolley I, Stockigt J "Exogenous glucocorticoid excess as a result of ritonavir-fluticasone interaction." Intern Med J 35 (2005): 67-8[4] Kandrotas RJ, Slaughter RL, Brass C, Jusko WJ "Ketoconazole effects on methylprednisolone disposition and their joint suppression of endogenous cortisol." Clin Pharmacol Ther 42 (1987): 465-70[5] Raaska K, Niemi M, Neuvonen M, Neuvonen PJ, Kivisto KT "Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole." Clin Pharmacol Ther 72 (2002): 362-369[6] Ulrich B, Frey FJ, Speck RF, Frey BM "Pharmacokinetics/pharmacodynamics of ketoconazole-prednisolone interaction." J Pharmacol Exp Ther 260 (1992): 487-90[7] Zurcher RM, Frey BM, Frey FJ "Impact of ketoconazole on the metabolism of prednisolone." Clin Pharmacol Ther 45 (1989): 366-72[8] Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR "Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals." J Acquir Immune Defic Syndr 48 (2008): 561-6[9] Yamashita SK, Ludwig EA, Middleton E Jr, Jusko WJ "Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone." Clin Pharmacol Ther 49 (1991): 558-70[10] Hillebrand-Haverkort ME, Prummel MF, ten Veen JH "Ritonavir-induced Cushing''s syndrome in a patient treated with nasal fluticasone." AIDS 13 (1999): 1803[11] Kotlyar M, Brewer ER, Golding M, Carson SW "Nefazodone inhibits methylprednisolone disposition and enhances its adrenal-suppressant effect." J Clin Psychopharmacol 23 (2003): 652-6[12] Itkin IH, Menzel ML "The use of macrolide antibiotic substances in the treatment of asthma." J Allergy Clin Immunol 45 (1970): 146-62[13] Skov M, Main KM, Sillesen IB, Muller J, Koch C, Lanng S "Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide." Eur Respir J 20 (2002): 127-33[14] Samaras K, Pett S, Gowers A, McMurchie M, Cooper DA "Iatrogenic Cushing''s syndrome with osteoporosis and secondary adrenal failure in HIV-infected patients receiving inhaled corticosteroids and ritonavir-boosted protease inhibitors: six cases." J Clin Endocrinol Metab 90 (2005): 4394-8[15] Garey KW, Rubinstein I, Gotfried MH, Khan IJ, Varma S, Danziger LH "Long-term clarithromycin decreases prednisone requirements in elderly patients with prednisone-dependent asthma." Chest 118 (2000): 1826-7[16] Glynn AM, Slaughter RL, Brass C, et al "Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion." Clin Pharmacol Ther 39 (1986): 654-9[17] LaForce CF, Szefler SJ, Miller MF, Ebling W, Brenner M "Inhibition of methylprednisolone elimination in the presence of erythromycin therapy." J Allergy Clin Immunol 72 (1983): 34-9[18] Lebrun-Vignes B, Archer VC, Diquest B, et al. "Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects." Br J Clin Pharmacol 51 (2001): 443-50[19] Varis T, Kivisto KT, Neuvonen PJ "The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone." Eur J Clin Pharmacol 56 (2000): 57-60[20] Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing''s syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9[21] Gupta SK, Dube MP "Exogenous Cushing syndrome mimicking human immunodeficiency virus lipodystrophy." Clin Infect Dis 35 (2002): E69-71[22] Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ "Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole." Clin Pharmacol Ther 64 (1998): 363-8[23] Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacin online de medicamentos de la AEMPS - CIMA. Available from: URL: https://cima.aemps.es/cima/publico/home.html." ([2018]):[24] Couturier J, Steele M, Hussey L, Pawliuk G "Steroid-induced mania in an adolescent: risk factors and management." Can J Clin Pharmacol 8 (2001): 109-12[25] Varis T, Backman JT, Kivisto KT, Neuvonen PJ "Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone." Clin Pharmacol Ther 67 (2000): 215-21[26] Bhumbra NA, Sahloff EG, Oehrtman SJ, Horner JM "Exogenous Cushing syndrome with inhaled fluticasone in a child receiving lopinavir/ritonavir." Ann Pharmacother 41 (2007): 1306-9[27] Main KM, Skov M, Sillesen IB, et al. "Cushing''s syndrome due to pharmacological interaction in a cystic fibrosis patient." Acta Paediatr 91 (2002): 1008-11[28] Penzak SR, Formentini E, Alfaro RM, Long M, Natarajan V, Kovacs J "Prednisolone pharmacokinetics in the presence and absence of ritonavir after oral prednisone administration to healthy volunteers." J Acquir Immune Defic Syndr 40 (2005): 573-80[29] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[30] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120985, 'Itraconazole', 'Progesterone', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Megestrol acetate, Megestrol acetate', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121123/', '[1] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ "Pregnancy associated with a combined oral contraceptive and itraconazole." N Z Med J 106 (1993): 436[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120986, 'Itraconazole', 'Progesterone (topical)', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121124/', '[1] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ "Pregnancy associated with a combined oral contraceptive and itraconazole." N Z Med J 106 (1993): 436[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120987, 'Itraconazole', 'Propafenone', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of propafenone, which may result in proarrhythmic events and exaggerated beta-adrenergic blocking activity.', NULL, 'Caution is advised when propafenone is administered with CYP450 3A4 inhibitors.', NULL, 'Caution is advised when propafenone is administered with CYP450 3A4 inhibitors. Therapeutic response to propafenone as well as clinical and electrocardiographic evidence of toxicity should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy, and the propafenone dosage adjusted as necessary. Patients should be monitored for potential adverse effects such as new or worsening arrhythmias or heart failure, edema, bradycardia, and atrioventricular block. Simultaneous use of propafenone with both a CYP450 3A4 inhibitor and a CYP450 2D6 inhibitor (or in patients with CYP450 2D6 deficiency) should be avoided.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Tocainide, Procainamide, Mexiletine, Bretylium, Moricizine, Ibutilide', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121125/', '[1] "Product Information. Rythmol SR (propafenone)." GlaxoSmithKline, Research Triangle Park, NC.[2] Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK "Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites." Mol Pharmacol 43 (1993): 120-6[3] "Product Information. Zokinvy (lonafarnib)." Eiger BioPharmaceuticals, Palo Alto, CA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120988, 'Itraconazole', 'Prucalopride', 'Minor', 'Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of prucalopride, which is thought to be a weak substrate of the efflux transporter.', NULL, '-', NULL, '-', 'Others', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole', 'Alvimopan, Sorbitol, Tegaserod, Bisacodyl, Methylnaltrexone, Lactitol, Sodium phosphate, monobasic, Sodium sulfate, Linaclotide, Plecanatide, Magnesium citrate, More', 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121126/', '[1] Cerner Multum, Inc. "Australian Product Information." O 0[2] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[3] "Product Information. Resotran (prucalopride)." Janssen Pharmaceuticals, Titusville, NJ.[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid."[6] "Product Information. Resotran (prucalopride)." Janssen Pharmaceuticals, Titusville, NJ.[7] "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical, Abbott Park, IL.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120989, 'Itraconazole', 'Quetiapine', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of quetiapine, which is primarily metabolized by the isoenzyme.', NULL, 'The dosage of quetiapine should be reduced when prescribed with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics.', NULL, 'The dosage of quetiapine should be reduced when prescribed with potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, nefazodone, cobicistat, delavirdine, protease inhibitors, and ketolide and certain macrolide antibiotics. The product labeling recommends a reduction to one-sixth of the original dosage. Following discontinuation of the CYP450 3A4 inhibitor, the dosage of quetiapine should be increased by 6-fold.', 'Metabolism', 'Micafungin, Caspofungin, Oteseconazole, Flucytosine, Anidulafungin', 'Chlorpromazine, Mesoridazine, Methotrimeprazine, Promazine, Fluphenazine, Asenapine, Perphenazine, Thiothixene, Thioridazine, Clozapine, Trifluoperazine, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121127/', '[1] DeVane CL, Nemeroff CB "Clinical pharmacokinetics of quetiapine - An atypical antipsychotic." Clin Pharmacokinet 40 (2001): 509-22[2] Hantson P, Di Fazio V, Wallemacq P "Toxicokinetic interaction between quetiapine and antiretroviral therapy following quetiapine overdose." Drug Metab Lett 4 (2010): 7-8[3] Geraci MJ, McCoy SL, Crum PM, Patel RA "Antipsychotic-induced priapism in an HIV patient: a cytochrome P450-mediated drug interaction." Int J Emerg Med 3 (2010): 81-4[4] Spina E, de Leon J "Metabolic drug interactions with newer antipsychotics: a comparative review." Basic Clin Pharmacol Toxicol 100 (2007): 4-22[5] Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB "Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics." Br J Clin Pharmacol 61 (2006): 58-69[6] Urichuk L, Prior TI, Dursun S, Baker G "Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions." Curr Drug Metab 9 (2008): 410-8[7] Schulz-Du Bois C, Schulz-Du Bois AC, Bewig B, et al. "Major increase of quetiapine steady-state plasma concentration following co-administration of clarithromycin: confirmation of the pharmacokinetic interaction potential of quetiapine." Pharmacopsychiatry 41 (2008): 258-9[8] Spina E, Scordo MG, D''Arrigo C "Metabolic drug interactions with new psychotropic agents." Fundam Clin Pharmacol 17 (2003): 517-38[9] "Product Information. Seroquel (quetiapine)." Zeneca Pharmaceuticals, Wilmington, DE.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120990, 'Itraconazole', 'Quinapril', 'Moderate', 'INTERVAL: Administration of quinapril with some oral medications may significantly decrease their absorption and may result in subtherapeutic serum concentrations. The proposed mechanism is chelation of the drug by the magnesium hydroxide excipient in quinapril tablets.', NULL, 'The manufacturer does not make a specific recommendation, but generally the administration of these drugs and magnesium-containing products should be separated by at least two to three hours.', NULL, 'The manufacturer does not make a specific recommendation, but generally the administration of these drugs and magnesium-containing products should be separated by at least two to three hours.', 'Absorption', 'Moexipril, Perindopril, Benazepril, Trandolapril, Captopril, Fosinopril, Moexipril, Perindopril, Bisoprolol, Benazepril, Trandolapril, More', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Posaconazole, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121128/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] "Multum Information Services, Inc. Expert Review Panel"[3] Ray K, Dorman S, Watson R "Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction." J Hum Hypertens 13 (1999): 717-20[4] Good CB, McDermott L "Diet and serum potassium in patients on ACE inhibitors." JAMA 274 (1995): 538[5] "Product Information. Vasotec (enalapril)." Merck & Co, Inc, West Point, PA.[6] "Product Information. Tequin (gatifloxacin)" Bristol-Myers Squibb, Princeton, NJ.[7] Wallace AW, Victory JM, Amsden GW "Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers." J Clin Pharmacol 43 (2003): 92-6', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120991, 'Itraconazole', 'Quinestrol', 'Moderate', 'Azole antifungal agents may increase the plasma concentrations of estrogens and progestins. The mechanism is decreased clearance of the hormones due to inhibition of CYP450 3A4 activity by azole antifungals.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', NULL, 'During concomitant therapy with azole antifungal agents, patients should be observed for increased or altered pharmacologic response to estrogens and progestins, and dosage(s) adjusted accordingly as necessary.', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121129/', '[1] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[2] Weisberg E "Interactions between oral contraceptives and antifungals antibacterials - Is contraceptive failure the result?." Clin Pharmacokinet 36 (1999): 309-13[3] Pillans PI, Sparrow MJ "Pregnancy associated with a combined oral contraceptive and itraconazole." N Z Med J 106 (1993): 436[4] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[5] Devenport MH, Crook D, Wynn V, Lees LJ "Metabolic effects of low-dose fluconazole in healthy female users and non-users of oral contraceptives." Br J Clin Pharmacol 27 (1989): 851-9[6] Sinofsky FE, Pasquale SA "The effect of fluconazole on circulating ethinyl estradiol levels in women taking oral contraceptives." Am J Obstet Gynecol 178 (1998): 300-4[7] Schubert W, Eriksson U, Edgar B, Cullberg G, Hedner T "Flavonoids in grapefruit juice inhibit the in vitro hepatic metabolism of 17B-estradiol." Eur J Drug Metab Pharmacokinet 20 (1995): 219-24[8] Weber A, Jager R, Borner A, et al. "Can grapefruit juice influence ethinyl estradiol bioavailability?" Contraception 53 (1996): 41-7', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120992, 'Itraconazole', 'Quinine', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of quinine, which is primarily metabolized by the isoenzyme.', NULL, 'Caution is advised if quinine is used in combination with potent and moderate CYP450 3A4 inhibitors.', NULL, 'Caution is advised if quinine is used in combination with potent and moderate CYP450 3A4 inhibitors. Patients should be monitored closely for adverse reactions associated with quinine such as hematologic toxicities and cardiac arrhythmias including torsade de pointes and atrial fibrillation. Patients should be advised to contact their physician if they experience increased side effects such as headache, flushing, sweating, nausea, vomiting, diarrhea, abdominal pain, tinnitus, dizziness, vertigo, hearing impairment, blurred vision, vision impairment, and irregular heart rhythm.', 'Metabolism', 'Risdiplam, Collagenase clostridium histolyticum, Onasemnogene abeparvovec, Hyaluronic acid, Artesunate, Mefloquine, Lumefantrine, Tafenoquine, Primaquine, Proguanil, Sulfadoxine', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121130/', '[1] Mirghani RA, Yasar U, Zheng T, et al "Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway." Drug Metab Dispos 30 (2002): 1368-71[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] Wanwimolruk S, Paine MF, Pusek SN, Watkins PB "Is quinine a suitable probe to assess the hepatic drug-metabolizing enzyme CYP3A4?" Br J Clin Pharmacol 54 (2002): 643-51[4] Mirghani RA, Ericsson O, Tybring G, Gustafsson LL, Bertilsson L "Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man." Eur J Clin Pharmacol 59 (2003): 23-8[5] Mirghani RA, Hellgren U, Westerberg PA, Ericsson O, Bertilsson L, Gustafsson LL "The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo." Clin Pharmacol Ther 66 (1999): 454-60[6] Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S "Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine." Br J Clin Pharmacol 43 (1997): 245-52[7] Zhao XJ, Ishizaki T "A further interaction study of quinine with clinically important drugs by human liver microsomes: determinations of inhibition constant (K-i) and type of inhibition." Eur J Drug Metab Pharm 24 (1999): 272-8[8] Mirghani RA, Hellgren U, Bertilsson L, Gustafsson LL, Ericsson O "Metabolism and elimination of quinine in healthy volunteers." Eur J Clin Pharmacol (2003):[9] Zhao XJ, Ishizaki T "Metabolic interactions of selected antimalarial and non-antimalarial drugs with the major pathway (3-hydroxylation) of quinine in human liver microsomes." Br J Clin Pharmacol 44 (1997): 505-11[10] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[11] "Product Information. Qualaquin (quinine)." AR Scientific Inc, Philadelphia, PA.[12] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[13] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[14] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[15] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[16] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[17] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[18] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[19] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[20] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[21] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[22] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[23] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[24] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[25] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[26] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[27] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[28] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[29] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[30] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8[31] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[32] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[33] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[34] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[35] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[36] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[37] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[38] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[39] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[40] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[41] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[42] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[43] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[44] "Product Information. Qualaquin (quinine)." AR Scientific Inc, Philadelphia, PA.[45] Ho PC, Chalcroft SC, Coville PF, Wanwimolruk S "Grapefruit juice has no effect on quinine pharmacokinetics." Eur J Clin Pharmacol 55 (1999): 393-8[46] Zhang H, Coville PF, Walker RJ, Miners JO, Birkett DJ, Wanwimolruk S "Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine." Br J Clin Pharmacol 43 (1997): 245-52[47] Hermans K, Stockman D, Van den Branden F "Grapefruit and tonic: a deadly combination in a patient with the long QT syndrome." Am J Med 114 (2003): 511-2[48] Mirghani RA, Yasar U, Zheng T, et al "Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway." Drug Metab Dispos 30 (2002): 1368-71', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120993, 'Itraconazole', 'Ramelteon', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 and/or 2C9 may increase the plasma concentrations and pharmacologic effects of ramelteon, which is partially metabolized by these isoenzymes.', NULL, 'Caution is advised if ramelteon is prescribed in combination with potent inhibitors of CYP450 3A4 (e.', NULL, 'Caution is advised if ramelteon is prescribed in combination with potent inhibitors of CYP450 3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, conivaptan, delavirdine, nefazodone, protease inhibitors, ketolide and certain macrolide antibiotics) and/or CYP450 2C9 (e.g., fluconazole, gemfibrozil, imatinib, miconazole). A reduction in the ramelteon dosage may be necessary in patients who experience excessive sedation.', 'Metabolism', 'Flurazepam, Methohexital, Methylphenobarbital, Pentobarbital, Dichloralphenazone, Valerian, Butabarbital, Secobarbital, Chloral hydrate, Quazepam, Paraldehyde, More', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121131/', '[1] "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America, Lincolnshire, IL.[2] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[3] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[4] "Product Information. Rozerem (ramelteon)." Takeda Pharmaceuticals America, Lincolnshire, IL.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120994, 'Itraconazole', 'Ranitidine (bismuth citrate)', 'Moderate', 'INTERVAL: Oral H2 antagonists may significantly decrease the plasma concentration of oral itraconazole capsules. The mechanism is related to an increase in gastric pH resulting in a decrease in absorption of the antifungal. Clinical monitoring of patient response is recommended.', NULL, 'H2 antagonists should be taken at least 2 hours after itraconazole.', NULL, 'H2 antagonists should be taken at least 2 hours after itraconazole. If necessary, an acidic pH may be produced by administration with an acidic beverage such as Coca-Cola(R) or Pepsi(R). However, clinicians should still consider the possibility of a reduced or subtherapeutic antifungal effect. It may be appropriate to switch to itraconazole oral solution or an agent like fluconazole or terbinafine whose absorption is not affected by stomach pH.', 'Absorption', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin, Voriconazole', NULL, 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121132/', '[1] Blum RA, D''Andrea DT, Florentino BM, et al "Increased gastric pH and the bioavailability of fluconazole and ketoconazole." Ann Intern Med 114 (1991): 755-7[2] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[3] "Product Information. Sporonox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[4] Lazar JD, Wilner KD "Drug interactions with fluconazole." Rev Infect Dis 12 Suppl 3 (1990): s327-33[5] "Product Information. Sporanox oral solution (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[6] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[7] Van Peer A, Woestenborghs R, Heykants J, et al "The effects of food and dose on the oral systemic availability of itraconazole in healthy subjects." Eur J Clin Pharmacol 36 (1989): 423-6[8] Penzak SR, Gubbins PO, Gurley BJ, Wang PL, Saccente M "Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers." Ther Drug Monit 21 (1999): 304-9[9] Katz HI "Drug interactions of the newer oral antifungal agents." Br J Dermatol 141 (1999): 26-32[10] Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakamura H "Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects." Int J Clin Pharmacol Ther 36 (1998): 306-8[11] Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van de Velde V "Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers." Antimicrob Agents Chemother 37 (1993): 778-84[12] Wishart JM "The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection." J Am Acad Dermatol 17 (1987): 220-3[13] Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A "Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in japanese subjects." Int J Clin Pharmacol Res 14 (1994): 87-93[14] Barone JA, Moskotitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L "Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers." Pharmacotherapy 18 (1998): 295-301', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120995, 'Itraconazole', 'Ranolazine', 'Major', 'Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ranolazine, which is primarily metabolized by the isoenzyme. Because ranolazine prolongs QT interval in a dose-dependent manner, high plasma levels of ranolazine may increase the risk of ventricular arrhythmias such as ventricular tachycardia, ventricular fibrillation, and torsade de pointes.', NULL, 'Concomitant use of ranolazine with potent CYP450 3A4 inhibitors is considered contraindicated.', NULL, 'Concomitant use of ranolazine with potent CYP450 3A4 inhibitors is considered contraindicated. Some authorities consider concomitant administration of ranolazine and itraconazole to be contraindicated during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'Adenosine, Regadenoson, Ubidecarenone', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121133/', '[1] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0[2] Cerner Multum, Inc. "Australian Product Information." O 0[3] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[4] "Product Information. Ranexa (ranolazine)." Calmoseptine Inc, Huntington Beach, CA.[5] "Product Information. Ranexa (ranolazine)." Calmoseptine Inc, Huntington Beach, CA.[6] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[7] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120996, 'Itraconazole', 'Regorafenib', 'Moderate', 'Coadministration with potent inhibitors of CYP450 3A4 may increase the plasma concentrations of regorafenib and decrease the plasma concentrations of its active metabolites.', NULL, 'Concomitant use of regorafenib with potent CYP450 3A4 inhibitors should generally be avoided.', NULL, 'Concomitant use of regorafenib with potent CYP450 3A4 inhibitors should generally be avoided. Some authorities recommend avoiding concomitant use of regorafenib during and for 2 weeks after treatment with itraconazole.', 'Metabolism', 'Fluconazole, Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Alpelisib, Lenvatinib, Trametinib, Alectinib, Dacomitinib, Tivozanib, Sorafenib', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121134/', '[1] "Product Information. Stivarga (regorafenib)." Bayer Pharmaceutical Inc, West Haven, CT.[2] "Product Information. Sporanox (itraconazole)." Janssen Pharmaceutica, Titusville, NJ.[3] Cerner Multum, Inc. "Australian Product Information." O 0[4] Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67[5] "Product Information. VFEND (voriconazole)." Pfizer U.S. Pharmaceuticals, New York, NY.[6] "Product Information. Stivarga (regorafenib)." Bayer Pharmaceutical Inc, West Haven, CT.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120997, 'Itraconazole', 'Relugolix', 'Major', 'Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the inhibitors are given orally. Relugolix is a substrate for intestinal P-gp.', NULL, 'Concomitant use of relugolix with orally administered P-gp inhibitors should generally be avoided.', NULL, 'Concomitant use of relugolix with orally administered P-gp inhibitors should generally be avoided. If coadministration is required, the manufacturer recommends taking relugolix first and separating the dosing by at least 6 hours. Patients should be monitored more frequently for adverse effects. Alternatively, treatment with relugolix may be interrupted for up to two weeks if a short course of treatment with a P-gp inhibitor is necessary.', 'Absorption', 'Caspofungin, Micafungin, Amphotericin B, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Nafarelin, Octreotide, Cetrorelix, Pasireotide, Ganirelix, Lanreotide, Gonadorelin, Anastrozole, Fulvestrant, Letrozole, Abarelix, More', 'Major', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121135/', '[1] "Product Information. Orgovyx (relugolix)." Myovant Sciences, Inc., Brisbane, CA.[2] "Product Information. Juxtapid (lomitapide)." Aegerion Pharmaceuticals Inc, Cambridge, MA.', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120998, 'Itraconazole', 'Remdesivir', 'Moderate', 'Concomitant use of remdesivir with other agents that are known to induce hepatotoxicity may theoretically increase the risk of liver injury. Data from investigational use and clinical studies suggest that remdesivir may be associated with hepatotoxic effects.', NULL, 'Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible.', NULL, 'Until more information is available, concomitant use of remdesivir with known hepatotoxic drugs should be avoided when possible. Liver function should be evaluated prior to starting remdesivir and monitored during treatment as clinically appropriate. Remdesivir should not be initiated in patients with ALT greater than or equal to 5 times the upper limit of normal (ULN) at baseline. Likewise, remdesivir should be discontinued immediately if ALT increases to 5 times ULN or greater during treatment (may be restarted when ALT falls below 5 times ULN), or if ALT elevation is accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR.', 'Synergism', 'Micafungin, Miconazole, Oteseconazole, Flucytosine, Anidulafungin', 'Tenofovir alafenamide, Cabotegravir, Zanamivir, Lenacapavir, Velpatasvir, Oseltamivir, Brincidofovir, Famciclovir, Voxilaprevir, Tecovirimat, Maribavir, More', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121136/', '[1] Gilead Sciences, Inc "About Remdesivir. Available from: URL: https://www.gilead.com/purpose/advancing-global-health/covid-19/about-remdesivir." ([2020]):[2] US Food and Drug Administration "Fact sheet for health care providers emergency use authorization (EUA) of remdesivir (GS-5734TM) Available from: URL: https://www.fda.gov/media/137566/download." ([2020, May 1]]):[3] European Medicines Agency "Summary on compassionate use. Remdesivir Gilead. Available from: URL: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-remdesivir-gilead_en.pdf." ([2020 Apr 03]):[4] Cerner Multum, Inc. "Australian Product Information." O 0[5] Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (120999, 'Itraconazole', 'Repaglinide', 'Moderate', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of repaglinide, which is partially metabolized by the isoenzyme.', NULL, 'Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, pharmacologic response to repaglinide should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy.', NULL, 'Because the antidiabetic effect of repaglinide is dose- and concentration-dependent, pharmacologic response to repaglinide should be monitored more closely whenever a CYP450 3A4 inhibitor is added to or withdrawn from therapy. Patients should be advised to regularly monitor their blood sugar and counseled on how to recognize and treat hypoglycemia, which may include symptoms such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, and palpitations.', 'Metabolism', 'Lixisenatide, Albiglutide, Guar gum, Acarbose, Pramlintide, Sitagliptin, Canagliflozin, Alogliptin, Liraglutide, Ertugliflozin, Semaglutide, More', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', 'Moderate', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121137/', '[1] Khamaisi M, Leitersdorf E "Severe hypoglycemia from clarithromycin-repaglinide drug interaction." Pharmacotherapy 28 (2008): 682-4[2] "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.[3] Hatorp V, Hansen KT, Thomsen MS "Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide." J Clin Pharmacol 43 (2003): 649-60[4] Niemi M, Backman JT, Neuvonen M, Neuvonen PJ "Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide." Diabetologia 46 (2003): 347-51[5] Niemi M, Neuvonen PJ, Kivisto KT "The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide." Clin Pharmacol Ther 70 (2001): 58-65[6] Bidstrup TB, Bjornsdottir I, Sidelmann UG, Thomsen MS, Hansen KT "CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide." Br J Clin Pharmacol 56 (2003): 305-14[7] Tornio A, Niemi M, Neuvonen M, et al. "The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo." Clin Pharmacol Ther 84 (2008): 403-11[8] Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41[9] Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8[10] Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32[11] "Grapefruit juice interactions with drugs." Med Lett Drugs Ther 37 (1995): 73-4[12] Libersa CC, Brique SA, Motte KB, et al. "Dramatic inhibition of amiodarone metabolism induced by grapefruit juice." Br J Clin Pharmacol 49 (2000): 373-8[13] Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10[14] Bailey DG, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit juice felodipine interaction: Effect of naringin and 6'',7''-dihydroxybergamottin in humans." Clin Pharmacol Ther 64 (1998): 248-56[15] Takanaga H, Ohnishi A, Maatsuo H, et al. "Pharmacokinetic analysis of felodipine-grapefruit juice interaction based on an irreversible enzyme inhibition model." Br J Clin Pharmacol 49 (2000): 49-58[16] Bailey DG, Dresser GR, Kreeft JH, Munoz C, Freeman DJ, Bend JR "Grapefruit-felodipine interaction: Effect of unprocessed fruit and probable active ingredients." Clin Pharmacol Ther 68 (2000): 468-77[17] Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS "Pharmacokinetic and cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice." Br J Clin Pharmacol 42 (1996): p662[18] Eagling VA, Profit L, Back DJ "Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-I protease inhibitor saquinavir by grapefruit juice components." Br J Clin Pharmacol 48 (1999): 543-52[19] Bailey DG, Arnold JM, Strong HA, Munoz C, Spence JD "Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics." Clin Pharmacol Ther 54 (1993): 589-94[20] Damkier P, Hansen LL, Brosen K "Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine." Br J Clin Pharmacol 48 (1999): 829-38[21] Min DI, Ku YM, Geraets DR, Lee HC "Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers." J Clin Pharmacol 36 (1996): 469-76[22] Josefsson M, Zackrisson AL, Ahlner J "Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers." Eur J Clin Pharmacol 51 (1996): 189-93[23] Majeed A, Kareem A "Effect of grapefruit juice on cyclosporine pharmacokinetics." Pediatr Nephrol 10 (1996): 395[24] Flanagan D "Understanding the grapefruit-drug interaction." Gen Dent 53 (2005): 282-5; quiz 286[25] Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31[26] Jonkman JH, Sollie FA, Sauter R, Steinijans VW "The influence of caffeine on the steady-state pharmacokinetics of theophylline." Clin Pharmacol Ther 49 (1991): 248-55[27] Ozdemir M, Aktan Y, Boydag BS, Cingi MI, Musmul A "Interaction between grapefruit juice and diazepam in humans." Eur J Drug Metab Pharmacokinet 23 (1998): 55-9[28] Edgar B, Bailey D, Bergstrand R, et al "Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine and its potential clinical relevance." Eur J Clin Pharmacol 42 (1992): 313-7[29] Kantola T, Kivisto KT, Neuvonen PJ "Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid." Clin Pharmacol Ther 63 (1998): 397-402[30] Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC "The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study." Clin Ther 21 (1999): 1890-9[31] Sato J, Nakata H, Owada E, Kikuta T, Umetsu M, Ito K "Influence of usual intake of dietary caffeine on single-dose kinetics of theophylline in healthy human subjects." Eur J Clin Pharmacol 44 (1993): 295-8[32] Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57[33] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin." Clin Pharmacol Ther 66 (1999): 118-27[34] Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A "Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation." Pharmazie 49 (1994): 522-4[35] Bailey DG, Arnold JM, Munoz C, Spence JD "Grapefruit juice--felodipine interaction: mechanism, predictability, and effect of naringin." Clin Pharmacol Ther 53 (1993): 637-42[36] Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E "Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers." Ther Drug Monit 23 (2001): 369-73[37] Yamreudeewong W, Henann NE, Fazio A, Lower DL, Cassidy TG "Drug-food interactions in clinical practice." J Fam Pract 40 (1995): 376-84[38] Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83[39] Garg SK, Kumar N, Bhargava VK, Prabhakar SK "Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy." Clin Pharmacol Ther 64 (1998): 286-8', 1767369485);
INSERT OR REPLACE INTO drug_interactions (id, ingredient1, ingredient2, severity, effect, arabic_effect, recommendation, arabic_recommendation, management_text, mechanism_text, alternatives_a, alternatives_b, risk_level, ddinter_id, source, type, metabolism_info, source_url, reference_text, updated_at) VALUES (121000, 'Itraconazole', 'Retapamulin (topical)', 'Minor', 'Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of retapamulin, which is primarily metabolized by the isoenzyme. However, dosage adjustments are not necessary due to the low systemic exposure to retapamulin following topical application.', NULL, '-', NULL, '-', 'Metabolism', 'Caspofungin, Micafungin, Amphotericin B, Oteseconazole, Flucytosine, Anidulafungin', NULL, 'Minor', NULL, 'DDInter', 'pharmacodynamic', NULL, 'https://ddinter2.scbdd.com/server/interact/121138/', '[1] "Product Information. Altabax (retapamulin topical)." GlaxoSmithKline, Research Triangle Park, NC.', 1767369485);